<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006359.pub2" GROUP_ID="MENSTR" ID="577206041900510652" MERGED_FROM="" MODIFIED="2010-09-21 02:03:40 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-01-27 14:14:04 +1300" NOTES_MODIFIED_BY="jane clarke" REVIEW_NO="DG 1351" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.11">
<COVER_SHEET MODIFIED="2010-09-21 02:03:40 +0200" MODIFIED_BY="Jane Clarke">
<TITLE>Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes</TITLE>
<CONTACT MODIFIED="2010-09-21 02:03:40 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="F5700CAE82E26AA201D6C2751ED8C26F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Demián</FIRST_NAME><LAST_NAME>Glujovsky</LAST_NAME><SUFFIX>MSc(c)</SUFFIX><POSITION>Egg Donor Co-ordinator</POSITION><EMAIL_1>demian.glujovsky@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Reproductive Medicine</DEPARTMENT><ORGANISATION>CEGYR (Centro de Estudios en Ginecologia y Reproduccion)</ORGANISATION><ADDRESS_1>Viamonte 1438,</ADDRESS_1><CITY>Buenos Aires</CITY><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+54-11-4372-8289</PHONE_1><FAX_1>+54-11-4371-7275</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-21 02:03:40 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="F5700CAE82E26AA201D6C2751ED8C26F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Demián</FIRST_NAME><LAST_NAME>Glujovsky</LAST_NAME><SUFFIX>MSc(c)</SUFFIX><POSITION>Egg Donor Co-ordinator</POSITION><EMAIL_1>demian.glujovsky@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Reproductive Medicine</DEPARTMENT><ORGANISATION>CEGYR (Centro de Estudios en Ginecologia y Reproduccion)</ORGANISATION><ADDRESS_1>Viamonte 1438,</ADDRESS_1><CITY>Buenos Aires</CITY><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+54-11-4372-8289</PHONE_1><FAX_1>+54-11-4371-7275</FAX_1></ADDRESS></PERSON><PERSON ID="FAD81E2782E26AA201D6C27529886214" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Romina</FIRST_NAME><LAST_NAME>Pesce</LAST_NAME><POSITION>Gynaecologist</POSITION><EMAIL_1>pescer@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Reproductive Medicine</DEPARTMENT><ORGANISATION>Hospital Italiano de Buenos Aires</ORGANISATION><ADDRESS_1>Gascon 450</ADDRESS_1><CITY>Buenos Aires</CITY><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>54 11 4959 0200</PHONE_1><FAX_1>54 11 4958 2738</FAX_1></ADDRESS></PERSON><PERSON ID="FA71AD1D82E26AA201D6C275403A50A9" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gabriel</FIRST_NAME><LAST_NAME>Fiszbajn</LAST_NAME><POSITION>Director of Reproductive Medicine</POSITION><EMAIL_1>glujovsky@cegyr.com</EMAIL_1><ADDRESS><DEPARTMENT>Reproductive Medicine</DEPARTMENT><ORGANISATION>CEGYR (Centro de Estudios en Ginecologia y Reproduccion)</ORGANISATION><ADDRESS_1>Viamonte 1438,</ADDRESS_1><CITY>Buenos Aires</CITY><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>54-11-4372-8289</PHONE_1><FAX_1>54-11-4371-7275</FAX_1></ADDRESS></PERSON><PERSON ID="E31DC46482E26AA2009C393D7FA53435" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><LAST_NAME>Sueldo</LAST_NAME><POSITION>Scientific Director</POSITION><EMAIL_1>drsueldo@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Reproductive Medicine</DEPARTMENT><ORGANISATION>CEGYR (Centro de Estudios en Ginecología y Reproducción)</ORGANISATION><CITY>Buenos Aires</CITY><COUNTRY CODE="AR">Argentina</COUNTRY></ADDRESS></PERSON><PERSON ID="16942" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roger</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Hart</LAST_NAME><SUFFIX>MD FRANZCOG MRCOG CREI</SUFFIX><POSITION>Professor Reproductive Medicine</POSITION><EMAIL_1>RHart@obsgyn.uwa.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Women's and Infants Health</DEPARTMENT><ORGANISATION>The University of Western Australia, King Edward Memorial Hospital and Fertility Specialists of Western Australia</ORGANISATION><ADDRESS_1>374 Bagot Road</ADDRESS_1><CITY>Subiaco</CITY><ZIP>6008</ZIP><REGION>Western Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 93401328</PHONE_1><FAX_1>+61 8 9381 3031</FAX_1></ADDRESS></PERSON><PERSON ID="13819" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Agustín</FIRST_NAME><LAST_NAME>Ciapponi</LAST_NAME><POSITION>Coordinator - Faculty</POSITION><EMAIL_1>agustin.ciapponi@hospitalitaliano.org.ar</EMAIL_1><EMAIL_2>aciapponi@gmail.com</EMAIL_2><URL>www.iecs.org.ar/cochrane</URL><ADDRESS><DEPARTMENT>Argentine Cochrane Centre IECS - Family and Community Medicine Service</DEPARTMENT><ORGANISATION>Institute for Clinical Effectiveness and Health Policy - Hospital Italiano de Buenos Aires</ORGANISATION><ADDRESS_1>2146 Viamonte 3rd Floor - Gascón 450</ADDRESS_1><CITY>Buenos Aires</CITY><ZIP>C1056ABH - C1181ACH</ZIP><REGION>Capital Federal</REGION><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+5411 4953 4058</PHONE_1><PHONE_2>+5411 4959 0381</PHONE_2><FAX_1>+5411 4953 4058</FAX_1><FAX_2>+5411 4959 0381</FAX_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-01-27 14:03:04 +1300" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Minor update: 11/16/07&lt;/p&gt;" NOTES_MODIFIED="2010-01-27 14:03:04 +1300" NOTES_MODIFIED_BY="Jane Clarke">
<UP_TO_DATE>
<DATE DAY="7" MONTH="10" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="10" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="11" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-21 01:19:58 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:19:58 +0200" MODIFIED_BY="Jane Clarke"><DATE DAY="20" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2010-09-21 01:19:58 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:19:58 +0200" MODIFIED_BY="Jane Clarke">
<DATE DAY="27" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>Minor editing made to text</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-09 12:03:33 +1300" MODIFIED_BY="jane clarke">
<DATE DAY="8" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="18" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>None form of support is provided to the authors of this review</NAME>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>None form of support is provided to the authors of this review</NAME>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-01-27 14:08:48 +1300" MODIFIED_BY="jane clarke">
<SUMMARY MODIFIED="2009-11-09 12:49:28 +1300" MODIFIED_BY="jane clarke">
<TITLE MODIFIED="2009-09-25 21:37:36 +1200" MODIFIED_BY="[Empty name]">Endometrial preparation for egg donor recipients or for frozen embryo transfers</TITLE>
<SUMMARY_BODY MODIFIED="2009-11-09 12:49:28 +1300" MODIFIED_BY="jane clarke">
<P>Couples undergo in vitro fertilisation (IVF) after a long period of subfertility, because women have blocked fallopian tubes or severe endometriosis, where the male partner has a reduced semen count, or when pregnancy has not resulted after previous less invasive fertility treatment. Subsequent to an unsuccessful fresh embryo IVF cycle, a frozen-thawed embryo transfer can be performed when frozen embryos are available. Alternatively for women who have:ovarian insufficiency (premature menopause), poor ovarian capacity to respond to stimulation, or or have had several unsuccessful IVF cycles, oocyte donation is a frequent treatment option, particularly for older women. Adequate hormonal preparation of the endometrium is of outmost importance in both egg donor and frozen embryo replacement cycles to provide the optimal chances of pregnancy. Many drugs and various modes of administration have been tried by several investigators in order to optimise implantation rates and consequently improve the success rates of the embryo transfer procedures. A total of 22 randomised controlled trials were included in this review. There is insufficient evidence from these trials to be able to identify one particular intervention for endometrial preparation that clearly improves the treatment outcome for women receiving embryo transfers with either frozen embryos or embryos derived from donated oocytes. Better quality studies are needed to more accurately evaluate each treatment.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-11-09 12:46:44 +1300" MODIFIED_BY="jane clarke">
<ABS_BACKGROUND MODIFIED="2009-11-09 12:45:54 +1300" MODIFIED_BY="jane clarke">
<P>If a fresh embryo, assisted reproductive technology procedure cycle is unsuccessful and there are frozen embryos available, a frozen-thawed embryo transfer is performed. In some specific cases women may undergo oocyte donation treatment. In both situations the endometrium is primed by the administration of estrogen and progesterone. To prevent the possibility of spontaneous ovulation, gonadotropin-releasing hormone (GnRH) agonists are frequently used.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-07-27 01:42:28 +1200" MODIFIED_BY="[Empty name]">
<P>To evaluate the most effective endometrial preparation for women undergoing transfer with frozen embryos or embryos from donor oocytes with regard to the subsequent live birth rate.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-09-25 21:28:45 +1200" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>), MEDLINE, EMBASE, LILACS, and abstracts of reproductive societies' meetings (from inception). No language restrictions were applied. Experts in the field were contacted.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-07-26 01:48:48 +1200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials evaluating endometrial preparation in women undergoing fresh donor cycles and frozen embryo transfers.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-11-09 12:03:54 +1300" MODIFIED_BY="jane clarke">
<P>Two review authors independently applied the inclusion criteria, assessed trial risk of bias, and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-11-09 12:46:44 +1300" MODIFIED_BY="jane clarke">
<P>Twenty two randomised controlled trials were included. Five studies analysed the use of a GnRH agonist versus control. No significant benefit was demonstrated when using GnRH agonists. No evidence of statistically significant benefit was found for one GnRH agonist over another, or vaginal over intramuscular progesterone administration. No difference in pregnancy rate was demonstrated when no treatment was compared to aspirin, steroids, ovarian stimulation, or human chorionic gonadotropin (hCG) prior to embryo transfer, although using hCG several times before the oocyte retrieval decreases the pregnancy rate. Finally, when oocyte recipients were studied further, starting progesterone on the day of oocyte pick-up (OPU) or the day after OPU produced a significantly higher pregnancy rate (OR 1.87, 95% CI 1.13 to 3.08) than when recipients started progesterone the day prior to OPU.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-07-27 00:26:45 +1200" MODIFIED_BY="[Empty name]">
<P>There is insufficient evidence to recommend any one particular protocol for endometrial preparation over another with regard to pregnancy rates after embryo transfers. These were either frozen embryos or embryos derived from donor oocytes. However, there is evidence of a lower pregnancy rate and a higher cycle cancellation rate when the progesterone supplementation is commenced prior to oocyte retrieval in oocyte donation cycles. Adequately powered studies are needed to evaluate each treatment more accurately.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-01-27 14:08:48 +1300" MODIFIED_BY="jane clarke">
<BACKGROUND MODIFIED="2009-11-09 13:40:34 +1300" MODIFIED_BY="jane clarke">
<CONDITION MODIFIED="2009-11-09 12:50:35 +1300" MODIFIED_BY="jane clarke">
<P>It is estimated that about 15% of couples will fail to achieve conception after 12 months of unprotected intercourse (<LINK REF="REF-te-Velde-2000" TYPE="REFERENCE">te Velde 2000</LINK>). Ultimately, more than half of these infertile couples will undergo an assisted reproductive technology procedure (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Less than 50% of the women under 40 years of age and only 10 to 15% of those over 40 years will get pregnant through a fresh ART cycle (<LINK REF="REF-SART-2003" TYPE="REFERENCE">SART 2003</LINK>). Increasingly couples are trying to achieve conception later in their reproductive life and, given that pregnancy rates decrease as women's ages increase, more and more of these women present with subfertility problems.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-09-25 21:57:38 +1200" MODIFIED_BY="[Empty name]">
<P>When a fresh cycle is unsuccessful and frozen embryos are available, a frozen-thawed embryo transfer may be performed. About 15% to 20% of all ART cycles performed using the woman's own oocytes use frozen embryos (<LINK REF="REF-ESHRE-2006" TYPE="REFERENCE">ESHRE 2006</LINK>; <LINK REF="REF-SART-2003" TYPE="REFERENCE">SART 2003</LINK>).</P>
<P>Oocyte donation is a frequent treatment option that is increasingly used for infertile women given the high percentage of ART patients over 40 years of age in most ART programs. Thirteen per cent of all ART cycles in Latin America (<LINK REF="REF-LA-Register-2003" TYPE="REFERENCE">LA Register 2003</LINK>), about 10% in the United States (<LINK REF="REF-SART-2003" TYPE="REFERENCE">SART 2003</LINK>), and between 10% and 20% in some European countries (<LINK REF="REF-ESHRE-2006" TYPE="REFERENCE">ESHRE 2006</LINK>) are performed using donated oocytes.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-11-09 13:25:51 +1300" MODIFIED_BY="jane clarke">
<P>Although more subfertile women undergo ART procedures every year, implantation failure of a fresh, transferred embryo remains one of the most important limiting factors that prevents conception. Most ART women obtain an acceptable number of oocytes and embryos but only few of these embryos implant after being transferred into the endometrial cavity (<LINK REF="REF-Garcia_x002d_Velasco-2000" TYPE="REFERENCE">Garcia-Velasco 2000</LINK>). Thus the endometrial preparation and profile is one of the main variables to be evaluated in women undergoing an embryo transfer procedure using donated oocytes, and also in frozen-thawed embryo transfers.</P>
<P>In the implantation process an interaction between an embryo and the endometrium exists.This process seems to be affected by two crucial factors (<LINK REF="REF-Devroey-1998" TYPE="REFERENCE">Devroey 1998</LINK>). These are: endometrial receptivity and, synchronization between the embryo developmental stage and endometrial profile during the window of implantation (<LINK REF="REF-Nawroth-2005" TYPE="REFERENCE">Nawroth 2005</LINK>). Endometrial receptivity depends on the hormone replacement protocol used for this purpose. In normal physiology the proliferative phase is characterized by a progressive mitotic growth of the functional endometrium in response to the increasing circulating estrogen levels. The secretory phase commences after ovulation, when progesterone is secreted by the corpus luteum, and is responsible for the histological and molecular changes in the endometrium that occur during the luteal phase. Therefore, in simple terms, progesterone completes the endometrial preparation after adequate estrogenic priming (<LINK REF="REF-Steiner-2006" TYPE="REFERENCE">Steiner 2006</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-11-09 13:40:34 +1300" MODIFIED_BY="jane clarke">
<P>With artificial endometrial preparation for women undergoing embryo transfer with frozen embryos or the transfer of fresh embryos derived from donated oocytes the aim is to stimulate the growth of the endometrium in a similar fashion to the natural cycle, by the sequential administration of estrogen and progesterone. Devroey has reported that hormonal replacement is different in women with functioning ovaries from those women with amenorrhoea; the former group may spontaneously ovulate leading to the decidualization of endometrial cells (<LINK REF="REF-Devroey-1998" TYPE="REFERENCE">Devroey 1998</LINK>). Due to this possibility, drugs that suppress ovarian function (such as GnRH agonists) are frequently used in conjunction with estrogens. Different routes and doses of hormone administration have been used worldwide in order to provide adequate endometrial preparation. However, no clear evidence exists about which is the best endometrial preparation protocol for maximizing the receptivity of the endometrium. This review set out to summarize and compare the evidence about the benefits and disadvantages of the different endometrial preparation methods.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-09-25 22:13:37 +1200" MODIFIED_BY="[Empty name]">
<P>To evaluate the most effective endometrial preparation for women undergoing embryo transfer with frozen embryos, or from using donor oocytes, with regard to the subsequent live birth rate.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-09 13:41:39 +1300" MODIFIED_BY="jane clarke">
<SELECTION_CRITERIA MODIFIED="2009-09-25 22:30:45 +1200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-07-27 01:48:54 +1200" MODIFIED_BY="[Empty name]">
<P>We included only randomised controlled trials (RCTs). We excluded quasi-RCTs and crossover studies unless pre-crossover data were available.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-09-25 22:21:43 +1200" MODIFIED_BY="[Empty name]">
<P>Infertile women undergoing an assisted reproductive technology procedure (ART) utilizing either fresh donor cycles or frozen embryo transfers were considered.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-09-25 22:28:29 +1200" MODIFIED_BY="[Empty name]">
<P>The interventions were compared to placebo, no treatment, or between different interventions.</P>
<P>
<B>Frozen embryo replacement cycles</B>
<BR/>1) GnRH agonists versus:<BR/>
</P>
<UL>
<LI>no treatment;</LI>
<LI>other types of GnRH agonists.</LI>
</UL>
<P>2) Estrogen versus:<BR/>
</P>
<UL>
<LI>estrogen (dosage).</LI>
</UL>
<P>3) Progesterone versus:<BR/>
</P>
<UL>
<LI>progesterone (route of administration).</LI>
</UL>
<P>4) Other miscellaneous drugs:<BR/>
</P>
<UL>
<LI>sildenafil versus no treatment;</LI>
<LI>low-dose aspirin versus no treatment;</LI>
<LI>corticosteroids versus no treatment;</LI>
<LI>antibiotics versus no treatment.</LI>
</UL>
<P>
<B>Donor oocyte embryo replacement cycles</B>
<BR/>The previous interventions and the following.</P>
<P>5) Recipient-donor synchronization<I> </I>(with time of endometrial preparation).</P>
<P>After data collection, the authors considered that outcomes not listed in the protocol should also be included, to meet the objectives of the review. The following outcomes were added to the inclusion criteria: day of starting the progesterone (which is important as some egg donor programs delay the time to starting the progesterone in order to avoid a cycle cancellation in the case of a total failed fertilization); artificial cycle versus cycle with ovarian stimulation (there are some authors claiming that ovarian stimulation makes a more natural environment than artificial stimulation); human chorionic gonadotropin (hCG) before oocyte retrieval versus placebo (some authors think that hCG could help embryo implantation).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-09-25 22:30:45 +1200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-09-25 22:30:12 +1200" MODIFIED_BY="[Empty name]">
<P>Live birth rate (number of births of one or more living infants per number of randomised women) (<LINK REF="REF-Zegers-2006" TYPE="REFERENCE">Zegers 2006</LINK>)</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-09-25 22:30:45 +1200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clinical pregnancy rate (number of pregnancies with at least one sac per number of randomised women)</LI>
</UL>
<UL>
<LI>Miscarriage rate (number of pregnancies ending in the spontaneous loss of the embryo or fetus before 20 weeks of gestation per number of clinical pregnancies)</LI>
</UL>
<UL>
<LI>Multiple pregnancy rate (number of pregnancies with two or more fetuses per number of total clinical pregnancies)</LI>
</UL>
<UL>
<LI>Cycle cancellation rate (number of women with at least one cancelled cycle per number of randomised women)</LI>
</UL>
<UL>
<LI>Endometrial thickness (in millimetres), by ultrasound scan</LI>
</UL>
<UL>
<LI>Other adverse effects such as local adverse effects, hot flushes (at least one adverse effect (excluding miscarriage) per number of randomised women)</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-11-05 09:06:34 +1300" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-11-05 09:06:34 +1300" MODIFIED_BY="[Empty name]">
<P>For searches (to October 2009) see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
<P>We searched the:</P>
<P>(1) Cochrane Menstrual Disorders and Subfertility Group Trials Register;</P>
<P>(2) electronic databases CENTRAL (<I>The Cochrane Library</I>), MEDLINE, LILACS, and EMBASE and PsychoInfo for studies in any language.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-09-25 22:34:53 +1200" MODIFIED_BY="[Empty name]">
<P>(1) We searched the National Institute of Clinical Excellence fertility assessment and treatment guidelines (NICE 2004).</P>
<P>(2) We checked references of identified RCTs and relevant systematic reviews.</P>
<P>(3) We personally contacted manufacturers, experts, and specialists in the field.</P>
<P>(4) We handsearched the conference abstracts of the European Society of Human Reproduction and Embryology, and the American Society for Reproductive Medicine.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-09 13:41:39 +1300" MODIFIED_BY="jane clarke">
<P>Statistical analysis was performed in accordance with the guidelines for statistical analysis developed by The Cochrane Collaboration. We analysed all the available interventions versus placebo, no treatment, or between each other.<I>
<B>
<BR/>
</B>
</I>
</P>
<STUDY_SELECTION MODIFIED="2009-11-09 13:41:39 +1300" MODIFIED_BY="jane clarke">
<P>Two review authors (DG, RP) independently undertook the study selection, both are experts in subfertility. Both review authors screened the titles and abstracts of articles found in the search. They discarded studies that were clearly ineligible but were overly inclusive rather than risking the loss of relevant studies. Both review authors independently assessed whether the studies met the inclusion criteria, with disagreements being resolved by discussion. If there was still no agreement, the disagreement was settled by a third review author (CS). Further information was sought from the authors if papers contained insufficient information to make a decision about eligibility. Risk of bias assessment was done using a pro forma.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-11-09 11:57:41 +1300" MODIFIED_BY="jane clarke">
<P>Both review authors independently extracted information from the results sections of the included studies using the pro forma's designed by the Review Group. Discrepancies were resolved by discussion. If there was still no agreement, the discrepancy was settled by a third review author. For each included trial, information was collected regarding the location of the study, methods of the study (as per the quality assessment checklist), the participants (age range, eligibility criteria), the nature of the interventions, and data relating to the outcomes specified above. If crossover trials were found, only first stage data were included.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-09-25 22:41:05 +1200" MODIFIED_BY="[Empty name]">
<P>DG and RP independently assessed the quality of all studies that were deemed eligible for the review, with discrepancies being resolved by discussion. If there was still no agreement the discrepancy was settled by a third review author (AC). The quality of allocation concealment was graded as Yes (adequate), Unclear, or No (inadequate) following the detailed descriptions of these categories provided by the Menstrual Disorders and Subfertility Review Group (see Review Group details for more information). The categories are briefly described in Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-07-09 14:55:57 +1200" MODIFIED_BY="jane clarke">
<P>For dichotomous data, results for each study were expressed as odds ratio (OR) with 95% confidence intervals (CI) and combined for meta-analysis with RevMan software.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-09-25 22:43:27 +1200" MODIFIED_BY="[Empty name]">
<P>The women were randomised.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-09-25 22:43:37 +1200" MODIFIED_BY="[Empty name]">
<P>Wherever possible, we attempted to collect missing data from the authors.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-09-25 22:45:23 +1200" MODIFIED_BY="[Empty name]">
<P>Variations between the results of different studies were examined by inspecting the scatter in the data points on the graphs and the overlap in CIs and, more formally, by checking the results of the I<SUP>2 </SUP>statistic. When possible, and if no heterogeneity was present, the outcomes were pooled.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-08-05 09:16:22 +1200" MODIFIED_BY="[Empty name]">
<P>The assessment of reporting biases are described in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-11-05 16:11:33 +1300" MODIFIED_BY="[Empty name]">
<P>Data synthesis and analyses were done using the Cochrane Review Manager software (RevMan 5). Dichotomous outcomes were reported as odds ratios (OR) and continuous outcomes as mean differences (MD), both with 95% CIs. The mean change was used in continuous outcomes, where possible, otherwise mean results at final follow up were used. Studies reporting change differences and end of treatment differences were entered into the same analyses. Interventions were compared on the basis of drug class. Where studies randomised recipients across arms involving comparisons of members of the same drug class, the data for arms comparing the same drug class were combined.</P>
<P>Heterogeneity in treatment effects across studies was assessed using inspection of forest plots, the Cochran Q test and I² quantity (where P &lt; 0.10 and &gt; 60%, respectively, were considered evidence of substantial heterogeneity). Where the authors considered it was reasonable to pool studies, the fixed effect model was used to combine study results where estimates of heterogeneity were minimal and the random-effects method of DerSimonian and Laird (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) where heterogeneity was moderate (I square &gt;40%). Where substantial heterogeneity was evident, summary estimates were not calculated but the estimates of effect were investigated further using subgroup and sensitivity analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-09-25 22:57:52 +1200" MODIFIED_BY="[Empty name]">
<P>As no heterogeneity was found between women undergoing frozen embryo transfer and women receiving fresh donor oocytes we decided not to do the subgroup analysis that had been previously planned. Heterogeneity was expected because of the following variables: amenorrhoea versus non-amenorrhoea, endometrial thickness, women's age (only for frozen-thawed embryo transfer because in cases of oocyte donation oocytes usually come from young women), embryo quality, embryo transfer quality (if reported as a difficult transfer or if an ultrasound guide was required), and obesity. As most studies were inadequately described, a subgroup analysis was only performed for studies where amenorrhoea was clearly stated.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-11-09 12:17:09 +1300" MODIFIED_BY="jane clarke">
<P>A sensitivity analysis was performed using fixed-effect and random-effects models to confirm or discard the consistency of results. No important differences were found. For continuous data, results from each study were expressed as a mean difference (MD) with 95% CI and combined for meta-analysis. Meta-analytic methods for continuous data assume that the underlying distribution of the measurements is normal. If data were clearly skewed and results were reported in the publication as median and range, with non-parametric tests of significance, the results would also have been reported in the 'Other data' section of the review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-01-27 14:08:24 +1300" MODIFIED_BY="jane clarke">
<STUDY_DESCRIPTION MODIFIED="2010-01-27 14:06:37 +1300" MODIFIED_BY="jane clarke">
<P>
<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2009-11-05 11:12:41 +1300" MODIFIED_BY="[Empty name]">
<P>After screening the trials identified using the search strategy, 39 randomised controlled trials were initially included. After a more in-depth analysis of these, 22 (3451 women) were included and 17 were excluded (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>
<B>Participants</B>
<BR/>Eleven of the 22 studies were performed in women undergoing fresh donor oocyte embryo replacement cycles (<LINK REF="STD-Caligara-2003" TYPE="STUDY">Caligara 2003</LINK>; <LINK REF="STD-Escriba-2006" TYPE="STUDY">Escriba 2006</LINK>; <LINK REF="STD-Gibbons-1998" TYPE="STUDY">Gibbons 1998</LINK>; <LINK REF="STD-Gutierrez-1999" TYPE="STUDY">Gutierrez 1999</LINK>; <LINK REF="STD-Neuspiller-1998" TYPE="STUDY">Neuspiller 1998</LINK>; <LINK REF="STD-Prapas-2009a" TYPE="STUDY">Prapas 2009a</LINK>; <LINK REF="STD-Remohi-1994" TYPE="STUDY">Remohi 1994</LINK>; <LINK REF="STD-Tesarik-2003" TYPE="STUDY">Tesarik 2003</LINK>; <LINK REF="STD-Tocino-2007" TYPE="STUDY">Tocino 2007</LINK>; <LINK REF="STD-Weckstein-1997" TYPE="STUDY">Weckstein 1997</LINK>; <LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>) and the remaining 11 studies involved frozen embryo replacement cycles (<LINK REF="STD-Bider-1996" TYPE="STUDY">Bider 1996</LINK>; <LINK REF="STD-Dal-Prato-2002" TYPE="STUDY">Dal Prato 2002</LINK>; <LINK REF="STD-Davar-2007" TYPE="STUDY">Davar 2007</LINK>; <LINK REF="STD-Ding-2007" TYPE="STUDY">Ding 2007</LINK>; <LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>; <LINK REF="STD-Lan-2008" TYPE="STUDY">Lan 2008</LINK>; <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>; <LINK REF="STD-Lightman-1999" TYPE="STUDY">Lightman 1999</LINK>; <LINK REF="STD-Moffitt-1995" TYPE="STUDY">Moffitt 1995</LINK>; <LINK REF="STD-Moon-2004" TYPE="STUDY">Moon 2004</LINK>; <LINK REF="STD-Ramos-2007" TYPE="STUDY">Ramos 2007</LINK>; <LINK REF="STD-Wright-2006" TYPE="STUDY">Wright 2006</LINK>).<BR/>Most treatment regimens varied from one study to the other. The publication dates of included studies were from 1994 to 2009.<BR/>
</P>
<P>
<B>Interventions</B>
<BR/>A variety of different protocols for endometrial preparation were used. The types of GnRH agonist used were daily leuprolide acetate (<LINK REF="STD-Gutierrez-1999" TYPE="STUDY">Gutierrez 1999</LINK>; <LINK REF="STD-Neuspiller-1998" TYPE="STUDY">Neuspiller 1998</LINK>; <LINK REF="STD-Remohi-1994" TYPE="STUDY">Remohi 1994</LINK>), nasal buserelin (<LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>), subcutaneous buserelin (<LINK REF="STD-Davar-2007" TYPE="STUDY">Davar 2007</LINK>), daily nafarelin (<LINK REF="STD-Gutierrez-1999" TYPE="STUDY">Gutierrez 1999</LINK>), depot leuprolide acetate (<LINK REF="STD-Neuspiller-1998" TYPE="STUDY">Neuspiller 1998</LINK>: <LINK REF="STD-Tocino-2007" TYPE="STUDY">Tocino 2007</LINK>), and daily triptorelin (<LINK REF="STD-Tocino-2007" TYPE="STUDY">Tocino 2007</LINK>) and depot triptorelin (<LINK REF="STD-Dal-Prato-2002" TYPE="STUDY">Dal Prato 2002</LINK>; <LINK REF="STD-Neuspiller-1998" TYPE="STUDY">Neuspiller 1998</LINK>; <LINK REF="STD-Ramos-2007" TYPE="STUDY">Ramos 2007</LINK>). Different<I> </I>types of progesterone were used: intramuscular (<LINK REF="STD-Caligara-2003" TYPE="STUDY">Caligara 2003</LINK>; <LINK REF="STD-Gibbons-1998" TYPE="STUDY">Gibbons 1998</LINK>; <LINK REF="STD-Lightman-1999" TYPE="STUDY">Lightman 1999</LINK>; <LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>), vaginal gel (<LINK REF="STD-Gibbons-1998" TYPE="STUDY">Gibbons 1998</LINK>; <LINK REF="STD-Lan-2008" TYPE="STUDY">Lan 2008</LINK>), vaginal ring (<LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>), and vaginal suppositories (<LINK REF="STD-Caligara-2003" TYPE="STUDY">Caligara 2003</LINK>; <LINK REF="STD-Lan-2008" TYPE="STUDY">Lan 2008</LINK>; <LINK REF="STD-Lightman-1999" TYPE="STUDY">Lightman 1999</LINK>). Glucocorticoids used also varied from one study to other: dexamethasone (<LINK REF="STD-Bider-1996" TYPE="STUDY">Bider 1996</LINK>) and 6-alfa-methylprednisolone (<LINK REF="STD-Moffitt-1995" TYPE="STUDY">Moffitt 1995</LINK>).<BR/>During the data collection we found three studies where the comparisons (starting day of progesterone, artificial endometrium stimulation versus ovarian stimulated, and use of hCG before oocyte retrieval) had not been included in our protocol; however, we decided to include them in the review because of the importance of the results (<LINK REF="STD-Ding-2007" TYPE="STUDY">Ding 2007</LINK>; <LINK REF="STD-Escriba-2006" TYPE="STUDY">Escriba 2006</LINK>).</P>
<P>
<B>Outcomes</B>
<BR/>The primary outcome was live birth rate but only four studies (<LINK REF="STD-Bider-1996" TYPE="STUDY">Bider 1996</LINK>; <LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>; <LINK REF="STD-Weckstein-1997" TYPE="STUDY">Weckstein 1997</LINK>; <LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>) evaluated this outcome. Other secondary outcomes were clinical pregnancy rate (which is a proxy of the primary outcome), multiple pregnancy rate, cycle cancellation rate, miscarriage rate, and endometrial thickness (before the embryo transfer). Finally, eight different comparison types were performed. Hheterogeneity was evaluated for each intervention. In those cases where we found heterogeneity, pre-specified sensitivity and subgroup analyses were performed. We also evaluated ad hoc subgroups. We added 'Summary of findings' tables for the clinically relevant outcomes (live birth rate, clinical pregnancy rate) with statistically significant differences.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-01-27 14:06:29 +1300" MODIFIED_BY="jane clarke">
<P>The included studies are described in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table. One trial (<LINK REF="STD-Tesarik-2003" TYPE="STUDY">Tesarik 2003</LINK>) was divided into two sub studies for analysing pre-specified variables that contributed to heterogeneity .</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-01-27 14:06:37 +1300" MODIFIED_BY="jane clarke">
<P>Of the 17 excluded studies, two were not randomised controlled trials (<LINK REF="STD-Check-1998" TYPE="STUDY">Check 1998</LINK>; <LINK REF="STD-Nardo-2006" TYPE="STUDY">Nardo 2006</LINK>), one used an inadequate method of randomisation (<LINK REF="STD-Sathanandan-1991" TYPE="STUDY">Sathanandan 1991</LINK>), one evaluated an outcome that was not primary for this review (<LINK REF="STD-Krasnow-1996" TYPE="STUDY">Krasnow 1996</LINK>), two had duplicated data from other publications (<LINK REF="STD-Lan-2007" TYPE="STUDY">Lan 2007</LINK>; <LINK REF="STD-Toner-2000" TYPE="STUDY">Toner 2000</LINK>), two did not shown how many patients were in each group (<LINK REF="STD-Page-2005" TYPE="STUDY">Page 2005</LINK>; <LINK REF="STD-Shiotani-2006" TYPE="STUDY">Shiotani 2006</LINK>), three did not appear to use one of our specified treatments for endometrial preparation (<LINK REF="STD-Bernabeu-2006" TYPE="STUDY">Bernabeu 2006</LINK>; <LINK REF="STD-Moon-2004" TYPE="STUDY">Moon 2004</LINK>; <LINK REF="STD-Prapas-2009b" TYPE="STUDY">Prapas 2009b</LINK>), one used doses for vaginal progesterone that were below the standard doses (<LINK REF="STD-Feliciani-2004" TYPE="STUDY">Feliciani 2004</LINK>), one had less than ten patients per treatment group (<LINK REF="STD-Check-2002" TYPE="STUDY">Check 2002</LINK>), two had an outcome that was histological in nature (<LINK REF="STD-Lewin-2001" TYPE="STUDY">Lewin 2001</LINK>; <LINK REF="STD-Taskin-2002" TYPE="STUDY">Taskin 2002</LINK>) and two used comparisons that were not equal (both treatment groups had more than one variable in their treatment regimen) (<LINK REF="STD-Check-2004" TYPE="STUDY">Check 2004</LINK>; <LINK REF="STD-Simon-1998" TYPE="STUDY">Simon 1998</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-11-09 11:58:22 +1300" MODIFIED_BY="jane clarke">
<P>Details on the quality of each individual study are described in the table '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>', where the individual quality criteria were rated for each study.</P>
<P>Although most authors gave a description of the randomisation method, only some of them described the allocation method. As a placebo was not used in most of the trials, there was no blinding of patients; blinding of healthcare workers was not described. Live birth rate was reported in a minority of cases; the rest of the authors used pregnancy rate, which was the most frequently reported final outcome. Even when comparability at baseline was not measured it was generally evaluated. There were very few trials with a relevant loss to follow up. There was heterogeneity in intention-to-treat analysis and it was not done by all the authors. Finally, outcome assessment was not generally described in terms of blinding of the evaluator. Both a 'Risk of bias' table (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) and a 'Risk of bias' graph (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) are presented.<BR/>
</P>
<ALLOCATION MODIFIED="2009-11-04 13:22:49 +1300" MODIFIED_BY="[Empty name]">
<P>In eight studies the method of concealing allocation was adequate (<LINK REF="STD-Bider-1996" TYPE="STUDY">Bider 1996</LINK>; <LINK REF="STD-Dal-Prato-2002" TYPE="STUDY">Dal Prato 2002</LINK>; <LINK REF="STD-Davar-2007" TYPE="STUDY">Davar 2007</LINK>; <LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>; <LINK REF="STD-Escriba-2006" TYPE="STUDY">Escriba 2006</LINK>; <LINK REF="STD-Lan-2008" TYPE="STUDY">Lan 2008</LINK>; <LINK REF="STD-Moffitt-1995" TYPE="STUDY">Moffitt 1995</LINK>; <LINK REF="STD-Prapas-2009a" TYPE="STUDY">Prapas 2009a</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-11-04 15:04:19 +1300" MODIFIED_BY="[Empty name]">
<P>Quality limitations were mainly in blinding, given that only one study stated that participants were blinding to treatment (<LINK REF="STD-Moffitt-1995" TYPE="STUDY">Moffitt 1995</LINK>). Because the assessed outcomes were very objective, lack of blinding of the outcome assessors did not introduce as high a risk of bias as if the outcomes had been subjective.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-11-09 11:57:56 +1300" MODIFIED_BY="jane clarke">
<P>Only four studies did a long enough follow up of the participants for the live birth rate to be evaluated (<LINK REF="STD-Bider-1996" TYPE="STUDY">Bider 1996</LINK>; <LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>; <LINK REF="STD-Weckstein-1997" TYPE="STUDY">Weckstein 1997</LINK>; <LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>).</P>
<P>The sample size of the analysed studies and sub studies varied from a minimum of 16 to a maximum of 354 women.</P>
<P>We contacted the authors for more information, as required.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-09-25 23:24:06 +1200" MODIFIED_BY="[Empty name]">
<P>Only four studies (<LINK REF="STD-Bider-1996" TYPE="STUDY">Bider 1996</LINK>; <LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>; <LINK REF="STD-Weckstein-1997" TYPE="STUDY">Weckstein 1997</LINK>; <LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>) reported the live birth rate, our primary outcome. This could represent a potential selective reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-11-09 11:58:22 +1300" MODIFIED_BY="jane clarke">
<P>All studies except seven (<LINK REF="STD-Caligara-2003" TYPE="STUDY">Caligara 2003</LINK>; <LINK REF="STD-Gibbons-1998" TYPE="STUDY">Gibbons 1998</LINK>; <LINK REF="STD-Gutierrez-1999" TYPE="STUDY">Gutierrez 1999</LINK>; <LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>; <LINK REF="STD-Ramos-2007" TYPE="STUDY">Ramos 2007</LINK>; <LINK REF="STD-Tocino-2007" TYPE="STUDY">Tocino 2007</LINK>; <LINK REF="STD-Weckstein-1997" TYPE="STUDY">Weckstein 1997</LINK>) reported baseline equality between groups with respect to age at stimulation, diagnosis of infertility, number of transferred embryos and number of previous pregnancies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-01-27 14:08:24 +1300" MODIFIED_BY="jane clarke">
<P>
<B>01) GnRH agonist versus no treatment</B>
<BR/>In five studies, a total of 778 women were included for an analysis of GnRH agonist versus control. Type of agonist and administration route were similar in two studies. In the other three studies other GnRH agonists were used.</P>
<P>
<I>01-Live birth rate (</I>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)<BR/>Live birth rate was described by only one trial (<LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>) in which nasal buserelin was compared with no treatment in 334 women undergoing a frozen-thaw embryo transfer. A statistically significant benefit was found with the nasal buserelin (OR 2.62, 95% CI 1.19 to 5.78).</P>
<P>
<I>02-Clinical pregnancy rate </I>(<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>)<BR/>Clinical pregnancy rate was determined by five trials. Four trials (<LINK REF="STD-Dal-Prato-2002" TYPE="STUDY">Dal Prato 2002</LINK>; <LINK REF="STD-Davar-2007" TYPE="STUDY">Davar 2007</LINK>; <LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>; <LINK REF="STD-Ramos-2007" TYPE="STUDY">Ramos 2007</LINK>) evaluated the efficacy of nasal and subcutaneous buserelin and intramuscular depot triptorelin for women undergoing a frozen-thaw embryo transfer. A fifth study (<LINK REF="STD-Remohi-1994" TYPE="STUDY">Remohi 1994</LINK>) tested daily leuprolide acetate in oocyte donor recipients. The comparator was no treatment in all five studies.<BR/>One study (<LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>) showed that the nasal buserelin group had a higher clinical pregnancy rate than the control group. On the other hand, there was no evidence of a statistically significant difference between women receiving GnRH agonists and those who did not in the other four studies. There was no evidence of differences between clinical pregnancy rates (OR 1.19, 95% CI 0.73 to 1.94; I<SUP>2</SUP> = 39%) with the use of GnRH agonists and no such treatment (see Additional <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>
<I>03- Cancelled cycles rate </I>(<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>)<BR/>Two of the three studies (<LINK REF="STD-Dal-Prato-2002" TYPE="STUDY">Dal Prato 2002</LINK>; <LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>) described the cancellation rates in a total of 530 women being prepared to undergo a frozen-thaw embryo transfer. There was no evidence of a statistically significant difference between the group that received GnRH agonists and the group that did not (OR 0.49, 95% CI 0.21 to 1.17; I<SUP>2</SUP> = 0%).<BR/>
<BR/>
<I>04- Endometrial thickness </I>(<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>)</P>
<P>In 530 women involved in two studies (<LINK REF="STD-Dal-Prato-2002" TYPE="STUDY">Dal Prato 2002</LINK>; <LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>) there was no evidence of any difference in terms of endometrial thickness (MD 0, 95% CI -0.28 to 0.28; I<SUP>2</SUP> = 3.4%).</P>
<P>
<I>05-Pregnancy loss rate </I>(<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>)<BR/>Only one study (<LINK REF="STD-Dal-Prato-2002" TYPE="STUDY">Dal Prato 2002</LINK>) evaluated the miscarriage rate and there was no evidence of a statistically significant difference (OR 0.77, 95% CI 0.20 to 2.94).<BR/>
</P>
<P>
<B>02) One GnRH agonist versus other types of GnRH agonists</B>
<BR/>Three studies evaluated the use of different types of GnRH agonists in fresh donor oocyte recipient cycles. One of them (<LINK REF="STD-Neuspiller-1998" TYPE="STUDY">Neuspiller 1998</LINK>) made comparisons between three intervention groups: intramuscular depot leuprolide acetate; intramuscular depot triptorelin; and daily subcutaneous leuprolide acetate. Another study (<LINK REF="STD-Gutierrez-1999" TYPE="STUDY">Gutierrez 1999</LINK>) reported results from a comparison between leuprolide acetate and nafarelin, both administered daily. And a third one, compared daily leuprolide acetate versus depot triptorelin (<LINK REF="STD-Tocino-2007" TYPE="STUDY">Tocino 2007</LINK>). A total of 301 women were analysed.</P>
<P>
<I>01-Pregnancy rate </I>(<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)<BR/>There was no evidence of a difference between using daily nafarelin or daily leuprolide acetate (OR 1.26, 95% CI 0.49 to 3.27); nor between depot triptorelin and depot leuprolide acetate (OR 1.46, 95% CI 0.71 to 3.00) and nor between depot triptorelin and daily leuprolide acetate (OR 1.93, 95% CI 0.62 to 5.98). A trend toward a higher pregnancy rate was found for recipients receiving leuprolide acetate in its depot form compared with daily administration of the agonist (OR 1.93, 95% CI 0.94 to 3.96).</P>
<P>
<I>02-Pregnancy loss rate </I>(<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>)<BR/>There was no evidence of a difference for any of the comparisons.<BR/>
<U>
<BR/>
</U>
<I>03-Cancellation rate </I>(<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>)<BR/>There was no evidence of a difference in any of the comparisons.</P>
<P>
<B>03) Intramuscular progesterone versus vaginal progesterone</B>
<BR/>Four RCTs (655 participants) compared vaginal progesterone with intramuscular progesterone administration; two of them made the same comparison while the other two trials used a different type of vaginal delivery formula. Gel, vaginal suppositories and vaginal rings were used in donor oocyte recipient settings (<LINK REF="STD-Caligara-2003" TYPE="STUDY">Caligara 2003</LINK>; <LINK REF="STD-Gibbons-1998" TYPE="STUDY">Gibbons 1998</LINK>; <LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>) and vaginal suppositories were used for transfer of frozen-thawed embryos (<LINK REF="STD-Lightman-1999" TYPE="STUDY">Lightman 1999</LINK>).</P>
<P>
<I>01-Live birth rate </I>(<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>)<BR/>Only one study (<LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>) reported live birth rate when comparing vaginal (delivered by a vaginal ring) versus intramuscular progesterone. There was no evidence of a statistically significant difference between the two routes of administration (OR 1.77, 95% CI 0.85 to 3.68). This trial was performed on donor oocyte recipients.</P>
<P>
<I>02-Clinical pregnancy rate </I>(<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>)<BR/>There was a trend in favour of using vaginal progesterone when clinical pregnancy rate was analysed (OR 1.44, 95% CI 0.98 to 2.10). No statistical heterogeneity was evident despite the use of three different forms of vaginally delivered progesterone (P = 0.53, I<SUP>2</SUP> = 0%).</P>
<P>
<I>03-Multiple pregnancy rate </I>(<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>)<BR/>Only one study described the multiple pregnancy rate and there was no evidence of any difference between vaginal and intramuscular progesterone for this outcome (OR 0.97, 95% CI 0.51 to 1.85).</P>
<P>
<I>04- Pregnancy loss rate </I>(<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>)<BR/>There were similar chances of miscarriage with the different interventions (OR 0.60, 95% CI 0.26 to 1.39). No heterogeneity was found (I<SUP>2</SUP> = 0%).<BR/>
</P>
<P>
<B>04) Day of starting progesterone</B>
<BR/>Two trials evaluated the outcomes for 331 women in order to identify the optimal day for starting progesterone in an oocyte donor program. One of them evaluated cycles that were transferred on day three after the oocyte retrieval (<LINK REF="STD-Escriba-2006" TYPE="STUDY">Escriba 2006</LINK>). Three interventions were compared: i) starting progesterone the day before oocyte pick up (OPU); ii) starting progesterone the day of OPU; and iii) starting progesterone the day after OPU. All recipients used vaginal suppositories of progesterone and had the embryo transfer on day three. The second trial evaluated women whose embryo transfer was performed in blastocyst stage (<LINK REF="STD-Ding-2007" TYPE="STUDY">Ding 2007</LINK>). In this study, they evaluated starting the progesterone six or seven days before the embryo transfer.<BR/>
<BR/>
<I>01-Clinical pregnancy rate </I>(<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>)<BR/>Starting progesterone on the day of OPU (OR 1.92, 95% CI 1.08 to 3.42) or on the day after (OR 1.81, 95% CI 1.01 to 3.24) led to higher pregnancy rates than when progesterone was started the day before OPU. When analysed together (Outcome 4.6: ad hoc), starting progesterone either on the OPU day or the day after showed better results than starting the day before (OR 1.87, 95% CI 1.13 to 3.08; I<SUP>2</SUP> = 0%) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). No differences were found between starting progesterone the day of OPU or the day after (OR 0.94, 95% CI 0.53 to 1.68) (<LINK REF="STD-Escriba-2006" TYPE="STUDY">Escriba 2006</LINK>). No differences were found (OR 0.75, 95% CI 0.24 to 2.34) between starting one or two days before the oocyte retrieval when the transfer is performed on blastocyst stage (<LINK REF="STD-Ding-2007" TYPE="STUDY">Ding 2007</LINK>).</P>
<P>
<I>02-Multiple pregnancy rate </I>(<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>)<BR/>There was no evidence of differences between the three intervention groups.</P>
<P>
<I>03-Pregnancy loss rate </I>(<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>)<BR/>There was no evidence of differences between the three intervention groups.</P>
<P>
<I>04-Cycle cancellation rate </I>(<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>)<BR/>Starting progesterone on the day after OPU reduced the cancellation rate when compared to starting the day before OPU (OR 0.24, 95% CI 0.07 to 0.89). A similar trend occurred in favour of starting progesterone the day of OPU compared with the day before (OR 0.31, 95% CI 0.10 to 1.01). When analysed together (day of OPU and day after OPU), starting progesterone before OPU was associated with a higher cancellation rate (OR 0.28, 95% CI 0.11 to 0.74) (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>There was no evidence of a difference in outcome for the day after OPU and the day of OPU (OR 0.77, 95% CI 0.17 to 3.53). Nor was there evidence of a difference in cancellation rate due to failed fertilization (Outcome 4.5: ad hoc), the most significant reason why starting the day after OPU may be of benefit, when starting the day of OPU (once fertilization had been checked) or the day after OPU (OR 0.10, 95% CI 0.01 to 1.82) (<LINK REF="STD-Escriba-2006" TYPE="STUDY">Escriba 2006</LINK>).</P>
<P>
<B>05) Low-dose aspirin versus no treatment</B>
<BR/>Only one study (<LINK REF="STD-Weckstein-1997" TYPE="STUDY">Weckstein 1997</LINK>) involving 28 donor oocyte recipients assessed any differences in the cycle outcome with administration of aspirin (81 mg) begun one week prior to starting estrogen therapy.</P>
<P>
<I>01-Live birth rate </I>(<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>)<BR/>There was no evidence of a difference with and without aspirin (OR 1.97, 95% CI 0.42 to 9.32).</P>
<P>
<I>02-Clinical pregnancy rate </I>(<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>)<BR/>There was no evidence of a difference with and without aspirin (OR 3.38, 95% CI 0.70 to 16.17).</P>
<P>
<I>03-Multiple pregnancy rate </I>(<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>)<BR/>There was no evidence of a difference with and without aspirin.</P>
<P>
<I>04-Endometrial thickness </I>(<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>)<BR/>There was no evidence of a statistically significant difference in the endometrium thickness between the two groups (MD 0.60, 95% CI -0.04 to 1.24).<BR/>
</P>
<P>
<B>06) Corticosteroids versus no treatment</B>
<BR/>Two studies (<LINK REF="STD-Bider-1996" TYPE="STUDY">Bider 1996</LINK>; <LINK REF="STD-Moffitt-1995" TYPE="STUDY">Moffitt 1995</LINK>) involving a total of 160 women who underwent a frozen-thaw embryo transfer evaluated the impact of taking steroids for one or two days prior to embryo transfer on reproductive outcomes. One trial used dexamethasone 0.5 mg orally for five days and the other used methylprednisolone 4 mg orally for four days.</P>
<P>
<I>01-Live birth rate </I>(<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>)<BR/>Live birth rate was described by one trial (<LINK REF="STD-Bider-1996" TYPE="STUDY">Bider 1996</LINK>). There was no evidence of a difference in outcome between using and not using steroids (OR 0.66, 95% CI 0.14 to 3.11).<BR/>
<BR/>
<I>02-Clinical pregnancy rate </I>(<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>)<BR/>There was no evidence of a difference between using and not using steroids (OR 0.90, 95% CI 0.40 to 2.03; I<SUP>2</SUP> = 0%).</P>
<P>
<I>03-Pregnancy loss rate </I>(<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>)<BR/>There was no evidence of a difference between using and not using steroids (OR 1.49, 95% CI 0.32 to 7.03; I<SUP>2</SUP> = 0%).</P>
<P>
<I>04-Multiple pregnancy rate </I>(<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>)<BR/>There were no multiple pregnancies in either of the studies.<BR/>
<B>
<BR/>07) Artificial cycle (priming with oestrogens) versus non-artificial cycle</B>
<BR/>Only one study (<LINK REF="STD-Wright-2006" TYPE="STUDY">Wright 2006</LINK>) compared the outcomes for women having a cycle in which the ovaries were stimulated with recombinant follicle stimulating hormone (FSH) and artificial cycles where the endometrium was stimulated with estrogen (17-beta estradiol). A total of 100 women undergoing frozen-thaw embryo transfer were stimulated with recombinant FSH injections (150 IU) on days six, eight, and ten of the menstrual cycle and then continued until the endometrium was thicker than 7 mm or follicles were bigger than 16 to 20 mm. The 99 women in the control group, with an artificial cycle, received 17-beta estradiol (4 mg) daily until the thickness of the endometrium was greater than 7 mm. Another study (<LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>) compared 39 women with a natural cycle who received an hCG injection for triggering the ovulation versus 45 women who received oral micronized estradiol.</P>
<P>
<I>01-Clinical pregnancy rate </I>(<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>)<BR/>There was no evidence of a difference between women who had ovarian stimulation with FSH and those who had an artificial cycle with estrogen (OR 1.12, 95% CI 0.47 to 2.66). However, we found statistically significant differences when comparing the artificial cycle versus a natural cycle either (OR 0.23, 95% CI 0.09 to 0.58).</P>
<P>
<I>02-Endometrial thickness </I>(<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>)<BR/>There was no evidence of any difference in terms of endometrial thickness (MD 0, 95% CI -0.29 to 0.29).</P>
<P>
<B>08) HCG before oocyte retrieval versus placebo</B>
<BR/>One study involving 266 ovulating women and 260 non-ovulating donor oocyte recipients was assessed to determine if there was a benefit to be derived from the administration of hCG (5000 IU) by intramuscular injection two days prior to oocyte recovery (<LINK REF="STD-Tesarik-2003" TYPE="STUDY">Tesarik 2003</LINK>). All the women had been stimulated with increasing doses of oral estradiol valerate. Another study analysed the use of 750 IU of hCG was injected every three days starting on day 2 of recipients&#8217; endometrial preparation up to the day of hCG injection to the donor versus not using hCG (<LINK REF="STD-Prapas-2009a" TYPE="STUDY">Prapas 2009a</LINK>).</P>
<P>
<I>01-Clinical pregnancy rate </I>(<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>)<BR/>There was no evidence of a difference between women who received one dose of hCG prior to oocyte recovery and those who did not (OR 1.08, 95% CI 0.73 to 1.60). However, we found statistically significant differences when repeated doses of hCG were used (OR 0.06, 95% CI 0.01 to 0.50).</P>
<P>
<I>02-Endometrial thickness </I>(<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>)<BR/>In ovulatory women, the hCG group had a thicker endometrium on day 19 than the women who had not received hCG (MD 1.50, 95% CI 1.30 to 1.70). In amenorrhoeic women, a slightly thinner endometrium was seen in the hCG group (MD -0.20, 95% CI -0.38 to -0.02).<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-01-27 14:08:48 +1300" MODIFIED_BY="jane clarke">
<P>Hormonal preparation of the endometrium is of utmost importance in oocyte donation cycles as well as for infertile women undergoing frozen embryo transfer procedures. There are multiple drugs and modes of administration that have been tried by investigators in order to optimise implantation rates and the success rates of the embryo transfer procedures. Although frozen embryo replacement and oocyte donation cycles have been used clinically for several years (<LINK REF="REF-Leeton-1986" TYPE="REFERENCE">Leeton 1986</LINK>; <LINK REF="REF-Mohr-1985" TYPE="REFERENCE">Mohr 1985</LINK>) there is no agreement about the optimal way to prepare the endometrium prior to and immediately following embryo transfer. Multiple drugs have been used, which meant that our review involved the assessment of eight different interventions. Of significance is the fact that none of the interventions included in our review were evaluated by two or more studies using similar populations. This limits the strength of our conclusions and generates a degree of heterogeneity in our results. Nevertheless, a meta-analysis was performed using a random-effects model in order to be conservative in our findings. When the heterogeneity was statistically and clinically significant we did not report summary statistics.<BR/>The quality of the included studies also limited our conclusions but, as the assessed outcomes were objective, blinding did not imply a risk of bias as high as if the outcomes had been subjective. The present review shows that endometrial preparation for frozen embryo transfers and fresh embryo transfers in oocyte donation cycles have been evaluated in many different ways. We investigated the need to use GnRH agonists for ovarian suppression, different types of endometrial estrogenic stimulation, different types and timing of initiating progesterone, and other peripheral interventions such as the use of low-dose aspirin, steroids, or hCG prior to embryo transfer procedures. More than one intervention may impact on clinical results and so we included randomised controlled trials where only one intervention was evaluated.</P>
<P>GnRH agonists, typically in a depot form or given on a daily basis, are administered with the purpose of suppressing ovarian function and avoiding interference with exogenous estrogenic stimulation and proliferation of the endometrium. When we analysed the results using GnRH agonists, only one study (<LINK REF="STD-El_x002d_Toukhy-2004" TYPE="STUDY">El-Toukhy 2004</LINK>) evaluated the live birth rate. This study reported better results in the nasal buserelin group than with no GnRH agonist (OR 2.62, 95% CI 1.19 to 5.78). However, when an intermediate outcome such as clinical pregnancy rate was analysed in four other studies, they did not show any difference between treatment and control groups. As expected, a non-statistically significant trend in favour of using GnRH agonists was found for cancellation rates, although the trials were underpowered for that outcome.</P>
<P>Three other studies compared different types of GnRH agonists but neither demonstrated statistically significant differences. When depot leuprolide was compared to daily leuprolide administration (<LINK REF="STD-Neuspiller-1998" TYPE="STUDY">Neuspiller 1998</LINK>) on pregnancy rates, a trend in favour of depot leuprolide suggested a potential benefit on this parameter (OR 1.93, 95% CI 0.94 to 3.96) that is clinically relevant. Although this trend could in theory have been explained by a more frequent cancellation rate among those women who used daily leuprolide, no differences were found in this parameter. On the other hand, we found no biological rationale to think that depot GnRH agonists are better than daily GnRH agonists. If depot GnRH agonists were better than daily GnRH agonists due to issues other than the recognized ovarian suppression, it would potentially have also been observed in regular ART cycles, but the Cochrane review comparing these two different types of GnRH agonists did not show any differences (<LINK REF="REF-Albuquerque-2005" TYPE="REFERENCE">Albuquerque 2005</LINK>). Endometrial development should be analysed in future studies in order to determine if depot and daily formulations can impact in a different way on endometrial implantation.</P>
<P>During the menstrual cycle, progesterone is produced by the luteinized granulosa cells in the post-ovulatory phase. In artificial cycles, such as those with ART, progesterone should be administered exogenously in order to mimic the type of secretory, receptive endometrium leading to embryo implantation. As the oral route is subject to hepatic first-pass metabolism, vaginal and intramuscular administration are the most common ways to give progesterone. Four different studies compared vaginal progesterone versus intramuscular (IM) progesterone but only one evaluated live birth rate, finding a lack of statistically significant difference between vaginal ring and IM progesterone (<LINK REF="STD-Zegers-2000" TYPE="STUDY">Zegers 2000</LINK>). When we analysed clinical pregnancy rate, a trend in favour of vaginal progesterone was found (OR 1.44, 95% CI 0.98 to 2.10). The trend observed in these artificial cycles was not demonstrated in the Cochrane review evaluating regular ART cycles, where it was suggested that IM progesterone was better in terms of live birth rate (<LINK REF="REF-Daya-2004" TYPE="REFERENCE">Daya 2004</LINK>). There is no reasonable justification to suggest that the vaginal route may be better in this setting and IM progesterone may be better in ART cycles where women use their own oocytes. Also of significance, the rate of pregnancy loss was not different in the present review.</P>
<P>There is some degree of controversy as to when in the replacement cycle progesterone should be started, in relation to the day of performance of oocyte aspiration. Only one study randomised fresh donor oocytes recipients to start progesterone the day before, the day of, and the day after oocyte retrieval in the donors that had the embryo transfer on day three. When comparing these three interventions, women starting progesterone either on the day of oocyte retrieval or the day after (OR 1.92 and 1.81, respectively) had a greater chance of getting pregnant compared to recipients that started progesterone the day before oocyte retrieval (<LINK REF="STD-Escriba-2006" TYPE="STUDY">Escriba 2006</LINK>). No significant differences in terms of clinical pregnancy rate were found between starting progesterone on the day of oocyte retrieval or on the day after retrieval. When recipients start progesterone the day after oocyte retrieval oocyte fertilization can be identified and checked and, in the case of fertilization failure, progesterone can be withheld. This avoids cycle cancellation as estrogen replacement can be continued while waiting for a new suitable donor in a busy egg donation program that uses either an egg sharing technique (<LINK REF="REF-Glujovsky-2006" TYPE="REFERENCE">Glujovsky 2006</LINK>) or where a large pool of egg donors are under controlled ovarian hyperstimulation (COH) and allocated to recipients on a daily basis (in those countries where this approach is acceptable). After subgroup analysis (post hoc) on this issue, we found that recipients that started progesterone after documented fertilization had a lower chance of cycle cancellation. If the estimations obtained in this systematic review are true, when progesterone is started the day after oocyte retrieval then the number of recipients needed to avoid one cycle cancellation because of complete fertilization failure would be 20 (95% CI 12 to 99). On the other hand, another study found no differences in pregnancy rate when analysed women who had the embryo transfer on blastocyst stage and started the progesterone six or seven days before the embryo transfer (<LINK REF="STD-Caligara-2003" TYPE="STUDY">Caligara 2003</LINK>).</P>
<P>Even though hormone replacement with estrogen and progesterone constitutes the main therapeutic objective for recipients during the treatment cycle, there are other medications that have been tried in order to optimise the implantation potential of the endometrium. Among them, low-dose aspirin has been used as a potential angiogenic factor that may benefit the endometrium (<LINK REF="REF-Rubinstein-1999" TYPE="REFERENCE">Rubinstein 1999</LINK>; <LINK REF="REF-Wada-1994" TYPE="REFERENCE">Wada 1994</LINK>). Only one small randomised controlled trial assessed the use of aspirin from the start of endometrial preparation and this particular study did not show any benefit of administering low-dose aspirin on the final results. Although the aspirin group showed a thicker endometrium, by 0.6 mm, this finding was not clinically relevant. However, other studies on IVF cycles or with a retrospective design suggest that aspirin could be of benefit. An RCT on IVF cycles showed better implantation rates in those women treated with aspirin (<LINK REF="REF-Rubinstein-1999" TYPE="REFERENCE">Rubinstein 1999</LINK>) and a retrospective study showed that aspirin may increase clinical reproductive outcomes in women with a thin endometrium, even if it was not thicker with aspirin (<LINK REF="REF-Frattarelli-2006" TYPE="REFERENCE">Frattarelli 2006</LINK>).<BR/>The use of steroids, in the form of oral methylprednisolone administered to recipients, showed a lack of clear benefit for the women. This is in agreement with a Cochrane review that evaluated steroids in standard ART cycles (<LINK REF="REF-Boomsma-2007" TYPE="REFERENCE">Boomsma 2007</LINK>). It is important to say that these studies have very low statistical power so that larger sample sizes are needed to evaluate these drugs in IVF cycles.</P>
<P>When we analysed the use of oestrogen priming of the endometrium before the embryo transfer, we found a study that did not show any difference when comparing the pregnancy result in comparison to women who had ovarian stimulation (<LINK REF="STD-Wright-2006" TYPE="STUDY">Wright 2006</LINK>). However, another cycle showed better results when a natural cycle was used (<LINK REF="STD-Lee-2008" TYPE="STUDY">Lee 2008</LINK>).</P>
<P>Finally, no benefit was found when administration of exogenous hCG to recipients was used (<LINK REF="STD-Tesarik-2003" TYPE="STUDY">Tesarik 2003</LINK>). Moreover, in a study where it was repeatedly used before the oocyte retrieval, the pregnancy rate significantly decreased (<LINK REF="STD-Prapas-2009a" TYPE="STUDY">Prapas 2009a</LINK>).</P>
<SUMMARY_OF_RESULTS MODIFIED="2009-09-26 22:47:17 +1200" MODIFIED_BY="[Empty name]">
<P>In summary, our review has demonstrated that few properly performed studies exist comparing pre-specified interventions. In those studies there was insufficient statistical power to reach definitive conclusions regarding the comparability of the interventions. More double-blinded randomised controlled trials with adequate power are required in the future in order to determine if any of the interventions assessed in our review do enhance the chances of live births among those infertile women undergoing frozen embryo transfer or oocyte donation cycles.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-09-26 22:49:11 +1200" MODIFIED_BY="[Empty name]">
<P>The exhaustive search strategy of published and unpublished studies and the limited body of evidence make it unlikely that any relevant study was omitted. Although patients, settings, and interventions could be representative of clinical practice, applicability could be limited by other sources as we found insufficient evidence.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-01-27 14:03:57 +1300" MODIFIED_BY="jane clarke">
<P>Overall the quality of the evidence was moderate because of methodological limitations. Few authors described the allocation method, there was no blinding of patients, and blinding of healthcare-workers was not described. Live birth rate was reported in a minority of cases. Finally, outcome assessment was not generally described in terms of blinding of the evaluator (<I>see</I> <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-09-25 23:37:16 +1200" MODIFIED_BY="[Empty name]">
<P>Since we followed the updated version of the Cochrane Handbook we are confident the review process was not biased.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-11-05 08:46:44 +1300" MODIFIED_BY="[Empty name]">
<P>Three studies compared different types of GnRH agonists but neither demonstrated statistically significant differences. When depot leuprolide was compared to daily leuprolide administration on pregnancy rates, a trend in favour of depot leuprolide suggested a potential benefit on this parameter that is clinically relevant, but the Cochrane review comparing these two different types of GnRH agonists did not show any differences (<LINK REF="REF-Albuquerque-2005" TYPE="REFERENCE">Albuquerque 2005</LINK>). Endometrial development should be analysed in future studies in order to determine if depot and daily formulations can impact in a different way on endometrial implantation. We did not find any other review of this particular topic.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-09 11:58:55 +1300" MODIFIED_BY="jane clarke">
<IMPLICATIONS_PRACTICE MODIFIED="2009-11-09 11:58:55 +1300" MODIFIED_BY="jane clarke">
<P>There is insufficient evidence to support the use of any particular intervention in endometrial preparation that clearly improves treatment outcomes for women undergoing embryo transfers with frozen embryos or embryos derived from donor oocytes. The results of this review should be carefully considered because of the small number of trials and the heterogeneity between some trials. The use of GnRH agonists was not found to be more effective than treatments where no GnRH agonists were used, and no differences were found among the various GnRH agonists evaluated. Vaginal progesterone did not show different results to intramuscular progesterone. There is evidence of a lower pregnancy rate and higher cancellation rate in fresh oocytes donation cycles when commencing progesterone prior to oocyte retrieval. One trial showed higher pregnancy rates when using natural cycles in comparison to artificial cycles. The repeatedly use of hCG before the oocyte retrieval showed detrimental impact on the pregnancy results. Finally, no evidence of clinical benefit was found with the other medications evaluated.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-09-26 22:54:52 +1200" MODIFIED_BY="[Empty name]">
<P>There is little comparative information on each of the treatments that might impact on endometrial preparation for women undergoing embryo transfers with frozen embryos or embryos derived from donor oocytes. Adequately powered and double-blinded RCTs are needed to evaluate each of the treatments more accurately. More studies are needed to specifically evaluate if GnRH agonist use is associated with fewer cycle cancellations and to see if this medication impacts on development of the endometrium. More studies are needed to evaluate if there is an optimal route of progesterone administration and to confirm the timing of this administration. Finally, more studies would help to determine if there is a subgroup of women who may benefit from any specific medication.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-11-09 11:59:00 +1300" MODIFIED_BY="jane clarke">
<P>Daniel Comande, librarian, who contributed to the search strategy and identification of the cited studies. Marian Showell who contributed to the update of the search strategy. Paul Bergh MD, Antonio Pellicer MD and Mark Sauer MD have been consulted as experts in the field in order to be thorough and include all the studies that should be part of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-07-26 01:08:02 +1200" MODIFIED_BY="[Empty name]">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-01-27 14:03:42 +1300" MODIFIED_BY="jane clarke">
<P>Demian Glujovsky: conceived the protocol of the review, and coordinated the whole review process.</P>
<P>Romina Pesce: conceived the protocol of the review and participated in the selection, assessment and data extraction.</P>
<P>Gabriel Fiszbajn: conceived the review and participated in the selection, assessment and data extraction.</P>
<P>Agustin Ciapponi: supervised the methods. He solved discrepancies of selection or assessment and conducted the analysis.</P>
<P>Carlos Sueldo: provided general advice on the protocol. He assisted in writing the review and solved discrepancies of selection or assessment.</P>
<P>Roger Hart: provided general advice on and assistance with the review and contributed to writing the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-09-26 22:58:25 +1200" MODIFIED_BY="[Empty name]">
<P>Administration of progesterone in relation to oocyte retrieval was not pre-specified but was added as an outcome when the review was being prepared, after protocol publication. The authors considered that this was a clinically significant outcome.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-11-09 13:02:29 +1300" MODIFIED_BY="jane clarke">
<STUDIES MODIFIED="2009-11-09 13:02:29 +1300" MODIFIED_BY="jane clarke">
<INCLUDED_STUDIES MODIFIED="2009-11-09 13:02:29 +1300" MODIFIED_BY="jane clarke">
<STUDY DATA_SOURCE="PUB" ID="STD-Bider-1996" MODIFIED="2009-09-04 13:37:59 +1200" MODIFIED_BY="jane clarke" NAME="Bider 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-09-04 13:37:59 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;0015-0282 (Print)&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:37:59 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bider D, Amoday I, Yonesh M, Yemini Z, Mashiach S, Dor J</AU>
<TI>Glucocorticoid administration during transfer of frozen-thawed embryos: a prospective, randomized study</TI>
<SO>Fertility and Sterility</SO>
<YR>1996</YR>
<VL>66</VL>
<NO>1</NO>
<PG>154-6</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:37:59 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caligara-2003" MODIFIED="2009-11-04 10:23:31 +1300" MODIFIED_BY="[Empty name]" NAME="Caligara 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-04 10:23:31 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Caligara C, Ruiz S, Terrero M, Mantrana E, Calderon G, Navarro J</AU>
<TI>Vaginal versus intramuscular progesterone in oocyte donation replacement therapy</TI>
<SO>ASRM annual meeting</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dal-Prato-2002" MODIFIED="2009-09-04 13:38:25 +1200" MODIFIED_BY="jane clarke" NAME="Dal Prato 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-09-04 13:38:25 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dal Prato L, Borini A, Cattoli M, Bonu MA, Sciajno R, Flamigni C</AU>
<TI>Endometrial preparation for frozen-thawed embryo transfer with or without pretreatment with gonadotropin-releasing hormone agonist</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>5</NO>
<PG>956-60</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:38:25 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davar-2007" MODIFIED="2009-11-09 13:00:10 +1300" MODIFIED_BY="jane clarke" NAME="Davar 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-09 13:00:10 +1300" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davar R, Eftekhar M, Tayebi N</AU>
<TI>Transfer of cryopreserved-thawed embryos in a cycle using exogenous steroids with or without prior gonadotrophin-realising hormone agonist</TI>
<SO>J Med Sci</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>5</NO>
<PG>880-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2007" MODIFIED="2009-11-04 10:30:14 +1300" MODIFIED_BY="[Empty name]" NAME="Ding 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-04 10:30:14 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ding J, Rana N, Dmowski W</AU>
<TI>Lenght of progesterone treatment before transfer and implantation rates of frozen-thawed blastocysts</TI>
<SO>ASRM annual meeting</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Toukhy-2004" MODIFIED="2009-09-04 13:38:44 +1200" MODIFIED_BY="jane clarke" NAME="El-Toukhy 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-04 13:38:44 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Toukhy T, Taylor A, Khalaf Y, Al-Darazi K, Rowell P, Seed P, Braude P</AU>
<TI>Pituitary suppression in ultrasound-monitored frozen embryo replacement cycles. A randomised study</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>4</NO>
<PG>874-9</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:38:44 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Escriba-2006" MODIFIED="2009-09-04 13:38:53 +1200" MODIFIED_BY="jane clarke" NAME="Escriba 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-04 13:38:53 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Escriba MJ, Bellver J, Bosch E, Sanchez M, Pellicer A, Remohi J</AU>
<TI>Delaying the initiation of progesterone supplementation until the day of fertilization does not compromise cycle outcome in patients receiving donated oocytes: a randomized study</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>1</NO>
<PG>92-7</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:38:53 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibbons-1998" MODIFIED="2009-09-04 13:39:01 +1200" MODIFIED_BY="jane clarke" NAME="Gibbons 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-09-04 13:39:01 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibbons WE, Toner JP, Hamacher P, Kolm P</AU>
<TI>Experience with a novel vaginal progesterone preparation in a donor oocyte program</TI>
<SO>Fertility and Sterility</SO>
<YR>1998</YR>
<VL>69</VL>
<NO>1</NO>
<PG>96-101</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:39:01 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gutierrez-1999" MODIFIED="2008-07-25 23:41:46 +1200" MODIFIED_BY="[Empty name]" NAME="Gutierrez 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-07-25 23:41:46 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gutierrez A, Hemandez F, Mendoza S, Monroy E, Perez-Petia E, Gallardo E</AU>
<TI>Nafarelin acetate vs leuprolide acetate in women with ovarian function undergoing oocyte donation</TI>
<SO>55th Annual Meeting of the American Society for Reproductive Medicine</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lan-2008" MODIFIED="2009-11-09 12:59:59 +1300" MODIFIED_BY="jane clarke" NAME="Lan 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-09 12:59:59 +1300" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lan VT, Tuan PH, Canh LT, Tuong HM, Howles CM</AU>
<TI>Progesterone supplementation during cryopreserved embryo transfer cycles: efficacy and convenience of two vaginal formulations</TI>
<SO>Reproductive biomedicine online</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>3</NO>
<PG>318-23</PG>
<IDENTIFIERS MODIFIED="2009-11-04 10:48:05 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18765001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2008" MODIFIED="2009-11-04 10:39:20 +1300" MODIFIED_BY="[Empty name]" NAME="Lee 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-04 10:39:20 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lee S, Kwon H, Kim J, Lee J, Jung Y, Jung J, Ko H</AU>
<TI>Comparison of clinical outcome of frozen-thawed embryo transfer cycles between natural and artificial (hormone-treated) cycles</TI>
<SO>24th Annual Meeting of the ESHRE</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lightman-1999" MODIFIED="2009-09-04 13:37:48 +1200" MODIFIED_BY="jane clarke" NAME="Lightman 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-09-04 13:37:48 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lightman A, Kol S, Itskovitz-Eldor J</AU>
<TI>A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>10</NO>
<PG>2596-9</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:37:48 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moffitt-1995" MODIFIED="2009-09-04 13:39:10 +1200" MODIFIED_BY="jane clarke" NAME="Moffitt 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-09-04 13:39:10 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;0015-0282 (Print)&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:39:10 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moffitt D, Queenan JT Jr, Veeck LL, Schoolcraft W, Miller CE, Muasher SJ</AU>
<TI>Low-dose glucocorticoids after in vitro fertilization and embryo transfer have no significant effect on pregnancy rate</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>63</VL>
<NO>3</NO>
<PG>571-7</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:39:10 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neuspiller-1998" MODIFIED="2009-09-04 13:39:29 +1200" MODIFIED_BY="jane clarke" NAME="Neuspiller 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-09-04 13:39:29 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neuspiller F, Levy M, Remohi J, Ruiz A, Simon C, Pellicer A</AU>
<TI>The use of long- and short-acting forms of gonadotrophin-releasing hormone analogues in women undergoing oocyte donation</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>5</NO>
<PG>1148-51</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:39:29 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prapas-2009a" MODIFIED="2009-11-09 13:01:21 +1300" MODIFIED_BY="jane clarke" NAME="Prapas 2009a" YEAR="2009">
<REFERENCE MODIFIED="2009-11-09 13:01:21 +1300" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prapas N, Tavaniotou A, Panagiotidis Y, Prapa S, Kasapi E, Goudakou M, et al</AU>
<TI>Low-dose human chorionic gonadotropin during the proliferative phase may adversely affect endometrial receptivity in oocyte recipients</TI>
<SO>Gynecological endocrinology : the official journal of the international Society of Gynecological Endocrinology</SO>
<YR>2009</YR>
<VL>25</VL>
<NO>1</NO>
<PG>53-9</PG>
<IDENTIFIERS MODIFIED="2009-11-04 10:47:28 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19165663"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramos-2007" MODIFIED="2009-11-09 13:01:31 +1300" MODIFIED_BY="jane clarke" NAME="Ramos 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-09 13:01:31 +1300" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="OTHER">
<AU>Ramos J, Caligara C, Tocino A, Rodr&#305;guez I, Carranza F, Fernandez-Sanchez M</AU>
<TI>Prospective randomized study to compare frozen thawed embryo transfer cycles outcomes in women with functioning ovaries and HRT for endometrium preparation with or without prior GnRH suppression</TI>
<SO>ASRM annual meeting</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remohi-1994" MODIFIED="2009-09-04 13:39:58 +1200" MODIFIED_BY="jane clarke" NAME="Remohi 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-09-04 13:39:58 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;0268-1161 (Print)&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:39:58 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Remohi J, Gutierrez A, Vidal A, Tarin JJ, Pellicer A</AU>
<TI>The use of gonadotrophin-releasing hormone analogues in women receiving oocyte donation does not affect implantation rates</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>9</NO>
<PG>1761-4</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:39:58 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tesarik-2003" MODIFIED="2009-09-04 13:40:06 +1200" MODIFIED_BY="jane clarke" NAME="Tesarik 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-09-04 13:40:06 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tesarik J, Hazout A, Mendoza C</AU>
<TI>Luteinizing hormone affects uterine receptivity independently of ovarian function</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>59-64</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:40:06 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tocino-2007" MODIFIED="2009-11-09 13:02:29 +1300" MODIFIED_BY="jane clarke" NAME="Tocino 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-09 13:02:29 +1300" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="OTHER">
<AU>Tocino A, Caligara C, Ramos J, Carranza F, Gonzalez A, Fernandez-Sanchez M</AU>
<TI>Prospective randomized study to compare use of daily vs. depot GnRH analogue in endometrial preparation for oocyte donations cycles in recipients</TI>
<SO>ASRM annual meeting</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weckstein-1997" MODIFIED="2009-09-04 13:40:13 +1200" MODIFIED_BY="jane clarke" NAME="Weckstein 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-09-04 13:40:13 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;0015-0282 (Print)&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:40:13 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weckstein LN, Jacobson A, Galen D, Hampton K, Hammel J</AU>
<TI>Low-dose aspirin for oocyte donation recipients with a thin endometrium: prospective, randomized study</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>68</VL>
<NO>5</NO>
<PG>927-30</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:40:13 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-2006" MODIFIED="2009-09-04 13:40:25 +1200" MODIFIED_BY="jane clarke" NAME="Wright 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-04 13:40:25 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright KP, Guibert J, Weitzen S, Davy C, Fauque P, Olivennes F</AU>
<TI>Artificial versus stimulated cycles for endometrial preparation prior to frozen-thawed embryo transfer</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>3</NO>
<PG>321-5</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:40:25 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zegers-2000" MODIFIED="2009-09-26 00:09:33 +1200" MODIFIED_BY="[Empty name]" NAME="Zegers 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-09-26 00:09:33 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zegers-Hochschild F, Balmaceda JP, Fabres C, Alam V, Mackenna A, Fernandez E, et al</AU>
<TI>Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>10</NO>
<PG>2093-7</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:40:32 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-11-09 13:02:04 +1300" MODIFIED_BY="jane clarke">
<STUDY DATA_SOURCE="PUB" ID="STD-Bernabeu-2006" MODIFIED="2009-09-04 13:40:49 +1200" MODIFIED_BY="jane clarke" NAME="Bernabeu 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-04 13:40:49 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernabeu R, Roca M, Torres A, Ten J</AU>
<TI>Indomethacin effect on implantation rates in oocyte recipients</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>2</NO>
<PG>364-9</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:40:49 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Check-1998" MODIFIED="2009-09-04 13:41:25 +1200" MODIFIED_BY="jane clarke" NAME="Check 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-09-04 13:41:25 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Check JH, Dietterich C, Lurie D, Nazari A, Chuong J</AU>
<TI>A matched study to determine whether low-dose aspirin without heparin improves pregnancy rates following frozen embryo transfer and/or affects endometrial sonographic parameters</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>10</NO>
<PG>579-82</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:41:25 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Check-2002" NAME="Check 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Check J, Lee G, Nazari A, Davies E, Choe J.</AU>
<TI>Neither sildenafil nor vaginal estradiol improved endometrial thickness in women with thin endometria after taking oral estradiol in graduating dosage</TI>
<SO>Annual Meeting of the Pacific Coast Reproductive Society (abstract)</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Check-2004" MODIFIED="2009-11-04 11:10:59 +1300" MODIFIED_BY="[Empty name]" NAME="Check 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-04 11:10:59 +1300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Check, J H&lt;br&gt;Graziano, V&lt;br&gt;Lee, G&lt;br&gt;Nazari, A&lt;br&gt;Choe, J K&lt;br&gt;Dietterich, C&lt;br&gt;Clinical Trial&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Italy&lt;br&gt;Clinical and experimental obstetrics &amp;amp; gynecology&lt;br&gt;Clin Exp Obstet Gynecol. 2004;31(2):99-102.&lt;/p&gt;" NOTES_MODIFIED="2009-11-04 11:10:59 +1300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Check JH, Graziano V, Lee G, Nazari A, Choe JK, Dietterich C</AU>
<TI>Neither sildenafil nor vaginal estradiol improves endometrial thickness in women with thin endometria after taking oral estradiol in graduating dosages</TI>
<SO>Clinical &amp; Experimental Obstetrics &amp; Gynecology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>2</NO>
<PG>99-102</PG>
<IDENTIFIERS MODIFIED="2009-11-04 11:07:22 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="0390-6663" TYPE="OTHER" VALUE="(Print)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feliciani-2004" MODIFIED="2009-11-09 13:01:47 +1300" MODIFIED_BY="jane clarke" NAME="Feliciani 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-11-09 13:01:47 +1300" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="OTHER">
<AU>Feliciani E, Ferraretti A, Balicchia B, Grieco N, Magli M, Gianaroli L</AU>
<TI>A prospective randomised study comparing the effect of intravaginal progesterone and intramuscular progesterone in frozen/thawed embryo transfer (FET) cycles</TI>
<SO>20th Annual Meeting of the ESHRE</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krasnow-1996" MODIFIED="2009-09-04 13:41:14 +1200" MODIFIED_BY="jane clarke" NAME="Krasnow 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-09-04 13:41:14 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;0015-0282 (Print)&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:41:14 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krasnow JS, Lessey BA, Naus G, Hall LL, Guzick DS, Berga SL</AU>
<TI>Comparison of transdermal versus oral estradiol on endometrial receptivity</TI>
<SO>Fertility and Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<NO>2</NO>
<PG>332-6</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:41:14 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lan-2007" MODIFIED="2009-11-04 11:10:24 +1300" MODIFIED_BY="[Empty name]" NAME="Lan 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-11-04 11:10:24 +1300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Using Smart Source Parsing&lt;br&gt;Vol. Suppl 1, pp.164, abstract&lt;/p&gt;" NOTES_MODIFIED="2009-11-04 11:10:24 +1300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lan VTN, Tuan P, Canh L, Tuong H, Howles CM</AU>
<TI>Comparison of the efficacy and tolerability of two formulations of vaginal progesterone for luteal phase support in frozen embryo transfer cycles</TI>
<SO>ASRM annual meeting</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewin-2001" MODIFIED="2009-11-04 10:55:30 +1300" MODIFIED_BY="[Empty name]" NAME="Lewin 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-04 10:55:30 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lewin A, Fatum M, Shufaro Y, Simon A, Reubinoff B, Laufer N, Safran A</AU>
<TI>Artificial endometrial preparation for frozen&#8211;thawed embryo transfer using oral oestradiol and a new low-dose vaginal progesterone preparation: Endometrin tablets</TI>
<SO>17th Annual meeting of the ESHRE</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moon-2004" MODIFIED="2009-09-04 13:42:00 +1200" MODIFIED_BY="jane clarke" NAME="Moon 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-04 13:42:00 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;0015-0282 (Print)&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:42:00 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moon HS, Park SH, Lee JO, Kim KS, Joo BS</AU>
<TI>Treatment with piroxicam before embryo transfer increases the pregnancy rate after in vitro fertilization and embryo transfer</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>82</VL>
<NO>4</NO>
<PG>816-20</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:42:00 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nardo-2006" MODIFIED="2009-09-04 13:41:49 +1200" MODIFIED_BY="jane clarke" NAME="Nardo 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-04 13:41:49 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;1472-6483 (Print)&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:41:49 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nardo LG, Sallam HN</AU>
<TI>Progesterone supplementation to prevent recurrent miscarriage and to reduce implantation failure in assisted reproduction cycles</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>1</NO>
<PG>47-57</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:41:49 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Page-2005" MODIFIED="2009-11-09 13:02:04 +1300" MODIFIED_BY="jane clarke" NAME="Page 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-09 13:02:04 +1300" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="OTHER">
<AU>Page K, Guibert J, Weitzen S, Davy C, Fauque P, Olivennes F</AU>
<TI>A Prospective Randomized Trial Evaluating Endometrial Preparation for Implantation of Frozen/Thawed Embryos Using an Artificial CycleVersus a Stimulated Cycle</TI>
<SO>ASRM annual meeting</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prapas-2009b" MODIFIED="2009-11-04 11:12:09 +1300" MODIFIED_BY="[Empty name]" NAME="Prapas 2009b" YEAR="2009">
<REFERENCE MODIFIED="2009-11-04 11:12:09 +1300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Prapas, Nikos&lt;br&gt;Tavaniotou, Asimina&lt;br&gt;Panagiotidis, Yannis&lt;br&gt;Prapa, Stella&lt;br&gt;Kasapi, Evangelia&lt;br&gt;Goudakou, Maria&lt;br&gt;Papatheodorou, Achilleas&lt;br&gt;Prapas, Yannis&lt;br&gt;Randomized Controlled Trial&lt;br&gt;England&lt;br&gt;Reproductive biomedicine online&lt;br&gt;Reprod Biomed Online. 2009 Feb;18(2):276-81.&lt;/p&gt;" NOTES_MODIFIED="2009-11-04 11:12:09 +1300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Prapas N, Tavaniotou A, Panagiotidis Y, Prapa S, Kasapi E, Goudakou M, et al</AU>
<TI>GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>2</NO>
<PG>276-81</PG>
<IDENTIFIERS MODIFIED="2009-11-04 11:11:43 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER OTHERTYPE="1472-6491" TYPE="OTHER" VALUE="(Electronic)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sathanandan-1991" MODIFIED="2009-09-04 13:41:05 +1200" MODIFIED_BY="jane clarke" NAME="Sathanandan 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-09-04 13:41:05 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;0268-1161 (Print)&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:41:05 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sathanandan M, Macnamee MC, Rainsbury P, Wick K, Brinsden P, Edwards RG</AU>
<TI>Replacement of frozen-thawed embryos in artificial and natural cycles: a prospective semi-randomized study</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>5</NO>
<PG>685-7</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:41:05 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiotani-2006" MODIFIED="2009-11-04 11:15:23 +1300" MODIFIED_BY="[Empty name]" NAME="Shiotani 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-04 11:15:23 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Shiotani M, Goto S, Kokeguchi S, Matsunaga M, Watanabe J, Hashimoto H, et al</AU>
<TI>Is hCG supplementation beneficial for cryopreserved-thawed embryo transfer in estrogen/progesterone replacement cycles?</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl</NO>
<PG>i82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-1998" MODIFIED="2009-09-04 13:40:58 +1200" MODIFIED_BY="jane clarke" NAME="Simon 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-09-04 13:40:58 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon A, Hurwitz A, Zentner BS, Bdolah Y, Laufer N</AU>
<TI>Transfer of frozen-thawed embryos in artificially prepared cycles with and without prior gonadotrophin-releasing hormone agonist suppression: a prospective randomized study</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>1O</NO>
<PG>2712-7</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:40:58 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taskin-2002" MODIFIED="2009-11-04 10:59:03 +1300" MODIFIED_BY="[Empty name]" NAME="Taskin 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-11-04 10:59:03 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Taskin O, Akkoyunlu G, Simsek M, Demir R, Onoglu A, Sadik S</AU>
<TI>Comparing the effects of GnRH-a on endometrial receptivity in patients undergoing ART and prepared frozen embryo transfer cycles</TI>
<SO>ASRM annual meeting</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toner-2000" MODIFIED="2009-11-04 11:14:09 +1300" MODIFIED_BY="[Empty name]" NAME="Toner 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-04 11:14:09 +1300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Using Smart Source Parsing&lt;br&gt;Suppl pp. Jun&lt;/p&gt;" NOTES_MODIFIED="2009-11-04 11:14:09 +1300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Toner JP</AU>
<TI>Vaginal delivery of progesterone in donor oocyte therapy</TI>
<SO>Human Reproduction</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>1</NO>
<PG>166-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-09-04 13:43:21 +1200" MODIFIED_BY="jane clarke">
<ADDITIONAL_REFERENCES MODIFIED="2009-09-04 13:43:21 +1200" MODIFIED_BY="jane clarke">
<REFERENCE ID="REF-Albuquerque-2005" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="Albuquerque 2005" TYPE="COCHRANE_REVIEW">
<AU>Albuquerque LE, Saconato H, Maciel MC</AU>
<TI>Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-06-21 08:05:37 +1200" MODIFIED_BY="Agustín Ciapponi">
<IDENTIFIER MODIFIED="2008-06-21 08:05:37 +1200" MODIFIED_BY="Agustín Ciapponi" TYPE="DOI" VALUE="10.1002/14651858.CD002808.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boomsma-2007" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="Boomsma 2007" TYPE="COCHRANE_REVIEW">
<AU>Boomsma CM, Keay SD, Macklon NS</AU>
<TI>Peri-implantation glucocorticoid administration for assisted reproductive technology cycles</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-06-21 08:06:56 +1200" MODIFIED_BY="Agustín Ciapponi">
<IDENTIFIER MODIFIED="2008-06-21 08:06:37 +1200" MODIFIED_BY="Agustín Ciapponi" TYPE="DOI" VALUE="10.1002/14651858.CD005996.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Daya-2004" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="Daya 2004" TYPE="COCHRANE_REVIEW">
<AU>Daya S, Gunby J</AU>
<TI>Luteal phase support in assisted reproduction cycles</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-06-21 08:10:11 +1200" MODIFIED_BY="Agustín Ciapponi">
<IDENTIFIER MODIFIED="2008-06-21 08:10:11 +1200" MODIFIED_BY="Agustín Ciapponi" TYPE="DOI" VALUE="10.1002/14651858.CD004830"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2009-08-10 15:34:39 +1200" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird M</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devroey-1998" MODIFIED="2009-09-04 13:42:17 +1200" MODIFIED_BY="jane clarke" NAME="Devroey 1998" TYPE="JOURNAL_ARTICLE">
<AU>Devroey P, Pados G</AU>
<TI>Preparation of endometrium for egg donation</TI>
<SO>Human Reproduction Update</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>6</NO>
<PG>856-61</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:42:17 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<REFERENCE ID="REF-ESHRE-2006" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="ESHRE 2006" NOTES="&lt;p&gt;(EIM)&lt;/p&gt;" NOTES_MODIFIED="2008-08-15 00:51:20 +1200" NOTES_MODIFIED_BY="Agustín Ciapponi" TYPE="JOURNAL_ARTICLE">
<AU>The European IVF-monitoring programme (EIM) for the European Society of Human Reproduction and Embriology (ESHRE)</AU>
<TI>Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>7</NO>
<PG>1680-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frattarelli-2006" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="Frattarelli 2006" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2008-08-15 00:51:20 +1200" NOTES_MODIFIED_BY="Agustín Ciapponi" TYPE="JOURNAL_ARTICLE">
<AU>Frattarelli JL, Miller BT, Scott RT, Jr.</AU>
<TI>Adjuvant therapy enhances endometrial receptivity in patients undergoing assisted reproduction</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>6</NO>
<PG>722-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Velasco-2000" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="Garcia-Velasco 2000" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Velasco JA, Martinez-Salazar FJ, Grimalt L</AU>
<TI>Implantation failure</TI>
<TO>Falla de implantacion</TO>
<SO>Reproducción asistida del siglo XXI, Cuaderno de Medicina Reproductiva</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>2</NO>
<PG>211-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glujovsky-2006" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="Glujovsky 2006" NOTES="&lt;p&gt;1556-5653 (Electronic)&lt;/p&gt;" NOTES_MODIFIED="2008-08-15 00:51:20 +1200" NOTES_MODIFIED_BY="Agustín Ciapponi" TYPE="JOURNAL_ARTICLE">
<AU>Glujovsky D, Fiszbajn G, Lipowicz R, Lavolpe M, Sueldo C</AU>
<TI>Practice of sharing donated oocytes among several recipients</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>6</NO>
<PG>1786-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-LA-Register-2003" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="LA Register 2003" TYPE="OTHER">
<AU>Red Latinoamericana de Reproducción Asistida</AU>
<TI>Latin American Register of Assisted Reproduction</TI>
<TO>Registro Latinoamericano de Reproduccion Asistida</TO>
<SO>http://www.redlara.com/ing/reg_2003.ASP</SO>
<YR>(accessed 18 August 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leeton-1986" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="Leeton 1986" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2008-08-15 00:51:20 +1200" NOTES_MODIFIED_BY="Agustín Ciapponi" TYPE="JOURNAL_ARTICLE">
<AU>Leeton J, Chan LK, Trounson A, Harman J</AU>
<TI>Pregnancy established in an infertile patient after transfer of an embryo fertilized in vitro where the oocyte was donated by the sister of the recipient</TI>
<SO>Journal of in vitro Fertilization and Embryo Transfer: IVF</SO>
<YR>1986</YR>
<VL>3</VL>
<NO>6</NO>
<PG>379-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0740-7769 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mohr-1985" MODIFIED="2009-09-04 13:42:32 +1200" MODIFIED_BY="jane clarke" NAME="Mohr 1985" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:42:32 +1200" NOTES_MODIFIED_BY="jane clarke" TYPE="JOURNAL_ARTICLE">
<AU>Mohr LR, Trounson A, Freemann L</AU>
<TI>Deep-freezing and transfer of human embryos</TI>
<SO>Journal of in vitro Fertilization and Embryo Transfer: IVF</SO>
<YR>1985</YR>
<VL>2</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:42:32 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<REFERENCE ID="REF-Nawroth-2005" MODIFIED="2009-09-04 13:42:39 +1200" MODIFIED_BY="jane clarke" NAME="Nawroth 2005" TYPE="JOURNAL_ARTICLE">
<AU>Nawroth F, Ludwig M</AU>
<TI>What is the 'ideal' duration of progesterone supplementation before the transfer of cryopreserved-thawed embryos in estrogen/progesterone replacement protocols?</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>5</NO>
<PG>1127-34</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:42:39 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<REFERENCE ID="REF-Rubinstein-1999" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="Rubinstein 1999" NOTES="&lt;p&gt;Clinical Trial&lt;/p&gt;" NOTES_MODIFIED="2008-08-15 00:51:20 +1200" NOTES_MODIFIED_BY="Agustín Ciapponi" TYPE="JOURNAL_ARTICLE">
<AU>Rubinstein M, Marazzi A, Polak de Fried E</AU>
<TI>Low-dose aspirin treatment improves ovarian responsiveness, uterine and ovarian blood flow velocity, implantation, and pregnancy rates in patients undergoing in vitro fertilization: a prospective, randomized, double-blind placebo-controlled assay</TI>
<SO>Fertility and Sterility</SO>
<YR>1999</YR>
<VL>71</VL>
<NO>5</NO>
<PG>825-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0015-0282 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SART-2003" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="SART 2003" TYPE="OTHER">
<AU>National Center for Chronic Disease Prevention and Health Promotion of the Centers for Disease Control and Prevention</AU>
<TI>2003 Assisted Reproductive Technology Success Rates. National Summary and Fertility Clinic Reports</TI>
<SO>http://www.cdc.gov/ART/ART2003/index.htm</SO>
<YR>(accessed 18 August 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steiner-2006" MODIFIED="2009-09-04 13:43:02 +1200" MODIFIED_BY="jane clarke" NAME="Steiner 2006" TYPE="JOURNAL_ARTICLE">
<AU>Steiner AZ, Paulson RJ</AU>
<TI>Oocyte donation</TI>
<SO>Clinical Obstetrics and Gynecology</SO>
<YR>2006</YR>
<VL>49</VL>
<NO>1</NO>
<PG>44-54</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:43:02 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<REFERENCE ID="REF-te-Velde-2000" MODIFIED="2008-08-15 00:51:20 +1200" MODIFIED_BY="Agustín Ciapponi" NAME="te Velde 2000" NOTES="&lt;p&gt;0140-6736 (Print)&lt;/p&gt;" NOTES_MODIFIED="2008-08-15 00:51:20 +1200" NOTES_MODIFIED_BY="Agustín Ciapponi" TYPE="JOURNAL_ARTICLE">
<AU>te Velde ER, Eijkemans R, Habbema HD</AU>
<TI>Variation in couple fecundity and time to pregnancy, an essential concept in human reproduction</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9219</NO>
<PG>1928-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wada-1994" MODIFIED="2009-09-04 13:43:14 +1200" MODIFIED_BY="jane clarke" NAME="Wada 1994" NOTES="&lt;p&gt;Journal Article&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:43:14 +1200" NOTES_MODIFIED_BY="jane clarke" TYPE="JOURNAL_ARTICLE">
<AU>Wada I, Hsu CC, Williams G, Macnamee MC, Brinsden PR</AU>
<TI>The benefits of low-dose aspirin therapy in women with impaired uterine perfusion during assisted conception</TI>
<SO>Human Reproduction (Oxford, England)</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>10</NO>
<PG>1954-7</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:43:14 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
<REFERENCE ID="REF-Zegers-2006" MODIFIED="2009-09-04 13:43:21 +1200" MODIFIED_BY="jane clarke" NAME="Zegers 2006" NOTES="&lt;p&gt;International Committee Monitoring Assisted Reproductive Technologies&lt;/p&gt;" NOTES_MODIFIED="2009-09-04 13:43:21 +1200" NOTES_MODIFIED_BY="jane clarke" TYPE="JOURNAL_ARTICLE">
<AU>Zegers-Hochschild F, Nygren KG, Adamson GD, de Mouzon J, Lancaster P, Mansour R et al</AU>
<TI>The International Committee Monitoring Assisted Reproductive Technologies (ICMART) glossary on ART terminology</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>1</NO>
<PG>16-9</PG>
<IDENTIFIERS MODIFIED="2009-09-04 13:43:21 +1200" MODIFIED_BY="jane clarke"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-01-27 14:09:35 +1300" MODIFIED_BY="jane clarke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-01-27 14:09:35 +1300" MODIFIED_BY="jane clarke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-09-25 23:38:03 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bider-1996">
<CHAR_METHODS MODIFIED="2009-09-25 23:38:03 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: participants were randomised using a computer-generated randomisation list. Assignment method was not stated.<BR/>Blinding: not stated.<BR/>Follow up: until live birth.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-04 16:22:18 +1200" MODIFIED_BY="jane clarke">
<P>N=99. women mean age at time of oocyte retrieval was not reported. Their mean age at time of embryo transfer was 33.7 years for dexamethasone group and 32.9 years for control group. Cause of infertility: tubal factor in 100%.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-07 00:46:25 +1200" MODIFIED_BY="[Empty name]">
<P>Dexamethasone (0.5 mg orally nightly for five days, beginning on the day of ovulation) versus no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-07 00:46:47 +1200" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (dexamethasone versus no treatment): 13.5% versus 12.8%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dexamethasone group transferred a mean of 2.8 embryos and the control group transferred 2.1 embryos.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-05 06:50:23 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caligara-2003">
<CHAR_METHODS MODIFIED="2009-11-05 06:49:42 +1300" MODIFIED_BY="[Empty name]">
<P>Single centre.</P>
<P>Trial design: parallel.</P>
<P>Allocation method: not stated.</P>
<P>Blinding: No.</P>
<P>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-05 06:50:23 +1300" MODIFIED_BY="[Empty name]">
<P>Seventy-six (N=76) recipients were randomized into two groups: Group I (N= 39) used 800 mg/d of vaginal micronized  progesterone, and Group II (N= 37):used 50 mg of oil intramuscular progesterone daily from the day before donation onwards. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-05 06:49:52 +1300" MODIFIED_BY="[Empty name]">
<P>Comparison of pregnancy rate and implantation rate of vaginal versus intramuscular progesterone replacement therapy in an oocyte donation program.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-05 06:50:12 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (vaginal versus IM oil progesterone): 76% versus 69%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 07:14:36 +1300" MODIFIED_BY="[Empty name]">
<P>Patients received either 800 mg of vaginal micronized progesterone or 50 mg IM oil progesterone daily from the day before donation onwards.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-25 23:39:39 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dal-Prato-2002">
<CHAR_METHODS MODIFIED="2009-09-25 23:39:39 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: on an individual basis by using sealed envelopes and randomly assigned sequential numbers.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-04 16:22:19 +1200" MODIFIED_BY="jane clarke">
<P>N=296. women mean age at time of oocyte retrieval was 32.9 years for tryptorelin group and 32.5 years for the no-treatment group. Their mean age at time of embryo transfer was 34.6 years for tryptorelin group and 33.9 years for the no-treatment group. Cause of infertility: not stated.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:22:19 +1200" MODIFIED_BY="jane clarke">
<P>A single intramuscular injection of tryptorelin 3.75 mg was administered in the mid-luteal phase of the cycle to the tryptorelin group. No injection was given to the other group of women.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-07 00:46:58 +1200" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (tryptorelin versus no treatment): 19.1% versus 22.6%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-26 01:13:00 +1200" MODIFIED_BY="[Empty name]">
<P>Both groups transferred a mean of 2.1 embryos.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 13:08:01 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Davar-2007">
<CHAR_METHODS MODIFIED="2009-10-22 08:53:34 +1300" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: randomisation by computer-generated list. Allocation method: not stated.<BR/>Blinding: No.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-22 08:57:56 +1300" MODIFIED_BY="[Empty name]">
<P>N=60. Women mean age at time of oocyte retrieval was 28.1 years for buserelin group and 27.8 years for the no-treatment group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-22 08:54:03 +1300" MODIFIED_BY="[Empty name]">
<P>Buserelin acetate was used from previous mid-luteal phase at a dose of 0.5 mg, subcutaneously.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-22 08:55:39 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (buserelin versus no treatment): 10% versus 6.6%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-09 13:08:01 +1300" MODIFIED_BY="jane clarke">
<P>Cryopreservation was performed on pro nuclear stage. Transfer was performed when endometrial thickness was at least 8 mm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 14:09:35 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Ding-2007">
<CHAR_METHODS MODIFIED="2009-11-04 06:31:00 +1300" MODIFIED_BY="[Empty name]">
<P>Single centre.</P>
<P>Trial design: parallel.</P>
<P>Allocation:Frozen thawed blastocyst transfer was randomly performed on either 6 th or 7 th day of progesterone administration. Allocation method: not stated.</P>
<P>Blinding: No.</P>
<P>Follow up: until ongoing pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:09:35 +1300" MODIFIED_BY="jane clarke">
<P>N=49.  Frozen thawed blastocyst transfers during 49 consecutive cycles were randomized into two groups according to the days of progesterone administration. Group 1 (N= 23 cycles) frozen blastocyst were thawed and transferred on the 6 th day, and Group  2 (N=26 cycles)on the 7 th day of progesterone administration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 06:31:18 +1300" MODIFIED_BY="[Empty name]">
<P>Frozen thawed blastocyst transfer performed on the  6 th versus  the  7 th day of progesterone administration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 14:09:22 +1300" MODIFIED_BY="jane clarke">
<P>Pregnancy rate (transfer on day 6 versus day 7): 60.9% vs 53.8%, Ongoing pregnancy rate: (56.5% vs. 50.0%), Implantation rate: ( 40.7% vs. 30.0%)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 06:31:23 +1300" MODIFIED_BY="[Empty name]">
<P>There were no differences between groupI and Group 2 in patient age, maximal endometrial thickness and mean number of embryos per transfer.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-26 22:59:48 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El_x002d_Toukhy-2004">
<CHAR_METHODS MODIFIED="2009-09-25 23:41:14 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: participants were randomised using a computer-generated randomisation list. woman enrolment and assignment to their treatment groups was carried out at the time of participation by medical staff not involved in the study.<BR/>Blinding: not stated.<BR/>Follow up: until live birth.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-26 22:59:48 +1200" MODIFIED_BY="[Empty name]">
<P>N=234. women mean age at time of embryo transfer was 32.8 years for buserelin group and 33.2 years for the no treatment group. Cause of infertility: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:22:21 +1200" MODIFIED_BY="jane clarke">
<P>Buserelin nasal spray was started in the mid-luteal phase of the cycle to the buserelin group. No pituitary suppression prior to steroid hormone administration was given to the other group of women.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-07 00:47:07 +1200" MODIFIED_BY="[Empty name]">
<P>Live birth rate (buserelin versus no treatment): 20% versus 8.5% (P=0.01).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Buserelin group transferred a mean of 2.3 embryos and the control group transferred 2.2 embryos.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-25 23:42:48 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Escriba-2006">
<CHAR_METHODS MODIFIED="2009-09-25 23:42:48 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: a computer-based randomisation divided recipients into three groups.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-26 01:19:13 +1200" MODIFIED_BY="[Empty name]">
<P>N=282. Oocyte recipients mean age was 39.4 years in both groups. Donor mean age was not reported. </P>
<P>Cause of infertility: age 47.6%; poor responders 25.6%; implantation failure 8.5%; severe endometriosis 8.5%; other causes: 9.8%.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-26 01:19:52 +1200" MODIFIED_BY="[Empty name]">
<P>Group "Before oocyte retrieval": participants started progesterone the day prior to oocyte pick up (OPU). Group "Day of oocyte retrieval": started progesterone the day of OPU. Group "After": participants started progesterone the day following OPU.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate ("before" versus "day of" versus "After"): 38.1% versus 54.2% versus 52.7%. Cancellation rate: 12.4% (8 out of 12 were because of fertilization failure) versus 4.2% (1 of 4 were because of fertilization failure) versus 3.3% (0 out of 3 were because of fertilization failure).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All embryo transfers were done on day 3. Endometrium was prepared with oral estradiol and intravaginal micronized progesterone.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-25 23:44:18 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gibbons-1998">
<CHAR_METHODS MODIFIED="2009-09-25 23:44:18 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: participants were randomised to receive vaginal or intramuscular progesterone in a ratio of 7:3, respectively. Method of randomisation and assignment was not stated.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-26 01:22:48 +1200" MODIFIED_BY="[Empty name]">
<P>N=72. Oocyte recipients mean age and donor mean age were not reported. Cause of infertility: poor responders or premature ovarian failure (not stated the proportions).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Vaginal gel progesterone prefilled supply that places 90 mg of progesterone (dilution 8%) every 12 hours versus intramuscular progesterone 100 mg./day (both treatments were started the day of donor follicular aspiration).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate (vaginal gel versus intramuscular): 48.1% versus 27.7%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-26 01:25:53 +1200" MODIFIED_BY="[Empty name]">
<P>Randomisation was done in a ratio 7:3. Endometrium was prepared with estradiol patches.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-26 00:04:48 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gutierrez-1999">
<CHAR_METHODS MODIFIED="2009-09-25 23:46:21 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: method of randomisation and assignment was not stated.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>N=68. Neither donor nor recipient mean age was reported. All the recipients were ovulating women. Cause of infertility: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-26 00:04:48 +1200" MODIFIED_BY="[Empty name]">
<P>1 mg/day sc of leuprolide acetate was given to one group of women and 100 &#956;g twice a day daily of nafareline acetate was given to the other group of recipients, starting at mid-luteal phase.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate (leuprolide versus nafareline): 48.5% versus 54.3%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-25 23:46:49 +1200" MODIFIED_BY="[Empty name]">
<P>Data were obtained from the abstract.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 13:07:20 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Lan-2008">
<CHAR_METHODS MODIFIED="2009-11-04 06:39:04 +1300" MODIFIED_BY="[Empty name]">
<P>Single centre.</P>
<P>Trial design: parallel.</P>
<P>Allocation: randomisation using a blocked randomization method ( Block size of four).</P>
<P>Blinding: No.</P>
<P>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-09 13:07:20 +1300" MODIFIED_BY="jane clarke">
<P>Two hundred patients underwent randomization ( 100 patients each in the vaginal progesterone gel and vaginal progesterone tablet groups. There were no significant differences in in patient age or duration of infertility </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-09 13:07:14 +1300" MODIFIED_BY="jane clarke">
<P>From the day 2 of the cycle , all women received oral estradiol for at least 10 days. After endometrial thickness &gt; 8 mm, patients were assigned randomly to received vaginal progesterone  gel  90mg daily, once daily versus vaginal micronized progesterone , 200mg three times daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-09 11:59:07 +1300" MODIFIED_BY="jane clarke">
<P>Pregnancy rate  (  iv progesterone gel vs  iv micronized progesterone  tablets): 31% versus 28%, Implantation rate :9.8% vs 8.8%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-09 11:59:10 +1300" MODIFIED_BY="jane clarke">
<P>Patient convenience was measured as an outcome  with a questionnaire </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 13:07:06 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Lee-2008">
<CHAR_METHODS MODIFIED="2009-11-04 07:20:14 +1300" MODIFIED_BY="[Empty name]">
<P>Single centre.</P>
<P>Trial design: parallel.</P>
<P>Allocation method: not stated.</P>
<P>Blinding: No.</P>
<P>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-09 13:07:06 +1300" MODIFIED_BY="jane clarke">
<P>Eighty four (N=84) frozen thaw embryo transfers cycles were randomized into two groups:Group A ( natural cycle) consist of 39 cycles and Group B (artificial cycles) consist of 45 cycles.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 07:20:39 +1300" MODIFIED_BY="[Empty name]">
<P>Comparison of pregnancy rate and implantation rate of frozen thawed embryo transfer cycles, between natural and artificial (hormone treated) cycles. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 07:22:20 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (natural cycle vs artificial cycle): 74.4% versus 40.4%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-09 13:06:56 +1300" MODIFIED_BY="jane clarke">
<P>Natural cycle group received an hCG injection when the leader follicle got to 18-20 mm. Then, they received vaginal progesterone supplementation, 90 mg every other day, started on the day after embryo transfer. Artificial cycle group received oral micronized estradiol, 2 mg three times daily, introduced on cycle day 2; progesterone 100 mg in oil was administered via IM injection 4 days before the embryo transfer. Cryopreservation was performed by vilification.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 13:06:42 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Lightman-1999">
<CHAR_METHODS MODIFIED="2009-09-25 23:48:13 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: participants were randomised using the last digit of the woman ID number.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-04 16:22:22 +1200" MODIFIED_BY="jane clarke">
<P>N=354. women mean age at time of oocyte retrieval was 31.3 years for vaginal progesterone group and 30.4 years for intramuscular progesterone group. Their mean age at time of embryo transfer was 32 years for vaginal progesterone group and 31.5 years for intramuscular progesterone group. Cause of infertility: male factor 62%; mechanical 16%; unexplained 14%; other 7%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-25 23:48:34 +1200" MODIFIED_BY="[Empty name]">
<P>Vaginal suppositories: progesterone 200 mg three times daily versus intramuscular progesterone 100 mg./day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate (vaginal suppositories versus intramuscular): 16.8% versus 15.9%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-09 13:06:42 +1300" MODIFIED_BY="jane clarke">
<P>Embryo transfer was done on the third or fourth day of progesterone treatment, according to the embryo age: embryos frozen on the second or third day post-retrieval were transferred after 48 hrs and 72 hrs exposure to progesterone, respectively.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-26 00:01:18 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moffitt-1995">
<CHAR_METHODS MODIFIED="2009-09-26 00:01:18 +1200" MODIFIED_BY="[Empty name]">
<P>Multicentre.<BR/>Trial design: parallel.<BR/>Allocation: randomised by pharmacist who equally packaged the tablets/placebo and randomly assigned sequential numbers.<BR/>Blinding: double blind, placebo.<BR/>Follow up: until live birth, however the paper was written before all women delivered. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-04 16:22:23 +1200" MODIFIED_BY="jane clarke">
<P>N=206. women mean age at time of oocyte retrieval was not reported. Their mean age at time of embryo transfer was 34.3 years for 6-alpha-methylprednisolone group and 33.6 years for control group. Cause of infertility: variety of causes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Methylprednisolone (4 mg orally nightly for four days, beginning the day before embryo thaw) versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate (methylprednisolone versus placebo): 25% versus 30.3%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-25 23:51:53 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neuspiller-1998">
<CHAR_METHODS MODIFIED="2009-09-25 23:51:53 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: participants were randomised using the time they came to the appointment and the order.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-26 01:32:41 +1200" MODIFIED_BY="[Empty name]">
<P>N=183. Oocyte recipients mean age was 40 years for depot leuprolide acetate group, 37.7 years for daily leuprolide acetate group and 38.1 years for depot tryptorelin group. Donor mean age were 26.9 years, 27.8 years and 28.5 years, respectively. Cause of infertility: poor responders 78%; failed IVF 13%; endometriosis 4%; genetic 4%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-21 07:54:58 +1200" MODIFIED_BY="[Empty name]">
<P>Recipients were desensitised with a long-acting GnRHa, either leuprolide acetate 3.75 (intramuscular) or tryptorelin 3.75 (intramuscular) given in the luteal phase of the previous menstrual cycle, or daily subcutaneous administration of 1 mg leuprolide acetate starting in the luteal phase of the previous menstrual cycle.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate (depot leuprolide versus daily leuprolide versus depot tryptorelin): 56.9% versus 40.6% versus 47.5%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 13:06:24 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Prapas-2009a">
<CHAR_METHODS MODIFIED="2009-11-09 13:06:24 +1300" MODIFIED_BY="jane clarke">
<P>Single centre.</P>
<P>Trial design: parallel.</P>
<P>Allocation: by opaque envelopes, after a randomisation with a computer-generated method.</P>
<P>Blinding: No.</P>
<P>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-09 13:06:21 +1300" MODIFIED_BY="jane clarke">
<P>A total of 50 donors and 100 recipients were initially recruited for the study protocol. As it became evident early on that pregnancy rates were extremely low in the group of recipients receiving hCG injection, the study was discontinued prematurely for ethical reasons when 22 oocyte donation cycles were completed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-04 06:45:03 +1300" MODIFIED_BY="[Empty name]">
<P>hCG versus no hCG.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-09 13:06:16 +1300" MODIFIED_BY="jane clarke">
<P>Clinical pregnancy rate ( 13.6% Group 1 Which received HCG during endometrial preparations vs. 45.5%, Implantation rate ( 1.7% vs 22.4%)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 06:50:39 +1300" MODIFIED_BY="[Empty name]">
<P>Two recipients were matched with one oocyte donor and divided into two different groups. In group I, 750 IU of hCG was injected every three days starting on day 2 of recipients' endometrial preparation up to the day of hCG injection to the donor. The second matched recipient received no hCG injection and continued only with endometrial preparation. The study was discontinued prematurely due to the interim analysis (44 recipients were included when it was planned to include 100 recipients)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 13:06:00 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Ramos-2007">
<CHAR_METHODS MODIFIED="2009-11-04 06:57:30 +1300" MODIFIED_BY="[Empty name]">
<P>Single centre.</P>
<P>Trial design: parallel.</P>
<P>Allocation: not stated.</P>
<P>Blinding: No.</P>
<P>Follow up: until evolutive pregnancy. Live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-09 13:06:00 +1300" MODIFIED_BY="jane clarke">
<P>N=119 . 66 patients were randomized to the group A which used GnRH agonist suppression (Triptorelyn 3.75 depot, 1+B34 ampoule IM). The other group B of 53 randomized patients, did not use GnRH agonist in their endometrial preparation. Average patients´s age was 35 years old, and the number of embryo transfer was 1.3. Endometrial thickness previous progesterone was 8 mm .</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-09 13:05:52 +1300" MODIFIED_BY="jane clarke">
<P>Women in treatment for frozen-thawed embryo transfer were randomized for this study and all of them used oral contraceptives pills the month before the embryo transfer. Sixty six patients were randomized to the group A which used GnRH agonist suppression (Triptorelyn 3.75 depot, one intramuscular ampoule). The other group B of 53 randomized patients, did not use GnRH agonist in their endometrial preparation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 06:59:13 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (Group A triptorelyn , estradiol and+ progesterone versus group B estradiol plus progesterone alone ):25.6% versus 24.3%. Ongoing pregnancy rate: 14.1%versus 17.1%, Miscarriage rate: 11.5% versus 7.1%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-09 13:05:41 +1300" MODIFIED_BY="jane clarke">
<P>GnRH agonist suppression (Triptorelyn 3.75 mg depot, 1 ampoule IM) was given on the day of contraceptive pill number 16 (in the previous cycle). In both groups endometrial preparation was performed with estradiol  transdermic patches, which were started from the second day  of menstruation and used every other day, with an initial dose of 100 mg/day and after two days increased to 200 mg/d. Progesterone was used vaginally, at a dose  of 800 mg/d, started at least 11 days after transdermic estradiol was started.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-25 23:53:15 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Remohi-1994">
<CHAR_METHODS MODIFIED="2009-09-25 23:52:59 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: not stated.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-26 01:34:17 +1200" MODIFIED_BY="[Empty name]">
<P>N=69. Oocyte recipients mean age was 37.1 years for daily leuprolide acetate group and 37.9 years for the no-treatment group. Donor mean age were 31.4 years and 31.1 years, respectively. Cause of infertility: poor responders 85%; premature ovarian failure 15%.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-25 23:53:15 +1200" MODIFIED_BY="[Empty name]">
<P>One group of recipients was desensitised with daily subcutaneous administration of 1 mg leuprolide acetate and the other group was not desensitised.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-07 00:47:15 +1200" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (leuprolide daily versus no treatment): 54.5% versus 58.3%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-25 23:54:30 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tesarik-2003">
<CHAR_METHODS MODIFIED="2009-09-25 23:53:53 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: randomisation was based on the oocyte-sharing policy used in the oocyte donation programme. According to this policy, oocytes from one donor are shared between two recipients selected from a waiting list. The decision on which of the oocyte sharing recipients would receive HCG and placebo respectively was based on the alphabetical order of the first letter of the woman&#8217;s surname.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-26 01:36:07 +1200" MODIFIED_BY="[Empty name]">
<P>N=526 ovulating oocyte recipients. Ovulating oocyte recipients mean age was 40.2 years for hCG group and 40.4 years for placebo group. Non-ovulating oocyte recipients mean age was 41.7 years for hCG group and 41.8 years for placebo group. Donor mean age was not reported. Cause of infertility: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Intramuscular injection of 5000 IU of hCG 2 days before oocyte recovery from the corresponding oocyte donor versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate (hCG versus placebo): 56.3% versus 49.6% (ovulating recipients) and 56.9% versus 60% (non-ovulating recipients).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-25 23:54:30 +1200" MODIFIED_BY="[Empty name]">
<P>It was a strength of the trial that they matched two randomised recipients by the same oocyte donor (it is a shared oocyte donor program). All women had received intramuscular tryptorelin and had been stimulated with increasing doses of oral estradiol valerate. Endometrial thickness was evaluated on day 19.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 13:04:59 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Tocino-2007">
<CHAR_METHODS MODIFIED="2009-11-04 11:41:37 +1300" MODIFIED_BY="[Empty name]">
<P>Single centre.</P>
<P>Trial design: parallel.</P>
<P>Allocation method: not stated.</P>
<P>Blinding: No </P>
<P>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-09 13:04:59 +1300" MODIFIED_BY="jane clarke">
<P>Forty- eight (N=48) recipients for oocyte donation, were randomized into two groups: Group A (N=23) used daily GnRH agonist suppression (Leuprolide  Acetate 0.1 mL/d)  and Group B (N=23) used a GnRH agonist depot (Triptoreline 3.75 mg / IM) </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-09 13:04:54 +1300" MODIFIED_BY="jane clarke">
<P>Forty- eight (N=48) recipients for oocyte donation, received oral contraceptive pills the month before the embryo transfer, and  were randomized into two groups: Group A (N=23) used daily GnRH agonist suppression (Leuprolide  Acetate , 0,1 mL/d) starting 5 days before ending the contraceptive pill.Group B (N=23) used a GnRH agonist depot ( Triptoreline, 3,75 mg / IM) 5 days before ending the contraceptive pill.In both groups the endometrial preparation was achieved by using estradiol transdermic patches, started from the second day of the menstruation and increasing the doses</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-04 11:41:49 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (Dayly leuprolide acetate vs Depot Triptoreline ): 65% vs 50%, Implantation rate: 48.8% vs 36.1%, Abortion rate (6.7% vs 40%)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-04 11:41:49 +1300" MODIFIED_BY="[Empty name]">
<P>In both groups , the average patient´s age was 38 years old and the  mean number of embryos transferred was 1.8. the endometrial thickness and estradiol levels previous to donation were similar in both groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-25 23:55:50 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weckstein-1997">
<CHAR_METHODS MODIFIED="2009-09-25 23:55:50 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: not stated.<BR/>Blindingof care-workers: not stated.<BR/>Follow up: until live birth.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-26 01:37:45 +1200" MODIFIED_BY="[Empty name]">
<P>N=28. Oocyte recipients mean age was 41.8 years for aspirin group and 39.4 years for control group. Donor mean age was not reported. Cause of infertility: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-07 00:47:23 +1200" MODIFIED_BY="[Empty name]">
<P>Aspirin (81 mg orally every day, beginning one week prior to start estrogen therapy) versus no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-07 00:47:31 +1200" MODIFIED_BY="[Empty name]">
<P>Live birth rate (aspirin versus no treatment): 46.6% versus 30.7%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>All transfers were done on days 2 or 3. Endometrium was prepared with estradiol patches and intramuscular progesterone.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-25 23:57:16 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wright-2006">
<CHAR_METHODS MODIFIED="2009-09-25 23:56:55 +1200" MODIFIED_BY="[Empty name]">
<P>Single centre.<BR/>Trial design: parallel.<BR/>Allocation: not stated.<BR/>Blinding: not stated.<BR/>Follow up: until pregnancy. Therefore live birth rate not included in outcomes.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-25 23:57:16 +1200" MODIFIED_BY="[Empty name]">
<P>N=199. Women's mean age at time of oocyte retrieval was not reported. Their mean age at time of embryo transfer was 34 years for both groups. Cause of infertility: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-26 01:39:35 +1200" MODIFIED_BY="[Empty name]">
<P>Stimulated women received recombinant FSH injections 150 IU on days 6, 8 and 10 of the menstrual cycle, and continued until endometrium was thicker than 7 mm or follicles were bigger than 16-20 mm. Women who had artificial cycles received 17-beta-estradiol 4 mg per day until endometrium over 7 mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate (FSH versus estradiol): 12.1% versus 11%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Both groups received progesterone 300 mg in vaginal suppositories.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 13:11:57 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Zegers-2000">
<CHAR_METHODS MODIFIED="2009-09-25 23:59:02 +1200" MODIFIED_BY="[Empty name]">
<P>Multi centre.<BR/>Trial design: parallel.<BR/>Allocation: not stated.<BR/>Blinding: not stated.<BR/>Follow-up: until live birth.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-26 01:40:44 +1200" MODIFIED_BY="[Empty name]">
<P>N=153. Oocyte recipients mean age was 39.2 years for vaginal progesterone group and 38 years for intramuscular progesterone group. Donor mean age was not reported. Cause of infertility: poor responders or premature ovarian failure (proportion not stated).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-09 13:04:25 +1300" MODIFIED_BY="jane clarke">
<P>Vaginal ring containing 1 gm of natural progesterone (placed the day of donor follicular aspiration) versus intramuscular progesterone 100 mg/day (started the day of donor follicular aspiration).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-04 16:18:00 +1200" MODIFIED_BY="jane clarke">
<P>Live birth rate (vaginal ring versus intramuscular): 32.5% versus 21.4%.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-09 13:11:57 +1300" MODIFIED_BY="jane clarke">
<P>If pregnancy test was positive, the vaginal ring was replaced by a new ring containing 2 gm of progesterone which was left in the vagina for 7 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-11-09 12:59:28 +1300" MODIFIED_BY="jane clarke" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bernabeu-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Indomethacin was not used for endometrial preparation. it was used just before embryo transfer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-26 01:42:13 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Check-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-26 01:42:13 +1200" MODIFIED_BY="[Empty name]">
<P>It was not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-04 16:22:25 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Check-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-04 16:22:25 +1200" MODIFIED_BY="jane clarke">
<P>Less than 10 women per treatment group and no clinically important outcome was evaluated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-04 07:52:07 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Check-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-04 07:52:07 +1300" MODIFIED_BY="[Empty name]">
<P>It compares different kind of stimulations (sildenafil versus oestradiol)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-04 07:19:00 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feliciani-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-04 07:19:00 +1300" MODIFIED_BY="[Empty name]">
<P>Doses used for vaginal progesterone were below the standard doses</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-26 01:42:32 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krasnow-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-26 01:42:32 +1200" MODIFIED_BY="[Empty name]">
<P>The outcome was not valid.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-09 12:57:49 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Lan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-09 12:57:49 +1300" MODIFIED_BY="jane clarke">
<P>Duplicated data from <LINK REF="STD-Lan-2008" TYPE="STUDY">Lan 2008</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-09 12:59:23 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Lewin-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-09 12:59:23 +1300" MODIFIED_BY="jane clarke">
<P>Excluded because the outcome was not clinical (but histological)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moon-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Piroxicam was not used for endometrial preparation. it was used just before embryo transfer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-26 01:42:48 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nardo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-26 01:42:48 +1200" MODIFIED_BY="[Empty name]">
<P>It was not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-04 07:07:41 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Page-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-04 07:07:41 +1300" MODIFIED_BY="[Empty name]">
<P>It is not shown how many patients were in each group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-04 07:31:46 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prapas-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-04 07:31:46 +1300" MODIFIED_BY="[Empty name]">
<P>No comparison included in our protocol was evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-23 07:16:22 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sathanandan-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-23 07:16:22 +1200" MODIFIED_BY="[Empty name]">
<P>Randomisation was not adequate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-04 07:30:12 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiotani-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-04 07:30:12 +1300" MODIFIED_BY="[Empty name]">
<P>It is not shown how many patients were in each group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-26 01:43:19 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simon-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-26 01:43:19 +1200" MODIFIED_BY="[Empty name]">
<P>Comparisons were not equal (the comparator group also used higher doses of estrogen).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-09 12:59:28 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Taskin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-09 12:59:28 +1300" MODIFIED_BY="jane clarke">
<P>Excluded because the outcome was not clinical (but histological).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-09 12:57:49 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Toner-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-09 12:57:49 +1300" MODIFIED_BY="jane clarke">
<P>Duplicated data from <LINK REF="STD-Gibbons-1998" TYPE="STUDY">Gibbons 1998</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-11-09 13:11:41 +1300" MODIFIED_BY="jane clarke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-11-09 02:09:29 +1300" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-11-04 11:42:30 +1300" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 22:59:09 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bider-1996">
<DESCRIPTION>
<P>The participants were treated according to a computer randomisation. However, it is not stated how allocation was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:12:57 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caligara-2003">
<DESCRIPTION>
<P>It is not described how allocation and randomization was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:40:11 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dal-Prato-2002">
<DESCRIPTION>
<P>The randomisation was performed by using sealed envelopes containing the name of one of the two treatment. Each envelope and allocation was sequentially numbered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 08:51:34 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davar-2007">
<DESCRIPTION>
<P>The study population was randomly divided into two groups according to a computer-generated list, but no information was found about the allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:31:55 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ding-2007">
<DESCRIPTION>
<P>It is not described how allocation and randomization was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:19:49 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Toukhy-2004">
<DESCRIPTION>
<P>The study population was randomly divided into two groups according to a computer-generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:23:36 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Escriba-2006">
<DESCRIPTION>
<P>A computer-based randomisation divided recipients into three groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:45:18 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibbons-1998">
<DESCRIPTION>
<P>Although it was a RCT, how randomisation and allocation was done not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:47:05 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gutierrez-1999">
<DESCRIPTION>
<P>Although it was a RCT, randomisation procedure not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:40:02 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lan-2008">
<DESCRIPTION>
<P>The study population was randomly divided into two groups according to a blocked randomization method (block size of four) prior to the time of starting progesterone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:22:52 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2008">
<DESCRIPTION>
<P>It is not described how allocation and randomization was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:01:37 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lightman-1999">
<DESCRIPTION>
<P>Randomisation was allocated by the last digit of the patient ID number: odds numbers were assigned to vaginal and even number to intramuscular (IM)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-06 13:57:38 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moffitt-1995">
<DESCRIPTION>
<P>Randomised by pharmacist who equally packaged the tablets/ placebo and randomly assigned sequential numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:28:15 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neuspiller-1998">
<DESCRIPTION>
<P>Allocation depended on time of attendance to the clinic and order of attendance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:47:33 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prapas-2009a">
<DESCRIPTION>
<P>The randomization was performed by using sealed envelopes containing the name of one of the two treatment . Each envelope and allocation was sequentially numbered- </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:00:55 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-2007">
<DESCRIPTION>
<P>It is not described how allocation and randomization was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:53:32 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remohi-1994">
<DESCRIPTION>
<P>It was not stated how performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:06:30 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tesarik-2003">
<DESCRIPTION>
<P>The decision of which of the oocyte sharing recipients would received hCG and placebo respectively was based on the alphabetical order of the first letter of the patient´s surname</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 11:42:30 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tocino-2007">
<DESCRIPTION>
<P>It is not described how allocation and randomization was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-09 03:01:38 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weckstein-1997">
<DESCRIPTION>
<P>Sealed envelopes were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:57:54 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-2006">
<DESCRIPTION>
<P>It was not stated how performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:59:40 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zegers-2000">
<DESCRIPTION>
<P>How allocation was done not described. They used randomisation tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-11-09 13:07:56 +1300" MODIFIED_BY="jane clarke" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-26 00:02:15 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bider-1996">
<DESCRIPTION>
<P>Patients were not blind to the treatment: some of them received dexamethasone 0.5 mg orally and the control group received no treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-04 07:13:08 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caligara-2003">
<DESCRIPTION>
<P>Patients randomized to one group received intramuscular progesterone, and patients of the other group received vaginal progesterone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-03 03:16:10 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dal-Prato-2002">
<DESCRIPTION>
<P>In group 1 patients received IM injection. In group 2 they did not received any IM injection (no patient blinding)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-09 13:07:56 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Davar-2007">
<DESCRIPTION>
<P>Patients randomized to group B had pituitary suppression (performed using buserelin acetate) prior to steroid hormone administration, while group A commenced steroid supplementation without prior pituitary sensitization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-04 06:32:26 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ding-2007">
<DESCRIPTION>
<P>It is not described if patients and care givers were blinded to the received treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-25 23:41:52 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El_x002d_Toukhy-2004">
<DESCRIPTION>
<P>Patients randomised to group A had pituitary suppression (performed using buserelin nasal spray) prior to steroid hormone administration, while group B started steroid supplementation without prior pituitary suppression</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-09 14:14:05 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Escriba-2006">
<DESCRIPTION>
<P>Patients received progesterone in different days respect to oocyte retrieval</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-06 11:35:33 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gibbons-1998">
<DESCRIPTION>
<P>Some patients received IM injection and some others received intravaginal progesterone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-06 11:38:58 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gutierrez-1999">
<DESCRIPTION>
<P>Some patients received once a day leuprolide acetate subcutaneously and some others was twice a day, daily doses of nafareline acetate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-09 11:59:41 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Lan-2008">
<DESCRIPTION>
<P>Patients were randomised to receive self-administered sustained-release progesterone gel 90 mg daily (Group 1) or micronized progesterone (Utrogestan ) 200 mg three times daily (Group 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-09 13:06:48 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Lee-2008">
<DESCRIPTION>
<P>Patients randomized to one group received only an hCG injection, and patients of the other group received oral 17-beta-oestradiol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-06 11:40:04 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lightman-1999">
<DESCRIPTION>
<P>Some patients received IM injection and some others received intravaginal progesterone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-09 02:57:51 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moffitt-1995">
<DESCRIPTION>
<P>Double blind, placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-25 23:52:21 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neuspiller-1998">
<DESCRIPTION>
<P>Short-acting GnRH daily injections in some patients and long acting, one injection in some others</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-04 06:47:44 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prapas-2009a">
<DESCRIPTION>
<P>Patients were randomized to receive hCG injections every 3 days (Group 1) or no injections (Group 2)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-09 13:05:25 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Ramos-2007">
<DESCRIPTION>
<P>Patients randomized to group A  had pituitary suppression (performed using triptorelyn depot intramuscular) prior to steroid hormone administration, while group B commenced steroid supplementation without prior pituitary sensitization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-03 03:32:01 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remohi-1994">
<DESCRIPTION>
<P>The control group did not use leuprolide acetate during endometrial preparation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-25 23:54:56 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tesarik-2003">
<DESCRIPTION>
<P>It was not stated if doctors were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-09 13:04:39 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Tocino-2007">
<DESCRIPTION>
<P>Patients randomized to group A  had pituitary suppression daily GnRH agonist suppression with Leuprolide acetate 0.1 mL/d while group B had pituitary suppression daily GnRH agonist suppression with GnRHa depot (Triproreline, 3.75 mg intramuscular)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-09 14:12:28 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Weckstein-1997">
<DESCRIPTION>
<P>Some patients received aspirin and some others received no treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-25 23:58:04 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wright-2006">
<DESCRIPTION>
<P>Patients randomised to the artificial cycle began taking oral 17 beta estradiol and vaginal micronized progesterone while patients randomised to the stimulated protocol received FSH</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-03 03:39:52 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zegers-2000">
<DESCRIPTION>
<P>Patients allocated to either IM progesterone or a vaginal ring</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-11-09 02:09:29 +1300" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-11-09 02:09:29 +1300" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2009-11-09 13:11:41 +1300" MODIFIED_BY="jane clarke" NO="7">
<NAME>Follow-up for live birth rate</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-09 02:54:34 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bider-1996">
<DESCRIPTION>
<P>Live birth rate in this study was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:08:10 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Caligara-2003">
<DESCRIPTION>
<P>The live birth rate in this study wasn't´an outcome </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:16:43 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dal-Prato-2002">
<DESCRIPTION>
<P>Live birth rate in this study was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:07:54 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Davar-2007">
<DESCRIPTION>
<P>The live birth rate in this study wasn't´ an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:32:49 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ding-2007">
<DESCRIPTION>
<P>The live birth rate in this study was not  an outcome </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:42:04 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Toukhy-2004">
<DESCRIPTION>
<P>It was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:24:27 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Escriba-2006">
<DESCRIPTION>
<P>Live birth rate in this study was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-06 11:35:55 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gibbons-1998">
<DESCRIPTION>
<P>Live birth rate in this study was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-06 11:39:18 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gutierrez-1999">
<DESCRIPTION>
<P>Live birth rate in this study was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 11:59:37 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Lan-2008">
<DESCRIPTION>
<P>The live birth rate in this study was not  an outcome </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:06:51 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Lee-2008">
<DESCRIPTION>
<P>The live birth rate in this study wasn't´ an outcome </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:01:50 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lightman-1999">
<DESCRIPTION>
<P>Live birth rate was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:50:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moffitt-1995">
<DESCRIPTION>
<P>It was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:04:21 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neuspiller-1998">
<DESCRIPTION>
<P>Live birth rate was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:11:26 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Prapas-2009a">
<DESCRIPTION>
<P>The live birth rate in this study wasn't an outcome </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:11:32 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Ramos-2007">
<DESCRIPTION>
<P>The live birth rate in this study wasn't an outcome </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:04:05 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Remohi-1994">
<DESCRIPTION>
<P>Live birth rate was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:03:41 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tesarik-2003">
<DESCRIPTION>
<P>Live birth rate was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:11:41 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Tocino-2007">
<DESCRIPTION>
<P>The live birth rate in this study wasn't  an outcome </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-06 14:01:40 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weckstein-1997">
<DESCRIPTION>
<P>Live birth rate was the main outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:04:59 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wright-2006">
<DESCRIPTION>
<P>Live birth rate was not an outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:59:45 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2000">
<DESCRIPTION>
<P>It was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2009-11-09 13:07:42 +1300" MODIFIED_BY="jane clarke" NO="8">
<NAME>Baseline equality</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 22:59:15 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bider-1996">
<DESCRIPTION>
<P>Both groups were similar in women age, infertility diagnosis and male factor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:13:33 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caligara-2003">
<DESCRIPTION>
<P>There is no data about the baseline characteristics of both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:17:47 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dal-Prato-2002">
<DESCRIPTION>
<P>Both groups were similar respect to age, causes of infertility, endometrial thickness and the day when the progesterone was started</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:07:42 +1300" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Davar-2007">
<DESCRIPTION>
<P>both groups were similar respect to age at stimulation, causes of infertility, endometrial thickness, number of transferred embryos, and day when the progesterone was started.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:07:34 +1300" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Ding-2007">
<DESCRIPTION>
<P>Both groups were similar respect to age at stimulation, endometrial thickness and number of transferred embryos</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:21:03 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Toukhy-2004">
<DESCRIPTION>
<P>Both groups were similar respect to age at stimulation, causes of infertility, endometrial thickness, basal FSH level and day when the progesterone was started</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:29:35 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Escriba-2006">
<DESCRIPTION>
<P>Both groups were similar respect to age of the recipient, body mass index, days undergoing oestrogen therapy, endometrial thickness achieved, and incidence of severe sperm pathology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:45:35 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibbons-1998">
<DESCRIPTION>
<P>It was not mentioned if groups were balanced in terms of reproductive predictive variables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:47:15 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gutierrez-1999">
<DESCRIPTION>
<P>It was not mentioned if groups were balanced in terms of reproductive predictive variables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 11:59:48 +1300" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Lan-2008">
<DESCRIPTION>
<P>Both groups were similar respect to age at stimulation, endometrial thickness, duration of endometrial stimulation, duration of infertility and number of transferred embryos</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:23:20 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2008">
<DESCRIPTION>
<P>There is no data about the baseline characteristics of both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:49:20 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lightman-1999">
<DESCRIPTION>
<P>Both groups were similar with respect to age at stimulation, diagnosis of infertility, and number of previous pregnancies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-09 03:00:03 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moffitt-1995">
<DESCRIPTION>
<P>Both groups in stimulation cycles were similar regarding age, prior IVF attempts, hormone levels, mature and total oocytes retrieved, fertilization rate, frozen embryos and cases with cryopreservation. Both groups in cryopreservation cycles were similar regarding age, hormone levels, mature and total oocytes retrieved, embryos frozen, fresh clinical pregnancy and implantation rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:30:29 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neuspiller-1998">
<DESCRIPTION>
<P>Recipient groups were similar regarding age, GnRH days and indication of oocyte donation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 13:06:05 +1300" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Prapas-2009a">
<DESCRIPTION>
<P>Both groups were similar respect to age of the recipient, endometrial thickness, duration of endometrial stimulation, and number of transferred embryos</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:01:27 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-2007">
<DESCRIPTION>
<P>There is no data about the baseline characteristics of both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-09 14:13:45 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Remohi-1994">
<DESCRIPTION>
<P>Both groups of recipients were similar respect to age, number of cycles, indication of oocyte recipient, number of transferred embryos</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:03:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tesarik-2003">
<DESCRIPTION>
<P>There were no differences in patient´s age, body weight and the number of embryos transferred between the mid-cycle HCG and placebo groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 11:43:12 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tocino-2007">
<DESCRIPTION>
<P>There is no data about the baseline characteristics of both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:56:24 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weckstein-1997">
<DESCRIPTION>
<P>There was no table showing baseline equality</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:06:35 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wright-2006">
<DESCRIPTION>
<P>Both groups were similar with respect to age, day 3 FSH concentration, and percentage with intracytoplasmic sperm injection (ICSI)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:08:21 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2000">
<DESCRIPTION>
<P>Both groups were similar with respect to age and number of transferred embryos</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2009-11-04 11:43:21 +1300" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Losses to follow-up</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:38:59 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bider-1996">
<DESCRIPTION>
<P>There are no losses of follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:13:41 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caligara-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:40:41 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dal-Prato-2002">
<DESCRIPTION>
<P>There were no losses to follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 08:45:43 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davar-2007">
<DESCRIPTION>
<P>There are no losses of follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:33:15 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ding-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:42:21 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Toukhy-2004">
<DESCRIPTION>
<P>There were no losses to follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:43:49 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Escriba-2006">
<DESCRIPTION>
<P>It was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:45:45 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gibbons-1998">
<DESCRIPTION>
<P>There were no losses to follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:47:27 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gutierrez-1999">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:40:46 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lan-2008">
<DESCRIPTION>
<P>There are no losses of follow up (&lt;10)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:23:38 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:49:25 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lightman-1999">
<DESCRIPTION>
<P>There were no losses of follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:50:59 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moffitt-1995">
<DESCRIPTION>
<P>It was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:30:43 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neuspiller-1998">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:48:26 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prapas-2009a">
<DESCRIPTION>
<P>There are no losses of follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:01:34 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:33:26 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remohi-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:35:32 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tesarik-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 11:43:21 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tocino-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-09 03:02:52 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weckstein-1997">
<DESCRIPTION>
<P>There were no losses of follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:58:13 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wright-2006">
<DESCRIPTION>
<P>There were no losses to follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:59:55 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2000">
<DESCRIPTION>
<P>There were no losses to follow up (&lt;10%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2009-11-04 11:43:30 +1300" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Intention-to-treat-analysis</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:39:07 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bider-1996">
<DESCRIPTION>
<P>Results were described as an intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:13:43 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caligara-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:40:58 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dal-Prato-2002">
<DESCRIPTION>
<P>Results were described as intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 08:46:07 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davar-2007">
<DESCRIPTION>
<P>Results were described as an intention to treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:33:31 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ding-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:42:30 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El_x002d_Toukhy-2004">
<DESCRIPTION>
<P>Analysis was performed on an intention-to-treat basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:25:30 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Escriba-2006">
<DESCRIPTION>
<P>Some patients were excluded when embryo transfer did not take place on day 3 of embryo development</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:45:59 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gibbons-1998">
<DESCRIPTION>
<P>Results were described as an intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:47:34 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gutierrez-1999">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:40:58 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lan-2008">
<DESCRIPTION>
<P>Results were described as an intention to treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:23:44 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:49:39 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lightman-1999">
<DESCRIPTION>
<P>Results were described as an intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:51:15 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moffitt-1995">
<DESCRIPTION>
<P>Results were described as an intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:31:02 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Neuspiller-1998">
<DESCRIPTION>
<P>Results were analysed as treated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:48:41 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prapas-2009a">
<DESCRIPTION>
<P>Results were described as an intention to treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:01:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:33:37 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remohi-1994">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:03:53 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tesarik-2003">
<DESCRIPTION>
<P>Results were described as an intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 11:43:30 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tocino-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:56:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weckstein-1997">
<DESCRIPTION>
<P>Results were described as an intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 23:05:56 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wright-2006">
<DESCRIPTION>
<P>Results were not assessed in all enrolled patients but only after excluding some of them</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:00:02 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2000">
<DESCRIPTION>
<P>Results were described as an intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2009-11-04 11:43:31 +1300" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Outcome assessment</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:02:27 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bider-1996">
<DESCRIPTION>
<P>It is not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:13:45 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caligara-2003">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-03 03:18:52 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dal-Prato-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-22 08:46:49 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davar-2007">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:33:32 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ding-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:02:02 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-El_x002d_Toukhy-2004">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:03:25 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Escriba-2006">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:03:51 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibbons-1998">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:47:59 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gutierrez-1999">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:41:15 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lan-2008">
<DESCRIPTION>
<P>Care givers were not blinded to the treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:23:47 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:05:35 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lightman-1999">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:51:33 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moffitt-1995">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:52:45 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neuspiller-1998">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 06:48:52 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prapas-2009a">
<DESCRIPTION>
<P>Care givers were not blinded to the treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 07:01:43 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramos-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:06:06 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Remohi-1994">
<DESCRIPTION>
<P>It is not stated if outcome assessments were performed by a blinded investigator or care-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:55:38 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tesarik-2003">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 11:43:31 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tocino-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:56:49 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weckstein-1997">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-25 23:58:56 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wright-2006">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-26 00:00:17 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zegers-2000">
<DESCRIPTION>
<P>It was not stated if outcome assessments were performed by a blinded investigator or healthcare-worker</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-11-05 10:50:56 +1300" MODIFIED_BY="Agustín Ciapponi">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-11-05 10:50:56 +1300" MODIFIED_BY="Agustín Ciapponi" NO="1" READONLY="YES">
<TITLE MODIFIED="2009-11-05 10:50:56 +1300" MODIFIED_BY="Agustín Ciapponi">Starting progesterone either on the oocyte pick-up day or the day after compared to the day before</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>starting progesterone either on the oocyte pick-up day or the day after compared to the day before for oocyte recipients</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> oocyte recipients</P>
<P>
<B>Settings:</B>
</P>
<P>
<B>Intervention:</B> starting progesterone either on the oocyte pick-up day or the day after</P>
<P>
<B>Comparision: </B>the day before</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>the day before</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>starting progesterone either on the oocyte pick-up day or the day after</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Clinical Pregnancy Rate</B>
<BR/>(follow-up: 9)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>OR 1.40 (1.05 to 1.87)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>282<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>381 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>533 per 1000<BR/>(400 to 712)</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>
<B>Cancellation rate</B>
<BR/>(follow-up: 9)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Population</B>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>OR 0.31 (0.12 to 0.76)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>282<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>124 per 1000</P>
</TD>
<TD ROWSPAN="1" VALIGN="MIDDLE">
<P>38 per 1000<BR/>(15 to 94)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio GRADE: GRADE Working Group grades of evidence (see explanations)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Intention to-treat analysis not done by the authors</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2009-11-05 10:48:48 +1300" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2009-11-05 10:48:48 +1300" MODIFIED_BY="Grade Profiler">Intramuscular progesterone versus vaginal progesterone for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Intramuscular progesterone versus vaginal progesterone for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Intramuscular progesterone versus vaginal progesterone<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Intramuscular progesterone versus vaginal progesterone</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Clinical Pregnancy Rate</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 1.44 </B>
<BR/>(0.98 to 2.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>655<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>261 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>337 per 1000</B>
<BR/>(257 to 426)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>282 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>361 per 1000</B>
<BR/>(278 to 452)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The confidence interval is relatively wide, crossing the null effect.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-09-26 00:07:50 +1200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-09-26 00:07:50 +1200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-09-26 00:07:38 +1200" MODIFIED_BY="[Empty name]">Quality assesment criteria</TITLE>
<TABLE COLS="4" ROWS="9">
<TR>
<TH>
<P>Assesment</P>
</TH>
<TH>
<P>Yes</P>
</TH>
<TH>
<P>Unclear</P>
</TH>
<TH>
<P>No</P>
</TH>
</TR>
<TR>
<TD>
<P>Allocation concealment</P>
</TD>
<TD>
<P>Adequate e.g. central randomisation / allocation, sealed envelopes, etc.</P>
</TD>
<TD>
<P>Not reported / unclear</P>
</TD>
<TD>
<P>Inadequate</P>
</TD>
</TR>
<TR>
<TD>
<P>Treatment blinding</P>
</TD>
<TD>
<P>Statement that containers were identical, drugs were identical in appearance and taste</P>
</TD>
<TD>
<P>Not reported / unclear</P>
</TD>
<TD>
<P>Interventions were not identical</P>
</TD>
</TR>
<TR>
<TD>
<P>Outcome assessment</P>
</TD>
<TD>
<P>Blinded, standardised assessment</P>
</TD>
<TD>
<P>Assesment procedures not stated</P>
</TD>
<TD>
<P>Assessment not blinded or not standardised</P>
</TD>
</TR>
<TR>
<TD>
<P>Follow-up completeness for first outcome (live birth rate)</P>
</TD>
<TD>
<P>Live birth rate reported</P>
</TD>
<TD>
<P>Pregnancy rate reported</P>
</TD>
<TD>
<P>Other outcome</P>
</TD>
</TR>
<TR>
<TD>
<P>Baseline equality</P>
</TD>
<TD>
<P>Groups balanced in terms of age and angina frequency</P>
</TD>
<TD>
<P>Balance not reported</P>
</TD>
<TD>
<P>Groups not balanced</P>
</TD>
</TR>
<TR>
<TD>
<P>Losses to follow up (not including early cessation of therapy followed up)</P>
</TD>
<TD>
<P>Losses of 10% or less</P>
</TD>
<TD>
<P>Not reported / unclear</P>
</TD>
<TD>
<P>Losses of more than 10%</P>
</TD>
</TR>
<TR>
<TD>
<P>Bias in the analysis: intention-to-treat (ITT)</P>
</TD>
<TD>
<P>ITT analysis done by the authors</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Not ITT analysis done by the authors</P>
</TD>
</TR>
<TR>
<TD>
<P>Risk of bias</P>
</TD>
<TD>
<P>All of the previous criteria met (all are assessment quality A)</P>
</TD>
<TD>
<P>One or more of the previous criteria partly met (at least one assessment quality B and no assessment quality C)</P>
</TD>
<TD>
<P>One or more of the previous criteria not met (at least one assessment quality C)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-11-05 11:06:46 +1300" MODIFIED_BY="Agustín Ciapponi">
<COMPARISON ID="CMP-001" MODIFIED="2009-11-04 11:20:00 +1300" MODIFIED_BY="[Empty name]" NO="1">
<NAME>GnRH agonists versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.7826726838833125" CI_START="1.1853289990574691" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.618085106382979" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.7621286106666698" LOG_CI_START="0.07383890953953809" LOG_EFFECT_SIZE="0.4179837601031039" METHOD="MH" MODIFIED="2009-04-07 00:50:08 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.017289665674899913" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="117" WEIGHT="100.0" Z="2.3804892462669462">
<NAME>Live-Birth Rate</NAME>
<GROUP_LABEL_1>GnRH agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GnRH agonist</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.7826726838833125" CI_START="1.1853289990574691" DF="0" EFFECT_SIZE="2.618085106382979" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.7621286106666698" LOG_CI_START="0.07383890953953809" LOG_EFFECT_SIZE="0.4179837601031039" MODIFIED="2009-04-07 00:50:08 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.017289665674899913" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="117" WEIGHT="100.0" Z="2.3804892462669462">
<NAME>Nasal Buserelin versus No treatment (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="5.782672683883311" CI_START="1.185328999057469" EFFECT_SIZE="2.6180851063829786" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="10" LOG_CI_END="0.7621286106666696" LOG_CI_START="0.073838909539538" LOG_EFFECT_SIZE="0.41798376010310384" ORDER="17" O_E="0.0" SE="0.40430477753104654" STUDY_ID="STD-El_x002d_Toukhy-2004" TOTAL_1="117" TOTAL_2="117" VAR="0.16346235313442903" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.592872392069354" CI_END="1.940193493557442" CI_START="0.7322220122697822" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1919112316130631" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="83" I2="39.328417689205565" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.2878450438445914" LOG_CI_START="-0.13535721937199072" LOG_EFFECT_SIZE="0.07624391223630035" METHOD="MH" MODIFIED="2009-11-04 11:20:00 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.15903200678067275" P_Q="0.0" P_Z="0.48005612689050803" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11683796780581246" TOTALS="YES" TOTAL_1="392" TOTAL_2="386" WEIGHT="100.00000000000001" Z="0.706212300887932">
<NAME>Clinical Pregnancy Rate</NAME>
<GROUP_LABEL_1>GnRH agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GnRH agonist</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.223362312622383" CI_START="0.3304427143430676" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.34701023982505896" LOG_CI_START="-0.48090381908628543" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2009-10-06 14:21:50 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7512639157972149" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="36" WEIGHT="17.489246764108582" Z="0.3169732296347735">
<NAME>Leuprolide acetate 1 mg versus No treatment (Oocyte donation)</NAME>
<DICH_DATA CI_END="2.223362312622383" CI_START="0.3304427143430676" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.34701023982505896" LOG_CI_START="-0.48090381908628543" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="18" O_E="0.0" SE="0.4863208164452109" STUDY_ID="STD-Remohi-1994" TOTAL_1="33" TOTAL_2="36" VAR="0.2365079365079365" WEIGHT="17.489246764108582"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1505535590819065" CI_START="1.2298782345045738" DF="0" EFFECT_SIZE="2.5168539325842696" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.7118539076305566" LOG_CI_START="0.08986211574794359" LOG_EFFECT_SIZE="0.40085801168925" MODIFIED="2009-04-07 00:50:00 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.011527275864705382" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="117" WEIGHT="24.686757151356296" Z="2.5262946427226916">
<NAME>Nasal Buserelin versus No treatment (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="5.1505535590819065" CI_START="1.2298782345045738" EFFECT_SIZE="2.5168539325842696" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" LOG_CI_END="0.7118539076305566" LOG_CI_START="0.08986211574794359" LOG_EFFECT_SIZE="0.40085801168925" ORDER="19" O_E="0.0" SE="0.3653610574608726" STUDY_ID="STD-El_x002d_Toukhy-2004" TOTAL_1="117" TOTAL_2="117" VAR="0.13348870230892704" WEIGHT="24.686757151356296"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29043241724682545" CI_END="1.406618587399599" CI_START="0.5537694294794544" DF="1" EFFECT_SIZE="0.882577119938803" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.1481763519880537" LOG_CI_START="-0.256671022903985" LOG_EFFECT_SIZE="-0.054247335457965645" MODIFIED="2009-11-04 07:03:06 +1300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5899436359497623" P_Z="0.5994101616857421" STUDIES="2" TAU2="0.0" TOTAL_1="212" TOTAL_2="203" WEIGHT="51.782724174713756" Z="0.5252489226747666">
<NAME>Tryptorelin (deposit) versus No treatment (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="1.4201389417713965" CI_START="0.46150812999142915" EFFECT_SIZE="0.8095712861415753" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" LOG_CI_END="0.15233083642017764" LOG_CI_START="-0.3358206439786633" LOG_EFFECT_SIZE="-0.09174490377924281" ORDER="20" O_E="0.0" SE="0.2867425959750782" STUDY_ID="STD-Dal-Prato-2002" TOTAL_1="146" TOTAL_2="150" VAR="0.08222131634652692" WEIGHT="31.044790198787766"/>
<DICH_DATA CI_END="2.4584436953111384" CI_START="0.4635309042504062" EFFECT_SIZE="1.067503924646782" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.39066026627853256" LOG_CI_START="-0.33392130553676075" LOG_EFFECT_SIZE="0.028369480370885936" MODIFIED="2009-11-04 07:03:06 +1300" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.42562280202092995" STUDY_ID="STD-Ramos-2007" TOTAL_1="66" TOTAL_2="53" VAR="0.18115476960014773" WEIGHT="20.73793397592599"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.049196296804714" CI_START="0.24079070753042686" DF="0" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="1.0021313296351002" LOG_CI_START="-0.6183602771572739" LOG_EFFECT_SIZE="0.19188552623891314" MODIFIED="2009-10-22 09:00:36 +1300" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6425286724651244" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.041271909821367" Z="0.46416620611472476">
<NAME>Subcutaneous Buserelin versus no treatment</NAME>
<DICH_DATA CI_END="10.049196296804714" CI_START="0.24079070753042686" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0021313296351002" LOG_CI_START="-0.6183602771572739" LOG_EFFECT_SIZE="0.19188552623891314" MODIFIED="2009-10-22 09:00:36 +1300" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.9518847913926644" STUDY_ID="STD-Davar-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.906084656084656" WEIGHT="6.041271909821367"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06818946555680273" CI_END="1.1740494472950918" CI_START="0.206914660924173" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.49287731059085754" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.06968638842366864" LOG_CI_START="-0.6842087363381788" LOG_EFFECT_SIZE="-0.30726117395725505" METHOD="MH" MODIFIED="2009-04-07 00:50:19 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.793991392859993" P_Q="0.0" P_Z="0.11012646778532341" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="263" TOTAL_2="267" WEIGHT="100.0" Z="1.5976249614134477">
<NAME>Cancelled cycles</NAME>
<GROUP_LABEL_1>GnRH agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GnRH agonist</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9536241313916605" CI_START="0.15838402479145647" DF="0" EFFECT_SIZE="0.5562579013906448" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.290841011089706" LOG_CI_START="-0.8002886251126842" LOG_EFFECT_SIZE="-0.25472380701148906" NO="1" P_CHI2="1.0" P_Z="0.36013614092105395" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="117" WEIGHT="47.73854366453029" Z="0.9151057237984246">
<NAME>Nasal Buserelin (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="1.9536241313916605" CI_START="0.15838402479145647" EFFECT_SIZE="0.5562579013906448" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.290841011089706" LOG_CI_START="-0.8002886251126842" LOG_EFFECT_SIZE="-0.25472380701148906" ORDER="21" O_E="0.0" SE="0.6409349494840922" STUDY_ID="STD-El_x002d_Toukhy-2004" TOTAL_1="117" TOTAL_2="117" VAR="0.41079760947017585" WEIGHT="47.73854366453029"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4661258521768081" CI_START="0.13283889324696546" DF="0" EFFECT_SIZE="0.4413145539906103" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.16617125172392427" LOG_CI_START="-0.8766747514020025" LOG_EFFECT_SIZE="-0.35525174983903907" MODIFIED="2009-04-07 00:50:19 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.181762806186308" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="150" WEIGHT="52.26145633546971" Z="1.3353469889940628">
<NAME>Tryptorelin (deposit) versus No treatment (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="1.4661258521768086" CI_START="0.13283889324696546" EFFECT_SIZE="0.4413145539906103" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.1661712517239244" LOG_CI_START="-0.8766747514020025" LOG_EFFECT_SIZE="-0.35525174983903907" ORDER="22" O_E="0.0" SE="0.6125729044071393" STUDY_ID="STD-Dal-Prato-2002" TOTAL_1="146" TOTAL_2="150" VAR="0.37524556321379815" WEIGHT="52.26145633546971"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.0348197758556785" CI_END="0.276835216569455" CI_START="-0.2772430532786623" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0391835460365702E-4" ESTIMABLE="YES" I2="3.3648154652713824" I2_Q="3.3648154652713824" ID="CMP-001.04" MODIFIED="2009-04-07 00:50:34 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3090296458897628" P_Q="0.3090296458897628" P_Z="0.9988489261237276" Q="1.0348197758556785" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.001514166959372111" TOTALS="YES" TOTAL_1="263" TOTAL_2="267" UNITS="" WEIGHT="100.0" Z="0.001442657662497368">
<NAME>Endometrial Thickness (mm)</NAME>
<GROUP_LABEL_1>GnRH agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GnRH agonist</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6742424721681513" CI_START="-0.2742424721681527" DF="0" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.40848299101513796" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="117" WEIGHT="33.265360548465445" Z="0.8265661974894157">
<NAME>Nasal Buserelin (Frozen-embryo transfer)</NAME>
<CONT_DATA CI_END="0.6742424721681513" CI_START="-0.2742424721681526" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="9.5" MEAN_2="9.3" ORDER="23" SD_1="1.8" SD_2="1.9" SE="0.24196489114540676" STUDY_ID="STD-El_x002d_Toukhy-2004" TOTAL_1="117" TOTAL_2="117" WEIGHT="33.265360548465445"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.23044235716708816" CI_START="-0.43044235716708745" DF="0" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2009-04-07 00:50:34 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5530918832488922" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="150" WEIGHT="66.73463945153456" Z="0.5931333989210692">
<NAME>Tryptorelin (deposit) versus No treatment (Frozen-embryo transfer)</NAME>
<CONT_DATA CI_END="0.23044235716708816" CI_START="-0.43044235716708745" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.5" ORDER="24" SD_1="1.4" SD_2="1.5" SE="0.16859613736455106" STUDY_ID="STD-Dal-Prato-2002" TOTAL_1="146" TOTAL_2="150" WEIGHT="66.73463945153456"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.2767266027106808" CI_END="2.957754766781262" CI_START="0.28500064639420264" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9181296315925076" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.47096216295067794" LOG_CI_START="-0.5451541549910793" LOG_EFFECT_SIZE="-0.0370959960202007" METHOD="MH" MODIFIED="2009-11-04 07:05:54 +1300" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5988548462775207" P_Q="0.0" P_Z="0.8862054633902696" Q="0.0" RANDOM="YES" SCALE="128.6786646823487" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="216" TOTAL_2="199" WEIGHT="100.0" Z="0.14310727007614502">
<NAME>Pregnancy Loss</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>GnRH agonists</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GnRH agonist</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2767266027106808" CI_END="2.957754766781262" CI_START="0.28500064639420264" DF="1" EFFECT_SIZE="0.9181296315925076" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.47096216295067794" LOG_CI_START="-0.5451541549910793" LOG_EFFECT_SIZE="-0.0370959960202007" MODIFIED="2009-11-04 07:05:54 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5988548462775207" P_Z="0.8862054633902696" STUDIES="2" TAU2="0.0" TOTAL_1="216" TOTAL_2="199" WEIGHT="100.0" Z="0.14310727007614502">
<NAME>Tryptorelin (deposit) versus No treatment (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="2.9358732263727667" CI_START="0.20331770052947568" EFFECT_SIZE="0.7726027397260274" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4677372984254198" LOG_CI_START="-0.691824810699647" LOG_EFFECT_SIZE="-0.11204375613711358" ORDER="25" O_E="0.0" SE="0.6811325228250766" STUDY_ID="STD-Dal-Prato-2002" TOTAL_1="150" TOTAL_2="146" VAR="0.4639415136500535" WEIGHT="76.78896616362292"/>
<DICH_DATA CI_END="18.424722932370294" CI_START="0.14331965857465898" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2654009657388268" LOG_CI_START="-0.8436942351090404" LOG_EFFECT_SIZE="0.21085336531489315" MODIFIED="2009-11-04 07:05:54 +1300" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.2388929611676585" STUDY_ID="STD-Ramos-2007" TOTAL_1="66" TOTAL_2="53" VAR="1.5348557692307692" WEIGHT="23.211033836377084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010229337971510889" CI_END="1.333221819753596" CI_START="0.5062929980418744" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8215843670481393" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.12490241279005126" LOG_CI_START="-0.2955980788008028" LOG_EFFECT_SIZE="-0.08534783300537577" METHOD="MH" MODIFIED="2009-04-07 00:51:08 +1200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9194391756566489" P_Q="0.0" P_Z="0.426254664618256" Q="0.0" RANDOM="YES" SCALE="13.62830616673436" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="186" WEIGHT="99.99999999999999" Z="0.795617042996645">
<NAME>Clinical Pregnancy Rate with most used GnRH agonists</NAME>
<GROUP_LABEL_1>GnRH agonists</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GnRH agonist</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.223362312622383" CI_START="0.3304427143430676" DF="0" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.34701023982505896" LOG_CI_START="-0.48090381908628543" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2009-04-07 00:50:58 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7512639157972149" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="36" WEIGHT="25.796601852566823" Z="0.3169732296347735">
<NAME>Leuprolide acetate 1 mg versus No treatment (Oocyte donation)</NAME>
<DICH_DATA CI_END="2.223362312622383" CI_START="0.3304427143430676" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.34701023982505896" LOG_CI_START="-0.48090381908628543" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="59" O_E="0.0" SE="0.4863208164452109" STUDY_ID="STD-Remohi-1994" TOTAL_1="33" TOTAL_2="36" VAR="0.2365079365079365" WEIGHT="25.796601852566823"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4201389417713965" CI_START="0.46150812999142915" DF="0" EFFECT_SIZE="0.8095712861415753" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.15233083642017764" LOG_CI_START="-0.3358206439786633" LOG_EFFECT_SIZE="-0.09174490377924281" MODIFIED="2009-04-07 00:51:08 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4612895875990479" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="150" WEIGHT="74.20339814743316" Z="0.7367250306216035">
<NAME>Tryptorelin (deposit) versus No treatment (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="1.4201389417713965" CI_START="0.46150812999142915" EFFECT_SIZE="0.8095712861415753" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" LOG_CI_END="0.15233083642017764" LOG_CI_START="-0.3358206439786633" LOG_EFFECT_SIZE="-0.09174490377924281" ORDER="61" O_E="0.0" SE="0.2867425959750782" STUDY_ID="STD-Dal-Prato-2002" TOTAL_1="146" TOTAL_2="150" VAR="0.08222131634652692" WEIGHT="74.20339814743316"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-11-04 11:47:02 +1300" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Among different GnRH agonists</NAME>
<DICH_OUTCOME CHI2="0.6628836061351678" CI_END="2.4577496037865822" CI_START="1.0651365160605446" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6179736865370908" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="83" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.390537634761538" LOG_CI_START="0.02740527385194909" LOG_EFFECT_SIZE="0.20897145430674358" METHOD="MH" MODIFIED="2009-11-04 11:47:02 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8818973999964814" P_Q="0.0" P_Z="0.024083320032393007" Q="0.0" RANDOM="YES" SCALE="565.2205826242771" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="176" TOTAL_2="183" WEIGHT="400.0" Z="2.255797435470917">
<NAME>Clinical Pregnancy Rate</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.272452501620979" CI_START="0.48646518270716316" DF="0" EFFECT_SIZE="1.26171875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.5148733516525525" LOG_CI_START="-0.31294823761404583" LOG_EFFECT_SIZE="0.10096255701925332" NO="1" P_CHI2="1.0" P_Z="0.6325924033931845" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="33" WEIGHT="99.99999999999999" Z="0.4780812148668917">
<NAME>Nafareline (daily) vs Leuprolide (daily) (Oocyte donation - ovulating recipients)</NAME>
<DICH_DATA CI_END="3.272452501620979" CI_START="0.48646518270716316" EFFECT_SIZE="1.26171875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.5148733516525525" LOG_CI_START="-0.31294823761404583" LOG_EFFECT_SIZE="0.10096255701925332" ORDER="26" O_E="0.0" SE="0.4862664993181549" STUDY_ID="STD-Gutierrez-1999" TOTAL_1="35" TOTAL_2="33" VAR="0.23645510835913314" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0010610528882156" CI_START="0.7069309446561943" DF="0" EFFECT_SIZE="1.456551724137931" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="29" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.47727483070067656" LOG_CI_START="-0.15062300744707707" LOG_EFFECT_SIZE="0.16332591162679977" NO="2" P_CHI2="1.0" P_Z="0.30790222027291025" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0" Z="1.0196337209091393">
<NAME>Leuprolide (deposit) vs Tryptorelin (deposit) (Oocyte donation - ovulating recipients)</NAME>
<DICH_DATA CI_END="3.0010610528882156" CI_START="0.7069309446561943" EFFECT_SIZE="1.456551724137931" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="29" LOG_CI_END="0.47727483070067656" LOG_CI_START="-0.15062300744707707" LOG_EFFECT_SIZE="0.16332591162679977" ORDER="27" O_E="0.0" SE="0.36883029827241687" STUDY_ID="STD-Neuspiller-1998" TOTAL_1="58" TOTAL_2="61" VAR="0.13603578892371998" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6499611949023575E-31" CI_END="3.9648673813745496" CI_START="0.9387278319650675" DF="0" EFFECT_SIZE="1.9292307692307693" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" I2="100.0" ID="CMP-002.01.03" LOG_CI_END="0.5982286654239983" LOG_CI_START="-0.02746030572031421" LOG_EFFECT_SIZE="0.28538417985184206" MODIFIED="2008-05-09 04:16:20 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.07378798642794006" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="64" WEIGHT="100.0" Z="1.7879257588451298">
<NAME>Leuprolide (deposit) vs Leuprolide (Daily) (Oocyte donation - ovulating recipients)</NAME>
<DICH_DATA CI_END="3.9648673813745496" CI_START="0.9387278319650675" EFFECT_SIZE="1.9292307692307693" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.5982286654239983" LOG_CI_START="-0.02746030572031421" LOG_EFFECT_SIZE="0.28538417985184206" MODIFIED="2008-05-09 04:16:20 +1200" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.36753279886052753" STUDY_ID="STD-Neuspiller-1998" TOTAL_1="58" TOTAL_2="64" VAR="0.13508035823825298" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.976881496218917" CI_START="0.6205896293075469" DF="0" EFFECT_SIZE="1.9259259259259258" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" ID="CMP-002.01.04" LOG_CI_END="0.7764746451513309" LOG_CI_START="-0.20719548619970737" LOG_EFFECT_SIZE="0.2846395794758118" MODIFIED="2009-11-04 11:46:34 +1300" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.25667317341741325" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.1342894463634539">
<NAME>Leuprolide (daily) vs Tryptorelin (deposit) (Oocyte donation - ovulating recipients)</NAME>
<DICH_DATA CI_END="5.976881496218917" CI_START="0.6205896293075469" EFFECT_SIZE="1.9259259259259258" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.7764746451513309" LOG_CI_START="-0.20719548619970737" LOG_EFFECT_SIZE="0.2846395794758118" MODIFIED="2009-11-04 11:46:34 +1300" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.5778127044012803" STUDY_ID="STD-Tocino-2007" TOTAL_1="25" TOTAL_2="25" VAR="0.33386752136752135" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6311448326129325" CI_END="2.074548340253072" CI_START="0.39946897264753517" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9103393291452061" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.3169235590302921" LOG_CI_START="-0.3985169473418847" LOG_EFFECT_SIZE="-0.04079669415579627" METHOD="MH" MODIFIED="2008-06-18 14:00:55 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7293712977030135" P_Q="0.0" P_Z="0.823125554170226" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="149" TOTAL_2="160" WEIGHT="300.0" Z="0.22352676573797634">
<NAME>Pregnancy Loss Rate</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.871443444768631" CI_START="0.36493860555579394" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.6876576649547096" LOG_CI_START="-0.4377801917381097" LOG_EFFECT_SIZE="0.12493873660829992" NO="1" P_CHI2="1.0" P_Z="0.663442871109057" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="35" WEIGHT="100.0" Z="0.4351647184604009">
<NAME>Leuprolide vs Nafareline (Oocyte donation - non-amenorrhea recipients)</NAME>
<DICH_DATA CI_END="4.871443444768631" CI_START="0.36493860555579394" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6876576649547096" LOG_CI_START="-0.4377801917381097" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="29" O_E="0.0" SE="0.6610877680286007" STUDY_ID="STD-Gutierrez-1999" TOTAL_1="33" TOTAL_2="35" VAR="0.437037037037037" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6808080021464966" CI_START="0.13921545931545506" DF="0" EFFECT_SIZE="0.610909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.42826571118758516" LOG_CI_START="-0.8563125353963846" LOG_EFFECT_SIZE="-0.21402341210439976" NO="2" P_CHI2="1.0" P_Z="0.5136926662686705" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="61" WEIGHT="100.0" Z="0.6530986815143411">
<NAME>Leuprolide (deposit) vs Tryptorelin (deposit) (Oocyte donation - non-amenorrhea recipients)</NAME>
<DICH_DATA CI_END="2.6808080021464966" CI_START="0.13921545931545506" EFFECT_SIZE="0.610909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.42826571118758516" LOG_CI_START="-0.8563125353963846" LOG_EFFECT_SIZE="-0.21402341210439976" ORDER="30" O_E="0.0" SE="0.7545676208082973" STUDY_ID="STD-Neuspiller-1998" TOTAL_1="58" TOTAL_2="61" VAR="0.5693722943722944" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8203496813060505" CI_START="0.17522518707618745" DF="0" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.5821031162392614" LOG_CI_START="-0.7564034676770616" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2008-05-09 04:16:55 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.7985481298728123" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="64" WEIGHT="100.0" Z="0.25522654532726563">
<NAME>Leuprolide (deposit) vs Leuprolide (Daily) (Oocyte donation - non-amenorrhea recipients)</NAME>
<DICH_DATA CI_END="3.8203496813060505" CI_START="0.17522518707618745" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5821031162392614" LOG_CI_START="-0.7564034676770616" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2008-05-09 04:16:55 +1200" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.7862453931068966" STUDY_ID="STD-Neuspiller-1998" TOTAL_1="58" TOTAL_2="64" VAR="0.6181818181818183" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010972122919094114" CI_END="1.8189111292701856" CI_START="0.5577133200924534" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0071896369891764" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.259811480256208" LOG_CI_START="-0.2535889829540736" LOG_EFFECT_SIZE="0.003111248651067183" METHOD="MH" MODIFIED="2008-06-18 14:01:01 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9165758519588632" P_Q="0.0" P_Z="0.9810479685148734" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="116" TOTAL_2="125" WEIGHT="200.0" Z="0.02375508298107205">
<NAME>Cancelled Cycles</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2544302115499693" CI_START="0.42232526949401994" DF="0" EFFECT_SIZE="0.9757575757575757" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.353036795771281" LOG_CI_START="-0.37435293213539417" LOG_EFFECT_SIZE="-0.010658068182056593" NO="1" P_CHI2="1.0" P_Z="0.9541973354634429" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="61" WEIGHT="99.99999999999999" Z="0.057436691721561815">
<NAME>Leuprolide (deposit) vs Tryptorelin (deposit) (Oocyte donation - non-amenorrhea recipients)</NAME>
<DICH_DATA CI_END="2.2544302115499693" CI_START="0.42232526949401994" EFFECT_SIZE="0.9757575757575757" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.353036795771281" LOG_CI_START="-0.37435293213539417" LOG_EFFECT_SIZE="-0.010658068182056593" ORDER="32" O_E="0.0" SE="0.4272723268096044" STUDY_ID="STD-Neuspiller-1998" TOTAL_1="58" TOTAL_2="61" VAR="0.1825616412572934" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.394125204019793" CI_START="0.451246141778607" DF="0" EFFECT_SIZE="1.0393939393939393" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.3791468586823657" LOG_CI_START="-0.3455864983525998" LOG_EFFECT_SIZE="0.01678018016488298" MODIFIED="2008-05-09 04:17:32 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9276829673960898" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="64" WEIGHT="100.0" Z="0.09076041128234502">
<NAME>Leuprolide (deposit) vs Leuprolide (Daily) (Oocyte donation - non-amenorrhea recipients)</NAME>
<DICH_DATA CI_END="2.394125204019793" CI_START="0.451246141778607" EFFECT_SIZE="1.0393939393939393" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.3791468586823657" LOG_CI_START="-0.3455864983525998" LOG_EFFECT_SIZE="0.01678018016488298" MODIFIED="2008-05-09 04:17:32 +1200" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.4257119614103143" STUDY_ID="STD-Neuspiller-1998" TOTAL_1="58" TOTAL_2="64" VAR="0.18123067408781693" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-11-05 11:06:46 +1300" MODIFIED_BY="Agustín Ciapponi" NO="3">
<NAME>Intramuscular progesterone versus vaginal progesterone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6782799263150627" CI_START="0.8496685788354331" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.767857142857143" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.5656447770575632" LOG_CI_START="-0.07075044187486418" LOG_EFFECT_SIZE="0.24744716759134955" METHOD="MH" MODIFIED="2008-06-18 14:01:10 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.12746602546247912" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="70" WEIGHT="100.0" Z="1.524170899237972">
<NAME>Live Birth Rate</NAME>
<GROUP_LABEL_1>Vaginal</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vaginal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6782799263150627" CI_START="0.8496685788354331" DF="0" EFFECT_SIZE="1.767857142857143" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.5656447770575632" LOG_CI_START="-0.07075044187486418" LOG_EFFECT_SIZE="0.24744716759134955" NO="1" P_CHI2="1.0" P_Z="0.12746602546247912" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="70" WEIGHT="100.0" Z="1.524170899237972">
<NAME>Vaginal Ring Progesterone versus Intramuscular Progesterone(Oocyte donation)</NAME>
<DICH_DATA CI_END="3.6782799263150627" CI_START="0.849668578835433" EFFECT_SIZE="1.7678571428571428" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.5656447770575632" LOG_CI_START="-0.07075044187486423" LOG_EFFECT_SIZE="0.2474471675913495" ORDER="34" O_E="0.0" SE="0.37382170180804747" STUDY_ID="STD-Zegers-2000" TOTAL_1="83" TOTAL_2="70" VAR="0.13974266474266475" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.192693534314299" CI_END="2.100010360703095" CI_START="0.9848333277235276" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4381099373083805" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="77" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.32222143739348263" LOG_CI_START="-0.006637262877804559" LOG_EFFECT_SIZE="0.157792087257839" METHOD="MH" MODIFIED="2009-11-05 07:25:17 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5333890320678626" P_Q="0.0" P_Z="0.059992438211171555" Q="0.0" RANDOM="YES" SCALE="217.8137260239402" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="360" TOTAL_2="295" WEIGHT="100.00000000000001" Z="1.8808491781767727">
<NAME>Clinical Pregnancy Rate</NAME>
<GROUP_LABEL_1>Vaginal</GROUP_LABEL_1>
<GROUP_LABEL_2>Intramuscular</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vaginal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.711808114286064" CI_START="0.7558247590997915" DF="0" EFFECT_SIZE="2.414285714285714" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.8871562148855054" LOG_CI_START="-0.12157888568667197" LOG_EFFECT_SIZE="0.3827886645994167" MODIFIED="2009-11-05 07:20:19 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1368800481184116" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="18" WEIGHT="10.628314717002208" Z="1.4875104393204504">
<NAME>Intramuscular Progesterone versus Vaginal Gel Progesterone (Oocyte donation)</NAME>
<DICH_DATA CI_END="7.711808114286064" CI_START="0.7558247590997915" EFFECT_SIZE="2.414285714285714" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="5" LOG_CI_END="0.8871562148855054" LOG_CI_START="-0.12157888568667197" LOG_EFFECT_SIZE="0.3827886645994167" ORDER="35" O_E="0.0" SE="0.592535991395376" STUDY_ID="STD-Gibbons-1998" TOTAL_1="54" TOTAL_2="18" VAR="0.35109890109890113" WEIGHT="10.628314717002208"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2562735207600597" CI_START="0.8360784137582304" DF="0" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="20" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.5127208776568547" LOG_CI_START="-0.07775298922904232" LOG_EFFECT_SIZE="0.21748394421390624" MODIFIED="2009-11-05 07:20:21 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.14879751659172663" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="70" WEIGHT="31.01825123002541" Z="1.4437919162215693">
<NAME>Intramuscular Progesterone versus Vaginal Ring Progesterone (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.2562735207600597" CI_START="0.8360784137582304" EFFECT_SIZE="1.65" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="20" LOG_CI_END="0.5127208776568547" LOG_CI_START="-0.07775298922904232" LOG_EFFECT_SIZE="0.21748394421390624" ORDER="36" O_E="0.0" SE="0.3468472723015568" STUDY_ID="STD-Zegers-2000" TOTAL_1="83" TOTAL_2="70" VAR="0.12030303030303031" WEIGHT="31.01825123002541"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8863021776827498" CI_START="0.6104833258157549" DF="0" EFFECT_SIZE="1.0731057855240862" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.2756112661256126" LOG_CI_START="-0.21432619348011578" LOG_EFFECT_SIZE="0.03064253632274838" NO="3" P_CHI2="1.0" P_Z="0.806327067079375" STUDIES="1" TAU2="0.0" TOTAL_1="184" TOTAL_2="170" WEIGHT="45.05441759604324" Z="0.24516707759344822">
<NAME>Intramuscular Progesterone versus Vaginal Suppositories Progesterone (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="1.8863021776827498" CI_START="0.6104833258157549" EFFECT_SIZE="1.0731057855240862" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" LOG_CI_END="0.2756112661256126" LOG_CI_START="-0.21432619348011578" LOG_EFFECT_SIZE="0.03064253632274838" ORDER="37" O_E="0.0" SE="0.2877916890019435" STUDY_ID="STD-Lightman-1999" TOTAL_1="184" TOTAL_2="170" VAR="0.08282405625859136" WEIGHT="45.05441759604324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.2529332263521615" CI_START="0.6586034603760762" DF="0" EFFECT_SIZE="1.8599999999999999" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="25" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="0.7204018802222771" LOG_CI_START="-0.18137599178644445" LOG_EFFECT_SIZE="0.26951294421791633" MODIFIED="2009-11-04 07:17:30 +1300" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.24138070517152643" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="37" WEIGHT="13.299016456929149" Z="1.1715427500074205">
<NAME>Intramuscular Progesterone versus Vaginal Suppositories Progesterone (Oocyte donation)</NAME>
<DICH_DATA CI_END="5.2529332263521615" CI_START="0.6586034603760762" EFFECT_SIZE="1.86" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="25" LOG_CI_END="0.7204018802222771" LOG_CI_START="-0.18137599178644445" LOG_EFFECT_SIZE="0.26951294421791633" MODIFIED="2009-11-04 07:17:30 +1300" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.5297087858903818" STUDY_ID="STD-Caligara-2003" TOTAL_1="39" TOTAL_2="37" VAR="0.28059139784946235" WEIGHT="13.299016456929149"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8487585566333464" CI_START="0.5089726798865498" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9700348432055749" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.2668801970604168" LOG_CI_START="-0.29330552865135257" LOG_EFFECT_SIZE="-0.013212665795467843" METHOD="MH" MODIFIED="2008-06-18 14:01:50 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.9263355118681174" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="83" WEIGHT="100.0" Z="0.09245629765370213">
<NAME>Multiple Pregnancy Rate</NAME>
<GROUP_LABEL_1>Intramuscular</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vaginal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8487585566333464" CI_START="0.5089726798865498" DF="0" EFFECT_SIZE="0.9700348432055749" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.2668801970604168" LOG_CI_START="-0.29330552865135257" LOG_EFFECT_SIZE="-0.013212665795467843" NO="1" P_CHI2="1.0" P_Z="0.9263355118681174" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="83" WEIGHT="100.0" Z="0.09245629765370213">
<NAME>Intramuscular Progesterone versus Vaginal Ring Progesterone (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.8487585566333464" CI_START="0.5089726798865498" EFFECT_SIZE="0.9700348432055749" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.2668801970604168" LOG_CI_START="-0.29330552865135257" LOG_EFFECT_SIZE="-0.013212665795467843" ORDER="38" O_E="0.0" SE="0.3290558682471574" STUDY_ID="STD-Zegers-2000" TOTAL_1="70" TOTAL_2="83" VAR="0.10827776442789058" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1468834829507717" CI_END="1.3940228460493738" CI_START="0.2611094691889811" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.603317963738247" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.14426989128844173" LOG_CI_START="-0.583177378112127" LOG_EFFECT_SIZE="-0.2194537434118426" METHOD="MH" MODIFIED="2008-06-18 14:01:57 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5635825664727687" P_Q="0.0" P_Z="0.23698750586089778" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="258" TOTAL_2="321" WEIGHT="100.0" Z="1.182550135116005">
<NAME>Pregnancy Loss Rate</NAME>
<GROUP_LABEL_1>Intramuscular</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vaginal</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.450424573513429" CI_START="0.04520945326135935" DF="0" EFFECT_SIZE="0.3949579831932773" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.5378725381425556" LOG_CI_START="-1.3447707450561823" LOG_EFFECT_SIZE="-0.4034491034568133" NO="1" P_CHI2="1.0" P_Z="0.40088723004849014" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="54" WEIGHT="14.93024580007837" Z="0.8400377484435587">
<NAME>Intramuscular Progesterone versus Vaginal Gel Progesterone (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.450424573513429" CI_START="0.04520945326135935" EFFECT_SIZE="0.3949579831932773" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.5378725381425556" LOG_CI_START="-1.3447707450561823" LOG_EFFECT_SIZE="-0.4034491034568133" ORDER="39" O_E="0.0" SE="1.1058739837854892" STUDY_ID="STD-Gibbons-1998" TOTAL_1="18" TOTAL_2="54" VAR="1.2229572680135883" WEIGHT="14.93024580007837"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.383716187312303" CI_START="0.28800386497013586" DF="0" EFFECT_SIZE="0.9871794871794872" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.5293939289966478" LOG_CI_START="-0.5406016840326447" LOG_EFFECT_SIZE="-0.00560387751799851" NO="2" P_CHI2="1.0" P_Z="0.9836207399085185" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="83" WEIGHT="46.22096855866888" Z="0.02052980026330277">
<NAME>Intramuscular Progesterone versus Vaginal Ring Progesterone (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.383716187312303" CI_START="0.28800386497013586" EFFECT_SIZE="0.9871794871794872" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.5293939289966478" LOG_CI_START="-0.5406016840326447" LOG_EFFECT_SIZE="-0.00560387751799851" ORDER="40" O_E="0.0" SE="0.6285207196571129" STUDY_ID="STD-Zegers-2000" TOTAL_1="70" TOTAL_2="83" VAR="0.395038295038295" WEIGHT="46.22096855866888"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.514899468750145" CI_START="0.10310295568013302" DF="0" EFFECT_SIZE="0.39520958083832336" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.1803838132899941" LOG_CI_START="-0.9867288845014233" LOG_EFFECT_SIZE="-0.4031725356057146" NO="3" P_CHI2="1.0" P_Z="0.17569901138843563" STUDIES="1" TAU2="0.0" TOTAL_1="170" TOTAL_2="184" WEIGHT="38.84878564125275" Z="1.3541171316844263">
<NAME>Intramuscular Progesterone versus Vaginal Suppositories Progesterone (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="1.514899468750145" CI_START="0.10310295568013302" EFFECT_SIZE="0.39520958083832336" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1803838132899941" LOG_CI_START="-0.9867288845014233" LOG_EFFECT_SIZE="-0.4031725356057146" ORDER="41" O_E="0.0" SE="0.6855677759837078" STUDY_ID="STD-Lightman-1999" TOTAL_1="170" TOTAL_2="184" VAR="0.4700031754672473" WEIGHT="38.84878564125275"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-11-05 07:31:15 +1300" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Day of starting administration of the progesterone</NAME>
<DICH_OUTCOME CHI2="4.884972770329469" CI_END="1.938086315535649" CI_START="1.021027818817769" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4067124949441268" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="139" I2="38.58717047060093" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.28737311509145824" LOG_CI_START="0.009037574990399205" LOG_EFFECT_SIZE="0.14820534504092867" METHOD="MH" MODIFIED="2009-11-05 07:31:15 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18041652142213993" P_Q="0.0" P_Z="0.03686605441177609" Q="0.0" RANDOM="YES" SCALE="612.0049787618121" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.07085610447206217" TOTALS="SUB" TOTAL_1="302" TOTAL_2="311" WEIGHT="400.0" Z="2.087244327412049">
<NAME>Clinical Pregnancy Rate</NAME>
<GROUP_LABEL_1>Treatment 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.424021360678534E-31" CI_END="3.423577069995713" CI_START="1.0804940625381454" DF="0" EFFECT_SIZE="1.923318667504714" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="37" I2="100.0" ID="CMP-004.01.01" LOG_CI_END="0.5344801089514354" LOG_CI_START="0.03362238471856152" LOG_EFFECT_SIZE="0.2840512468349985" MODIFIED="2008-05-07 09:32:41 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.02620857035851109" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="97" WEIGHT="99.99999999999999" Z="2.2231072283570987">
<NAME>Day before oocyte retrieval (T1) versus day of oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.423577069995713" CI_START="1.0804940625381454" EFFECT_SIZE="1.923318667504714" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="37" LOG_CI_END="0.5344801089514354" LOG_CI_START="0.03362238471856152" LOG_EFFECT_SIZE="0.2840512468349985" ORDER="42" O_E="0.0" SE="0.2942063065001105" STUDY_ID="STD-Escriba-2006" TOTAL_1="94" TOTAL_2="97" VAR="0.08655735078443696" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6775340235671652" CI_START="0.5280448183729259" DF="0" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="51" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.224671337244981" LOG_CI_START="-0.27732921468967925" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2008-05-09 04:01:08 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8371092447003012" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="94" WEIGHT="99.99999999999999" Z="0.20559248968189597">
<NAME>Day of oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.6775340235671652" CI_START="0.5280448183729259" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="51" LOG_CI_END="0.224671337244981" LOG_CI_START="-0.27732921468967925" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2008-05-09 04:01:08 +1200" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.29487760914922817" STUDY_ID="STD-Escriba-2006" TOTAL_1="91" TOTAL_2="94" VAR="0.08695280437756497" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.235323717820027" CI_START="1.012807420709339" DF="0" EFFECT_SIZE="1.8101822752985544" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="37" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.5099177415207082" LOG_CI_START="0.005526874704590365" LOG_EFFECT_SIZE="0.2577223081126493" MODIFIED="2008-05-09 04:01:56 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0451862316869573" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="97" WEIGHT="100.0" Z="2.0029166868220796">
<NAME>Day before oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.235323717820027" CI_START="1.012807420709339" EFFECT_SIZE="1.8101822752985544" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="37" LOG_CI_END="0.5099177415207082" LOG_CI_START="0.005526874704590365" LOG_EFFECT_SIZE="0.2577223081126493" MODIFIED="2008-05-09 04:01:56 +1200" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.2962816919428458" STUDY_ID="STD-Escriba-2006" TOTAL_1="91" TOTAL_2="97" VAR="0.08778284098051539" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3410963912855736" CI_START="0.24027203753499135" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.3694192955170465" LOG_CI_START="-0.6192967687336463" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2009-11-05 07:31:06 +1300" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6203599756734498" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="100.0" Z="0.49534023544319555">
<NAME>One day before oocyte retrieval versus two days before oocyte retrieval</NAME>
<DICH_DATA CI_END="2.3410963912855736" CI_START="0.24027203753499135" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.3694192955170465" LOG_CI_START="-0.6192967687336463" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2009-11-05 07:31:06 +1300" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.580776710364308" STUDY_ID="STD-Ding-2007" TOTAL_1="26" TOTAL_2="23" VAR="0.3373015873015873" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.156397417943321" CI_END="1.4049877401556756" CI_START="0.5835530386591066" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9054749389390276" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="50" I2="7.25271773384361" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.14767253462830926" LOG_CI_START="-0.2339196651539031" LOG_EFFECT_SIZE="-0.043123565262796905" METHOD="MH" MODIFIED="2008-06-18 14:02:13 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.34020800775827165" P_Q="0.0" P_Z="0.6577734600467544" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.011804941243296334" TOTALS="SUB" TOTAL_1="288" TOTAL_2="276" WEIGHT="300.0" Z="0.44298932131360813">
<NAME>Multiple Pregnancy Rate</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3231115947321745" CI_START="0.2943790229014216" DF="0" EFFECT_SIZE="0.6240963855421687" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.12159647527782844" LOG_CI_START="-0.5310931405395102" LOG_EFFECT_SIZE="-0.20474833263084083" NO="1" P_CHI2="1.0" P_Z="0.2188173560563762" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="94" WEIGHT="100.0" Z="1.2296790024720807">
<NAME>Day before oocyte retrieval (T1) versus day of oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.3231115947321745" CI_START="0.2943790229014216" EFFECT_SIZE="0.6240963855421687" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="20" LOG_CI_END="0.12159647527782844" LOG_CI_START="-0.5310931405395102" LOG_EFFECT_SIZE="-0.20474833263084083" ORDER="45" O_E="0.0" SE="0.3833931111968097" STUDY_ID="STD-Escriba-2006" TOTAL_1="97" TOTAL_2="94" VAR="0.14699027771316928" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8759785499440254" CI_START="0.6520119803409384" DF="0" EFFECT_SIZE="1.3693693693693694" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="0.45878564260247023" LOG_CI_START="-0.18574442428623997" LOG_EFFECT_SIZE="0.13652060915811512" MODIFIED="2008-05-09 04:03:52 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4063712661022333" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="91" WEIGHT="100.0" Z="0.8302963378854334">
<NAME>Day of oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="2.8759785499440254" CI_START="0.6520119803409384" EFFECT_SIZE="1.3693693693693694" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.45878564260247023" LOG_CI_START="-0.18574442428623997" LOG_EFFECT_SIZE="0.13652060915811512" MODIFIED="2008-05-09 04:03:52 +1200" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.37860015176571477" STUDY_ID="STD-Escriba-2006" TOTAL_1="94" TOTAL_2="91" VAR="0.14333807491702227" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1793718987115893E-31" CI_END="1.886894314867854" CI_START="0.3870766529787148" DF="0" EFFECT_SIZE="0.8546184738955823" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="100.0" ID="CMP-004.02.03" LOG_CI_END="0.27574757597040295" LOG_CI_START="-0.41220302291585453" LOG_EFFECT_SIZE="-0.06822772347272577" MODIFIED="2008-05-09 04:04:06 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.6974536007712124" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="91" WEIGHT="100.0" Z="0.3887601260037855">
<NAME>Day before oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.886894314867854" CI_START="0.3870766529787148" EFFECT_SIZE="0.8546184738955823" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.27574757597040295" LOG_CI_START="-0.41220302291585453" LOG_EFFECT_SIZE="-0.06822772347272577" MODIFIED="2008-05-09 04:04:06 +1200" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.4041055871961739" STUDY_ID="STD-Escriba-2006" TOTAL_1="97" TOTAL_2="91" VAR="0.16330132560316452" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.124624587206245" CI_END="1.9731321358241067" CI_START="0.5525707456572407" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.044171966475154" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="60.972750960274226" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.29515616986330784" LOG_CI_START="-0.2576121113412262" LOG_EFFECT_SIZE="0.018772029261040747" METHOD="MH" MODIFIED="2008-06-18 14:02:19 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.07712629011578653" P_Q="0.0" P_Z="0.8940977787006957" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4992109490947442" TOTALS="SUB" TOTAL_1="288" TOTAL_2="276" WEIGHT="300.0" Z="0.1331208845348278">
<NAME>Pregnancy Loss Rate</NAME>
<GROUP_LABEL_1>Treatment 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2549896412340362" CI_START="0.16175018559579998" DF="0" EFFECT_SIZE="0.45054945054945056" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.09864014113700607" LOG_CI_START="-0.7911552123397223" LOG_EFFECT_SIZE="-0.3462575356013581" NO="1" P_CHI2="1.0" P_Z="0.12715634272353343" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="94" WEIGHT="100.0" Z="1.525412099540722">
<NAME>Day before oocyte retrieval (T1) versus day of oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.2549896412340362" CI_START="0.16175018559579998" EFFECT_SIZE="0.45054945054945056" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.09864014113700607" LOG_CI_START="-0.7911552123397223" LOG_EFFECT_SIZE="-0.3462575356013581" ORDER="48" O_E="0.0" SE="0.5226701951902657" STUDY_ID="STD-Escriba-2006" TOTAL_1="97" TOTAL_2="94" VAR="0.2731841329402305" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.45840759497985" CI_START="0.8494651527333814" DF="0" EFFECT_SIZE="2.5170731707317073" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.8726461134599393" LOG_CI_START="-0.07085443231702518" LOG_EFFECT_SIZE="0.40089584057145705" MODIFIED="2008-05-09 04:05:06 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.09579558079936835" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="91" WEIGHT="100.0" Z="1.665587609013869">
<NAME>Day of oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="7.45840759497985" CI_START="0.8494651527333814" EFFECT_SIZE="2.5170731707317073" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.8726461134599393" LOG_CI_START="-0.07085443231702518" LOG_EFFECT_SIZE="0.40089584057145705" MODIFIED="2008-05-09 04:05:06 +1200" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.5542168909924138" STUDY_ID="STD-Escriba-2006" TOTAL_1="94" TOTAL_2="91" VAR="0.30715636226129706" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8523437427103007" CI_START="0.33385015167519944" DF="0" EFFECT_SIZE="1.134065934065934" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.5857250320614642" LOG_CI_START="-0.4764484221212663" LOG_EFFECT_SIZE="0.05463830497009894" MODIFIED="2008-05-09 04:05:19 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.840197020509191" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="91" WEIGHT="100.0" Z="0.2016414729552952">
<NAME>Day before oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.8523437427103007" CI_START="0.33385015167519944" EFFECT_SIZE="1.134065934065934" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5857250320614642" LOG_CI_START="-0.4764484221212663" LOG_EFFECT_SIZE="0.05463830497009894" MODIFIED="2008-05-09 04:05:19 +1200" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.6239259448303315" STUDY_ID="STD-Escriba-2006" TOTAL_1="97" TOTAL_2="91" VAR="0.38928358463242185" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3620120753614129" CI_END="0.7621826897857674" CI_START="0.16823615364369238" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3580875369282783" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-0.11794091887517424" LOG_CI_START="-0.7740806694136" LOG_EFFECT_SIZE="-0.44601079414438716" METHOD="MH" MODIFIED="2008-06-18 14:02:25 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.506107619998497" P_Q="0.0" P_Z="0.007708685902797795" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="276" TOTAL_2="288" WEIGHT="300.0" Z="2.6645698344652047">
<NAME>Cancelled cycles</NAME>
<GROUP_LABEL_1>Treatment 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment 1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.014098149486224" CI_START="0.0977305477552619" DF="0" EFFECT_SIZE="0.31481481481481477" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.0060799902216112246" LOG_CI_START="-1.0099696671110003" LOG_EFFECT_SIZE="-0.5019448384446946" NO="1" P_CHI2="1.0" P_Z="0.05280559542497305" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="97" WEIGHT="100.0" Z="1.9365073320532107">
<NAME>Day before oocyte retrieval (T1) versus day of oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.014098149486224" CI_START="0.0977305477552619" EFFECT_SIZE="0.3148148148148148" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="0.0060799902216112246" LOG_CI_START="-1.0099696671110003" LOG_EFFECT_SIZE="-0.5019448384446945" ORDER="51" O_E="0.0" SE="0.5968325982440951" STUDY_ID="STD-Escriba-2006" TOTAL_1="94" TOTAL_2="97" VAR="0.3562091503267974" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.526489011252973" CI_START="0.16683980226831824" DF="0" EFFECT_SIZE="0.7670454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.547342534895598" LOG_CI_START="-0.7777003335338852" LOG_EFFECT_SIZE="-0.11517889931914368" MODIFIED="2008-05-09 04:05:49 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7333005271793802" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="94" WEIGHT="100.0" Z="0.34073840148591467">
<NAME>Day of oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.526489011252973" CI_START="0.16683980226831824" EFFECT_SIZE="0.7670454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.547342534895598" LOG_CI_START="-0.7777003335338852" LOG_EFFECT_SIZE="-0.11517889931914368" MODIFIED="2008-05-09 04:05:49 +1200" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.7783367399834604" STUDY_ID="STD-Escriba-2006" TOTAL_1="91" TOTAL_2="94" VAR="0.6058080808080808" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8858658276224776" CI_START="0.06582404628960552" DF="0" EFFECT_SIZE="0.24147727272727276" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="-0.05263205095238754" LOG_CI_START="-1.181615424575289" LOG_EFFECT_SIZE="-0.6171237377638382" MODIFIED="2008-05-09 04:06:04 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.032136631345994524" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="97" WEIGHT="100.0" Z="2.142707019927948">
<NAME>Day before oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="0.8858658276224776" CI_START="0.06582404628960552" EFFECT_SIZE="0.24147727272727273" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.05263205095238754" LOG_CI_START="-1.181615424575289" LOG_EFFECT_SIZE="-0.6171237377638382" MODIFIED="2008-05-09 04:06:04 +1200" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.6631704222239228" STUDY_ID="STD-Escriba-2006" TOTAL_1="91" TOTAL_2="97" VAR="0.43979500891265594" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.29527590113317E-32" CI_END="1.8236640578283587" CI_START="0.006042706612734315" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.10497555363819386" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" I2="100.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.2609448387793065" LOG_CI_START="-2.218768491232874" LOG_EFFECT_SIZE="-0.9789118262267836" METHOD="MH" MODIFIED="2008-06-18 14:02:32 +1200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.12175171582033645" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="191" WEIGHT="100.0" Z="1.5474626846768644">
<NAME>Cancelled cycles because of failed fertilization (by subgroups)</NAME>
<GROUP_LABEL_1>Treatment 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment 1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.29527590113317E-32" CI_END="1.8236640578283587" CI_START="0.006042706612734315" DF="0" EFFECT_SIZE="0.10497555363819386" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" I2="100.0" ID="CMP-004.05.01" LOG_CI_END="0.2609448387793065" LOG_CI_START="-2.218768491232874" LOG_EFFECT_SIZE="-0.9789118262267836" MODIFIED="2008-05-09 04:07:37 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.12175171582033645" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="191" WEIGHT="100.0" Z="1.5474626846768644">
<NAME>Day before or day of oocyte retrieval (T1) versus day after of oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.8236640578283587" CI_START="0.006042706612734315" EFFECT_SIZE="0.10497555363819384" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="0.2609448387793065" LOG_CI_START="-2.218768491232874" LOG_EFFECT_SIZE="-0.9789118262267837" MODIFIED="2008-05-09 04:07:37 +1200" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="1.4565958848281033" STUDY_ID="STD-Escriba-2006" TOTAL_1="91" TOTAL_2="191" VAR="2.1216715716981653" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6424177575467247E-4" CI_END="3.081825097768119" CI_START="1.1306496549418807" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8666720342317102" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.48880798764989464" LOG_CI_START="0.05332805453089014" LOG_EFFECT_SIZE="0.27106802109039235" METHOD="MH" MODIFIED="2008-06-18 14:02:38 +1200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9897748429162118" P_Q="0.0" P_Z="0.014687627833551134" Q="0.0" RANDOM="YES" SCALE="17.09" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="185" TOTAL_2="97" WEIGHT="100.0" Z="2.4399909997805933">
<NAME>Clinical Pregnancy Rate (by subgroups)</NAME>
<GROUP_LABEL_1>Treatment 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment 2</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7843262004025284" CI_START="0.9267235169677354" DF="0" EFFECT_SIZE="1.872705018359853" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="19" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="0.5779885645503016" LOG_CI_START="-0.033049815979934866" LOG_EFFECT_SIZE="0.2724693742851833" MODIFIED="2008-06-11 09:51:58 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0804738807021014" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="49" WEIGHT="50.792467935557525" Z="1.7479430998285632">
<NAME>Day before oocyte retrieval (T1) versus day of oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.7843262004025284" CI_START="0.9267235169677354" EFFECT_SIZE="1.872705018359853" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="19" LOG_CI_END="0.5779885645503016" LOG_CI_START="-0.033049815979934866" LOG_EFFECT_SIZE="0.2724693742851833" MODIFIED="2008-06-11 09:51:58 +1200" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.358926969412226" STUDY_ID="STD-Escriba-2006" TOTAL_1="94" TOTAL_2="49" VAR="0.12882856937144502" WEIGHT="50.792467935557525"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.802086507620271" CI_START="0.9103765634879629" DF="0" EFFECT_SIZE="1.8604651162790697" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="18" I2="0.0" ID="CMP-004.06.02" LOG_CI_END="0.5800219940009437" LOG_CI_START="-0.04077893117622954" LOG_EFFECT_SIZE="0.26962153141235706" MODIFIED="2008-06-11 09:52:10 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.08866668482861975" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="49.207532064442475" Z="1.7024732715207807">
<NAME>Day before oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="3.802086507620271" CI_START="0.9103765634879629" EFFECT_SIZE="1.8604651162790697" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="18" LOG_CI_END="0.5800219940009437" LOG_CI_START="-0.04077893117622954" LOG_EFFECT_SIZE="0.26962153141235706" MODIFIED="2008-06-11 09:52:10 +1200" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.3646615364632121" STUDY_ID="STD-Escriba-2006" TOTAL_1="91" TOTAL_2="48" VAR="0.13297803617571058" WEIGHT="49.207532064442475"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08455931057084552" CI_END="0.736036312107456" CI_START="0.10584505555692823" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2791161126608965" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="-0.13310075935967436" LOG_CI_START="-0.9753294247914456" LOG_EFFECT_SIZE="-0.55421509207556" METHOD="MH" MODIFIED="2008-06-18 14:02:44 +1200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7712113062234742" P_Q="0.0" P_Z="0.009895897051998963" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="185" TOTAL_2="97" WEIGHT="100.0" Z="2.579445855359915">
<NAME>Cancelled cycles (by subgroups)</NAME>
<GROUP_LABEL_1>Treatment 2</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment 1</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Treatment 1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1879370438707717" CI_START="0.08540355498019842" DF="0" EFFECT_SIZE="0.31851851851851853" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="0.07479342530509848" LOG_CI_START="-1.0685240511359377" LOG_EFFECT_SIZE="-0.4968653129154196" MODIFIED="2008-06-11 09:59:09 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08846882792499353" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="49" WEIGHT="54.26581790681392" Z="1.7035305390640025">
<NAME>Day before oocyte retrieval (T1) versus day of oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.1879370438707717" CI_START="0.08540355498019842" EFFECT_SIZE="0.31851851851851853" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.07479342530509848" LOG_CI_START="-1.0685240511359377" LOG_EFFECT_SIZE="-0.4968653129154196" MODIFIED="2008-06-11 09:59:09 +1200" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.6715903451742484" STUDY_ID="STD-Escriba-2006" TOTAL_1="94" TOTAL_2="49" VAR="0.45103359173126617" WEIGHT="54.26581790681392"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0010081761197034" CI_START="0.05688995895152095" DF="0" EFFECT_SIZE="0.23863636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" ID="CMP-004.07.02" LOG_CI_END="4.3762476120583335E-4" LOG_CI_START="-1.2449643795937044" LOG_EFFECT_SIZE="-0.6222633774162494" MODIFIED="2008-06-11 09:59:11 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.05016122579479544" STUDIES="1" TAU2="0.0" TOTAL_1="91" TOTAL_2="48" WEIGHT="45.73418209318607" Z="1.9585865517629957">
<NAME>Day before oocyte retrieval (T1) versus day after oocyte retrieval (T2) (Oocyte donation)</NAME>
<DICH_DATA CI_END="1.0010081761197034" CI_START="0.05688995895152095" EFFECT_SIZE="0.23863636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="4.3762476120583335E-4" LOG_CI_START="-1.2449643795937044" LOG_EFFECT_SIZE="-0.6222633774162494" MODIFIED="2008-06-11 09:59:11 +1200" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.7315553021974212" STUDY_ID="STD-Escriba-2006" TOTAL_1="91" TOTAL_2="48" VAR="0.5351731601731602" WEIGHT="45.73418209318607"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-04-07 00:51:49 +1200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Aspirin versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.316598826233985" CI_START="0.4160291362536614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.9692573951235848" LOG_CI_START="-0.3808762528562333" LOG_EFFECT_SIZE="0.29419057113367575" METHOD="MH" MODIFIED="2009-04-07 00:51:33 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.3930263263118259" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.8541419953143669">
<NAME>Live Birth Rate</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.316598826233985" CI_START="0.4160291362536614" DF="0" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.9692573951235848" LOG_CI_START="-0.3808762528562333" LOG_EFFECT_SIZE="0.29419057113367575" MODIFIED="2009-04-07 00:51:33 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3930263263118259" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.8541419953143669">
<NAME>Aspirin vs No treatment (Oocyte donation)</NAME>
<DICH_DATA CI_END="9.316598826233985" CI_START="0.4160291362536614" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.9692573951235848" LOG_CI_START="-0.3808762528562333" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="55" O_E="0.0" SE="0.793075188092689" STUDY_ID="STD-Weckstein-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.628968253968254" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="16.167528782298575" CI_START="0.704537171597388" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.2086436427740839" LOG_CI_START="-0.15209608843999625" LOG_EFFECT_SIZE="0.5282737771670437" METHOD="MH" MODIFIED="2009-04-07 00:51:39 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.12805525395728037" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="1.5218157498797227">
<NAME>Clinical Pregnancy Rate</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.167528782298575" CI_START="0.704537171597388" DF="0" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="1.2086436427740839" LOG_CI_START="-0.15209608843999625" LOG_EFFECT_SIZE="0.5282737771670437" MODIFIED="2009-04-07 00:51:39 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.12805525395728037" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="1.5218157498797227">
<NAME>Aspirin vs No treatment (Oocyte donation)</NAME>
<DICH_DATA CI_END="16.167528782298575" CI_START="0.704537171597388" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="1.2086436427740839" LOG_CI_START="-0.15209608843999625" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="56" O_E="0.0" SE="0.7993052538854533" STUDY_ID="STD-Weckstein-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.6388888888888888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.264810754160541" CI_START="0.30154972235434196" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="1.1227010583884514" LOG_CI_START="-0.520641067060489" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2009-04-07 00:51:44 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.47272117819681103" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.7180585717736276">
<NAME>Multiple Pregnancy Rate</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aspirin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.264810754160541" CI_START="0.30154972235434196" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="1.1227010583884514" LOG_CI_START="-0.520641067060489" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-04-07 00:51:44 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.47272117819681103" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.7180585717736276">
<NAME>Aspirin vs No treatment (Oocyte donation)</NAME>
<DICH_DATA CI_END="13.264810754160541" CI_START="0.30154972235434196" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.1227010583884514" LOG_CI_START="-0.520641067060489" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="57" O_E="0.0" SE="0.9653072991634228" STUDY_ID="STD-Weckstein-1997" TOTAL_1="15" TOTAL_2="13" VAR="0.9318181818181819" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.2380068937825386" CI_START="-0.03800689378253941" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2009-04-07 00:51:49 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.06529888063152163" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="13" UNITS="" WEIGHT="100.00000000000001" Z="1.8432064013478469">
<NAME>Endometrial Thickness (mm)</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Nothing</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aspirin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2380068937825386" CI_START="-0.03800689378253941" DF="0" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" MODIFIED="2009-04-07 00:51:49 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.06529888063152163" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.00000000000001" Z="1.8432064013478469">
<NAME>Aspirin vs No treatment (Oocyte donation)</NAME>
<CONT_DATA CI_END="1.2380068937825386" CI_START="-0.03800689378253941" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="6.0" ORDER="58" SD_1="0.66" SD_2="1.0" SE="0.32551970281854975" STUDY_ID="STD-Weckstein-1997" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-07-25 23:59:30 +1200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Steroids versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1070048684823037" CI_START="0.13942008530228492" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6581632653061225" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.4923419337677981" LOG_CI_START="-0.8556746558822523" LOG_EFFECT_SIZE="-0.18166636105722708" METHOD="MH" MODIFIED="2008-06-18 14:03:11 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5973107553495545" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0" Z="0.5282717254496834">
<NAME>Live Birth Rate</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1070048684823037" CI_START="0.13942008530228492" DF="0" EFFECT_SIZE="0.6581632653061225" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.4923419337677981" LOG_CI_START="-0.8556746558822523" LOG_EFFECT_SIZE="-0.18166636105722708" NO="1" P_CHI2="1.0" P_Z="0.5973107553495545" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="100.0" Z="0.5282717254496834">
<NAME>Dexamethasone (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="3.1070048684823037" CI_START="0.13942008530228492" EFFECT_SIZE="0.6581632653061225" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4923419337677981" LOG_CI_START="-0.8556746558822523" LOG_EFFECT_SIZE="-0.18166636105722708" ORDER="59" O_E="0.0" SE="0.7918316175501757" STUDY_ID="STD-Bider-1996" TOTAL_1="52" TOTAL_2="47" VAR="0.6269973105521278" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15472606713186116" CI_END="2.0260618694460764" CI_START="0.39802513537656575" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.898010885160961" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.3066527031904857" LOG_CI_START="-0.40008950126637" LOG_EFFECT_SIZE="-0.04671839903794209" METHOD="MH" MODIFIED="2008-06-18 14:03:17 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6940594406925894" P_Q="0.0" P_Z="0.7955407775050799" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="0.2591224323446417">
<NAME>Clinical Pregnancy Rate</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Steroids</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.423662860760738" CI_START="0.3300238097567644" DF="0" EFFECT_SIZE="1.0629629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.5344909917176967" LOG_CI_START="-0.4814547265676866" LOG_EFFECT_SIZE="0.02651813257500498" NO="1" P_CHI2="1.0" P_Z="0.9185045530830218" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="48.39283275118543" Z="0.10231764128498116">
<NAME>Dexamethasone (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="3.423662860760738" CI_START="0.3300238097567644" EFFECT_SIZE="1.0629629629629629" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5344909917176967" LOG_CI_START="-0.4814547265676866" LOG_EFFECT_SIZE="0.02651813257500498" ORDER="60" O_E="0.0" SE="0.5967715439332465" STUDY_ID="STD-Bider-1996" TOTAL_1="52" TOTAL_2="47" VAR="0.3561362756484708" WEIGHT="48.39283275118543"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3796093846158453" CI_START="0.24700599248673177" DF="0" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.37650567301088667" LOG_CI_START="-0.6072925104150256" LOG_EFFECT_SIZE="-0.11539341870206953" NO="2" P_CHI2="1.0" P_Z="0.645671835437605" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="33" WEIGHT="51.60716724881457" Z="0.4597832126939257">
<NAME>6-alpha-methylprednisolone (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="2.3796093846158453" CI_START="0.24700599248673177" EFFECT_SIZE="0.7666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.37650567301088667" LOG_CI_START="-0.6072925104150256" LOG_EFFECT_SIZE="-0.11539341870206953" ORDER="61" O_E="0.0" SE="0.5778879228239293" STUDY_ID="STD-Moffitt-1995" TOTAL_1="28" TOTAL_2="33" VAR="0.33395445134575563" WEIGHT="51.60716724881457"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17775481665496" CI_END="7.032248358510224" CI_START="0.31531741335029145" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4890904480394322" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="0.8470942003515287" LOG_CI_START="-0.50125204475124" LOG_EFFECT_SIZE="0.17292107780014435" METHOD="MH" MODIFIED="2008-06-18 14:03:23 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6733098631853001" P_Q="0.0" P_Z="0.615162428409837" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="80" WEIGHT="100.0" Z="0.5027181792319223">
<NAME>Pregnancy Loss Rate</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.837062993003732" CI_START="0.05483115201596464" DF="0" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="1.1713479405542557" LOG_CI_START="-1.2609726293869803" LOG_EFFECT_SIZE="-0.04481234441636228" NO="1" P_CHI2="1.0" P_Z="0.9424271658081976" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="30.729906218318256" Z="0.07221957681424913">
<NAME>Dexamethasone (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="14.837062993003732" CI_START="0.05483115201596464" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1713479405542557" LOG_CI_START="-1.2609726293869803" LOG_EFFECT_SIZE="-0.04481234441636228" ORDER="62" O_E="0.0" SE="1.428757142964485" STUDY_ID="STD-Bider-1996" TOTAL_1="52" TOTAL_2="47" VAR="2.0413469735720375" WEIGHT="30.729906218318256"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.009866366777217" CI_START="0.2880631552712576" DF="0" EFFECT_SIZE="1.8599999999999999" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="1.079538175055351" LOG_CI_START="-0.5405122866195184" LOG_EFFECT_SIZE="0.26951294421791633" NO="2" P_CHI2="1.0" P_Z="0.5143221659040483" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="33" WEIGHT="69.27009378168175" Z="0.6521224820223915">
<NAME>6-alpha-methylprednisolone (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="12.009866366777217" CI_START="0.28806315527125753" EFFECT_SIZE="1.86" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.079538175055351" LOG_CI_START="-0.5405122866195186" LOG_EFFECT_SIZE="0.26951294421791633" ORDER="63" O_E="0.0" SE="0.9516256605669386" STUDY_ID="STD-Moffitt-1995" TOTAL_1="28" TOTAL_2="33" VAR="0.9055913978494623" WEIGHT="69.27009378168175"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-18 14:03:30 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="52" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Multiple Pregnancy Rate</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Dexamethasone (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="64" O_E="0.0" SE="0.0" STUDY_ID="STD-Bider-1996" TOTAL_1="52" TOTAL_2="47" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-11-05 07:52:17 +1300" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Artificial cycle versus not artificial cycle</NAME>
<DICH_OUTCOME CHI2="5.8870464338121185" CI_END="1.0124815607856563" CI_START="0.28346007563893516" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5357220359508551" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="40" I2="83.01355337956021" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.005387122630448832" LOG_CI_START="-0.5475081013238452" LOG_EFFECT_SIZE="-0.2710604893466982" METHOD="MH" MODIFIED="2009-11-05 07:52:17 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01525270154409819" P_Q="0.0" P_Z="0.054634673126366134" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.0361710924845406" TOTALS="SUB" TOTAL_1="144" TOTAL_2="139" WEIGHT="200.0" Z="1.9217702513387953">
<NAME>Clinical Pregnancy Rate</NAME>
<GROUP_LABEL_1>Artificial cycle</GROUP_LABEL_1>
<GROUP_LABEL_2>Not artificial cycle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stimulated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artificial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6633986159944136" CI_START="0.4676085679467172" DF="0" EFFECT_SIZE="1.115987460815047" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.4254361697327524" LOG_CI_START="-0.3301175399013642" LOG_EFFECT_SIZE="0.047659314915694063" NO="1" P_CHI2="1.0" P_Z="0.80470407253212" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="100" WEIGHT="100.0" Z="0.2472638002342622">
<NAME>Artificial cycle (Estradiol) versus Stimulated cycle (FSH 150 IU/d) (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="2.663398615994414" CI_START="0.4676085679467171" EFFECT_SIZE="1.115987460815047" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.42543616973275244" LOG_CI_START="-0.3301175399013643" LOG_EFFECT_SIZE="0.047659314915694063" ORDER="65" O_E="0.0" SE="0.44381598909026165" STUDY_ID="STD-Wright-2006" TOTAL_1="99" TOTAL_2="100" VAR="0.19697263217216723" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5849636928771311" CI_START="0.09034259782626682" DF="0" EFFECT_SIZE="0.22988505747126434" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="29" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="-0.23287108857156957" LOG_CI_START="-1.0441074253377052" LOG_EFFECT_SIZE="-0.6384892569546374" MODIFIED="2009-11-04 07:27:13 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.002034106389340408" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="39" WEIGHT="100.0" Z="3.0852068415362157">
<NAME>Artificial cycle (Estradiol) versus Natural cycle (Frozen-embryo transfer)</NAME>
<DICH_DATA CI_END="0.5849636928771311" CI_START="0.09034259782626682" EFFECT_SIZE="0.22988505747126436" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="29" LOG_CI_END="-0.23287108857156957" LOG_CI_START="-1.0441074253377052" LOG_EFFECT_SIZE="-0.6384892569546373" MODIFIED="2009-11-04 07:27:13 +1300" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.4765242399010592" STUDY_ID="STD-Lee-2008" TOTAL_1="45" TOTAL_2="39" VAR="0.22707535121328223" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2921741801921939" CI_START="-0.2921741801921939" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="100" UNITS="" WEIGHT="100.00000000000001" Z="0.0">
<NAME>Endometrial Thickness (mm)</NAME>
<GROUP_LABEL_1>Artificial cyle</GROUP_LABEL_1>
<GROUP_LABEL_2>Stimulated cycle</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Stimulated</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Artificial</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2921741801921939" CI_START="-0.2921741801921939" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-007.02.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="99" TOTAL_2="100" WEIGHT="100.00000000000001" Z="0.0">
<NAME>Artificial cycle (Estradiol) versus Stimulated cycle (FSH 150 IU/d) (Frozen-embryo transfer)</NAME>
<CONT_DATA CI_END="0.2921741801921939" CI_START="-0.2921741801921939" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="8.7" ORDER="66" SD_1="1.1" SD_2="1.0" SE="0.14907119849998599" STUDY_ID="STD-Wright-2006" TOTAL_1="99" TOTAL_2="100" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2009-11-05 08:10:52 +1300" MODIFIED_BY="[Empty name]" NO="8">
<NAME>hCG before retrieval versus placebo</NAME>
<DICH_OUTCOME CHI2="8.25587695742531" CI_END="1.4130421749850701" CI_START="0.7146723507369545" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0049189882209606" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="154" I2="75.77483276078617" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.15015512440336676" LOG_CI_START="-0.14589301957037032" LOG_EFFECT_SIZE="0.002131052416498234" METHOD="MH" MODIFIED="2009-11-05 08:10:52 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.016116151426005643" P_Q="0.0" P_Z="0.9774891284413293" Q="0.0" RANDOM="YES" SCALE="895.32" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.3614379442200578" TOTALS="SUB" TOTAL_1="285" TOTAL_2="285" WEIGHT="300.0" Z="0.028216937484830583">
<NAME>Clinical Pregnancy Rate</NAME>
<GROUP_LABEL_1>hCG before retrieval</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hCG</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1271307527590966" CI_START="0.8100915228926242" DF="0" EFFECT_SIZE="1.3126959247648904" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="66" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="0.3277941864031834" LOG_CI_START="-0.09146591242774232" LOG_EFFECT_SIZE="0.11816413698772055" MODIFIED="2009-11-05 08:10:39 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.26925005295312465" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="1.1047912902085417">
<NAME>One dose of hCG vs Placebo (Oocyte donation - non-amenorrhea recipients)</NAME>
<DICH_DATA CI_END="2.1271307527590966" CI_START="0.8100915228926242" EFFECT_SIZE="1.3126959247648904" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="66" LOG_CI_END="0.3277941864031834" LOG_CI_START="-0.09146591242774232" LOG_EFFECT_SIZE="0.11816413698772055" ORDER="67" O_E="0.0" SE="0.24627545742424614" STUDY_ID="STD-Tesarik-2003" TOTAL_1="133" TOTAL_2="133" VAR="0.060651600929521675" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4431669835441583" CI_START="0.5377597369916011" DF="0" EFFECT_SIZE="0.8809523809523809" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="78" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="0.15931658461818005" LOG_CI_START="-0.269411717279991" LOG_EFFECT_SIZE="-0.05504756633090548" MODIFIED="2009-11-05 08:10:52 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6147475630943575" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="130" WEIGHT="100.0" Z="0.503308258248741">
<NAME>One dose of hCG vs Placebo (Oocyte donation - amenorrhea recipients)</NAME>
<DICH_DATA CI_END="1.4431669835441583" CI_START="0.5377597369916011" EFFECT_SIZE="0.8809523809523809" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="78" LOG_CI_END="0.15931658461818005" LOG_CI_START="-0.269411717279991" LOG_EFFECT_SIZE="-0.05504756633090548" MODIFIED="2008-05-09 04:19:12 +1200" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.2518371267743071" STUDY_ID="STD-Tesarik-2003" TOTAL_1="130" TOTAL_2="130" VAR="0.06342193842193843" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5027540027120591" CI_START="0.006494838638448612" DF="0" EFFECT_SIZE="0.057142857142857134" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="-0.2986444630507831" LOG_CI_START="-2.187431634321806" LOG_EFFECT_SIZE="-1.2430380486862944" MODIFIED="2009-11-05 08:10:02 +1300" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.009886869466139116" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="2.5797610698495124">
<NAME>Repeated doses of hCG vs Placebo (Oocyte donation - non-amenorrhea recipients)</NAME>
<DICH_DATA CI_END="0.5027540027120591" CI_START="0.006494838638448612" EFFECT_SIZE="0.05714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.2986444630507831" LOG_CI_START="-2.187431634321806" LOG_EFFECT_SIZE="-1.2430380486862944" MODIFIED="2009-11-05 08:10:02 +1300" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="1.1094829340518857" STUDY_ID="STD-Prapas-2009a" TOTAL_1="22" TOTAL_2="22" VAR="1.230952380952381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="147.4898904926354" CI_END="0.6904370199672684" CI_START="0.4178306384642091" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5541338292157387" ESTIMABLE="YES" I2="99.32198742797905" I2_Q="99.32198742797905" ID="CMP-008.02" MODIFIED="2008-05-09 04:20:15 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="-2.220446049250313E-16" P_Q="-2.220446049250313E-16" P_Z="1.6108566352046228E-15" Q="147.4898904926354" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.4352027183342964" TOTALS="SUB" TOTAL_1="263" TOTAL_2="263" UNITS="" WEIGHT="200.0" Z="7.968135902687436">
<NAME>Endometrial Thickness (mm)</NAME>
<GROUP_LABEL_1>hCG before retrieval</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hCG</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.704647418968025" CI_START="1.295352581031975" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.01" NO="1" P_CHI2="1.0" P_Z="8.468952625713691E-47" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="14.36590791926593">
<NAME>hCG vs Placebo (Oocyte donation - non-amenorrhea recipients)</NAME>
<CONT_DATA CI_END="1.704647418968025" CI_START="1.295352581031975" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="8.2" ORDER="69" SD_1="0.9" SD_2="0.8" SE="0.10441386708238397" STUDY_ID="STD-Tesarik-2003" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.01726756703638227" CI_START="-0.3827324329636163" DF="0" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-008.02.02" MODIFIED="2008-05-09 04:20:15 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.031938967001358905" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="130" WEIGHT="100.0" Z="2.145173632017789">
<NAME>hCG vs Placebo (Oocyte donation - amenorrhea recipients)</NAME>
<CONT_DATA CI_END="-0.01726756703638227" CI_START="-0.3827324329636163" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="9.5" MODIFIED="2008-05-09 04:20:15 +1200" MODIFIED_BY="[Empty name]" ORDER="68" SD_1="0.7" SD_2="0.8" SE="0.09323254631461962" STUDY_ID="STD-Tesarik-2003" TOTAL_1="130" TOTAL_2="130" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-11-09 13:11:42 +1300" MODIFIED_BY="jane clarke">
<FIGURE FILENAME="ScreenHunter_05 Nov. 04 19.05.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2009-11-05 11:09:33 +1300" MODIFIED_BY="Agustín Ciapponi" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow of information through the different phases of the systematic review</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a
HBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5PTgyPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIy
MjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAHfAqMDASIA
AhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQA
AAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3
ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWm
p6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEA
AwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSEx
BhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElK
U1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3
uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD36gUh
6V8469p/wz1HxTrc3inxVq0WqC/lRlhjYoqA4VR+5b7o+Xr/AA8cYpX1sFtLn0RHIkwLI6sAxUkH
OCDgj8xU4rkvh5Dotv4HsIfD1zcXOlI0ogmuBh3/AHjZJ+Vf4s44HGK62m1Z2EtRaKK8s8QP4n1n
4pzeHtH8US6NbQ6Ul4dtqk4ZvM2ng4x1HftQM9Torzf/AIQbx9/0VGf/AMFEf/xdH/CDePv+ioz/
APgoj/8Ai6APSKK83/4Qbx9/0VGf/wAFEf8A8XR/wg3j7/oqM/8A4KI//i6APSKK83/4Qbx9/wBF
Rn/8FEf/AMXR/wAIN4+/6KjP/wCCiP8A+LoA9Iorzf8A4Qbx9/0VGf8A8FEf/wAXR/wg3j7/AKKj
P/4KI/8A4ugD0iivN/8AhBvH3/RUZ/8AwUR//F0f8IN4+/6KjP8A+CiP/wCLoA9Iorzf/hBvH3/R
UZ//AAUR/wDxdH/CDePv+ioz/wDgoj/+LoA9Iorzf/hBvH3/AEVGf/wUR/8AxdH/AAg3j7/oqM//
AIKI/wD4ugD0iivN/wDhBvH3/RUZ/wDwUR//ABdH/CDePv8AoqM//goj/wDi6APSKK83/wCEG8ff
9FRn/wDBRH/8XR/wg3j7/oqM/wD4KI//AIugD0iivN/+EG8ff9FRn/8ABRH/APF0f8IN4+/6KjP/
AOCiP/4ugD0iivN/+EG8ff8ARUZ//BRH/wDF0f8ACDePv+ioz/8Agoj/APi6APSKK83/AOEG8ff9
FRn/APBRH/8AF0f8IN4+/wCioz/+CiP/AOLoA9Iorzf/AIQbx9/0VGf/AMFEf/xdH/CDePv+ioz/
APgoj/8Ai6APSKK83/4Qbx9/0VGf/wAFEf8A8XR/wg3j7/oqM/8A4KI//i6APSKK83/4Qbx9/wBF
Rn/8FEf/AMXR/wAIN4+/6KjP/wCCiP8A+LoA9Iorya2Xxd4c+JHhfStU8XS6xaaoLoyRtZJAB5cR
YdCSeSD26V6zQAUUUUAFFFFABRRRQAUV5h4yuvEl78R9H8OaNr8mkRXVjJO8iW6zfMpPZsenrU//
AAg3j7/oqM//AIKI/wD4ugD0iivN/wDhBvH3/RUZ/wDwUR//ABdH/CDePv8AoqM//goj/wDi6APS
KK83/wCEG8ff9FRn/wDBRH/8XR/wg3j7/oqM/wD4KI//AIugD0iivN/+EG8ff9FRn/8ABRH/APF0
f8IN4+/6KjP/AOCiP/4ugD0iivN/+EG8ff8ARUZ//BRH/wDF0f8ACDePv+ioz/8Agoj/APi6APSK
K83/AOEG8ff9FRn/APBRH/8AF0f8IN4+/wCioz/+CiP/AOLoA9Iorzf/AIQbx9/0VGf/AMFEf/xd
H/CDePv+ioz/APgoj/8Ai6APSKK83/4Qbx9/0VGf/wAFEf8A8XR/wg3j7/oqM/8A4KI//i6APSKK
83/4Qbx9/wBFRn/8FEf/AMXR/wAIN4+/6KjP/wCCiP8A+LoA9Iorzf8A4Qbx9/0VGf8A8FEf/wAX
R/wg3j7/AKKjP/4KI/8A4ugD0iivN/8AhBvH3/RUZ/8AwUR//F0f8IN4+/6KjP8A+CiP/wCLoA9I
orzf/hBvH3/RUZ//AAUR/wDxdH/CDePv+ioz/wDgoj/+LoA9Iorzf/hBvH3/AEVGf/wUR/8AxdH/
AAg3j7/oqM//AIKI/wD4ugD0iivN/wDhBvH3/RUZ/wDwUR//ABdH/CDePv8AoqM//goj/wDi6APS
KK83/wCEG8ff9FRn/wDBRH/8XR/wg3j7/oqM/wD4KI//AIugD0iivN/+EG8ff9FRn/8ABRH/APF1
janH4y8I+JfDCXvjObVbbUtSS3lgNhHCNvGeQT/SgD2GiiigAooooAKKKKACiiigAooooAQ14v4i
sNbu9duZfDvw28PajY/aJBJeahHC8txKHPmN8zqyjduHOenpgV6h4j1y38PaDdateRzSW1soZxAu
5yCQOBkevrXz94y1v4Xa34kuru+0/wAR216JCtwbRYVSZhxuKuxIPHbb781P2g6Hu/hMW3/COQC3
0pNKCtIsllEylYJQ7B1BX5SN27pxXRVy3gDUNL1TwXp91otk9lpmHjt4JDllVXZeeTycZ6nr1NdT
VvcS2Frzu1/5OEvv+xcT/wBHivRK87tf+ThL7/sXE/8AR4pDPRKKKKAEopayNYS/fSrtNLMS37RM
tu0xIRXIwpbAPAPPTtSegI1qK8c8ORL4M0rxXu8ORaX4ks7Brl7lLmS4hvVAfbKhdiVG4HK9eRn0
G/Dp9v4e1DwpNYDyp9TdrbUJgPnuyYHk8yQ/xOHXO45PzMOhNMD0SiuGvfDFja+KNDuNFgW21GKV
pL+5j+/NbFCGEzf8tCzhMbsnIJHQ10OuarBomlSX04dlVkRY0xukd2CqozxyzCkBsVmwavptzqM2
nQahaS30AzLbJOrSRj/aUHI6jr61gr4n1WPVpdFvNJtodUe1a6s9l6z286qQGUyeUGVhkHGw8HrV
P4eQy3/g/R9Q1Kws/tawEwXSP5krK/LsSUUoWPUAnPrTWoHeUVxs/inUv+EsudGttBLi2hiuGup7
xI0MbOVZgAGPG0kA4ztPTjdV0r4gTarqNoI9Dvhpl2CYr3yLj5FxlXk3QrGFPqsjdR+CDY7yiuQ0
7xVfX1xps50WRdH1FWe3vUlLvGoXcrTJsxGrDODvbqM4zxW/4TeYWWn6rJp6jQb+dIYbxLndKu87
Ud4tgCqT6OSMjI6gMR3FUXvbWO7itHuIluJlZoomcB3C/eIXqcZGfrXJr42vPtms+fobWun6NKRe
XU12m4R+V5m9UUNuPT5c/wAQ5zkLkrdX1/8AEbwxqN1o1tYNPY3bRyJP5srphCFk+QbSu7O0Fh8x
waEM9Qo71xnhfxdN4nn/AHVhbLZGJn86C982SFwwHlTR7F8uTBzjJ6HBPWn+JruCPXPDdtdaRJcr
Nf8A7m5M+xbeURuQcA5Y43cY2++cUdg7nR3t5bWMBnu7mKCIELvmcIuScAZPqSBV2vKvHesya/4f
u2ttHt5tMstUggF9LOPMWVZ0Vmjj2H5ckpu3A8txjruax45m0/VLqz0/Q73U1snVLkwQ3DNuKq22
PZC6MwVgcO6dR9aOgHdUlcbN4q1OTxDd6RYeHZJJILOO7SW6ulgR1YsMEAMy/dIGVznOQowTm6p4
n1m7tfCF/olvbfZdWnXzYri4KOSY2cIWVGwvynJ5PAGOTSA9ErNg1fTbnUZtOg1G0lvoBmW2SZWk
jH+0oOR1HX1rmo79j431lINEVNXt9NhKXE92VS4jLvhcKG2qCG+YruPoBiuUs5o5Ph1oGoa94dtt
R3yQIk8V1h0EkqEyOxVWUlyCVTduPU4oQHsVU7m4gs7eSe4mSGCNSzySMFVFHUkngCuS1jxxNp+p
3Nnp+h3uprZMqXJghuGbcVVtseyF0ZgrA4d06j61n+Ntbk1nw34l02y0aG8trKxLXkl3L5Zido/M
UIhRtzqNrHJXBxg56Del0NLWx6FFIk0ayRuro4BVlOQw9RViszQP+Rd03/r1i/8AQRWlTejsSndX
FooooGed+LP+Sy/D7/c1H/0RXoled+LP+Sy/D7/c1H/0RXolABRRRQAUUUUAFFFFAHm+sf8AJfPD
X/YKuP5tXpFeb6x/yXzw1/2Crj+bV6RQAUlcv4j0PQ9SguJ9es1vIREUCzLv8vPH7ofwuc4yvzE4
9BVrwta6hZeF9MtdVmaa/it0Wd3bcxbHc9yOme+M0kBvVSvbu2sYTPd3MUEQIXfM4Rck4AyfUkCu
Vm8Yz2fi200W+sLS3F3cNDARfq9yVCsVlaELxGxQjO7PTIFYPjrWZNf8P3jW2j202m2OqQQC+mmH
mLKk6K7Rx7D8uSU3bgeW4x1e9g2PSbq6gs7d7i5mSGGJS8kkjBVRR1JJ6CpIpEmjWSN1dGAKspyC
PUGvP/HWry6poXinSrLSLa+g0+zb7ZNcThBHIY96+Wuxt7KMNyVxxg56WLK7gPiLwzaPpDvcjSJJ
LW+e42oPljDIEXOc5XJYcds80kwfQ9AzRXl1v4g1e4+H/iW98QaTBqMUMl1DJBaXZTeisyuvzKux
AB94FmPXGeK6U67Kktto+iabBcXaWUdy8NxdmJIomyqrvCOWYlT26AkkcZEwOsorgf8AhYTzWmjz
2Wg3c7ajdvZyI00cZt5k37kOTycoenGOc5wpv2niXUru21aNdEjfVNOnEDWkd4DHIWVWDCVlXC7X
ycrng4BpgdFdXMFlbSXN1NHBBEpeSWVwqoo6kk8AVYR1kQOjBlYZBByCK841fxFa+Mfhz4vSa2sJ
DYQyoTbXAu4GYRCRXR9q5IJ9OCtd3p7FdEtGCM5FuhCjGT8o45pB2NGivP7bx9cvplzqd34fmtbG
C5ktCBcCWZp1lEaIsaKc7iex4ION3BMtn48n+y3kmo6Je2skLRJBtimEdy8jBFRWmiiO7cRnK4AI
OTzh+gHd/WjNcbL4svNNh1D+3dGe0e1MIia2mM0N0ZTtVUkZE+bdwQRxkHNOTxTqNtqsuk6ponl6
h9ka7tUsroTJcKpAZQ7rHtYEjgjGD1oA7CqMd7bXE88MNxFJJbkLMiOC0ZIyAw7cc81yFj46v7vQ
9O1J/D6xNqvlR6fCbwM0srbiQ2E+RFVS27k4/hzxWRpWrt4bu/G+pXemWtpIl5bGSCCYmEM8aDe0
gQELltzNsyOeCaOrA9UorB8Oavc61Yy3Nxa20IEu2KS1u/tMM6bQQ6PtXI5I6dVNYsmtWNh4y1y6
vdLktpNP0uOWS+e43edBukOFjBIABVuThj6dMp6AtTqnvLaK9itHuIkuJlZoomcB3C/eKr1OMjP1
q9XmS3d5e/Efwzql9pNtp3nWF2ySrcCWVo9qELJ8g2lc5wCw+Y81o6Z49n1bUbQQeHdRfTbsEwXS
QT5A25Vn3xLGFbsyyN1HqcMDvKK4G28f6hPYjUJvDxtbGPUf7PnaW9QyI3m+UGVVBDAMRuyy47bh
zVmHVtfPxJvNNeG1fTYbGOaNEnYSAMzjdgphmLJjG4ADueaQHYu6xozuwVFGSxOABVLT9W07VoDc
abf2t7AG2GW2mWRQfTKk88ivNtR1OeTwBdz6RokVis+tGK8guL0s283Sq3IVgd5yGAOFBON1bpey
g8e6Ybvw5DbanNZT3D6jBcApkCMOvABk42/M6jGBjvgQHe1nz3lraSwpPcRQtM/lwrI4UyPgnaue
pwDwPSuU0nx9Jq19aLHol6NLu8mK98i4GxcZDyboVjVD6rI3Ue+MfVdVn8Q6j4O1f+yreLTpNXX7
HetPunZCknVNnyK+0Nw5+6uQOx2A9Urzf4mf8jR4A/7Da/0r0gdK83+Jn/I0eAP+w2v9KYHpFFFF
ABRRRQAUUUUAFFFFABRRRQBm6it+9nKunSwRXeP3TzxNJGD7qrKf1/PpXlFjqnxj09J4LfwrpM8f
2md/MklAyWkZjt3Tg7ck446Yr2ivnjxr4X0G98TaxqGqSeIL68s3NxqUVtsHk2zMwiMRdMMFUJkZ
xgk5+VhU7Ma1R7H4LTUl8J2P9r/Zv7QcO8wgfeilnY7d2TuIBAJyckHk9a6SuK+F4tB8OtGFlFcx
W+x9guTlz+8b5uOME8j2IrtauW7JWwted2v/ACcJff8AYuJ/6PFeiV53a/8AJwl9/wBi4n/o8Uhn
olFFFACVm6pFeT2Lx2F2ttdEqUmeHzFGGBIK5GQRkdR160k2rWkGr2+lPKPttxG8scY67Fxlj6DJ
ArN8PazqOp6tr9nfwW0X9nXawxC3ZmyjRq4LMQMn5uwGOnOMk3DYlh0V5UuzrLw3095D9mmMUBhj
8r5vkClmIzuOSWOfbgVT0/wvd209k97qqXi6ZG0emhrYqYyV275TvPmMF+XI2DluMkEdZRQgPPdP
8I+LLfWTd3fjdp7WWcTXFtHpccRkA6IJNxZV7fT611PiHRIdf0SfTZpJIg5VkliOGikVgyOPcMAa
2aKQdbnIJ4c1Z7z+0L3VbS51aK1a1t51sCkUasVLs0fmksx2joyj0A5zf8KaHeeG/DtrpE9/Fepa
qI4ZEtjCdg6BgXbJ9xj6VW8Y61qOg6XBd2EFrKGu4IZjcM3yo8ioSoA+Y/N3Ix156V1NNCOWXQry
Pxld61LqFu9tcWq2rWotGDBFLEHzPMxnLnPy9PTrUWg+GdQ0WBNNbWBcaLAT9ntjbbZlT+GNpQ2G
Qf7oJ4ycZB605wcDJrmfCetX+tafey6jDbRXNtfz2pS3ZigEblRyeT9cD6Ckuw33INB8NX+iQRac
+ri40W2yLe3NttmVP4Y3l3YZB/ugnAycZBqWXhCW2tbXSJ9VW40S0uFntrRrbEy7G3ojS78MisP7
gPAGfXqNT1a00az+03soSIyLEuerOzBVUepJNaIpgcZD4PuJZfEkep6hBc2etg+bFBatE8fyCMYY
yMD8q/3evPtUNr4R1ldW0S9vvECSLpEckUYgsFjeZGCgh2Z2H8IyVVfbHWr41vUU8fNoksFsunnT
zdRSKzGVmDqpzwAo5PHPTOR0rqu1JbXC+tjjNE8JXGna7FrOpX9te38VqbU3EFkbeSdTt+aZt7eY
QEXHAxz17XvEGh3msX+jXFvfwWyaddfaiklsZTKdpXGQ67eGbsecemD0uKMUwPPr/wCH+oXFlqem
WOvR2umX14LzynsvNlgk8xZGCPvA2llzhlPWtFfC+p2Os3V7peuGKO+VPtkVxaLKXkVQvmoVZAjl
VH8LLnnb2rsKKAOR/wCEc1VPEl/qsGsWq/aLJLOKOWydzGFLFWZvNG45Zs8DPHTvUt/Bd7beHNA0
xdXgNzotwssNybI7XUIyYZPM64c87uvau5opAcnJ4b1QeI7/AFa21e0X7RZpaIktizldhJDMyyru
OWbgBe3pznjwVqi+B7Pw3/bdoRaSwtHcNpzZKRsHVSvnddyjnPTjGea7yuW8Ya1qOhaVBeWEFrKG
u4IZjcMw2o8ioSqgfMfm7kY689KPICP/AIRrUrfXLrUdM1n7ImoBWvLeS0EoMgUL5kR3jY21QPm3
r7Gqep+Cb2aXWl0zWEtLXWoPKvIbi1NwQ3l+XvRvMUglcZzu6V27ZCkqMnHA9ao6VcXl3pkE1/Y/
Ybt1zLbecJfLPpuHBosFyLRrCXTNNtbGS5kuWgjCGaRFUvj2UAD/AD161rUlHamJKyFooooGed+L
P+Sy/D7/AHNR/wDRFeiV534s/wCSy/D7/c1H/wBEV6JQAUUUUAFFFFABRRRQB5vrH/JfPDX/AGCr
j+bV6RXm+sf8l88Nf9gq4/m1ekUAcb4n8NeI9b1K2uNL8VLpMFv8yQjTlnJf+8xd8H2+XitrRbK8
0/TIbfUNSfUb1cmW6eMR+YxJPCjhR2wPStiko8gPPx4F1BNSiubfWrZUj1STUoxLYl3dnDArI4lG
/CthTgYCjrTdQ+H+oT2Wp6XYa9Ha6ZfXgvPKey82WCTzFkbY+8DaWXOGU9a9CopbBucLqHgm/nOs
rp+trDBrNuIr1bqyEzM/l+WZUKsgViuMjBGRwBU9r4U1C11fRbw6ulwml2j2zLNaDzJt+3cdysqr
9xcDaehyTnNS634rZPB+ra34f+zXj2Ky4adyIyY87sbQS2MHjjOOo610tlO1zYwTuAGkjVyB0BIz
QgZyLeDb0eHtf0eLV41g1SSdoy1mWMImYs+fnG8/MQD8oHcGpj4X1GHUbPVLHV4YNSjtFs7ppLRp
ILiNclT5fmBlYEnB3nqetdjRQgZw03gmdE0WPTtThgj0+8e/k86zMjXEz79xJDqFB8xuMenYYqK6
8Dahex68lzrFuy6rcw3JC2BCoY9gCODKfMQqgBXjOTz2rvqXNMDgJPBurS2fiO2fWrQnXUAlcaaw
8pvLWM7R53TaOAeh7npXU6dbXVnpMNrPcRTXEUQjMywlEYgYB2bjjtxu/Ks6z1i/m8aajolzBapa
QWkVxA6MzSPvZ1O7IAH3egz9ecDpqW6DqcRa+B7g+Gr/AEi/1WOQ3N217HcWtqYWhmMnm7sM77sP
jA44GDmrN14a1DV9Dmsdc1gXE5CeRcWlt5HlOjB1k2lmy+5QfTAwAMnPXZrKOr20mqT6VA6SX0MA
meLPCBiQu49s4NAGPd+G7zV9Cn0/XdX+0SuE8qazt/s4iZCGWTaXfL7gDnOOAAo5ykPh3Unul1C/
1S0udWitXtbadbExxRqxUszR+YSzEqOjKMdAOc2PCOs3+uaTPcajDbw3MV7PbMluWKARyFRgtyen
XAz6DpXTUAcND4Ju4vCekaWusRrfaPMktleR2mANoK4eMud2VZgcMvXtimw+D9chutZv08SLHfak
9vIDDYBYY2i2j7hcs2VTbjeBhj1ru6KYHMeGPDaeG4L1UMAe7n8+RLO3+zwI21V+SPc23hQTyckn
6VBe+EJdU17V7y9vInsNS08ae9sluVkVBuO4SbyM5dv4fT056+kzQ9QvY4W38JawdU0a71DXlmj0
qOSFVhsFjedHCgiRmdh/CMlVXvjHWr2h+G9S0W3j0+PWlm0q3JNpA1piWNR9yNpA/wAyL6bQx4Bb
GQesooA88bwJrDeH5tIbX7P97qX9oNN/Zjfe83zduPO6bgOc9OOvNbp0O5TxX/bSakieZZx21xCL
bO/YzMCrbvlGXORgnHcda6aigDz+TwLrD+HJ9IGvWSmbUTftMNNbhvNEu0Dzv7w/Lj3rXn0DUbvx
FpWr3Go2jLZ2skE0KWTDzvM27yD5p2j5FwMNjnk546nNFAHIaF4Y1DRYI9NbWRcaLAT9ntjbbZlT
+GNpQ2GQf7oJ4ycZBzI/h/qcdnpWmx+IxHpmlXgubQLYA3CKAwEZkLlDgMRny69Coo8wAdK84+Jn
/I0eAP8AsNr/AEr0ivN/iZ/yNHgD/sNr/SgD0iiiigAooooAKKKKACiiigAooooAQ15BqvxUHg7x
Rqtn4lTWn8x/9BggsYUhjjGQHSRn3SbuCSeAcjHFdv48vtT0zwbqN5oxcamiqLby4POYuzqoATBy
TnHQ1wqaf8XNTklubDxXpEdu0rrHG8Ue5NrFdrYhbBBHI3EjoeaW7Dod94NvNW1LwtYXmtWb2moS
K3mwyLtYYYhSwwMEqASMDk9BXSCub8Hwa1beH4YfEF3HeaokkonniYFWPmNjGAMDGOMDHTFdJVPc
SFrzu1/5OEvv+xcT/wBHivRK87tf+ThL7/sXE/8AR4pDPRKKKKAPO/E9no8XxG8OXmo2dmWkt7hV
kmhVmeVTF5YHGWcZbaBz1xXLa5P4fu3+Is9zeWUt3bsGtQ9yp8uVbdFDoueHDjbuHzZ+X1Fe2UUr
DueSaifD/iDxx4Y+23lpeC80udZIWviySFvL2DZuxyd3bkrnkqMVNQWxm07Xre8EUPjSC6l/svGF
utu7NuLc/eMe3Awvy/f3dzXs1HWmSeZ3g0fSfHOrLrSWUK6no0IdHQYvZQ8gcKuP3j/d+UAscrx0
rn7bUtOj8A+Bn1Fop9OjR1uNOvCkCXOI8Bh55SN9jEEAnBzkZK17ZWBq2nalc6ha3umanHayQK6G
K5tjPC4bHzbVdCHGMA7uhYY5pdLDPMJLfQNI+Flyba80y3S91mJ/9GuIiYl+0q6xNIjEM6R8nBO3
nHAzXUeG7nRbP4j6np2l3dm8c2nW8zRQTK3mS7pNznn5nKlSzdTkE9a6fR9FXSZL28llWe+vpRNd
TJH5aswUKAq5O1QAOpJ65Jre70xdDg/G81mniXw/Hr/kjw44n883I/0c3GF8oS5+XGN+N3GfcCuO
0/UvD0fhi405ra0l05vEk8cM14HWwgBLsju3CyqAOEzgkrkrwR7dRSGeIAaXffC+6guW0+5XS9bA
IEahLaI3g5CMSY0KFuCfu98VZ8fz6DNBdW1taaVbSW+iGWxnuoy25Pn2paRZUKw27vMHQbflYcj2
aigEeVX1z4evvFWj6lrl7YS6RNorKs13Mv2aeUSLlTk7JCOTtOcEZ6is6dbSHRtE0nWrW1VZHvX0
2fWw7xQW4fESGJmXfKUZQqsQyj3+U+zUUPawloeHSahp994E8JfaNW0WaVLKRDa6zta1mZRGHVnz
mKZVPynk8sO9WbuLTL6bRbbxNc3Gi6PLo0AsI7tLeSJJQG8xWeeJlWQLsw3ykj8q9oop7jW1jF0O
3+y6JZwJdXk8aRBUmuzmZ17M3A5x6jPrzXlGgFvL1F/Dn2DUb+TRrg2+p2AEd0GOwhbuMZ/fFs7X
3fNtbj09xNFHW4LRWPIdGj8L2emX+t6VqmoapINOm+32ECwQuQAc+eIokcSbsgMx3csRkbjVfwvc
6Fa65rFsNQ0a10+70eGUR6XMbeJSrSbv3gfLuo4aQbT6ha9mopMDxLRYNFtfh94Y1MRxy6c7xQ67
NGxl/dqj7Um5PyLIyZU8AYBG2tPxEvh3S/AV4mlanGml3erW0kLLOi26N5sbOtuVwNo2sx25AO70
OPWqKd+oHl9jceGrfxl4h0+yv7K3sJtIhnmFvebCzgyF5C6sDu2FSzZ3YIJPNc9azaHc+Fvhytzq
MQYTrGyLfMgCiOQNlVYD721STzzt74PuNFIDx8XmlponxA07RtTsrG3t7lTAkEwRIg0cYcDb9xWf
cpYcAk+lXPA1v4avfG17q+kWuk2R+xxxR2NvPayyqwLb5QIXYIuGVeuT3A4z3etadPqmnG3trxrO
YOkiybN6kqwba65G5TjBGRkd6p2ui3T6xBq2sXltdX1tHJDbm1tTAiK+3cSGdyW+UfxYx27009dQ
e1jpqKKKAPO/Fn/JZfh9/uaj/wCiK9ErzvxZ/wAll+H3+5qP/oivRKACiiigAooooAKKKKAPN9Y/
5L54a/7BVx/Nq9IrzfWP+S+eGv8AsFXH82r0igAooooAKidFkRkdQysMFSMgipaKQHjFsugaV8Of
HMUUdhZ3aSX8MoRFjYAu4hRj+ICqfwFX9Mu/Dun+MvD/ANh1CxBv9JnW6lW8Becgx7C77sseHCk9
ACB049X6UlC0Bs8T0u2sB4M1nUdBxeX9vqc6PNb3LT3C2bXILhW3FvmjUnjk5JHJJroNKsND1LxK
R4YhsJ/D91pkiajBaKptWk3L5QZB8okwWz3wOe1em0dqAPEtN1HRxpPw7jDRzanYXSwXCQRGWa3H
lSAo4UFk+YD5T12k/wAJIj8Qr4f1LV9V0/VZtKkv21dJI9UvLq2X7NCjIWhZJHEmAFdQoUq24HPJ
x7j1rkLjwvqdza3ul3OsxTaRetL5yvZZuSkhJK+b5m3jO0Hy+FAHbNF9bhpY5vUl8MXPxD1Sy1Ob
TvsltosKfZZZ1WJdrSHDJnHyqVYZHy5B44NdJ8OtQXUvAOiTLci4kS1SORhJvIdRggnPX611EEUd
tBHDEoWONQiqOwHAFT01orC31PG9T+xXdp4hh1DavjeK7lOmk4W7I3Zt/IP3jHtxkLx9/d3Nblva
aVZ/Feaa+trFL+XS4JI5DCu95d0gkdTjP3cbj2GM8V6RRSWlhvU8K+2eH4/DF3rK6hYPqMPiMvBO
10paJGu8nZ83yq0e5jt+8vJyBWprVro+r+L9Vh8S67c2MpMcukGNID5kGxMG2keJmEnmbuI2DE4w
K9hpKFsD7nltraaBf/FW9tr2ZLu5Gn2riC5uvMcTo7sfk3YDKApwo4yf7xztfEg2o0exF1eWNoGv
AIxqUIktJn8tyEnBIwhx17MFPau4paOlgT1ueQWtxZRab4aXV9PtbbwqZLyOdC4msvO8z905YgKY
W+coWGBlfQGo73ToU8G6tcRxxy6Laa3b3Okyt8ywQb4jI0R7RAmTGONue1ex0U+orHllvqPhy78e
eIZre5iWxutHiae9tmaOJyHk3OZ0wo4wu7d1UrnKkDG0WHRLX4feGNTEcUunM8UOuzRsZf3ao+1J
uSdiyMmVPAGARtr2w0UtkN6nkur22j2fh2N9JvbmPwrNqplv5bNY5reGNo2BWNSjIYRJt3Day5Le
+INR0/QdN8Kxx6d4it5tOm1IPDJqUUEmmyS+U58orGqIsZIySowr4P3gcew96KYXOR+H7RnwjaCG
yjs4llmVY4ZfMhI81vmibAzG3VfYjr1rr6bTqG7iQUUUUDCvN/iZ/wAjR4A/7Da/0r0ivN/iZ/yN
HgD/ALDa/wBKAPSKKKKACiiigAooooAKKKKACiiigDk/H8mlxeBtWbWIrmXTvJxMtqMy4JABXPGQ
cHnjjmvnW4tvhfp9xPaXc3jCSSKV0JijtkGNxwMNznGMnjPoOg+odQW/exlXTpreK7x+7eeJpIwf
dVZT+vHv0ryuy1T4x6fDPBD4a0ieP7TO/mSSAZLSMx27p1O3JO3jpiktx9DsvhV/Zv8AwrvTv7H+
1/2fvn8j7Xt83b5z/e28Z69K7auW8Gx6nH4ZtF1f7ONRy5uEgbcqMXY7S2TuYcAkkkkHJJ5rqaqW
5KFrzu1/5OEvv+xcT/0eK9EryzxAnifRvinN4h0fwvLrNtNpSWZ23SQBW8zceTnPQdu9IZ6nRXm/
/Cc+Pv8Aol0//g3j/wDiKP8AhOfH3/RLp/8Awbx//EUAekUV5v8A8Jz4+/6JdP8A+DeP/wCIo/4T
nx9/0S6f/wAG8f8A8RQB6RRXm/8AwnPj7/ol0/8A4N4//iKP+E58ff8ARLp//BvH/wDEUAekUV5v
/wAJz4+/6JdP/wCDeP8A+Io/4Tnx9/0S6f8A8G8f/wARQB6RRXm//Cc+Pv8Aol0//g3j/wDiKP8A
hOfH3/RLp/8Awbx//EUAekUV5v8A8Jz4+/6JdP8A+DeP/wCIo/4Tnx9/0S6f/wAG8f8A8RQB6RRX
m/8AwnPj7/ol0/8A4N4//iKP+E58ff8ARLp//BvH/wDEUAekUV5PbfE3xbdatfaXb/D2WS+sRGbm
IasmY943Ln5Mcj0rQ/4Tnx9/0S6f/wAG8f8A8RQB6RRXm/8AwnPj7/ol0/8A4N4//iKP+E58ff8A
RLp//BvH/wDEUAekUV5v/wAJz4+/6JdP/wCDeP8A+Io/4Tnx9/0S6f8A8G8f/wARQB6RRXm//Cc+
Pv8Aol0//g3j/wDiKP8AhOfH3/RLp/8Awbx//EUAekUV5v8A8Jz4+/6JdP8A+DeP/wCIo/4Tnx9/
0S6f/wAG8f8A8RQB6RRXm/8AwnPj7/ol0/8A4N4//iKP+E58ff8ARLp//BvH/wDEUAekUV5v/wAJ
z4+/6JdP/wCDeP8A+Io/4Tnx9/0S6f8A8G8f/wARQB6RRXm//Cc+Pv8Aol0//g3j/wDiKP8AhOfH
3/RLp/8Awbx//EUASeLP+Sy/D7/c1H/0RXoleTWzeLvEfxI8L6rqnhGXR7TSxdCSRr1JwfMiKjoA
RyAO/WvWaACiiigAooooAKKKKAPN9Y/5L54a/wCwVcfzavSK8w8ZWviSy+I+j+I9G0CTV4rWxkge
NLhYfmYnu2fX0qf/AITnx9/0S6f/AMG8f/xFAHpFFeb/APCc+Pv+iXT/APg3j/8AiKP+E58ff9Eu
n/8ABvH/APEUAekUV5v/AMJz4+/6JdP/AODeP/4ij/hOfH3/AES6f/wbx/8AxFAHpFFeb/8ACc+P
v+iXT/8Ag3j/APiKP+E58ff9Eun/APBvH/8AEUAekUV5v/wnPj7/AKJdP/4N4/8A4ij/AITnx9/0
S6f/AMG8f/xFAHpFFeb/APCc+Pv+iXT/APg3j/8AiKP+E58ff9Eun/8ABvH/APEUAekUV5v/AMJz
4+/6JdP/AODeP/4ij/hOfH3/AES6f/wbx/8AxFAHpFFeb/8ACc+Pv+iXT/8Ag3j/APiKP+E58ff9
Eun/APBvH/8AEUAekUV5Po3xR8WeINNj1DSvh3Jc2khYLKurIASDg9UHetD/AITnx9/0S6f/AMG8
f/xFAHpFFeb/APCc+Pv+iXT/APg3j/8AiKP+E58ff9Eun/8ABvH/APEUAekUV5v/AMJz4+/6JdP/
AODeP/4ij/hOfH3/AES6f/wbx/8AxFAHpFFeb/8ACc+Pv+iXT/8Ag3j/APiKP+E58ff9Eun/APBv
H/8AEUAekUV5v/wnPj7/AKJdP/4N4/8A4ij/AITnx9/0S6f/AMG8f/xFAHpFFeb/APCc+Pv+iXT/
APg3j/8AiKP+E58ff9Eun/8ABvH/APEUAekUV5v/AMJz4+/6JdP/AODeP/4ij/hOfH3/AES6f/wb
x/8AxFAHpFeb/Ez/AJGjwB/2G1/pR/wnPj7/AKJdP/4N4/8A4isbU5PGXi7xL4Ye98GTaVbabqSX
Es5v45ht4zwAP60Aew0UUUAFFFFABRRRQAUUUUAFFFFACGvnDXtP+Geo+Kdbm8VeKtVi1QX8qMkM
bFFQHCqP3LfdHy9f4eOMV9HmvANT1nwzp3xF1iLxLFoEFgFnUW66R5t0Ji25ZXd4WDMwJIwxXBXI
qftB0PU/h5Dotv4GsIfD1zPc6UjSiCa4GHf942SflX+LOOBxius7Vx3w6uI73wHpl1BYrZRTK7rD
HF5S8u3zBASFDfewDgbuK7Gre4lsLRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnfhP
/ksvxB/3NO/9EV6JXnfhP/ksvxB/3NO/9EV6JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUA
FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeb/Av/klGm/9
dZ//AEY1ekV5v8C/+SUab/11n/8ARjV6RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFF
ABRRRQAUUUUAFFFFABRRRQBg+J7vWrLw9dT+H7OK81Vdgggl+4xLqDn5l6KSeo6V5JcT/EzXZGuL
zwB4X1CSBjD5tzFFIVKnlQWn7HPTvnvXs2qanaaRYte386QWyMivLIwVU3MFBYngDJHNeSa9pWhX
2sXF7onxXj0OC5kM01pBqatH5rH5mULMuM9T15/Kktx9D0fwdf6pqfhi0utaiSDUnMgnijxtRg7D
HBOMAYxnI78109cz4LttJs/C1rbaNdNd2ETSIly0okMzb23vuHDZbcciulqnuSthaKKKQwooooAK
KKKACiiigAooooAKKKKACiiigAoorOvZbiGxuJbW3FxcJGzRQs+wSMBwu7Bxk8ZxQBxnhP8A5LL8
Qf8Ac07/ANEV6JXzt4G+I91qPxW1V7fQCbjXpLeJoWu8fZRCm12J2fNwC2MDpivomgAooooAKKKK
ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA
KKKKACiiigAoorkvGvie78JeGZdag0r+0UgdfOiE/lFEPG7O1s4OPwOe1AGJ8C/+SUab/wBdZ/8A
0Y1ekV4l8BfE11e6M3h1NKxa6crSyX5m6s7kqmzb16/xfw17bQAUUUUAFFFFABRRRQAUUUUAFFFF
ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBi+INDs/EekTaTfpvtJ2jMqbiNyq6tjIIIztxx
XM/8KT+Hv/Qv/wDk7cf/AByvQKKQGF4e0Gz8NaPHpenIY7SF5DEm4tsDOWxkkk4z3NbtFFPcAooo
oAKKKKACiiigAooooAKKKKACiiigAooooA47x14qvPC8Glf2dp6ahd6herZxQPP5WWYHHzHjqMc+
tZH/AAlXxP8A+ibwf+DmH/GpPih/yFPAv/Yx2/8AWvRKAPC9H0vxtovjHU/E1t8O4ftOogDyzq0G
2EnlyvP8RAP5+tdZ/wAJV8T/APom8H/g5h/xr0iigDzf/hKvif8A9E3g/wDBzD/jR/wlXxP/AOib
wf8Ag5h/xr0iigDzf/hKvif/ANE3g/8ABzD/AI0f8JV8T/8Aom8H/g5h/wAa9IooA83/AOEq+J//
AETeD/wcw/40f8JV8T/+ibwf+DmH/GvSKKAPN/8AhKvif/0TeD/wcw/40f8ACVfE/wD6JvB/4OYf
8a9IooA83/4Sr4n/APRN4P8Awcw/40f8JV8T/wDom8H/AIOYf8a9IooA83/4Sr4n/wDRN4P/AAcw
/wCNH/CVfE//AKJvB/4OYf8AGvSKKAPN/wDhKvif/wBE3g/8HMP+NH/CVfE//om8H/g5h/xr0iig
Dzf/AISr4n/9E3g/8HMP+NH/AAlXxP8A+ibwf+DmH/GvSKKAPN/+Eq+J/wD0TeD/AMHMP+NH/CVf
E/8A6JvB/wCDmH/GvSKKAPN/+Eq+J/8A0TeD/wAHMP8AjR/wlXxP/wCibwf+DmH/ABr0iigDzf8A
4Sr4n/8ARN4P/BzD/jR/wlXxP/6JvB/4OYf8a9IooA83/wCEq+J//RN4P/BzD/jR/wAJV8T/APom
8H/g5h/xr0iigDzf/hKvif8A9E3g/wDBzD/jR/wlXxP/AOibwf8Ag5h/xr0iigDzf/hKvif/ANE3
g/8ABzD/AI0f8JV8T/8Aom8H/g5h/wAa9IooA83/AOEq+J//AETeD/wcw/40f8JV8T/+ibwf+DmH
/GvSKKAPN/8AhKvif/0TeD/wcw/40f8ACVfE/wD6JvB/4OYf8a9IooA83/4Sr4n/APRN4P8Awcw/
40f8JV8T/wDom8H/AIOYf8a9IooA83/4Sr4n/wDRN4P/AAcw/wCNH/CVfE//AKJvB/4OYf8AGvSK
KAPN/wDhKvif/wBE3g/8HMP+NV7zXPiNqFlcWV18NbaW3uI2ilQ6xDhlYYI6+leoUUAeJeCrfx94
H0EaVZfD6OYvK0sk8mrQBpGPTOD2UAfh71s33xB8a6M9lJrfgiGytLm6jtfO/tOOTDOcD5VyfX8q
9Urzv4w/8gDQ/wDsO2n82oA9EooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooo
oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzv4of8AIU8C/wDY
x2/9a9Erzv4of8hTwL/2Mdv/AFr0SgApjbtp2gFscAnFPqtIzJEzqjyMASEXGT7DOB+dAHKXj+IN
J1zRpP7UfUIb+5a3urJoI1SIFGfzIiqhwF2Hh2fIb1xWLda7q8niLVbJNTlt9TtrmJbDRvJj2XkB
25kLMpZgfnyVYBNvI9bWn6r44uPEnmXngr7PBJJ5SXkuqQsLaDIz+7XJLHGTg8kL2FQat4b1W9vb
9ZNKe41BrwT6ZrSTRgWSfLhTlhIoXDZRVZW3e5wLdCZt+ItQ1Ww17w6La6jjsru9+z3EPkbnk/dy
N98ngfKOAufftXWg9K4vxdDqc2paBLY6RdX0dle/ap3hkhUBfLdMfvJFJOWB9Md66+RPMiZAxQsp
G4dRRrYfVehhL4r0h9SishdsJJZDDFI0MiwyyDqiSlfLduCMBicgjsaw7O9i8VeL9VtftetWTabP
EtsbdJ4I8BVd/MDL5bbicYcHKgFeuapWfh3W5vDOmeFLzTmi/s26hcakJozFLFFIGDKu7zA7AYwV
AHPzeux4di1GDxV4imvNIu7S1v7hJoJ5JIGBCxJHghJGYElSRx0646UluDNfVvFGjaLNaw6nfR28
125S3iILPIcdlUE+31IHUgVWm8ZaJBbxXElzcCGRFkMn2SYrCrdDKdmIhg5+fbxzVbxfb6lcar4d
ksdKub1LO/8AtMzxSQqFXy3THzupJy4PHYGse68MeX4v1W5vfCFlr1rqDpNBdSrAz27hFQxv5nzb
Pl3ZTdjJ+UmhAzqNR8WaLpMxivbwoVCtI6wySJCGOFMjqpWMHsXIo1LxTpGkSNHd3MqlEDymO3kl
WFT0aRkUiNevLYHB9DWEmmalpmq6zZPoUWq6XqzRyKytGsUTiNIyksbnPl/ID8oc4z8ppDputaRr
GvCLShqtjrCo6SRSxoIJBEsRSRZGH7vCg5XcQMjaaGBq6h408O6ZeRWtzqkRuZYDcxxQq0zvGBnc
AgOeOR6gEjgGsHx54nt/7Ha307VL+3vobu2VzawyBMtImYpJdm1TtbO3crdOxwV0zQtV0fXPCtsu
nXN3aaVp0lnPeq8ITe/l8hWcPtGw/wAPpjNZ+paP4kTw9rWg22hS3rXGqfbbe9S6iWN0adZiH3MH
VhgrwrdKfVC6HcXXifSrPU/sM084naVIMpayvGsj42o0iqUVjkcEg8j1FT6pqlppGny39/MYraLG
99pY8kAABQSSSQAByc1x+oaLrU/ip7yz0y6sbhri3eW4gu4pLG6QCMv50TtuLLtdVdYw33Tx1HUe
KP7Y/sKYaEpa+3x4CFA+zeN+zf8AJu27sbuM0ug+pnat40sYfC2r6vYfaJZLFHQxvZzK8coTcA6M
oZRyDuIAwetYEHiKLw++kXccniO8GsskUqXUNzKkTKrMzqjIXDNzhU+UgZC4FQ/2LrkGh+MrGDw/
qbf2sn+iedewzP8ANAseJHeYnIIOeSMdCa29StNXvNN8L3cWi3An069WW4s2mhEgUROmQ2/YRlgf
vZx2zxR1+4Da1DxRpGmTFLy4kQLhpXW3ldIAehlZVKxD/fK+tQz+NfD8eryaSNSWW/j2b4II3lZd
52rnYDjkjPpkZxkVzs/hd4/FGpXV94PsNdg1FkniuZBAzWz7FQxv5uG8v5d2VDHk/LmtXTrLUYPH
1zdPpU0Vg+nQ2iXCGER7o2djhA5cL8wA4/xpoGbmp6nZ6PYtd38vlQghc7SxZicBVUAlmJOAACTX
G6H4qtrS/wDF+o3+palJplrcwlTc20u63UxAsvlBAyKDn+EdMknrW74v07ULxdHvtOtvtUum36XT
WpkCGZdrIQpb5dw35GSBx1rB/sXX9WPjfzdI+wQaxbKtqbm5jaQuIBHgrGWUDI67vTg9lfdjSV0d
XL4n0mHUEsprswzPbNdqZY3SMwqAWbzCNnGRnnIzVOx8eeG7+SzW11IyLeyeVby+RKInk5+TzCu0
OdpwpIJ4wORnLtLbxDd+LPDt6+gNZ2ljZTW1w11dxbwzCPlVjL5Hy8cjPOduBuxvDdnf694M0zR4
tKmhtk1NrmTUHki8sLHdNIdihi+8kbeVA5Jz0y9Li6GlHq8mkjxy+o+I5bWK2ulEF5dASi23wIwC
R4AOC3CgfN7kk10N34j03RbG3N5eSTStbiZmgtZJXZAOZWSNWKL7kYHSuYvdO164tPHkKeH7zOrD
FmTPb4k/crFz+9+Xkbuf4ffir0VprWma1Dqi6HNfW17pkNpdWiywCa3ePeR95wjKd5Bw3bvSX+QM
17zxnoWnpE1xfMySW4u/Mt7eWdRCekjNGpCr/tNgcGob/wAXW9h4u03Qja3kn2yJpftEdrJInGAA
CqnP3gS3RRjJ5rA8VaN4iv8ATrnR7XSpG05tK8q0g0y6S2giuCGBEnzIzIF2hQAUOTuXpt1GsdXO
ueF9Tj0ibbbWc1rcRPNEGgZ/LwzEMQV+Q/d3HpxTQM1rjxTpdtqCWc1w6yNKIfN+zyGESHgIZtvl
hs8bS2ckDvSReJtKl1hNLWeY3UjvEjC2l8p3QEuqy7dhIwcgNwQR1Fctp3hP7Dq17bXvhDT755L6
S5ttZeOBxtkdn/eBv3m5M4G0HOByo5Eum6LrEPi5by10+8sLU3s8l2klxFLZXCHzNssab2kjmbcm
cBR97PoRA+tjqNb8RaR4ethc6vfw2cTyrGjSH7zE9ABz9fQcnimN4w0dbVbnzLtwS3yR2M7yKFJB
Zo1Qsq5BG4jHvVHx1aX97oqWmm6fPezNd28hWJ4k2rHKrkkyOvZSBjviszXNAa48WJrNz4Vi12yu
rKOCS2lW3aazdC7AgSsEIO/Bw3Ve9IDdn8aeHre6t7RtWhee5g+0QRQBpWkj4wVCA5JyNoHLdgaZ
B438PXK20kN87JcSCFXFtLtjkL7Ash24iYtwA+0msh9M1G28V+H5bXw60dhY2VxE5tHgWKJpShCq
pdWwNpBIUdeB6ZDaZ4hbwTeWI8NXgu5tb+2rF9otuY/tImyW83H3V2/X25p9Q6Hbal4p0nSJWjvb
iVTGgeUx20kqwqejSMikRjry2BwfQ05PE+lya7Bo0U8r3txD9ojCW0rRvFjO8SBdm3kc7upA6msI
WWs6drOuyJo8t/aa0qSoRNErW0nlrGY5Qz8rwDlN3fg8ZSTwpqemeHfDUekTRSavoyxwebJwskTA
JKD/ALPRgP8AYFAG6fFWlmy+0hrwqZGhWIWM/muynDbYtm9gO5CkCmyeK9HXTLW+F4zw3TmOBYYZ
JJXcZyoiVS+4YOV25XBzjFYfiPwwxv8AQ7uPQ4Nfs7GKS2nsrnymchyh85fNwpcFOckZ3HmmS6Jf
6bqeha1pXhyKK2tVuIpdJtGhieJZduHHzCMv8nzYb+LALYyUBZ+HN9NqGj38st9dXqrql0kU10T5
hQP8uRgbeP4cDHoK7jtXGeCbLV7KDVf7U0/7EtxqU9zApnWSRkkct8wXKr1HRj36d+z7U+wurFrz
v4w/8gDQ/wDsO2n82r0SvO/jD/yAND/7Dtp/NqBnolFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFF
FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFVre4huoEnt5o5YXGVkjYMrD2IoAs0VnWupWN/LcRWd9a
3Mls/lzpDKrmJv7rAH5TweDWjQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAed/FD/kKeBf+
xjt/616JXBfEfRdb1aLQbjQ7KK7utN1OO8MUsqxghAe5Priqn9vfFb/oS9K/8GK/40AekUV5v/b3
xW/6EvSv/Biv+NH9vfFb/oS9K/8ABiv+NAHpFFeb/wBvfFb/AKEvSv8AwYr/AI0f298Vv+hL0r/w
Yr/jQB6RRXm/9vfFb/oS9K/8GK/40f298Vv+hL0r/wAGK/40AekUV5v/AG98Vv8AoS9K/wDBiv8A
jR/b3xW/6EvSv/Biv+NAHpFFeb/298Vv+hL0r/wYr/jR/b3xW/6EvSv/AAYr/jQB6RRXm/8Ab3xW
/wChL0r/AMGK/wCNH9vfFb/oS9K/8GK/40AekUV5v/b3xW/6EvSv/Biv+NH9vfFb/oS9K/8ABiv+
NAHpFFeb/wBvfFb/AKEvSv8AwYr/AI0f298Vv+hL0r/wYr/jQB6RRXm/9vfFb/oS9K/8GK/40f29
8Vv+hL0r/wAGK/40AekUV5v/AG98Vv8AoS9K/wDBiv8AjR/b3xW/6EvSv/Biv+NAHpFFeR6P44+I
Wttfrp/hPTJDYXcllPm+27ZU+8OTz161qf298Vv+hL0r/wAGK/40AdzcW63ELwOXCSAqxjdkYA8c
MpBU+4Oap6JoVj4es2tNNSZbcuXCS3Ek20nk4LsxAJ5wO5J71yX9vfFb/oS9K/8ABiv+NH9vfFb/
AKEvSv8AwYr/AI0AekUV5v8A298Vv+hL0r/wYr/jR/b3xW/6EvSv/Biv+NAHpFFeb/298Vv+hL0r
/wAGK/40f298Vv8AoS9K/wDBiv8AjQB6RRXm/wDb3xW/6EvSv/Biv+NH9vfFb/oS9K/8GK/40Aek
UV5v/b3xW/6EvSv/AAYr/jR/b3xW/wChL0r/AMGK/wCNAHpFFeb/ANvfFb/oS9K/8GK/40f298Vv
+hL0r/wYr/jQB6RRXm/9vfFb/oS9K/8ABiv+NH9vfFb/AKEvSv8AwYr/AI0AekUV5v8A298Vv+hL
0r/wYr/jR/b3xW/6EvSv/Biv+NAHpFFeb/298Vv+hL0r/wAGK/40f298Vv8AoS9K/wDBiv8AjQB6
RXnfxh/5AGh/9h20/m1R/wBvfFb/AKEvSv8AwYr/AI1j6/a/EXxYumWepeGLC0trfUILt5Yr5WIC
Nzxn0JoA9gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBp6
GvnbwlcaFoHjRprZfFces2SN/a6zxxvbJCq/P8q5k2A7dv8AwGvok5xXjltZfGPW4f7RtPEukWVv
OzMtq8SloPmIKH9y3KkY+8enWp6j6Fj4O3cE3h7TYYnDXCx3cl0uPmG+ZTGW/wB4A49cH0NeuZrJ
0CO4Tw/pyXl0l3dLbRia4RtyyvtG5ge4J5rWq5bkruLRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAU
UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB538K/+Pjxx/2N
F5/Na9Erzv4V/wDHx44/7Gi8/mteiUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUU
UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO+J
PEdr4Zsobu9iuZI5rhLdRAm5gznAJGRx/nrXzHj4WA4nbxk0v8bItqqlu+Bk4H4mvr09K8YstP8A
jBqlql7YeItF0+0kLeXZGFR9nAJHl/6hvu4x1PSpW4+h6L4J8r/hB9B+z7/J/s+Dy/Mxu27BjOO+
K6KsTw1Bc2vhvTLe5ninuIrWNJJYTlJGCjLKcDgn2rbq5bslbC0UUUhhRRRQAUUUUAFFFFABRRRQ
AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVi+Jbu/03
QL+/0u0ju7y3iMqQyEgSbeSOO+M496AOV+Ff/Hx44/7Gi8/mteiV4D8G/GWr6r4r1TT4tNtxa395
Pqt5MWbMG/Hyr6/Ngc+/pXv1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA08qa+aLD4
d+G76PW7qez8QWlvp0CXEc95PFbLdoc7mQNCQo4O3LHOVyV619MGvnp/B/hTX9b8Qa5N4f1jTbKy
CXiJc3Qtob5CSXK7kyqnBxh8HcOU7T9oOh7N4UitYfCejxWc7T2qWUKwysu0umwbSR2OK36y9Fls
rjRLCbTVC2MlujW6gYAjKjaMduMVqVUt2THYWiiigoKKKKACiiigAooooAKKKKACiiigAooooAKK
KKACiiigAooooAKKKKAMbxHqMukeGNV1OFFeSys5rhEf7rMiFgDjtxXCaX4k+KWsaXaalaaB4eNt
dwrNEWuHB2sMjI3e9dp47/5J74l/7BV1/wCimqP4f/8AJOvDf/YMt/8A0WtAHN/2n8Xf+he8Of8A
gS//AMVR/afxd/6F7w5/4Ev/APFV6RRQB5v/AGn8Xf8AoXvDn/gS/wD8VR/afxd/6F7w5/4Ev/8A
FV6RRQB5v/afxd/6F7w5/wCBL/8AxVH9p/F3/oXvDn/gS/8A8VXpFFAHm/8Aafxd/wChe8Of+BL/
APxVH9p/F3/oXvDn/gS//wAVXpFFAHm/9p/F3/oXvDn/AIEv/wDFUf2n8Xf+he8Of+BL/wDxVekU
UAeb/wBp/F3/AKF7w5/4Ev8A/FUf2n8Xf+he8Of+BL//ABVekUUAeKeFfDvxC8Iy6nLp3hvw+jaj
cmeTdcN8g7IuD90ZbA966P8AtP4u/wDQveHP/Al//iq9IooA83/tP4u/9C94c/8AAl//AIqj+0/i
7/0L3hz/AMCX/wDiq9IooA83/tP4u/8AQveHP/Al/wD4qj+0/i7/ANC94c/8CX/+Kr0iigDzf+0/
i7/0L3hz/wACX/8AiqP7T+Lv/QveHP8AwJf/AOKr0iigDzf+0/i7/wBC94c/8CX/APiqP7T+Lv8A
0L3hz/wJf/4qvSKKAPN/7T+Lv/QveHP/AAJf/wCKo/tP4u/9C94c/wDAl/8A4qvSKKAPN/7T+Lv/
AEL3hz/wJf8A+Kp/hzxV4rn8enw14j07TLZzpxv0azdnyPMCDkn/AHv0r0WvO5P+TiIf+xX/APbk
0AeiUUUUAFFFFAHnXi3xb4nsPGtj4b8N6fp11NdWTXRN4zLjDEHkEelM/tP4u/8AQveHP/Al/wD4
qjVP+TgdD/7Ak3/obV6RQB5v/afxd/6F7w5/4Ev/APFUf2n8Xf8AoXvDn/gS/wD8VXpFFAHm/wDa
fxd/6F7w5/4Ev/8AFUf2n8Xf+he8Of8AgS//AMVXpFFAHm/9p/F3/oXvDn/gS/8A8VR/afxd/wCh
e8Of+BL/APxVekUUAeb/ANp/F3/oXvDn/gS//wAVR/afxd/6F7w5/wCBL/8AxVekUUAeb/2n8Xf+
he8Of+BL/wDxVH9p/F3/AKF7w5/4Ev8A/FV6RRQB5v8A2n8Xf+he8Of+BL//ABVH9p/F3/oXvDn/
AIEv/wDFV6RRQB5v/afxd/6F7w5/4Ev/APFUf2n8Xf8AoXvDn/gS/wD8VXpFFAHm/wDafxd/6F7w
5/4Ev/8AFUf2n8Xf+he8Of8AgS//AMVXpFFAHm/9p/F3/oXvDn/gS/8A8VR/afxd/wChe8Of+BL/
APxVekUUAeb/ANp/F3/oXvDn/gS//wAVR/afxd/6F7w5/wCBL/8AxVekUUAeb/2n8Xf+he8Of+BL
/wDxVH9p/F3/AKF7w5/4Ev8A/FV6RRQB5s2q/FxFLHw/4cwBk/6S/wD8VW38PPEtz4r8GWOtXkMM
M9wZA0cOdo2uyjGST0Wupm/495f9w/yrgPgd/wAkk0j/AH5//Rz0AeiUUUUANPA6V4vpHwp8OeMp
JvEF/pOo6NK95IJNNF2rRsVfDE/JuUMQeARjtxivaD0NeAWPwl8GXugX2szSeKIba0Ds0k5ggFwq
jJkjVlzsPUbiKS3uPoe52cFvBZQQ2iottHGqRKn3QoGAB7Yq7WN4ZgtbbwvpMFhObmzjs4lgmIwZ
Iwg2t+IxWzTe5K2FooooGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHP
+O/+Se+Jf+wVdf8Aopqj+H//ACTrw3/2DLf/ANFrUnjv/knviX/sFXX/AKKao/h//wAk68N/9gy3
/wDRa0AdJWRqVvfXrJDaajNYRgFnlgjjaQnsB5isoHXPyk9OnfXrjfFeoeJra1ig8P8Ah+XUmlP7
+RbyK38tO4VmOdx9dvH1pMEZE3iHX7XwE97cv/pFtftZ3GpQ2+7FukpR7oRcjO0E4wQDk4xxW54d
u76+TUPK1P8AtG0BX7BqUsaHzSV+bIjCK6q3ddueR1XNZksfifU/C8KyaDFprw3UW7SI7tJDNapj
dH5gwnzf3TgEDBOCau+FNKl0p9Xnt9Km03T53WS20syRlkcKd5UIxRAx24UNjjPGafcRN4J1DUNR
0a6fVbpLq5h1C5tzKkQjUqkrKMKOgwO5J9Sa1NQ1mz0pEN1JIGdtqRwwvNJIepCogLNgcnA4HPSs
XwXbalZWGoQ3+lXNk8l/cXMfnSRPuWSRmGPLdsEAjOfwzS+ILDVI/Emja/p1s1+tmk1vPZpIqOyS
7fnQuwXIKDgkZHel2H1ZX8S+NrOHwk2oaXPcS+fcJaB4LaRmhYyKjhgFzG4DHAYA7sDBPFbGhWUG
nWMlxDf6nLaTnz1TUpJGaAYAIHmjzFHGcOTjnpXIatomsHRdVktNGuJbvVtWgv8A7JHNCv2dI2iO
HZnC7m8tj8pYZPXvXocU00lqs72s0TFNxt3Kb1OPukhiufoce9HRgYll418P6k7mz1VJ408zdIkT
+WNjBWG/btzkrgZydwIyCKli8WaTcQXcpu3txZgNcJdwyWzxqejFJFVsHscYJ4rlIvDus6l4I1bT
ZtHNtdNqj38NveyRPHcr9o84RtsZxyBtOeOe4qafwzNdeH520rwlYaBfRvbziApApuJIpFk2FoSR
s+XAJ5JOdq45AfkdTbeKdIvoryRLpovsIBuVuoZLZ4QRkFlkVWAI6HGDSW3i/Q7gXQN61s1rF506
XsEls6R/39sqqdvvjFYetaVqfibRrx4tFTSNSP2dwLl42kuHikEgRniZv3fGASc5JO0Y5e1rqeoa
/F4in0W7s5LOwlthZtLA0tw8hU8FXK7RtONzLknoO4wNC28ceHr2ye9t9RaS2VEcSi3lw+8lVVPl
+diwK7Vy2RjGaxvDPiGL+1fFt3c6jfz2UF3AIluonV4t0a/u1i2Bgdx2hQu5uPvE5NG10LX4fBfh
VRpMgv8AQrmOSWxkniBnUIyEoysVz8+RuI6dqJ9L1u+uPFU9z4VaWz1Ga0litpr2NJ5NgjVsbH2q
VCswbzByF60+rA7fSdbstbgmlsnmYQSmGVZreSFkcAEgq6qw4Ydu9Q3XibSrTVBYTTTCdpUhylrK
8ayPjajSKpRWORwSDyPUVR8G2GrafYXceoyXjxtPutft7RPdCPYo/evGSrncDg5J24yewxdW0TV5
fF0t7pmn3lm7XcDNdJcRNZ3cSiPd58LOW3rtdVZEz93nuDqkHQ6efxXo1vqiWEt6wmecWwcQyGIS
npGZQuwP/sls8jjkVBbeNtAudRmsItVjnuIZTDL5UbukbBSx3OF2qMBuScfKRnINZOlafqunyXWi
3ehR31odQe7tdQd4mhUPKZcujNvDoSQNqnJC8r1EC6Hq2qjxxZT6dcWEesZ+y3MskTKf3KxchHZh
yCenT34pdA0udFbeKtIuJ2gW6kiljiMuLiCSAPGOroZFUOo/vLkcj1FNi8X6I7zK96bbyYjOxu4J
LdWjBwXQyKodenzLkcj1Fczb+FP7T8P3tgPBmneH9QmspbaS8jjgIdmUqPLMXzbT1O4Lxxg5yLmg
6b9gh85PAFlpepQQMJHtVtQ1w3TbCysDg9SX244GDnIGCNfTfG+g6tNZx2OoGf7aCbdxDII5CBkq
HK7d4AJKZ3D0qa58UaXbagtlLcOsjSiHzfIkMIkPAQy7fLDZ42ls5IHeuMsNO8Q2uj+CbJvD14Jd
KuA95tubfCKI3Tj9782d+foD9Ksad4T+w6te2174RsL9pL6S5ttakjgf5ZHZ/wB4G/ebkzgbQc4H
KjkPqLoT/EDxLbRaXJZ2GqXtvfW95bI5tIn2ZMiZieUKVU7TnbuVunY4PoteU6jo/iNPD2taDbaF
Letcap9ttr1LqFY3Rp1mIfcwdWGCvCt0r0mE3JgUzxokpUb0Riyq3cBiBke+B9KFsPqXq87k/wCT
iIf+xX/9uTXoleQ+J/DVt4n+NdvYXlze20SeHRKHs5vKckXDDGcdPm6UAevUV5t/wpbQv+g34j/8
GP8A9jR/wpbQv+g34j/8GP8A9jQB6TXM6j4v0HStfh0LUdQjtL2aFZ4hN8qOpZlADHjOVPB9q5z/
AIUtoX/Qb8R/+DH/AOxrjde+BlzqfiiBbLUZ00pbVfNur6bz5fM3vlUXjjG084HJoA7PUzn9oDQy
On9iTf8AobV6RXjWjeGrbwl8W/D+k2l1d3MaaPMd9zKXIO48L2VeOgr2WgDifET+IdJSHVrbU2mP
22GJtL8mPyZY5JBHtVtvmBwGDbt2MqflxxTfiH4jvtD8PXT6QQL6NVkaRgCIIy4Xdg8EknAB9GP8
NZ1/q3jd/EBaHwS09lC220lm1SBAhPBlZAWJODxzkDPqam8Z+EtV1Tw/q403VNQmubwxsbIC2WJi
GXjc0e4AAZHz0lsHU6LV7DVL6OQ2etS6WEizG8MMTkvg8yeYrAqOOF2nrz0weG9SudS8K6dqmoxJ
bXE9ss0yjhVyM5Geg789M1z/AIkuvFVs1rplh4duNds1Qfa7ia+t7Yz/AOx24/vfKAenQ1rTWWqe
JPA95Y6jbJpV/f2ssJiWTzRBuBVQWHDcYzijo7B2uTWXi7Sr67+zRTSiZo2liWS2lj89F6tEWUea
O/ybuCPWsLwrdx+K9TudV+16zb3FpfzIsOJobd4VZkVGR18snjccfOG6kYxRDYazqc2gzX2jSWUu
hu00jieJxct5TRhYcNnDEg/Ps4wPpf8AA8Gp2VpqFvqWkXNgZL+e5jaWWFw6ySM4H7t2wQDzn8Ca
fUXQuT+NNAttZl0ltRV9QiKCS3hieVk3ttXO0HHJGfTIzjIqWDxPpE+px6fHdP50pYQs0EixTEDJ
EcpUI568Kx6H0NZsdnqT/EHULl9PuorGfT47RLvzIdu5WkYnAffj5wB8vXPTrWR4T8J/2bBaadd+
DdOt76yHl/20iQESqowJFI/eiRvcDHJ3HoUmN7nV2vivRbzU4rCC8Zp5S4hYwyLFMU++I5SuxyO4
Vj0PoaYvizSJNQisvtbCWWQwxSGCRYZZB1RJSvls3BG0MTkEdjWL4b0/VbfT9N0PUtDRZNKXyo9U
LxPGUVdoeIZ8xZGBxyoA+bk9Dn2fh3WpvDWmeFL3TmQabdQuNSE0ZikiikDAqu7zA7AbcFQBz83q
xHSW/jXQLrUpdPt9USe5hmMMoijd1jcKW+ZwNqjAPJOPlIzkGsGPxDDq3xJ0EadqV+9nLZ3TPA0M
kVvJjbtkXci+ZnJ+YFl4GMZ5kXRNX1P/AITmyl06409NYBFrczSxFT+4WLkI7MMkE9OnvxTLa38S
XXiDwtcS+GmtI9Pt5re8ae7h8sb1jGY9jMzfcOAVXrzjrSQ2dLp3ibSdW1D7DZ3EzTmIzputpY0k
jBA3o7KFdckcqSDmreoavZ6ZGrXLSkucIkMLzSP67UQFjjvgcVyPg3RNY07VIpG0+90yxFqyzWF1
cRXEMUpKY+ylXZ0T5WJViByuBxxZ8Y6BLe6xpOpf2Jba9b2ySwXFjOIiQshQ+ZH5vy7l2dCRwetN
9A6s0j400NJNMUXkjf2nJ5VqUtZWDSZwUJC4RgQcq2CMHOMVMvijSZLCTUVnnW2SY2+ZLWVHeQHG
xEZQznORhQckEdRWJe6ENS0m28PL4cGl6bdO00z2nkJ9i2/MnAb/AFhIGWQMFzjJ+9VKCz8Vy6Jp
Dy6EUv8AQbsNHC0sCLfQ7HjyoR2WN9rZ2n5Qeh9ACz4r1yLVPCqX+i6rdQG31S2hlWJWhfd56K0U
isodeGzj5c8dQeelfxPpcd7qFmZbg3OnxCa4iFrKWCHOGX5fnHB+7npXNeJbHU9R8NTHTvDMkV1d
X9vcPbo9ukp8uRGZ5W37SSEwMMx+7nuFuXltq9v4vm1e10aa6ivdMitgoniTyJVd2xLl/u/OOUD9
DweMrYDSk8WaUNJstSW7d7a/A+yeVbySSTZGfljVS54yfu8Y5rC8E66qeHb68vtTu7yNdVuYoZbh
WeaQBztURhd27A+4qj2A6VnaPoXiTRrHwhfTaOLibS7SazubG3u0Miq4XEil9qFhswRu78E1VPhn
XrrTJZbrw7a3At9dn1GLTbu4jc3cUm8FWGDGrDeCMseR24p9XYOh3K+LNIbTptRN0Ughl8mRZIZE
lWQ4AQxFd+85GF25ORjOaxfBmoyal4k8Ut9tvrqCO7h8lbtGjaEGIEoI2VSgB7bQT1OTzVW/8PXI
sNOv9D8L22nGx1JLs6ZH5MMk6hGRiShMe758qN3QfeBOBo+GLXWV8VeIr+80hrGxvnhkhNxcRtKS
sSoQUjLKBwed3pwewt3/AF2A7Gb/AI95f9w/yrgPgd/ySTSP9+f/ANHPXfzf8e8v+4f5VwHwO/5J
JpH+/P8A+jnoA9EooooAxNa1yw0G0ju9SaVIGkWLdHBJMdzHCjCKx5PH1IHevE/GHh74XaF4ks7n
UjrcR1BluHsbZdkcaE8mRHUSIp5+UHcMHAHFeveMY/EB0iO58OJbS6lazCZLe5/1cw2spUnIwfmy
ORyBzXHeG9A8S6FBqPifVNCOs+LdUcgwpPCi2sY4CF2bAGP7u7gKPeku4/I9L0yOzi0u0j09UWyW
FFgEf3RHgbce2MVerH0SA22h2FubY2xit40MBK5jwo+X5SRx7HFbFN7krYWiiigYUUUUAFFFFABR
RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc/47/5J74l/7BV1/wCimqP4f/8AJOvDf/YM
t/8A0WtW/E+ny6t4V1fT4CgnvLKa3j3nC7nQqMn0yRXBaPafFjRNHstLtbXwo8FnAkMbStOWKqMD
OCOePSgD1aivN/tHxk/58vB353H/AMVR9o+Mn/Pl4O/O4/8AiqAPSKK83+0fGT/ny8Hfncf/ABVH
2j4yf8+Xg787j/4qgD0iivN/tHxk/wCfLwd+dx/8VR9o+Mn/AD5eDvzuP/iqAPSKK83+0fGT/ny8
Hfncf/FUfaPjJ/z5eDvzuP8A4qgD0iivN/tHxk/58vB353H/AMVR9o+Mn/Pl4O/O4/8AiqAPSKK8
3+0fGT/ny8Hfncf/ABVH2j4yf8+Xg787j/4qgD0iivH9F8W/FHX5dSjsbHwqG029exn8wTrmROu3
5+RWx9o+Mn/Pl4O/O4/+KoA9Iorzf7R8ZP8Any8Hfncf/FUfaPjJ/wA+Xg787j/4qgD0iivN/tHx
k/58vB353H/xVH2j4yf8+Xg787j/AOKoA9Iorzf7R8ZP+fLwd+dx/wDFUfaPjJ/z5eDvzuP/AIqg
D0iivN/tHxk/58vB353H/wAVR9o+Mn/Pl4O/O4/+KoA9Iorzf7R8ZP8Any8Hfncf/FUfaPjJ/wA+
Xg787j/4qgD0ivO5P+TiIf8AsV//AG5NR/aPjJ/z5eDvzuP/AIqjw3oHjCX4hnxP4oj0iMLphsEW
wd/+eocEhs+rd/SgD0iiiigAooooA831T/k4HQ/+wJN/6G1ekV5r4u8O+LZfHen+JPDa6U721i1q
y6g7gZZmJ4X2I7077R8ZP+fLwd+dx/8AFUAekUV5v9o+Mn/Pl4O/O4/+Ko+0fGT/AJ8vB353H/xV
AHpFFeb/AGj4yf8APl4O/O4/+Ko+0fGT/ny8Hfncf/FUAekUV5v9o+Mn/Pl4O/O4/wDiqPtHxk/5
8vB353H/AMVQB6RRXm/2j4yf8+Xg787j/wCKo+0fGT/ny8Hfncf/ABVAHpFFeb/aPjJ/z5eDvzuP
/iqPtHxk/wCfLwd+dx/8VQB6RRXm/wBo+Mn/AD5eDvzuP/iqPtHxk/58vB353H/xVAHpFFeb/aPj
J/z5eDvzuP8A4qj7R8ZP+fLwd+dx/wDFUAekUV5v9o+Mn/Pl4O/O4/8AiqPtHxk/58vB353H/wAV
QB6RRXm/2j4yf8+Xg787j/4qj7R8ZP8Any8Hfncf/FUAekUV5v8AaPjJ/wA+Xg787j/4qj7R8ZP+
fLwd+dx/8VQB6RRXm/2j4yf8+Xg787j/AOKo+0fGT/ny8Hfncf8AxVAHoc3/AB7y/wC4f5VwHwO/
5JJpH+/P/wCjnqJ5fjE6FTZ+DsMMH5rj/wCKra+G3h2+8LeBbDR9RMRuoDKXMLbl+aRmGDgdiKAO
vooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAC
iiigAooooAKKKKACiiigAooooAKKKKACiiigDzf4Vf8AIT8d/wDYy3X869Irzf4Vf8hPx3/2Mt1/
OvSKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAo
oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiqMlzAt5HbtNGs
8qMyRlhuYLjcQO4G5c/UVeoAKKKKACiisTxLPq1p4cvrnRIoJtShiMkEU6MyyEclcKQckZA564oA
5L4Vf8hPx3/2Mt1/OvSK+fPgx4q1/WPFmrW8VrZLY3l1LqWoS+W5ZHfoiHdgZbpnPANfQdABRRRQ
AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAB
RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAleP+Kde1OLxfquk+DtL1yfX/Mja4mjnT7GoMKlN
yyBkX7uOiMdvD9q9TnFy0DCCRI5ipCO6F1DdiVBGR7ZH1rymS++Lum61qy2Hh/R7+KW5D+eW2I2I
0UFFaYEDCjPX5t3NJbh0Omt/Fes+H30q38Z22nRz6nci2t30uWR8SN0DI68AdCwduSOMcjva4fwj
DrmoaO9x4usrEapFetNDboVl+yZUYwSzbW5Yj5uAwHA4HcdqbEhaKKKBhRRRQAUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBjeJ9Ql0nwrq+oQBDPZ2U1xHvGV3IhYZHpkCuC0e7+L
Gt6PZapa3XhRILyBJo1lWcMFYZGcA88+tdt47/5J74l/7BV1/wCimqP4f/8AJOvDf/YMt/8A0WtA
HN/Z/jJ/z++DvyuP/iaPs/xk/wCf3wd+Vx/8TXpFFAHm/wBn+Mn/AD++DvyuP/iaPs/xk/5/fB35
XH/xNekUUAeb/Z/jJ/z++DvyuP8A4mj7P8ZP+f3wd+Vx/wDE16RRQB5dY6X4tv8AxlZReLZdKyNP
upLGbSt4eCQSW+Wy468j1BG4HIOC1rn4ojWp9OhvPDIZPmge4imQ3Ef99Qu4Z6bhng+xBPQ+INSj
0nxZpE8iySySWF5FBBEuXmkMlsVRR68E88AAkkAE1mz32o+ItSt9PeW10udTIqv5TTPDdxHlVbcn
VCHXI+Zd2RjimBH9n+Mn/P74O/K4/wDiaPs/xk/5/fB35XH/AMTXpFFIDzf7P8ZP+f3wd+Vx/wDE
0fZ/jJ/z++DvyuP/AImvSKKAPHNA8GfEnwzLqL6XJ4QibULg3E/E5+Y9h8vCjJwPc1t/Z/jJ/wA/
vg78rj/4mvSKKAPN/s/xk/5/fB35XH/xNH2f4yf8/vg78rj/AOJr0iigDzf7P8ZP+f3wd+Vx/wDE
0fZ/jJ/z++DvyuP/AImvSKKAPN/s/wAZP+f3wd+Vx/8AE0fZ/jJ/z++DvyuP/ia9IooA83+z/GT/
AJ/fB35XH/xNH2f4yf8AP74O/K4/+Jr0iigDzf7P8ZP+f3wd+Vx/8TR9n+Mn/P74O/K4/wDia9Io
oA83+z/GT/n98Hflcf8AxNHhvX/GEXxDPhjxRJpEgbTDfo1gj/8APUIAS2PRu3pXpFedyf8AJxEP
/Yr/APtyaAPRKKKKACiiigDzXxBr/jGf4iSeGvDL6PGsWnLes2opJ3faQCufbt6077P8ZP8An98H
flcf/E1Ja/8AJwl9/wBi4n/o8V6JQB5v9n+Mn/P74O/K4/8AiaPs/wAZP+f3wd+Vx/8AE16RRQB5
v9n+Mn/P74O/K4/+Jo+z/GT/AJ/fB35XH/xNekUUAeb/AGf4yf8AP74O/K4/+Jo+z/GT/n98Hflc
f/E16RRQB5v9n+Mn/P74O/K4/wDiaPs/xk/5/fB35XH/AMTXpFFAHm/2f4yf8/vg78rj/wCJo+z/
ABk/5/fB35XH/wATXpFFAHm/2f4yf8/vg78rj/4mj7P8ZP8An98Hflcf/E16RRQB5v8AZ/jJ/wA/
vg78rj/4mj7P8ZP+f3wd+Vx/8TXpFFAHm/2f4yf8/vg78rj/AOJo+z/GT/n98Hflcf8AxNekUUAe
b/Z/jJ/z++DvyuP/AImj7P8AGT/n98Hflcf/ABNekUUAeb/Z/jJ/z++DvyuP/iaPs/xk/wCf3wd+
Vx/8TXpFFAHm/wBn+Mn/AD++DvyuP/iaPs/xk/5/fB35XH/xNekUUAebPF8YkQsbzwdhRk/Lcf8A
xNbXw28RX3inwLYaxqIiF1OZQ4hXavyyMowMnsBXVTf8e8v+4f5VwHwO/wCSSaR/vz/+jnoA9Eoo
ooAxvEb20XhrVZLzz/sq2crTeQcSbAh3bf8AaxnHvXzJNdfCy5bzJ/8AhMDtRI4wotuFVFUZJJye
D6DnGOK+otTgmu9KvLe2MSzywukZmTegYggbh3GeorybWm+J+lSxfbfH3hrS0ZFVPtrQxecwRd7L
uiORuJ9PoBip6j6G58FP7C/4RfUv+Ed/tH+z/wC0Dt/tDZ5u7yo852cYr081x3gCy8R2ul3j+J76
2v764uRKlza7fLePy0CkYVfQ9q7Gre5K2CiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKA
CiiigAooooAKKKKAOf8AHf8AyT3xL/2Crr/0U1R/D/8A5J14b/7Blv8A+i1qTx3/AMk98S/9gq6/
9FNUfw//AOSdeG/+wZb/APotaAOkooooA89+IFyum20d1JqmpWV080SWtxC0yWtr865afb+7ZSeu
/qDgAcmr2pMNZ8Y/2FdX13bWy6cLqAWl29u0zs7KzbkIZtgC8Z2/Pkg8Yk1nT/EOs/2ppEsOmf2P
ex+Slx50nnxIyYfMewqzZzg7lxweelJrmgSa1Da6cNO0iWyjj2i7voxcSwcYPlxMm3OAPmLcHqrY
wUBL4H1O61bwxb3F5OtxPHLNbtcKABMI5WQPxxyFB47mmX/jWx07z55LO9fTbWbybrUYkQwwPnaQ
w3bzgkAlVIHrwcbml6ZaaPpVtptjEIra3QRxp6D/AB71yL+ENYXTtZ8PwPZPouqzSyG4eRluLcSk
tIojCbX5J2ksuM8g45b3EiDUxD4l8f3Oh6toE97pkdgjRs7xbIy7uDMuJNwyFADKN4weADkzeO4I
dG0n7fa6ddXF1LLBbmaOYfIrOsZJ3uPnZGZN4y3PJAq9aaPrNn45m1JLfTxpj2cdkoF05mVYy7Bt
vlYyd2Mbu2cnpVjxlpWra1oqWOlR2RkNxFM7XU7RhRHIrjG1Gznbjtj3pLZIfW5V0mbSdA1ZdGsf
Dt5pkuowvfCFTEIdyBVZQqyFUblc4AU+prL8Uata+IPB0d/HbXds1vq8ERhncIyyJcqjBgjFWHXq
SOh9K3NT0rWp9Y0XXLWCwa8tIJoZ7WW7dI/3mzlZBEScFO6DOe1YL+D/ABQvhO60sT6TcXM+rfbw
26WFEXz/ADvRySSAMYG3PVscnVXDoadnbxw/FTWXXzN02lWztmRmGfMlHGT8o46DA6nuat+NPEF/
4e0OO6sdPku5JLmKElWQeWHcLnDEZJzgD1POBVGTw9qOpeKdQuNUs7BtL1DTUsZ4o7yQycF2P/LN
eCXK/eBwM+1Jd/D7T9O8K3Ok+F7SGzaW6guts08jI7RyI2Cx3FchccA/ShbK/wDWoaXuixrPxA0r
w/5EWoRyxXskInaze5t45I0OepeVUY5BGFZjRJ480tJtP22t29nqFu1xbXx8pIJAqFim53BD8Y2k
D8gSHXGk+IrbxCmu6f8A2dNLcWqW9/aTzSRJlCzI0cgRjwXYHK8j0pNd8P6n4gR7LURbSWcduZYJ
YLl4Jftn8LcIdirn5TliMZIbsdA6kOreLtUtF8PNa+H9QCapc7JI52gWZBtZgm0yYDELnk8AHPzc
V1Vxci1spbl45WEaFzGiF3OBnAUdT7CuVuNI8VX+k6FJqH9lyaxpl6J5DHPIIZ18t0zny8q3z5xj
HHUZ46LVrW/utBvbWyulg1CWBkiuAMBJCuA2Occ/Wh7MOqM+y8WwXUl7DcaZqdlcWdul09tPEskr
xvu2lViZ8nKkbevtXP6n8QrmXwxBq2i6FqkkFw9uFuLhYolCySbDgM+WbPHTbyDnbzRonhbXNI1q
81GDS9Fi+1WCW8kcV9LlplLnzHcw5ctuGWPP+9ViLwnrR+G9n4elNgt/ZNbmMrcO0UgikV+W8sFc
7SPunHvTA0JNXgm8YaTaTjWbS8NlNP8AZmwtsR8mRIQSruuRjaWxk56iltPGFlfahZWotL6K31Le
tlfOqiK5KjJ24beuQCQWVc44J4yy90bWb3xZo+pSx2X2W3tJ4LnbcOH3S7c7F2EELsHJYZz0GME8
N6X4j0SxttGnawlsLFfLt7pJH86WJRhEdCm1T0ywZunC85C6agY3hnWtL8I+FL2a9m8uEazeQQrJ
ON0jec+F3yMBnAPzOw9zWlZfETRr+xFxZie4uGuxZrZxSwGRpSpYAP5nlEbQTkPjt97is228JeJI
9NDK+mW+p2mrS6labZpJYX83fujk+RSBtkI3AH6Vq65pWta/oqW97p+j3Ikn/f6fPO5h8nYw+Wby
twk3FWDBRjGB6kV7a+QaX08zf0jVBq+mpeLbXNruZ0aG5UCRGVipDBSR1U9DWvXOeFdIutE0OKxu
7hppFdyoadpvKQsSsYkYBmCghQSB06CujpsSCvO5P+TiIf8AsV//AG5NeiV53J/ycRD/ANiv/wC3
JoGeiUUUUAFFFV/MQymMMN6gErnkA5wcfgfyoA4O1/5OEvv+xcT/ANHivRK87tf+ThL7/sXE/wDR
4r0SgDidNN5D8SNXtZdSu7i2bT4J44ZWGyEtJKCEVQB/COTlvUmsrxV4Sunkkvl8V+JIb6+ulit7
azvjFAhZsABAM4VMs3PO1jxmt220rWo/Ht3rDQWA06e0jtQVunMwCM7Btnlhed+MbuMZyelatzYS
3WvWN07J9mtEkZUz8xlbChvoF3j/AIFSj0B7s0o0EcaoCTtGMsST+dY2o6+LC6FjBY3moX3l+c9t
aeXuSPJG8mR1XBIIAzk4OBwcb9cjqGjatB4q/t7SBaTvNara3VreTNCpVWZkdHVHIILMCCuCD2o6
h0MbxH4qi1nT/D39n6bc6jpup3wjnjAiXzAquWgZZHX5tycg/LhSCecHr9H0mz0TTls9Otja225p
BBvLCMsdxAySFGSeBwO1clP4U1qyg0aLS0064NnqMuo3L3FxJCJJJPM3IqrG+F/ecEnsOO9ehJu2
jcAGxyAc01sD3OC8U3LXvjPRtAu9Em1HTZoZ5ZYz5JjlYbAG2u4yE3EnI6kFQSOLVt4m07RPD2qJ
b6RqqW/h4iCa3LI8gQIGDKWlO5QpB5bPtVnVNL1uXxrpeq2dvp7WNnDLC/m3TpIwkKZIUREfLs4G
7nPasvWfDGv3H/CU22mf2d9m15Bie5mkDwt5IjI2KhDA7R824YznDYwVsh6Mnu0iuPib4dvU87Nz
pd3w0jYC5iIwucKfm5I68egqfwBGq6HfQJuMceq3qLlmZsCd+rMSSfcnNRf2Hr8fiLw/fEaZNFp1
lJbXD+dJEzl9mSqbGwBsHVucnpVOy+H66potzp3i7T7K4iOozX8CWl5MQDIzMQSFQ8bsd8+1PbYn
pqauo+JNSs/HemaJDpM81rcwSSvPG8WSVKjozghV3ZPc5GAeaq3PxI8OWmtf2Y1yGYXAtmmE0OEl
zt2lN/m9eNwQrz1wDixL4Vn0/WPD0+hx2sVlplvNaGGeVyUjfZhl4JYjZ0JHXrSaRpHiLQ7u8sLe
XT5NInunuIZ3dxcW4kcu67NpV/mY4O4YzkhuhS6DZGfHMSajd6f/AGHqv9oW08cItD5Akm37iHjB
l+ZMKSW7c+jYng8S6lL4+utBbSZ1sobWOVbgNEQdxb52+fIX5doABOckgDFZ2raB4ju7uPXbZbKL
Xba6225+2y+QbPvG4EWWLdSMdcENwFrVi0jVk8Y/2zizEFxYxW9wvmuzRujOx2DaAwO/GSVxjoel
C6B3Orrlv+ErjTXINOuNL1O3juLl7SC8mjRYpZFUtgDfvwQrYYrg44NdTXmcvg7xC2u2uqSQ6Vd3
Vpqj3SXk91IJpIGDhYf9U3lqoYfKpKkjPBJJOodDa/4TaOe7v7PTND1i9urCUwyDyFgTds3j5pGX
CnpnHocYKk5K+LDqfw/0zUtZg1eya+ngVZdP25YtIuCGVmCxnO079pIyMZIra0PSNYs9b8Q3V9DY
pb6nMssRhuXkddsaxgMpjUchc8H296xm8L+IE+H1h4eC6W1zaTW+1jcyKjJE6vu3eWTuYqBtxxnq
aF/l/wAEDa1jxha6LJds9ve3NvYbft1zbIhjtd2CN25gzcEMQgYgdeorPhls9M+Iuu6hPMY7f+xr
e4mlkkZlVQ8uSMk4GB0Xj8TVuPSNf0zXr+601tOkstTZJpluJXV7WYIqMyYQiRdqg7Ts5HUVX1Lw
nqWra9rDXJtV0zUtLGnGZZmNwuN537PLC9X6bu2fajUNLO4tj8T/AA7f3F3Gs5i+z2z3e4ywyiSJ
OWI8p3KkDna4VuenBxt6P4g/tme4hbTL2xeGOOUfafKYSI+7DI0bupHynvWZBbeK5tCuLK//ALHF
ytrJFFLEzyJcSFSEMiMnyL0JUb8+wGCzwj4auvD93ezNbW1ha3IUrp1ldST26SZYvIm9F8vduA2K
MfKPwYuh2E3/AB7y/wC4f5VwHwO/5JJpH+/P/wCjnrv5v+PeX/cP8q4D4Hf8kk0j/fn/APRz0DPR
KKKKAMnVdQj0nSLvUp0dobSF55FQAsVUFjjOOeK+ftV8c/DfxD4iv9W1/Rtc1BpRGtuCwQQoq4Kg
LMP4stnJ+90GOfoXUoLi40u7htGiS4khdYmlXcgcg4LDuM9RXkV3P8TRrZ0xfHfh+0u0MUHk3Cxx
tNKY0Y+WDCS2S3b8hwKnqPodf8Lr3SdQ8LzSaCJoNIW6ZLa2nk3yQDau5T8zYy25gCTww9a7+vPP
Bmq39neXnh/xdrUF/wCIDMJlNvGxjWFkUKCwRVQkhvlOCffNeh1bJWmgtFFFIYUUUUAFFFFABRRR
QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc/wCO/wDknviX/sFXX/opqj+H/wDyTrw3/wBg
y3/9FrUnjv8A5J74l/7BV1/6Kao/h/8A8k68N/8AYMt//Ra0AdJRRRQAlFeU+K9Tmj1q6vdLu9Q3
2Oo2VtcNJqLxQxl2j/dx26jbJlWyxfHX5ScYE3iC4vrfxa9zNPezabFf2sRl0+9kQ2RPlYimttwW
RHL53jLDd7AULUD1A0CvLbe71GDxhDPdTXtzBPf3MNvd2l/I9vI4WXFtNbMwEbJs+8qkHaM8kml8
HLq+qx6V4lm8VRFp22XVksMzbpCvzQlGnZEZSM5SNThcngmkD0PUaK8h0m+1K1a5N5qN3DPcaPcT
22qC+kurG5wEYziNjmFl3fcC45OOgBRtY1PRNM1uJ2v9PvkWzLyXF9JqFtHA8zRtcxO77tpXcSp2
kbRz6MNj1+uZt/EDzeMLvQ3sHiEFol0ty0ikShmK8KOQBjqcHrxjBPIakdX8KeHtSuY/FS3kVwlu
ylFlf7JG8io04kmmlbBUnAJ25XIHDVc0m3sNK+Ks1nFqM0hudGiaFby+ed3PmSE7DIxYjA3YB45N
LqhPZnWa1qv9mQQCOITXN1MLe2iaTYryEE8tg4ACsScHgdDUmkT391ZeZqdj/Z9yHZWhE6zLgE4Z
WAGQRg8gH1Fc345023vdY8JtM90m/VBERFeSw8GGU8bGGGyPvDntnBqC5kbVtY8TWV1ql9p8ukxo
bHybySLZGYg3nMAQJRvyDv3D5cdzkT0bY2tUeiUV5bbtrGv6n4TXUtW1S0/tLRppLq2tZvIXzAIv
m+UBg2Wz14xgYBYHpvG+o3ej+D5bizuPs7rJDE9zIpk8mNpFV5DyM4Uk9R9abVgRa8S6xJ4e8P3+
rR2Ul4bWJpTCkipuA5OWboB+J9AelWo9W33OnwfYrs/bYWm85I90UOADtduxOeOOcGuF1HTL3S/B
3ihbjxEup29xpMk0UCrM4jGxhvEks0rYb03Y+UkfxVqQyXkXjLwyE1G6a0uNJmZrUOBDuURYbAHJ
+Y8sT7Y5pLewPZHfVyfiLxdJommapdx6Nfz/ANnyRoxfbDHIGAO9XY/Mozg4BOeMd65GxtdU1q/0
hmvNb+3rqEr6nJHc3MVlJbgvtMbKRGR/qwoTk5O7+KjxC94fDvxCtbnULq6WG5iELTsD5atHE21Q
AFABPYfXJyaEHWx6sXwm7BPGcDrXJv4ukjfw9nRr2JdYnMJN1the2O1mAdMltx29Onv0BpPbXVj4
uGmWOsam8V1pkst4z3HnNBIGURyrvDLGW3SDaAFO3hflrIs7qe68M/Da5u7iSeeS9jZ5JnLM7eRL
yWPU0efoB3MerRtPqKS29zbR2BG+4uI9kTgruLI2fmUdCexBrTilSaJJUO5HAZT6g15jrMEt54b+
I9lqF9eXsVqTJCZpivl/6OsgUBNo2hu2MHvnmruq2f8AY2kaHr1nfanJZ6WyHULZdRncPC33mYbz
uKFg2DxtBB4xgXn5A/8AM9Jpa5jw7H9oS71YT3UsWozedAks7uiRAYTYrHChsb+P73sK6enYAryH
xPB4huPjdbp4bvLO1vf+EeBZ7xCybPtDZGAOudtevV53J/ycRD/2K/8A7cmgCP8Asz4u/wDQw+HP
/AZ//iaP7M+Lv/Qw+HP/AAGf/wCJr0iigDzf+zPi7/0MPhz/AMBn/wDia8y8X6T8SJfiPZpDObrW
lsIytxpStFHHF5kmA7HAHIb73B4r6VooA8g8Gpr8fxZlTxNPbT6oPDy73tVwuPPGM9t3rgAV6/Xn
dt/ycHff9i4n/o8V300nlQvJtLbVJwO9JuwEtFeb+Hb7xhrcem65Je6fDpd+gaWEXKt5auML5a/Z
wRIGxw8jgnI9MGj6hr7eK/8AhHtR164JhnkniuxBCq38ShcwAeVtDIT85U55OP8AYfWwHpFYWkeI
LXWr7U7e2iuY30+4FvKZ4jHubaGyoPOMHqQM9sjBrnrG+13W92rWOrQwR2+qSW81hNGgh+zxyNG2
5tpk8wgbgdwXoMdc595c3tlF8Rr3Trx7O7tJUnjlREc5W1jbBDgjBxS82FtbHptYWq+IbfR7zS7W
eK5eTUbj7PC0cRKK2CfnbovTp1PYcHGO2q6lbeLtDja/lls73TJp5rXyo8b4xHhlIXdk7zxnFcz9
p1PWrXwV4gvNTkeO/wBXjkFiI4xFACku0KwXeSAMHcxySeBT6iWx65WBrviCDw/p63t5FcyRtNHC
BbxFyC7BQT2Uc9SR+ZArlLPU/GWs3k2p6fc6db6dbX8sD289yAnlRSMjb1+zlg5A3ZEoHTjqKzPE
d7qev+FNW1R9TlgtLfV47VNOSGPYUjukTLsV37yfm4YDGBjvQtWhnr1FZaW16utS3TX5axaBUSy8
lRskBJL7+pyMDHTitSgAooooAKKKKACiiigAooooAKKKKACiiigCKb/j3l/3D/KuA+B3/JJNI/35
/wD0c9d/N/x7y/7h/lXAfA7/AJJJpH+/P/6OegD0SiiigBM14l480B5/G0zt4Autdmv/AC/supQ3
00KW+EVcOEG1cMC2WI6+1era5JHDoGoyyXb2UaW0jNcxqWaEbTlwB1I6/hXz/carps8m4fGnV4VR
ERdtpeHftQAscMMEnPr7kml1GtjuNATVn+IPiG4u9E1W2N7LYQxTS2xKMYCvmNvXKhcKSDnB6deK
9frzr4SSQy6DqZg8S3PiFft5/wBPuI5I3b91H8uJCW4r0WqemhKFooopDCiiigAooooAKKKKACii
igAooooAKKKKACiiigAooooAKKKKACiiigDn/Hf/ACT3xL/2Crr/ANFNUfw//wCSdeG/+wZb/wDo
tak8d/8AJPfEv/YKuv8A0U1R/D//AJJ14b/7Blv/AOi1oA6SiiigDAvPDGg6jdSXF7omnXNxKoWS
Wa1jdnUYwCSMkcD8qlTw5ocd/HfxaNp63kYVUuBaoJFAXaAGxkYXj6cVtUUAYtt4f0azvpNQttKs
Ib6XJkuY7ZFlfcctlgMnNPh0LSrfUpdSg0yziv5QRJdRwIsr5xnLgZPQVrUtIDEtPDOh6fHcRWei
6bbpcJ5c6w2qIJV/utgfMOTwfWn2WhaTptrLbafpllaW83+tit7dI0fjB3ADB44rXopgZFn4f0mw
tJrSx0uytbWYnzYILdESTIwdygYPHFGneHtF0eRptM0iwsZGXYzW1skRK5zglQOM81sUUAZGpeHd
F1eRJNS0fT76SMbUe6tklKj0BYHFOvND0rUJ7ea+0uxuZbb/AFEk9ujtF3+UkfL0HStWikBkz6Dp
Fzfx6lPpVjLfxY2XUlujSpjphyMjFXJoUmieKRFeN1KsrDIYHqCPSrVFMDBTwv4fj06XT49D01LG
VxJJbLaRiJ2GMErjBPA59qRfDOjQSRTWuj6dBcWyFLWZbNN0A5+7gcDJJwMdT61v0UgPMbbwC15D
aW91ofh6ylgmjmfVrBcXMrI4bIXyl8stjn5225xg128Gg6RbyXbwaVZwveAi6dIEUz5zneQPm6nr
61rUAUwMa28PaNZWE9la6RYW9ncZ863itkSOTIwdygYPHHNQt4S8ONDBC3h/SjHbktChtI8REnJK
jHy5IHSugooAyINB0i3ku5INJsoXvARdMkCKZ85zvIHzdT19aqXmmyrYx6PpllY22lSRtFMY5DE0
KHqI41Qqcgn+JcZzzXQ0UgI441iRURQqKMKB0AqWiimAV53J/wAnEQ/9iv8A+3Jr0SvO5P8Ak4iH
/sV//bk0AeiUUUUAFFFFAHndt/ycHff9i6n/AKPFeiV53a/8nCX3/YuJ/wCjxXoDFgp2gE44BOKT
A56y8I6Lp13NPaWskDSu8jJHcyiNXYYZ0j3bUbHG5QDyeabN4J0Oex06ylgujb6dIZbVRfTho3zn
duD7iRzjJOM8YqtonjJL5bn+2RpmkvFdTWsSHUd5maEkSEbkTgdeM8dcVrN4i0aLTE1STVrFdOc4
S7a4QRMc4wHzt6g96fmBUHhbSYNSm1OK1dLmV1klCTyLFK69HeINsZh13FScgHqKfb+FtJtptTnS
2md9TUreLNdSypMCMcqzFRxxwOBx0qbUddstP0v+0JL6wjgdcwTXN0sUMjEZUeZzwfUA/Q1S0TxV
bz+C9L17XLyxsPtcKO7vKIogzdgWP9aQeY+18EeH7PULS/Swaa6s0KW891cS3DxKccKZGbAGOB2y
cYyc138A+GHdC+mF4kuPtS2zXMpt1l5O4Q7vLHU/w45rav8AXdI0iOKTUtVsrJJf9W1zcJGH+hYj
NQS+IdGt/tPnaxYRi1VHuN9yg8pWxtLc/KDkYz1zTArDwtoqa1Nqsdo8d3M6yTbJ5Fjldfus8QbY
zDqCVJzz1FQ6h4E8N6nLdvd2EjLeOJLmGO6ljimcYwzRqwRm4HJGa1BrelnUV04alZG9dd62wuE8
1lxnITOSMc5rP0/xl4e1GxvL221eza1s5DHcTNMqrHzjJJPCk5wT17ZpAX7bQ9NtdQN/bWqQ3H2Z
LQFCQohQkqgX7oAJPQVr1StrmC9to7m1mSeCVQ8csTBldT0II4Iqlba/pN7DcXFnqllcQ22fPkhu
EdYscncQfl49aYGzRWDH4p8Py+XIut6a0cpcROt5GQ5QZcA552ggn0zU1t4g0e7ntorfV7CaW6Qv
AkVyjNKozkqAfmAweR6GgDZorDtvEmhXk0Fva6zp881xuMMcV0jNJtzu2gHnGDnHoaUeJtBe1urh
Na01oLUhbmRbqMrCScAOc4XnjmgDborm7LW7W91e/WDVtLnsrWFWdYbkNNE+W3mTBwq4C4/4FVuH
xHotxp02pQavp0thC22W6S6Roozxwz5wOo/MUAbNJWOfEWiiC2nOsaeIbpWa3kN0m2YL94oc/Njv
jpTZfE+g29jBeza3psdpcEiGeS6jWOUjrtbOG/CgDapaQEEZHNYGv6pfaVYvc2VjbzrFG8szXN39
njRFH97a3zHtxjg5I4ybBub9HaqNlc/a7OG4MUkXmxq/lyrtdMjOGHYir9Ak7oim/wCPeX/cP8q4
D4Hf8kk0j/fn/wDRz1383/HvL/uH+VcB8Dv+SSaR/vz/APo56BnolFFFAGP4ieOLw3qkk1oLuJLS
Vnti23zhsOUz2z0z71xEMHgaK3kh1zSvBei6uBzaSPbTGElQRvBVDnnkDj0bmu38SQXNz4X1aCzG
bqSzlSEYz85QgfrXlk/gv4v3V/aX0/ibw9JdWm77PM1uhaPcMNtP2fjIpdR9DuvBVsbGDVLNtN02
zaG9xu02HyYZ1MaMsgjydp2kAjJ5WuwrjvAmn+J9PsdRTxVdwXuoyXe8XEC7UdPLQDGEXpgjpXY1
TJQtFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc940iebwL4ghjj
aSSTTblERFyzExMAAO5rgvDfxIi0TwxpWl3PhPxW8tnaRQSNHpoKllUA4y4449K9eooA83/4XFZ/
9Cb4x/8ABYP/AIuj/hcVn/0JvjH/AMFg/wDi69IooA83/wCFxWf/AEJvjH/wWD/4uj/hcVn/ANCb
4x/8Fg/+Lr0iigDzf/hcVn/0JvjH/wAFg/8Ai6P+FxWf/Qm+Mf8AwWD/AOLr0iigDzf/AIXFZ/8A
Qm+Mf/BYP/i6P+FxWf8A0JvjH/wWD/4uvSKKAPN/+FxWf/Qm+Mf/AAWD/wCLo/4XFZ/9Cb4x/wDB
YP8A4uvSKKAPN/8AhcVn/wBCb4x/8Fg/+Lo/4XFZ/wDQm+Mf/BYP/i69IooA8ug+M+l3TSi28MeK
pvJkMUnlWCtscdVbEnBHpVn/AIXFZ/8AQm+Mf/BYP/i6k+Ff/Hx44/7Gi8/mteiUAeb/APC4rP8A
6E3xj/4LB/8AF0f8Lis/+hN8Y/8AgsH/AMXXpFFAHm//AAuKz/6E3xj/AOCwf/F0f8Lis/8AoTfG
P/gsH/xdekUUAeb/APC4rP8A6E3xj/4LB/8AF0f8Lis/+hN8Y/8AgsH/AMXXpFFAHm//AAuKz/6E
3xj/AOCwf/F0f8Lis/8AoTfGP/gsH/xdekUUAeb/APC4rP8A6E3xj/4LB/8AF0f8Lis/+hN8Y/8A
gsH/AMXXpFFAHm//AAuKz/6E3xj/AOCwf/F1neG9Zn8UfGH+2Y9F1fT7OPQmtS2oWpiy4n3cckdG
9c8GvWaKACiiigAooooA87tf+Tg77/sXE/8AR4r0FyQpIUsQOg7159a/8nB33/YuJ/6PFdxMZRCx
h2tIFJUM20E9snBwPwoYHmUGka3IbOO48K3rRJ4jl1R/MltSqxN5m3jzjlgXU/hx2q/aWXiKDSXR
dBuonbWLq4yrWj3EMUpkZXh3uYw3zBW3dmbAOc1pWfjK7nt9ahk0qCDV9NDSfZHvG8ueJWKmRJPL
zjKuPudQM4zmtyTXbPTba0fXLzT9Onn4WOS7G1m9EZwpbqOwpW0sDepxej6Rr+l2Phie40a5uv7N
s57K4sxNB5iswXbMmZAhGFZfvA4bp1qGDw5q0eheFkvNF1CVLC1msryxtdQW3mG4LtdWSZVZfkwV
L9Gzjiu6u/EOiWMs0N5rOn28sJUSpLdIjRluVDAnjPbPWo/E2r3Oh6De6pa2sVybSJpnikmMWUUE
nDBW546Y/EUN9WNX2RxPiLS7zRdD1loNCmk02bw99lhCXEbNYCNHyj72yy4YHKluV+hq1rWl6xPF
eS6fpUt8upeHFsEaOWJBFIA5G/e6nB8zsD0rUtNb/tvUj4f8R6JaKtzYi+QeeLqCWMMAQ4eNMMpK
n7pHvxTtN8QXlxpP2zw74ail0KFWW1WO5WGWZVyAYodm0ISONzqcc7egI1vcSfYwzp/iSXWdJuD4
fu4ILO9inaOF7QLIn2fyy7t5m9pQW28HbtX+I4pZ/D2ttZyRDSryRbXXpdQ2wXywG7glaQfunSRW
VlDhsNsBxjJrc1TxNr1hfWcMehWbQ314bS2efUXictsZtzKIW2j5W6E9q6DTLi8ubFZb+zW0udzq
8SSGRRtYgEMVUkEAEcDrT31DbQxY/D+/wNe6LptlNpRuYJ0iiurgzOjSbiS7hn6sxJwzdaoX9lqe
teG5vI8OLpmpxrbExzSw4uhFIH8kPGzfu+GUbsfe6da72ijzA8t1PQtR1DxVZ60fDV0kEl7bST20
ktsSvkpKvmuPM2k5lQLgscRdvlFJZ6Lq0EllIPC11C48ST6lMwltciJxIFJxLycSKMc/dPtn1KkI
BBBGQe1IL33PKNM0+71eG+tbLRijJ4mnvG1ORohHmOdjxhjIWIHl/dxhjzjqxNG8UPba35+gXoe/
0IWEcEb2ccUMo3jZGqycRDzPlLEtgHPYV6Xp2jaXpEbx6XptnYo53OtrAsQY+pCgZrRotpYd9bnn
FtpGoNdXnmeGrmKyk0CKyEK3EEe50L5jUpIdvDgA9OOop8eleJRYWV5Jb3F5JY6qLhbW7eBLqeDy
vL/eNGfKaRSxZTkZCrkg16JQKYjzO48P6i95Z3Q0CZ4bjXxqktp5kBFqgi8vLAvtLl/3nybu/Oet
ZNI8Ri2maDRNTtL43l7JA/n2jwmOaTeEnjMhDRnI3bfmG07ff1WgULQLjV4UZxnHbpXN+I4otQtF
0658OS61bTg7lBhCRnoC3mOrDqeVBIx6101YOv6pfaVYvc2Vjb3AijaWVrm7+zxoij+9tb5j24xw
ckcZTBeRNolnc6fodhaXlwbi6ggSOaYsWMjhQCcnk89zzWxVKyuftlnDcmKSLzY1fy5V2umRnDDs
RV2m9xK1iOb/AI95f9w/yrgPgd/ySTSP9+f/ANHPXfzf8e8v+4f5VwHwO/5JJpH+/P8A+jnoGeiU
UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWXrOsWOg6VPqepStDZwAGSQRs+0E4zhQT39KAON+FTE3
3jlew8TXZH4kf4V6NXjHws8XaFN4g8S6fFfM91quuXN3ZRrBJ+8iPzBs7cLwD97Fez0AFFFFABRR
RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB53a/8nCX3/YuJ/wCjxXoR4BwCfavPbX/k4S+/7FxP
/R4r0SgDzjU9D1TX/Dk1xBp0ula5aT3D2bXLxN5scrMWjYxuw2srYOSMMAe2av6nYanB4hubqPR2
1ixvtMWzaFZo1MLKzZDCQqDG4fkjJ+X7pq03jO3aC5u7XS9Uu9Mty6vf28SNExXrsXd5jjPG5UK+
+ASOpjdZY1dT8rAEUgueWXPhXWLaK/tF0WfUJF8Mx6TBeiSD95L827bvkDKvzr1A+4fbPTeIbfUL
34eXVjBplzLqFzYm3Ft5kQZHZCuWYvtwD1wx/Guwo70PVWBOzTPPdE0O/wBGvkkTSr2e21K2SC58
+6SS5sGX5ceY0h3QnltqsxU5wPmwJ/Di674c0eDw6dEluPsY8i2v47iIW8kf8DuC4kU84YBG5HGc
13lFO4jjfFMGpzah4dkttJur9bK+FzO8DxIAvlumAJJFOcuD34B5rsuwrPtZrqW5vEntDDFFKFgk
80N567VJbA+78xZcH+7nvWhSGLRRRTAKKKzrm9trR4EuJlRp5BFErHmR8Z2gdzgE/gaANGiiigAo
oooAKKKKACuZ8RxR6hZjTrnw5LrVtODuAMISI9AW8x1YdTyoJGPWumopNAY2h2dxp+hWFneTm4uY
LeOOWZmLGRwoBOTyee55rYopae4iKb/j3l/3D/KuA+B3/JJNI/35/wD0c9d/N/x7y/7h/lXAfA7/
AJJJpH+/P/6OegZ6JRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAV5JEhjaSR1REBLMxwFHqar/29o/8A0FbH/wACE/xrP8d/8k98S/8AYKuv/RTV
xfhD4Y+DdS8F6HfXmgwy3NzYwyyyGWQFmZASeGoA9E/t7R/+grY/+BCf40f29o//AEFbH/wIT/Gu
X/4U/wCAf+hcg/7+yf8AxVH/AAp/wD/0LkH/AH9k/wDiqAOo/t7R/wDoK2P/AIEJ/jR/b2j/APQV
sf8AwIT/ABrl/wDhT/gH/oXIP+/sn/xVH/Cn/AP/AELkH/f2T/4qgDqP7e0f/oK2P/gQn+NH9vaP
/wBBWx/8CE/xrl/+FP8AgH/oXIP+/sn/AMVR/wAKf8A/9C5B/wB/ZP8A4qgDqP7e0f8A6Ctj/wCB
Cf40f29o/wD0FbH/AMCE/wAa5f8A4U/4B/6FyD/v7J/8VR/wp/wD/wBC5B/39k/+KoA6j+3tH/6C
tj/4EJ/jR/b2j/8AQVsf/AhP8a5f/hT/AIB/6FyD/v7J/wDFUf8ACn/AP/QuQf8Af2T/AOKoA6j+
3tH/AOgrY/8AgQn+NVL3UNA1CxuLK61HT5Le4jaKVDcJhlYYI6+lYX/Cn/AP/QuQf9/ZP/iqP+FP
+Af+hcg/7+yf/FUAcX8K/CGneDNb1y/vdUsXkEptbFzcJloOG39f4vlHttavXP7e0f8A6Ctj/wCB
Cf41y/8Awp/wD/0LkH/f2T/4qj/hT/gH/oXIP+/sn/xVAHUf29o//QVsf/AhP8aP7e0f/oK2P/gQ
n+Ncv/wp/wAA/wDQuQf9/ZP/AIqj/hT/AIB/6FyD/v7J/wDFUAdR/b2j/wDQVsf/AAIT/Gj+3tH/
AOgrY/8AgQn+Ncv/AMKf8A/9C5B/39k/+Ko/4U/4B/6FyD/v7J/8VQB1H9vaP/0FbH/wIT/Gj+3t
H/6Ctj/4EJ/jXL/8Kf8AAP8A0LkH/f2T/wCKo/4U/wCAf+hcg/7+yf8AxVAHUf29o/8A0FbH/wAC
E/xo/t7R/wDoK2P/AIEJ/jXL/wDCn/AP/QuQf9/ZP/iqP+FP+Af+hcg/7+yf/FUAdR/b2j/9BWx/
8CE/xo/t7R/+grY/+BCf41y//Cn/AAD/ANC5B/39k/8AiqP+FP8AgH/oXIP+/sn/AMVQB1H9vaP/
ANBWx/8AAhP8adbanYXbmO1vraeQDO2KVWOPXANcr/wp/wAA/wDQuQf9/ZP/AIque0Tw7pHhf44r
YaLZJaW0nh0ytGrMcubjBPzE9lH5UAes0UUUAFFFFAHndt/ycHff9i4n/o8V3dxGZoJIw5QupUMO
q5HWuEtv+Tgr7/sXE/8AR4r0Fm2qWwTgZwOtJ6oDg/CWozeHPD9r4cvdL1L+0tPX7Mois5HhuMfd
dZgvlqrAj7zDacg9KzPEGm3F5qOuxXek3UusTeU2h6hBbtItudi4CzKv7nbIGZtxXcG79K9C028/
tDT7e7+z3Ft50YfyblNkkeezL2PtV+m99QPGda0i1a68TTroupm7bVLOS2nt9NuQePL86WIonyk7
ZcuvJ45OVpdasbCHRvFMC6VdW2nx6rY3Fqv2GaED5oUkeE7R8xO8ZT5jn3r0qHXLafxDdaIkc4ur
aBJ3d4isZVyQNrH733T047ZyCAmr6NZ+ILNbO/Wd4BIshWK4khyynIyY2UnB5x6gHsKSHfU4h7CC
3t9fn07w9cnQrt7RRYvZzRhpg2JJvs+0SMgHl7lC/vNh7ZNZNtp8UmlaDY3+i3si2uvXD4j0W5jR
LV/MOAu0lIm3R5Qk8cNnaa9Ls9XtX1640GNLr7RZ28czSSI2xlYkDDty5+Xk8j3zkDep+YvI8tk0
y3VPGFjFYXlnZPd2pi8nR3ljcKkanEW3EyblO4LnK59QactlssPD/wDanhpW0EfahcWFppzyRpKz
5imNthnCsA5C7SUMmDXbabrFvql/qdrbx3CSadOIJjNGUDMVDZXPJGCOcYPbIwatWF79uheX7NcW
+2V49lxHsY7WK7gP7pxkHuCKAZ5lFocCar4eTWdIvrm2itL4MHsZp9lu0ga3hlZVO7agb5GJwccZ
Iqe4tJLz4QaPbXmm6lJeQPaJ5X2Kfz4mSRdxAC71wgb5xj2PPPq1FLpYLnlX2S4isfFdno2k3sVr
9tt50tUs3gFxAFiFwsRdVDFtsg465/2qo3/h7T5dYtdTtfDs48PxX8DGzbSZBsbypRK6W5Tcqk+Q
DhcMy57Zr2OimFwHQYpaSloEgoqLzE8wR7hvxnbnnHrUtAxKKKxdT1230m+020njnaTUZzBCY4yV
DBS3zN0HCn3PYHBwgNuiisTVtcstEiWW+edQQWCw28kzBVHzMVjViFHGWxgZHPNMDboqtDNFdQRz
QuskUih0dTkMDyCDVmgCKb/j3l/3D/KuA+B3/JJNI/35/wD0c9d/N/x7y/7h/lXAfA7/AJJJpH+/
P/6OegD0SiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiii
gAooooA5/wAd/wDJPfEv/YKuv/RTVH8P/wDknXhv/sGW/wD6LWpPHf8AyT3xL/2Crr/0U1R/D/8A
5J14b/7Blv8A+i1oA2pp47eJ5ZZFSJFLO7HAUDqSe1ZGm+JtL1XUZLC2nlW8jiExgnt5YHaMnG9R
Iq7lyMblyOnqK3JI0kXa6hlPUEZFc0ba11fxNa6sSv2ayjltbdieJ5JNu/HqoCY9yW9OV1DoWLbx
XpF1qsOmx3EguZwzQeZBJGk4XG7ypGULJgHPyk8c10Fcrqdva6tq2ngsi2mkXIuJJc4XzdjIkYPt
vyf+Ajvxa8Ya3J4e8Oy30ITzTLFCrSDKIZJFTc3I4G7P4UAdDXP2HiWPUb9beHTtREEgd4L8xKbe
YKcHDKxK+28LuxxmsRpNb0/xP/wj8mt3dza32nS3EV40MIuLaSNlB+7GEKkOPvKTnvU/wyt5ofh/
o7y3s9wJbZHVJQgEQx91dqqcf72T70LuB2lRB1MjICCygEgHkZrz/XNd1fT/ABekVxfXdjprXkEU
EsEEU1o6ny98c7bDJFIxfCnIXBX3NLoGnXo8SeNNmuaiCLlVUsIW2s0CMGGY/wCHO0D7uOoJ5o6X
Cx6JWDr3iC28O2K315DcyRtNHCBBEXIZ2Cgnso56kj06kCuV0/Xdan0nwHqEmqSF9SlWG9j8mLZN
mJ23fdypyg+6QPasvxHe6n4g8Katqj6nLBa2+rx2iackUewpHdImXYrv3k/NwwGMDHen1sB6QNVt
H1mTSVmJvo4FuGj2NxGxKg5xjqDxnNalef6n4l1fRNb8UNJNFc2tho6X1rbCHYFbMgO5slm+4OeB
jsOpbZy+N7WK5vrq/wBJmt5rKSS3V7tWAn2lkKEQRYj65DMxwM7uDlJ6XC2p6FWZPq1lb6raaZLO
UvLtJHhj2Mdypjcc4wMbh1rm/Berahe3+pWeo3upNdQJEWtNTtoo5oTlwzK0SKkkbFflYZ6GrF/f
6rD4+0uwivIl0+6sbl/I8jJEiGPDM2ckfN0G3vnPZ9RHXiivK7XWvEcGgS6zc60JmtdbNk0EVlGk
csX2kRENnLcA/LtYY77utbV3ea/reoa3Do2rR2FxpU8cMFu8SNFMTGkhMxKs207io2bSME89haje
5t2uvWt34kvdEjiuVurOKOaRpIysbK5IG0n733TyBj3znG93rh9stx8Q9Y8i6a3kfQ7YrPBtYqfM
m5G4FT+IrP0/Xtan0nwHqMuqSF9TlWG9j8mLZNmJ23fdypyo+6QPaktgtqdTr/iC38Pael9eQ3Mk
bTRwgW8RcguwUE9lHPUkenUgV0HWvI/El5qfiDwtq2qPqcsFpb6vHaJpyRR7Ckd0iZdiN+4n5uGA
xgY71s6jqHi/Wte1e28P3FnappcyQqs9wFEjGNJMyIYHLKd2BtdDwfrTW1wOr1zWbfQdGu9Uu4ri
SC1jMjrBEZHIHoB/M4A6kgc1ds7pLyygukDBJo1kUN1AIzzXm/iLUNU1/SPGEaambO20yxMZgto4
3Wdmt/MdmZ1LbDu2rt2nqfp3miq3/CN6eEIVvskeCRkA7Bzil3B7odp2q2WrxTSWUxlSCd7eQ7GX
bIhww5Azg9+lateXza/4mXwPNfR6tbrfwa21nJM1mCHT7UIgFXd8owe+4475+aui0W81KHxdqWj3
2pSX0SWcF3G8kMaGMu0iso2AfL8gxnJ/2jQtQeh19edyf8nEQ/8AYr/+3Jr0SvO5P+TiIf8AsV//
AG5NMD0SiiigAooooA87tv8Ak4O+/wCxdT/0eK7S9aNLOZppRFGEYvIZNm1ccnd/D9e1cXa/8nB3
3/Yup/6PFegsyqpZiAAMkntSeqA8c0nWLK+TwYt94pmiW40m4N9t1RkMmzbtLnfwwPmfMMN8pGcA
iren+II7/wAOeFX1rXZLfS7mzkSe9ivWg3XShdqyTqwKnb5hwW+Zhz6V6Lpuu6RrPmHS9Usr/wAv
HmG1uEl2Z6Z2k46Vq0wueUanc282q69Z6frE1zep4YiNvKl1suZHRpXVsptOeUbjAIYdmp0Xikz6
lrMug6t/aN0fDsdxBAt0Zla4XzA2xMkbsBMhR168mvVDWTPrOnQavFpMl1GNQlhadLcZLGNTgscd
Bz3684zg0kgPONM1Kzj1nW5vDGstqt+/h2OW38y8N1I06mUkBWYkHlSU4ALdBmn2eqXEXhPUtRsf
Fv8AalvMbZp/syys+nxs4Ez5kllZW2EnbkbduQBzXo8GsWFzo8erR3KfYJIfPE7/ACKI8Z3HdjAx
61JpmpWur6bb6hZTedbXCCSKQKV3Ke+DzT2A47wLPpLa74qh0zVFv4ftUMiP9uN0xUwIM7yzMwyC
OSemO1c8NbtbhNKi/wCEmnjLeJbq13R6mdzW+ZMIcsdy/wCqAJ5XcNpBIr2KjFLrcDi/AWoJfaFf
pbagL/7Jf3UMTtc+e3liRvLDOSSflxgk9MVg6Bevqtzowh1a9k1S5E0evWD3cmYBsbcfL3f6OVkC
qpTbkN36j1KimB4TfeJ4V8OaWs3iWWPUF0K8juwNVkR1uowhjDYf/W7t3+03TkV3N7HEnwu1G7s9
Vvbh30+S6W9W+dnMgjzuV1b5RuX7q4XqMY4rvaydd0sa3ot3pr3M9vFcoYpHh279h4YDcrDkZHTv
Sd7MaeqPM77VIV0nVLjTPE13dWg0F5by5GqMywXgK+TtdWxG7EuCi4BwPl9dSe8s7eHw8LzXb0aD
fwyzT6kdRkQPc7U2K06sPLUjzCFUqu4Yx2rv9PsjYWENqbiWfyUCebKF3MB67QB+QFX6bJWx4tps
t7aatqF6l5PPrMmiO2lefcuGvQkk4iPlZCyN5QjbG3qd2AWJrXstSuAl1ceE9Wu9UjOjSyzxz3D3
LQ3Y2+Vw5YpI2XzHwPlHyivUqKQ27u55bJqmkx2Nnc6X4k1C70e6uYU1WX+0HlNohR8Mz53wbn2B
vmUKOy81A+pw29xokc2sJcab/wAJJ/xLLi4uA7SwfZ2Bw7HMirI5QMc/w8nivWaKfUArl/FtzYf2
VJp114kTRLm7RlikWWNZX4xhQ3LdR93DehFdTWXqOr6bpUKzanqFrZQu2xZLmZYlLegLEc8GkwRF
4ea5k8Oaa15bpa3JtozJBGhRYm2jKhT93HTHatmmggjI5p1N6iRFN/x7y/7h/lXAfA7/AJJJpH+/
P/6Oeu/m/wCPeX/cP8q4D4Hf8kk0j/fn/wDRz0DPRKKKKAMDxRBrlx4cuIfD1zFbas2wQTTAFU+d
dxOQ38O7sa8xsrH4v6ik8lr4v0Zlhne3c+Wp+dDhulvxzkc4/LFe2dq8J1/wf4f8ZfEbUY20TWLB
VglkfUhKILa6njOGA3ROPqwPY/Keplbh0PTPAlzqF14PspNVvYb2+DSpPPC+5WdZGBwcAcYxxxxx
xXVVzPgmbS7jwhpzaJAsGnBCsUQfeEKsQw3ZO75g3zZOetdNVvcSFooopDCiiigAooooAKKKKACi
iigAooooAKKKKACiiigAooooAKKKKACiiigDn/Hf/JPfEv8A2Crr/wBFNUfw/wD+SdeG/wDsGW//
AKLWpPHf/JPfEv8A2Crr/wBFNUfw/wD+SdeG/wDsGW//AKLWgDWvbOHULOW0uPM8mZdr+XK0bEez
KQR+BrmdI+GfhHw/fC/0rSDbXQRkWRbqZmUMMHGXODjuOa7SikBxNn8L/BunatFq1toxF/FL5yTS
XU0h35zuO5yCc8811V5ZW2oWU1neQpPbTKUkicZVlPYise+8X6Pp1+1rc3cgcSrA7x20skaSNjaj
SKpRWOR8pIPI9RU7+J9LS91CzMtx9p0+ITXEQtJSwQ5wy/L844P3c9KOgdbkdr4T0iztpreGO7Al
jEJka+neVYx0RZGcui+ykCrOh6DYeHbFbHTI5o7VTlY5LiSUJ7LvY7R7DiqEvjHRorLT70XE8sOo
IZbXyLSaV5EAyW2KhYAAjJI4yKLvxp4dsotNmudUt4k1MBrPJOZQRkEDGQPrjkgdTimIfL4V0iXV
ZdTlhnNxNIksq/a5fKkdAAjNFu8skbVxleoB61YXQtOi1e41WKEreXGPNbzWKsQoXdsztDbQBuAz
is3UfGmnWvhfUtctFu7sWG5ZbdbaRJVcDOHRlDIMEEkgADmo5PE1teP4dCas2mz3s4YWktmwkulC
NuTa4DIued+McDnml5DfcsJ4E8Mebas2mGZbWXzbaOeeWSOBufuIzFUHP3QAOF4+UYTUPAnhvVJb
t7uwkZbxxJcxJdTRxTOMYZo1cIzcDkjNR6d43s9Q1PXLWaC7s4dKYh5ri2kRSqqGZyxXao54BOSO
cYqxa+LdJvbS9ntDeTNawrPJB9imSZkYHaVR1DMDg4IGOKLgTL4W0e31SXUIrRlmltxaunnSGLyQ
MBBFu2BR6Be59TVe08F6DYWlxY29nKLWeF4Ghe6ldEjf76xhmPlg99mO3oKyY/Gtrq/g6x1M6o2h
XF7PFHE09mzlmZ1OxFYDzMqdu9cgZJzxW9D4l0y51a902Jrprywj8y4j+xzfKvbB2YbODgKTuwcZ
xTYEmleHrHR95tEm8x1VWe4uZZ32rnaoaRmIUZPyg45PrSXXhzTbvV7fU50uPttvG0UUiXcsYVW+
8NqsF5+nYegqOTxZpEVrBetLdNHPH5qJHZTvII/77RqhdV4+8wArXtbu3vrSK6tZkmt5lDxyI2VZ
T0INAHPHwB4f/s06f9nvfshuPtRj/tK55lzu358zOd3zfXnrVm68J6LdagL+a1l+0iJYWkW4lXzo
16LKFYCUez7s1B/wnGghLhzc3IWC3a6d/sM+1oVIBkQ7MSLyPmXIxz0q0vijSXs9NuxcTiHUm22r
taSjdwWycr8g2gtlsDAz0oAfH4d02LxDJrqR3H9oSR+Uzm6lKlOy7C2zHU4x1OetUk8C+GjJbFtM
85bWTzbaOeeWWOBufuI7FUHP3QAOF4+UYS18e+Gr3yvsuqCZJLj7MJI4ZGjWTdtCs4XauT93cRu7
ZpqeLIpvGd14aW2vYnigVxcfZZCrM27kNtKhRtPzNwTwM4oAXUPA3hvVJbx7qwdlvHElxDHdSxxT
OMYZo1cIzcDkjNS3Hg3Qrm/S9aw8qdIVt/8ARpZIFeIdI3VGCunGNrAjHHSsDwl4ms7OzmstW1i4
ubv+1bm1WWcNIQfOZY1kdV2x56KDtB/hHFdLqXifTNHlMV5cSIUwZXSCSRIAehldVKxj3cjjmhbI
O6ItT8GaFq15PdXdrL5txD5E5gupYBNHyNriNlDjn+LNamn6XZ6Vp8VhYWyW9rEu2OOLgKP8ffrW
bd+KNKs9RSxlnm855Y4QyW0rxB3xsVpFUorHKnBIOGB7iqmn+ILAza5djXhfWdrcJD5UNsT9mfao
8tSoJlZmPbJydvWgCRvAXh9rBtPa3vTatcfaih1K55lzu3Z8zOd3zfXnrVy08MadZ63JrMS3X26S
MRPI95M4ZB0BVnK8c9upJ71Y0nWrLXIZpbNpmWGUwyrNbyQujgAkFZFVhww7d61qNgFrzuT/AJOI
h/7Ff/25NeiV53J/ycRD/wBiv/7cmgD0SiiigAooooA87tv+Tg77/sXU/wDR4r0Q9K87tf8Ak4S+
/wCxcT/0eK9AZQ6lWAIIwQec0mB5Tp9xqlvsTTtSez+1+LL21mAhSQMh8xs/MMhhs4IOOeQ3StE6
rrv/AAjLal/a9yV0nVZ4r50gh33FrHMysxGzAZVG75QMgHuRjqI/BfhaJleLw5o6OjBkZLGIFWHc
fLwatWWi6VpcEsOnabZ2kMxLSx28Cxq5xjJCjmhaKwPU5+/vrwWUMsGs3/majds9lDbW1u0zxBGI
SMyKEUYG/dJnj5c5IrJ0m/utbvfBF/dSlbu50m8aSVVXIfEOWAxtBzz0xXb3+j6bqsCWuo6fa3lu
hDLHcQrIikDAIDAjPJrKk0LwhZSOZNK0KCa1haVy1vCrQxNuyx4+VT82T0+9QCMDS9e1fWrHwpYN
qslnc6lp8t3NeRxRGSRo9o2KrKUGd+4/L0XjFXPDWoTaR8GbLUYYvPmtNKMyR4++yqTj9K6FvDWg
z6bFp7aNpsmnxt5kdsbWMxKxz8yrjAPJ59zVzTtNsdMtBb2Flb2duCSIbeJY0BPXheKb6gt7nBaj
q2u2VldfYvEMt/HPoUupQ3Qhg3QyR7Su3am1o33YwylvlOG9Ga3quqSW3iOBNYuUjHhyO/j8kRq0
MpEm7awXOG2DqSeTtI4x3Vloek6akyWGl2VqtwczCC3WMSf72Bz1PWq9p4Y0CzbzLPQtMtm8toy0
NpGh2N1XgdD3FJoEzmrSXVp7qHRIvEc1pJbaZFdRzvBDI1wWZgS4KAGNNqjCbW+blu9M1jX9WZ/E
l1Y6p9nm0PyjFYiKNo7sGNXy+VL/ADksi7GH3e9dJD4f8L6hp1mINJ0e4sIsvabLaJ4k3HJMeBgZ
POR1rQudH0y8v4L66060nvLf/U3EsCtJHzn5WIyPwpsS0PP7TVfFEi2Dtr8hM+u3GllJLSE4iXzf
mO1RmQbOCML0yrc5nl8R63H4et7ZL1JL2bXJ9LF9OyQHarSbCSInQOdir/qyDnpzmusXwf4Zj8vZ
4d0hdknmptsoxtfj5h8vB4HPsKli8NaFDp89hFomnJZ3DBprdbVBHIRjBZcYJ4HX0pDGeHxqqaRD
HrctrPqMZZJZLZtytgnbn5V+bGM4UDOcACt6qVnZ2un2sdtaW0NtBGMJFCgREHso4FXabEgooooG
FFFFACVznibT7y+0i6Gn3Fnb3hgkjW4uoPNVEYfMOoxnA55HHKmujrIv9D0nVZYptQ0uzupbc5he
4t1kaPoflLA46Dp6UmrjRD4YmS58LaVPHbG3je0iZIC+/wAsbBhdx649a3aKO1NslKyI5v8Aj3l/
3D/KuA+B3/JJNI/35/8A0c9d/N/x7y/7h/lXAfA7/kkmkf78/wD6OegZ6JRRRQBheJvENr4V8PXW
tX0c8ltbbS6wKC53MFGASB1Yd6+efE/iP4V+J9ak1S4sfFFpdTczfZFt1WRv7xDM3P0x+dfTckay
ABgGAIOCM8g5BrzPV2+J2h6teQ+HtL0rVtNuJ3uI5p22SpvOdj5lTO3oCM/KBz2C6j6HT+BLzSb/
AMG6dPoVo1pphV1ggd9zIFdhycnnIJPJ69TXWVz3hKzvLDw9bW+oXUVzeK0hme3/ANWrF2JRfRVz
tA7ba6Gqe5K2FooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDn/Hf
/JPfEv8A2Crr/wBFNUfw/wD+SdeG/wDsGW//AKLWpPHf/JPfEv8A2Crr/wBFNUfw/wD+SdeG/wDs
GW//AKLWgDpKKKKAPJNcg1bR/D15pV3pkrQPrkVzHqKzRmN0ku0kG5d3mBgW2424+XO6ujvbTV7L
xhdanZaTLfwXmmx2isk0aCKRXc/PvYHZhxyoY8Hg8Z29Z8P2PiC1W11AzvCjiQJFcyw/MDkE+Wy5
wQCM9xmtCGJYYkjXeQqhQXYsTj1J5J9zStpZhc870/SvFVn4W8OaRdaZOLSK2eK9g06/RJd42+UW
kLIQv3iwjYngcsMgs0zStfttC8F2Mnhy983SLlXuz59sQqrG6ZX97zkvn1wD7A+p1mz3tvaSwxSy
4lnk2RpjLOfYD0HJPYcmnfUDiZtI1m/tfHds2lXFv/aqsbJpZoish8hY8fK7FSSueQOMfSrl9a6x
dp4TZdFus2V6s1wgmhzCgiaP5v3gBOXzhS3APfiu7ozzS/4H4Bc4ZLLxDp+p+L5NNsFM19i4sbmS
VPLLrAqKu3O7O5e4C479qqeGtK1i28W3V9daVqkcN7p8cLz3t5FMwmVnLFgsjbVO4YVBtHovSvRa
KLAeYf2T4gT4Z6Zon9hXDX1pNao0STwZZYpFdnyXC7SFwOd2TyBW7r2h397rdhqWnsIPtELWWpZb
DfZ2G4EEfxq2QMf89DXZUUwPPNd8M/8AFVLqknhm21/T5rOO2aFlgMlq0ZcgoJiFKtvwcMDx3rrd
Pt/smmQ28drbWqomBb2ygRx/7KjgcfQZ9BWt2o7Uulg6nnPg3QdVsNUieSwvNN077K6T2F3cRXEM
cp2f8epV3dEO1iysQORgeljwrpN1pupX1o8i3GmaTI8WmKp+cCRQ5Q54+QHYvPQmug8Q6ppmm2AT
VLw2sd3IttGUd0d3c4CoU+YH3HTrV2ysYbC2S3tw6xrn78jOxJOSWZiWYk9yc0wZ522meIz4NurF
fDV6LyXXPtqx/aLbiL7SJs583Gdoxj19ua6NrPU4vH0mqLpkj2d1psMJk82MeS6PIzKw3ZJwwxjI
z3HWux71SF5bG+ezFxEbpUEhgDDeEJwGK9cZB5pBc83Ona//AMIpe6enhu/W7m1v7co8+15j+0ib
JPnddq4+pHbmrs/htl8U6pdXvg6z1u31NknhuJlt2ktX2Ihjk8w52fLuym7vwa7q7vbbT4hNdSrF
HuVN7n5QScDJ7c8ZNX6FoB5rfaBq6+KTcaXptzYuLi33XUEsX2G6iVY93mwM5YMu11QouR8vPenX
Wl6jO3i0TeGp7uK+vbeaCJ7mKMzxoI0Yoyy5RhsZlJ2/w9+K9IooA5TwXY6pp9hdx6lJePG1xutR
ftE90I9ij968ZKucg4OSduMnsOropae4BXncn/JxEP8A2K//ALcmvRK87k/5OIh/7Ff/ANuTQB6J
RRRQAUUUUAed23/Jwd9/2Lqf+jxXeSxJPE8UiK8bqVZWGQwPUEVwdr/ycJff9i4n/o8V3M8YljeM
7sMpUlWKnHsRyPqKTA8t0rwr4ffwXr141jaWVxaX180N/bxrDNbeXK+wrIuGULgcZxgY6VetfGHi
MaDczymx+0QeHINWQyWz53kNvVwHGc7DjG3G7vjnoE8A+HUQxNa3U1uZTM9tc39xNC7k7izRu5Vj
nnkHnmr+reFdH1uUyahbyuzQm3cR3MsQeI9UYIwDD2OaNUrBpe5gXGt+JrjWbqx059HVV0uG/ja5
hkOGbcPLbDjIJQndxtH8LViSanHdXGt+IbaxtFe78KwX0kFzCJEkOZTtkAI3/KAuc9APpW2/gtp/
FLS3ER/sVdPjsUVNWuRKwUs37xRjeDv24Z24Hvitu78IaLez3Us9vcbrm2FpKsd5NGhhHRAiuFUd
egHU+po31H5PyM99W1u9vRYaQNNhnt7GG6kF2jsspkLAIu1gUA2H5sN1Hy8VDe+Kb+z8ZWOnGWyl
s7m6Fs0MNvK8kRMJfLzZEatuH+rI3bSG78a8/hLSLg2haK5WS0h+zxSxXs0cnl8HY7q4Z14HDE/q
aguPBuiXOofb5Le5SfzluMQ3s8SCVVChwiuFDbRjOORnPU0+olsc5ZeJvEVlpc3nTw6lf3etXGn2
gjtlTy/LMmTtaZVYYj4Xcp56seug+reINRtdP0S70+wstVv7e4kukvI/Ph8qMhMbEk5371ON52jd
97Fas/hDRLiO6iktZSlzcLduoupQEmDbhJHhv3bZJJKbc96ln8LaVdQWsMsVyTaOzQzrdzLOpbhv
3wfzDnvlucD0FK2lmD30K/w3BHw50AEAEWadOnSurrK0nSLLRLCLT7COSO3hGI0eV5do9AzknHtm
tWm3diQUUUUDCiiigAooooAKKKKACuc8SaXpGoWDHV7GO/iVSkVtKAwaRuBtB43noG6jJwRk10VY
uqeH7HWLiCe8N4JLfPlNBezQbSRgn92684JGfelYExdAsrrT9BsbK9uDc3UECRyzEkl2AwTk8n6n
rWzWZYWkOn2i2tuHEaZxvkaRiSckszEsxJJOScmtPtTeolsRzf8AHvL/ALh/lXAfA7/kkmkf78//
AKOeu/m/495f9w/yrgPgd/ySTSP9+f8A9HPQM9EooooAQ9K+dPEeh/CiXxNqsms+LdVi1FryZriK
GBgiOXOVH7lunTOTnFe2eKrzWrLw7dT6DZx3mqqUEEEo+ViXUHPI4AJOcjpXkL6V8RJppZp/hf4Q
nmldpZJZoYZHdmJYks05J5NLqPoei/C+K3g8A6dHYNK9qrTiKSUYMi+c+HxgYDdQOwNdxXMeDW1Z
vC1oNbsIbDUELo9pAgSOJVdgioASNu0Ljk109VLclbC0UUUhhRRRQAUUUUAFFFFABRRRQAUUUUAF
FFFABRRRQAUUUUAFFFFABRRRQBz/AI7/AOSe+Jf+wVdf+imqP4f/APJOvDf/AGDLf/0WtSeO/wDk
nviX/sFXX/opqj+H/wDyTrw3/wBgy3/9FrQB0lFFFABRRRQAlcfos73/AIr8S3bIDJZPHYW4ZsAK
I1kb6bmkGf8AdHpXYHmuXFlNpnia7uoIna01ZUWd4gC0E6jarkd1Zdozg4KjPBJCA5hPGXin+w5N
XntNJEdtqpsJbeMyMZh5/lfK5I2YyOSrbvReh1pfFeo6Lea9HrK21wmnaamoobSNo+CZAYzuZtx+
QfN8vX7opT8PLdtFfSzr+seTJe/bmbNvvMu/zOvk9N/zYx+nFX38I29xrN1qd3qF5dC7tBZXFrII
vJkiweCFjDdWY53d/TijWwaGfp+qeNb6WeK70uOwt5bZngvWiiP2eTsCi3D+aMd/k6dOeM7w7qut
Wvw00e+n1bTRPceWfPubeVjtbPARX3TSs3QKVzngcYPT6P4cXSFSI6rqV9DChS3jvZEcQg+hVVZu
OMuWIHAIyc50PgO1i0rTrGHVdUjOmzCWzuA8ReHCsm0AoUK4Y9VJPc0MEVrD4iabZeF49X8TXKWW
b2az3pbTAO6OwB8vDOmQucN06VD4m8az2empq2iX2nS2T2DXkMMlpPNPcAd9qFfKjxgeYwIBPOO/
R+H/AA7HoENzDBfXlxHcTvcFbkodjuxZsFVU8k55zVPWvBlprd1e3D6hqFr9usxZXcds8YWaMbsZ
3IxBG9vuke+aGC8yDUNf11/E+kaXpsGnR2+oWctwJ7hpHdGXZzsXaCBv6bvm9VxzXh8T6nN4UW9a
40y0vYtQksp5Zo5XjbZIyfuolO93baNqbs89T0OjH4Q26rp2otruqPNp9u1vEGFvtKtjdkCLr8q9
MfdHvmrB4CtrWzihTW9W86C+e/huSYDJHK4YPj91tIbe3BU+2KARh6nrVxrnw4+13SIs8esQ27lI
3iDbLxFDbH+ZMgD5TyK3W8Q6pYeLNV07VJ7GGzSyN5p7pbvvkUff3EyYJQ4yoAyGByOlRHwLbNpM
2lf25q620159tODAWEm/zOCYicb8Nz6emRVjVLCz1/VtMtJbe6nk0qcTyXU9u8QbC4AV9qrJuYqS
Fyvy844p+QGPrninxBokNimoSaZYXMtqrm4ubSX7LNcMWJgEgkAhICjlyQ2e2K0ZdXvoPFevRppN
lNPaaTHcWrQZM9yCZMIzkDA3LwozjOcnOBoaz4Vj1u7nml1K/ghubZbS4tYjEYpowWOGDoxB+dhl
SDUV14Ot59R1C8/tHUEF9Y/2e8MZjVI4gCBsOzcGG5iCWPJ+mFv+I9Cp4W8QSeKP7Ttr68029gjV
YpIYrSS2ljY7hJHNDI7MuMYz0PPpV7wLcy3HhzyZmZ3srmey3s2SyxSMikn12gUW+lHw+bjURLf6
vqc8aW6yTiMOVUnYpKIihQWYlmGeep4FXvDml/2NolvZOyvMN0kzqOHldizsPYsxp9STcooooGFF
FFABXncn/JxEP/Yr/wDtya9ErzuT/k4iH/sV/wD25NAHolFFFABRRRQB53a/8nB33/YuJ/6PFegO
u5GBzgjHBxXn9r/ycHff9i4n/o8V6CyllIDFSR1HahgeX6FrF9occiwQ3eqm81+501PtWpys0IQu
Y8eZuG0BW3HIPA4Y8V0dv4pnudOt2TTY/wC0576awW0+0nyhJEX3Ey7M7NsZOdmegxVeHwFDB5Lj
X9ZfytQbUQrC2wZ2zuJxD0O5uPfjtVmPwVbJp7Wx1TUjL9ubUIbrMSywTMSWK7YwuDuYEMrDDEUl
tqDt0HSa9qoaz09dGhTWLlZZDay3uIljjYKz+aqMSDuTb8oPzchcVQh8b397c6bb2GhLJLex3AZZ
73yzBNA4WVHwjZXJ4ZdxP90Dmta68NLdCwmOraiupWRfy9RUxecQ/DKylPLKnjjZ/CCOearf8IfD
Fd2FzbapqFtJZQzRxiLySGaU5kkbdGxLs2G9Mjp1yMCto3ja91c6bjREgXVLGW6szJeZJePblXCo
dqkuMMNxx1UHio9L8XXWtwaSb/RnsrDXInSGaK+LSJIELbTtVSoZVcqytn5RkKTU9p4MTQ/7MuLX
UdWuzpNtJDbWpNv+8VuSpPlrydqjO5fujnrmn4O8JXtt4f0z+2LnU4L2ygeKCCZrZltXZdpkj8tS
GOCQN5bqeOaHrdAZ+h+J20TwD4YtbWymvL24sTIkKJMw2JtDEmKORgcuuMrj1I76S+MtRj1u6lvN
OW20a30ePUpEkLLdx7t+QybcbgUK7dwx1yc4FuDwNa2unaVb2+ranDcaUHS1u0MXmiNhho2Bj2Mv
TquflBzVu58KWt3qJubm7vJRLZfYbqJyhS6i+b7/AMu4HLsfkK/lxTb1uGgnh/xPc6xLereaRdae
luFdJZIpljlU56GWKM7hjkYI5GCa5+z1K61rx74d1Y2HkWV1pt21oxu2dpY8xEFoioWNiCDwWJBG
T8uK67RdCbSLQWsmq32oxLGsUYvTGdiAYx8iLu+rZPvWNY+BrawvLGWHVdVNvYxyw21o7RFI4pMZ
QN5fmY+VcEtkbRzR1uCKFx431B7DxHHDaacmqaVYfa/KW/8AtCp9/cku1BtkXZygyDkfN3qxeeMd
Q0a00mTVLCwVbvyUd/7SAd2kcKfKTywZCoKs33cbuM4qez8A2lnFNE2q6jcQS6f/AGY0UvkAeQAw
VRsiU5G5sHOeec0y68ARXakSa9q2WihilYC3zIInLxE/ueNpP8OAcDIPORbgzuKKrRKyRqrszlQA
WbGW9zjirNABRRRQAUUUUAJWF4gsYrqxd7u8v4LeKNmxY3DwOW7HchDMewXoSeQeMbtYGs6FLq89
rImsahY/Zm3qlsISrN2ZhJG+SO3p160mCLGgrqKeH7FdXffqIgQXLDHMmBnpxnPpxWv2rNsbT7Hb
rG91cXLrktNMQXck5JO0Ad+gAA7AVpdqbEtiOb/j3l/3D/KuA+B3/JJNI/35/wD0c9d/N/x7y/7h
/lXAfA7/AJJJpH+/P/6OegZ6JRRRQAhrx/VNN+IXh/xNq934a8P6PqkWpv5kl5PK3nbedsbh5VA2
g4AUYwB3r2A184a9YfDPUfFOtzeKvFeqxaoL+VGSGNiioDhVH7lvuj5ev8PHGKn7QdD2vwVYahpP
hKxsNUvYry9t1ZJZYTlAd7YUdOFGF6D7tdJXJ/D2HRrbwPYReH7q4udKRpRBNcjDv+8bJPyrxuzj
gcYrrKt7iWwtFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc/47/5
J74l/wCwVdf+imqP4f8A/JOvDf8A2DLf/wBFrUnjv/knviX/ALBV1/6Kao/h/wD8k68N/wDYMt//
AEWtAHSUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV53J/
ycRD/wBiv/7cmvRK87k/5OIh/wCxX/8Abk0AeiUUUUAFFFFAHndr/wAnCX3/AGLif+jxXoh4Fed2
3/Jwd9/2Lqf+jxXoZ6UmBx2k+L7jU7aDUX06CLSZzIUvEvQ/kIgYkzqVURn5cYDNg5BIxzqDxR4f
IkYa7phEcQmc/bI8LGcYc88KcjnpyK5K30fUYtftNYtPDtzpOof6zVGtLiH7NfDYx2BPM+aQs3DM
q45yx4zU0Lw/qWmnwl5/haf/AIlVjdJcbWtTiZ9uCv73kttbn/bGf4sA+p3lzr2jWNtBc3mrWFtB
c4MMs1wiLLxkbSThuPSsLXvFOsaXfeIYbazsnXT9JW/tvMkfLklw2/A4xsOFHXH3hn5ebuNE8Snw
Fpuix6LPFcDS57OZ4jatMjnaFUs7lRC3VtmW+Vfu4q5qOn6/eHWSvh2/zd+Hk0+PdPbczfPkH970
/eDn/Zb2yPyBWOxuNbtdM8Of2vqk6W9tHCss0mDgZA4A69TgDr0qCHxl4bu4BLB4g0olguAbuPIZ
gSoPzcHg8expl/ZXmpeALvTltnhvZ9NeBYZWXKuYyoBKkr19DWJo9tqn/CW/2nd+Gb2GNNIjtEkl
kti29GZmUbZTgNlce45xjNHVkrZHQW3iOytdD0+81rWdHhkukGJorpVglfHPlMx+YVHbareyeNL7
RpYrdbSKyhuYZEZi7lndTu6Acr0GfXPOBxdzoniRvAmm6NHo00dx/ZU9nM8TWrTRyHaFQs7lRC3V
tmW+Vfu4rpNEg1Y+K/t11o13awNpUFsZZpYCPMRnYjCSMf4+uOx/F9RvRHb0UUUAFFFFABRRRQAU
UUUAFFFFABXOeJ9ak0DSPtyWE14BLGjKsqoEDMF3MTzgZ7AnOPqOjrlPHNve3nhiW00+xmvbiWaL
EcbxrgK6sSS7KMfLjrnJFJgdXRVSGV5Ikd4XiZlBKORuX2OCRn6E1bpgRTf8e8v+4f5VwHwO/wCS
SaR/vz/+jnrv5v8Aj3l/3D/KuA+B3/JJNI/35/8A0c9AHolFFFAHN+L9WvNB8M3GpWNjJfXULxbL
WMHdNukVSowCckE9jXkr+JZZppZ5/gVNcSyyNLJLPaNI7MxLElmtyTyTXvDRK6gMoIBB59Qcg/nU
tJAcl8P5/tPg62mGj/2PvmnP9n7dv2f98/y42rj8hXW1WgCDIjUKCSSAMZJ5JqzVN3EkLRRRSGFF
FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+MYJrjwRr9vFHJNNLp1wkcU
almdjEwAAHJJPauG8N+PdQ0PwxpWlT+A/FsktnaRQO6ac21iqgEjP0r12igDzf8A4Wtef9E88Zf+
C40f8LWvP+ieeMv/AAXGvSKKAPN/+FrXn/RPPGX/AILjR/wta8/6J54y/wDBca9IooA83/4Wtef9
E88Zf+C40f8AC1rz/onnjL/wXGvSKKAPN/8Aha15/wBE88Zf+C40f8LWvP8AonnjL/wXGvSKKAPN
/wDha15/0Tzxl/4LjR/wta8/6J54y/8ABca9IooA83/4Wtef9E88Zf8AguNH/C1rz/onnjL/AMFx
r0iigDzf/ha15/0Tzxl/4LjR/wALWvP+ieeMv/Bca9IooA83/wCFrXn/AETzxl/4LjR/wta8/wCi
eeMv/Bca9IooA83/AOFrXn/RPPGX/guNH/C1rz/onnjL/wAFxr0iigDzf/ha15/0Tzxl/wCC40f8
LWvP+ieeMv8AwXGvSKKAPN/+FrXn/RPPGX/guNH/AAta8/6J54y/8Fxr0iigDzf/AIWtef8ARPPG
X/guNH/C1rz/AKJ54y/8Fxr0iigDzf8A4Wtef9E88Zf+C41Q8Oahf+I/i9/bknh/WdJs49Da0zqN
o0QZxNu4PTo36GvV6KACiiigAooooA8n1/UdQ8OfFubW4/Dus6rZzaOlqG0+0aUB/N3cnp0H6itD
/ha15/0Tzxl/4LjXpFFAHm3/AAtW9/6J54y/8Fxo/wCFrXn/AETzxl/4LjXpNFAHm3/C1b3/AKJ5
4y/8Fxpf+Fq3n/RPPGX/AILTXpFFAHm3/C1rz/onnjL/AMFxpf8Ahat7/wBE88Zf+C416RRQB5t/
wta8/wCieeMv/BcaX/hat7/0Tzxl/wCC416RRQB5v/wta8/6J54y/wDBcaP+FrXn/RPPGX/guNek
UUAeb/8AC1rz/onnjL/wXGj/AIWtef8ARPPGX/guNekUUAeb/wDC1rz/AKJ54y/8Fxo/4Wtef9E8
8Zf+C416RRQB5v8A8LWvP+ieeMv/AAXGj/ha15/0Tzxl/wCC416RRQB5v/wta8/6J54y/wDBcaP+
FrXn/RPPGX/guNekUUAeb/8AC1rz/onnjL/wXGj/AIWtef8ARPPGX/guNekUUAeb/wDC1rz/AKJ5
4y/8Fxo/4Wtef9E88Zf+C416RRQB5rJ8Urx4nQfD3xjllI/5Bxq78JLK60z4baXZ31rPaXKNNuhn
jaN1zK5GVbkcc13tFABRRRQB/9k=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-11-05 11:09:33 +1300" MODIFIED_BY="Agustín Ciapponi" NO="2" REF_ID="CMP-004.07" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 Day of starting administration of the Progesterone, outcome: 4.7 Cancelled cycles (by subgroups).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAycAAAFQCAMAAACSz/HLAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAijUlEQVR42u1dzYseyXlvSe+oJKPVyhqNvte7a7MCEwUfNqeQQ3Jw
IFAkhj3kH0ggBBzIJb7mmuRiQm6BQIwJIbBgcOHkkGNICNgHxxswu2x2Ze1qtdKMPkZaz5RHH3nf
7q7u+u6q7q5+q2d+v11N99tdn931q+d5quupOkYKAAA6cByPAADAEwAATwBgEiyyKQkt/zLrLeaL
x5roLFHaqwTYJA+AKdkpuep1WJZtilJN9eozr3k+PHFXnnbTq4xLnW1+WNodoUZrLL4a1C2FSswt
DglLZlHzRZ59S/0sygNd9SB0daybuwhSXaw6fZYw7clossyy7Subg145peCHgC+zqHmG9gkrH9jq
D2WrA6seB606HSpuVldY3LPqmTabttlQ5cBUnioFt9yfNWGyrfki5wenPAdTajBLv5Qk7an7a0al
w7J1KOLw0NBiVjXPdbyLUk/Tp9QlvhOlvc6uoi0RY5ONKaDmM5EnzPdc2CCaxKe9bpnamLArLf6I
0CSzmuf7/cTbsRs3455hXNrT6ZiSBVsf6OGnxSxqfjzXR0crhZTqpkRzU7czKA1r4H3SnrDOBRMD
eOIgtxdWDTm0ZWOHgElzqPkxzIMEgBnrXQAAngAAeAIA4AkAgCcAAIAnABAP+Xt8PSytuWT4BqlF
jO6QXfB4iHhcRLRY1F6UpGlXc4yZdLm9L86UTERoaVqAFNVV0q63wMTLoM0HiPbW+r+wzL7SC61U
5fSA8NorjgHD0NFgHXHkp0HXknZ3ZjTuKcQ+0NZ9g4lGY97KGjOo9MLSOpr5/UxiftVoFA+OtpJN
oxJB67nRTOK2uMo6idfGbb1A/M4GrWOCO2CitEW/Qi2VLUSG2lvr7ovkQmoOGbK3jKPzpbJky4Ul
8660Yp/U0wIUTYpqxapbA5NiKFoIbSO1zh5qgJDOQvMC8TsbVHfrmQ8dXgkp0q6vtgk1j6CHi0wV
TSqk4ZDReMvoseisZ9xnXenjqr5gZlo3JascMGKwLj3H02BW87P0nJjWXkNEuO25pUzbW1PmusUc
L5rKk88cD9Tlv8nqGYVZMmbmlV6YOldU5WNjBKr1eo0ZDbXLdBGYPO2+loiit1pEU3BajMrDKeU4
TIyRuTaLZFaVXtgUiFimpOl9jHxCCBnQ4kdNm1VdYT11NdhTTBoEsqTIYl0zZ+HiOOtKH9esE6Nv
9A2ySTGo0p9Sz1PqpB2zlGaMKdQp0zYfScBLZIy5Hn6YoKodM6mqE1LVLyA3B815Vvq4qn7XeqLm
CqBq6MwWgwkVhimRWmcPKYDbPrFmU5eH+qweueB02rRtT0d9bobMZYV/ER6q5mR3yFCyZdptan1f
a1a15lzpMP+TqHwpc0U4Mi6r7kfgjdIrn7k/p3lUehHEkjjN8RAtwda374x+BKBJ3pWGPyMAAMDc
8U4WpVhAngB5I4sWinn1AACeAMAoepfyS1ltjJnXLEMN1JgUEj8e4XECYdZc9MzFlAUxZbnfQIp3
+j2brAr1FzQmxfcNnxk5O+th2zeEMnAgmifttzjbp/WQWf29vpDQ7jusKwGmcnzc199dqxGrINwn
pP2PfB4VNOoxswiCA055Yunm5ItMzGxWPASkjUNkNw3dVUXedqRQUlF9O6R4VHSz7X4XqheJ2QaV
9c41jxPDH0YpXZu57m+j7IOSvApiap80gUDaIKQjZ6vXhnXfkPoeo+BArH1i7VpMvyRzW4pm4xDV
n0PxPxHbjiiHQm4LzYUmXu25wcz9LpRSUEt5Vf82S3nUJIW3g1Y5pRiTVUG+ZnP/8eRs89pw7RtS
8wtEGWDHU+cOOdUsHNmZo6/gZszp2OKJ1LQT6rhvhDVqZvc8YdbKraEKYZOenTmbO7c4coLC1U/v
CtRUXV4CNFZz9wek/hAxvgpy36u0LdPzhA5SREaqQg8jj/Z6ZUAv+4QWrSLOom3auMudAZk3RLSv
gtKZM/uvwRM1x6lCn0Kw0QdXAJfeVXoGyDLat8kI09eVKZyT/l3qBdVXBtAdYGh3lG4NR/U4oUqp
qWNFleA8UlTBvCdvENKdMyTHhPaJs1FYlF3WODez1oJhhXYubzvCVB8BixOI5PWhXZKtJE9nygpr
RNUfxnAY0StnOKtMUoXaW4apBgYrAnK2em349w2BrAlB7/nC4wjzRKkMTTYmfuIq9FGBJ38BKZHH
B55F38c7xvOlI/VmjI46lhNTrORVYDRtzhAnaeUJABwheYJ5kAAAngAAeAIAWdvxADACns2mIUKe
AAB4AgBj6128/GsZKOZk9b9+sQpqPSQB7065yZ5HlSKw1NxdQy4enMi4eR4ktjBSDvpDXaXmvqtV
vDor7/ICo/9j2ieup0kcjabmj3FIQ5OwhiwacyQBw0joDkvUQrbPg5NYmjQ5mA+VeO8qFedSYoSj
oaew49XOsH7TXO29nC9/nl3XsFIbVCAjlonElIMbZ2uGd1rmD0LCuVZmWDtP5M6waQPGBVenm0qc
RLz46EYSUmpvoqJnsYThZB1sz6a3YkPDZTi/i7dPuP2r9GqkowVYLZkpwftxMKbU3N5AtRRK6i1p
s/y/f9/Bg8wtPv4TAQLsE+Kxa3lK9WWYES+aZTxTSXgB6iwc1gmRL61+kWF9R0BMe4HC7gLD7BO3
clXqXWtQKMpcuzMkEWF7FoBEFnIMQ8FbGbKejuuI4bhXZnDLxfXQhBDS/c55RNieBeBhGfORmNn9
pKF0rc0+qfUuoujVRFK4q7BcDSsd1oWe2cdEs4dVr3LSXqjOSXxp2kS4/InEuNtesMmfNb+QXtpM
loD/yYzgESwdlv6M3zL8T4C+mtg00QDwZJYgpJ+9TrIVJ4+Pnd565eyXT//n69C7AMCC1//6289/
tb082dxZ/byw2D+/uJWt3nUCDijA5FLk+6dO/dZ//fPuk1+ufu2V1375dP/hzvkvvfLv33uhBr7x
fm7yRJ1I027MYaG2dFNaQ71cHETeuqMQK6NP0ydIC8azFKl7diJpnh1VluenReRuLK71/ZudH1y3
1feilJZmtKrKxvdrKeLG5sbGie2DfO14WhhL0Rfawu+Wt9qulV6vJ6kmKPYjmYYmLOES7FSrko6y
+tIC9KxPA3Wt71/l4L+tVFwOlAlJHl+/+M4rT791+852sSkoYTvu3L395OmZL1+8spGRCNTVLrFR
jegbpR1NqLbVhlX6FNoGUvUSkYd9MU/qWVu4X4fo2i+gk8rT9Uvh+MrffPvZwbWd4p82K3tkZ2WT
dB6fXjhx8kQmZFHGu/TVcdUdTapT564dlNKgVzhBo2VrSLSqPlUW/B24KGV8Aradk9YtRa5dPP/N
D751+7Ptlbke92/789sff/Du+Ys/3s9JnjB9tWf7ur3U+Y5ou/PM0Vtl0NgZbvDzECnSHnPT83n+
t4snp24PSuHly9+/n5U8URTsUA1DLPLMhJJO2breUl2UlOLEtbkPY3ahM8Lz8NLEs9lQ591pcPPT
vYc/P/OTc5e/UdsfMf8uf+/N9y4/vH/nIDP7hEXTpB3ryqJPb8z40clSJ9pR2/Gz7pAm/vLk8m4O
frPYe3jm4oM/+of7pe1RqlX+46XFmxu3Hv5x8XZ+4126GRj0iMWWAdTQ46ttOyZ8T3VRjHG3USgo
bQ7DHFnLoSzPI64mlLppom1Ro4kN424mOPh077u7Z3527uRW9XunsB+LK9ffuEEebd+5lZFafVyV
0tLmIO3GJvJWHsauHbUWreyqQSWx32fcZiwTYbos9E1FrM8jVHVU9jwRu6HYb/urPMEDiSbLb+w9
2P3ga+eufMN298Ll6z+48fTB/c9uFZlh2LyVUBMTO58lVsDo/Dae27j44PTFn1bnS1XrwsZf/eWJ
X0RXbSoMm7fyfuCkghugyWDc8Mzg6KJJ8X5+9Xnx5Nne9s9/dPZPHhSvnty6cH/vh08eW+ud3bwV
AMhQjsL/BABmAvAEAMATAABPAAA8AQDwBADmA+nziVisTfzUdtJwY6JVb9Jlw7FuIhDME5L3Ok88
KQE5iAJE6l2c83oVwvJMu1y0N5ZhrCFnCNAECJQnavdK9N1O5B/ivAxDEm+kJbJMSERszAYMsONt
+6txmQ/kcHTJ2JkNiJcnLpuAe4yF5Os9JxVWECbAEJ5wZSMD4mtZ6fUu2NpApnqXIThWUoOTDlmT
pstPsacJAPSXJ6TZlFPZtYyYu3Co+v1smzHB9xMgiieWPUyJvj8zsQWZop2RGaYMHBG9CwAA8AQA
wBMAAE8AADwBAPAEAObKEy79Vc8CwS3fJUNT5OZd3rMYAJC1PCG21j8kOgDkzBPdA0V2MeG8ckKR
PFDkYG34sulzI0U9rkii9m2RkiuaO7N3bwFmDus8SNMDpT1d/V9oHiit+wkRbiLElaIRVxxEODNX
eBwCWfGEh6lEsrOG2XhXVCHyL2dixJoEMQIAQFY8IY32000dHmiH2IjSqUPxQXYOAEyidxWk27Ym
/U1w1a0lKAAkC5ChHe8XKdwvUjQJYnWp5VIMbkudG3cgUoDM5InigdKYEdVp7ZOi+mxIv2qScO1m
k2LRJFEe24MIS4wA8BAB1o1e+590DD0FjkyZjAIAA3nsfxK9nRbvtBbQ8IEjYsd7QEYIoYQDq4AZ
2/EAAIAnAACeAAB4AgDrs+O51a4Wo7dR9rY8tVFE11Jopz5arXllNT2ibFFST7U0yiN9w6k/1qwO
GH0DxuWJb07uwNbGPe2V2JLnyl1lwjAn9jhtEGUuMgFRgDR6F5ecQGpnE80VpXDshmI6iohENA+W
ylXFyULlAho6kJM80TpmuTvWXFEKz24oartWPFlkf5XVJWKTIUTXqTSa6PqcVQVT5BV4BqTgiaYT
+a5pvibBHw2tTT+iOXMboRzhACANT+pOOnzuIXe3zIApvz36+6AYyiriADA2T0i3Xe9qtobnSMSO
W/6Br5g4MWwCgP56Fw8cUCWc6M2ZF91GuW7C9G7WvjiwS4CUPGkdTZTxV6fHSaE6qSi6jhJJ8mAp
0+XVoC93NnhOzHScZnkdZDU+oFQAdAGG49jsWlFsuwdP5o08/E/mN28l0jYHTYAjyZNIOwY0AY4m
TwAAPAEA8AQAwBMAAE8AADwBAAA8AQDwBADAEwAATwAAPAEA8AQAwBMAAMATAABPAAA8AQDwBADA
EwCYGdT1VmjBqsMKzWl7zeLST9WL1BqoA+6lAsQdak9VXKasLfLqWq+1B6i75KtaxaU5YpWqV9Ak
uDqhhfsxGzk760WZeS+PVRsy5wmtj6w5Lxtd/ezas15tzRep8w7rSoCpHB/3ddO6ta6lSuIV1FWi
2lsJz9kWkkUQHDxxN3j1obHyfZUn4g02YevLBW06QOmv9FrkQxORMlVwMSm5JqSSsfqSmdZMqr5Y
Dav+ZU3jZ7oklSvXFKMwajZVlVghVakpvfQufDkr9aoyUd4VlR/J6gej4ESXfRLUlVDGtM61fC/L
Z1x1eaw+XT186VycqYdCfvfNhSYeq942Y1ICllIopWHGNXt51CTrZqpXrvrNqiKoNZuwSvI1qnVm
HTmLeokL1btiUkm0e0UBokTY8ZL+pKlSK4lfvQtxo6+gZkxOJTRS0y6o474R1qgZs/5ilso5s5my
SkHarDtnZvxw5ASFK0zvoizoHVGHbKaxmro/IPWHoDEagtTXKm2JUXMYglH/7wFWSt8q9TD6aJe9
BanR3z6hDVnaN2OjSdHZk/fppVhnPNa36TCt82b2X2ayNKBUyavUZ2yEjT7YAr1LFt2KTKZ6dyt3
xe0PObz1tbgkDS3UgUktoCWeEaVbo2FKWlQpNaXGCIBeueDaJKuSea+0I3RB6MwZkiOhfSK/ALWN
mcptNU7SNjrpVDqvz9SD3CyVRtsG0y/JVpKn82SFNWKbLtNLZ7NHpN/eQqatUv0KmGpgsCIgZ6Oi
Uk5MfBNTiglZY0Xv9erHEd6JUhma7JD4iavk/RrKMnkhYyKPDzqLvo9zjOdJR+q9TKuUratYyavE
aNqcIU7GlScAcITkCeZBAgB4AgDgCQCAJwCQCxZ4BMD0eDa3Bgh5AgBx8qTaSNcyUMyJZdtcsb28
7ZAAQSmLQJGb/AaWmvtqKG7WBaifJO+xg32bQ3NWp7BKzbirFqjJS77LsZvrqHqX62kSR7uo+WMc
UtAkJGURiCdIu07VFZarT6puouUjiaVJk0NzxtsXYdxVC8StrydyK3Eg0D5p+qLyKddvmqu9l/Pl
p+m6SFRL40nT9wsc64+0dSZDap5I+PtxIjzouyRXnrR9kdRZGRdcT2j91SI93isZxr76pqQDcTIa
Xzpav1T4XNSrznI8Cw+a4fwu3ha8/UuKQr/sbgFWS2asPirIhugpB0JLTby2jN6LLEMv/x/Qd4So
g+keOeC1T3xtgU+gvriS7mwOVbNMI4BasWob03DpomSEhtwRGRxZm33iVq5kKznDXixlibivxsZN
Se3iQynCC0iMXO0TgwrygOMaaMLJWIH6U5CTjptj51+lRw4hTRazLnBtn9R6F1H06upXq9nwymht
w0qHFM00JOWe2cdE84atb3L1ewaJs0/aRLjlY017V33k+lBb8hdyxAD/kxnBI1b8EmfO8gj+J0AP
G2nCaAB4MksQ0m8Eg2QnTh5f33rnzCvnTl/5yj70LgAwsP+1F796/vnqbHOnvHBp4+n5E7/IXe86
gYn1wETY+I8fko2/ePjoyRflz73q6he7+w8f/N6jv/3x+cfWWDfez02eqFuctBtxWKgt3ZTWTC8X
A5G36ijESujT9AnSAvEsRerenUdo+xQKed38uN1YjPX95SXnLcv/a8usUNvmAHTtq6js/y999uxg
pyvYN+6fPPFvN3O342lhLEVfaAu/W95quzZ6vZ6kmmCzj8okNGEJl1ynWpUcz4lVC3szcexZBVtl
LMv/r9ael0JQNZn6sNaG9vr1v988u3Xz40/uLmmyWV90HH/KP/7wrVfOXbz6enZWi652iY1pxNZU
0o4mVNtawyp9Cm3DKNb0q9NhfSuFUmvf3qudsuCqsgwqbsN7v37l4PnB+8Wf71S2yPLfTsBxe3Np
vVw4d/LExmcH+VRGGe/SV8NVdzSpTp27dFD/yrtTVipFB9rR2pvOgdJJ81UzzGWRuo3rlzdffWv/
o08+2y6KlboV/e/z2x9/8PSbm1eO7WXHE6Yzxb5ur6sh1HpAiraSAU3k6vvSb3uRdkOuvs8jSGOS
9a6M1nJ8/NsvNwcn8t8vHl39MD95wlhAx6+/PLGoMxPaOWXrel+xu/r06NZd9onYwtJYWn7A86gG
Bma5junBJ3vv7vL33jj3na3S9oj/d/Ham197uftw79ObOdonLJom7VhXBkhZFOrXgYzbg81naWfF
mZLl7aL4bnHm7PMvHdxfqVIr+yPgWFzeWPyQrOhxKqPKHLdaJxGDVGKLAGro05UeNiGHKE2nexiD
edbbdW0pDbcvXDURGzPY8jUeqnKBZmXOH9zZ29l9eerNa5fFsLDzuLl19bVTL54+vHfn7Zu5kf64
qrZIm4O0G5vIW3cYu3TUOzQrijs1lfkpesSQjbvT2ieO27RX+tS0a1zbyTiS6bSmpsKpl3e2H5K3
/uW1qxfsAb5++bU33tre3bn38nSewnHYvBUaPHyJ7QKGK36s03yawePfP33p2bPn29WP1XDw1uLk
8Y1bfau2Djs+4cgSaDKSidSPJhnh1Mu724+efPDm9Utf37x0+qunXu4+uHvnVvbPHvMggcx7B/if
AMBMAJ4AAHgCAOAJAIAnAACeAMB8IM3v0rYmsK52Z8Ukq96kXIgKi1wB4TzJet1BnrB0nGBhUiBe
7+Kc1+s9lmfa5aK9sQxjDZkAqZsxaAIEyhO1eyX6bifyD06kXVJI0o20ppFW4AnQ3463NJ7Vdh7E
HiBxU+PpeIid2YB4eVIYpr35g5v0Sc2ThNvhQJgAQ3ii7glKfC0LpjBwZPUuQ3CspAYnHbImkQUB
AFnJE6FDlVp7q7jLqhXRNy1PrnelzACbhABxPLHsYUq0nUwLYguSvp2RmaYNHAm9CwAA8AQAwBMA
AE8AADwBAPAEAObKEy79Vc8CwS3fJUNT5OZd3rMYAJC1PCG21j8kOgDkzBPdA0V2MeG8ckKRPFDk
YG34sulzI0U9rkii9m2RkiuaO8ndWwDAC+s8SNMDpT1d/V9oHiit+8kyDrfJhjZFI644iHBmrvA4
BLLiCQ9TiWRnDbPxrqhC5F/OxIg1CWIEAICseEIa7aebOjzQDrERpVOH4oPsHACYRO8qSLdtTfqb
4KpbS1AASBYgQzveL1K4X6RoEsTqUsulGNyWOjfuQKQAmckTxQOlMSOq09onRfXZkH7VJOHazSbF
okmiPLYHEZYYAeAhAqwbvfY/6Rh6ChyZMhkFAAby2P9kEc2RTmsBDR84Ina8B2SEEEo4sAqYsR0P
AAB4AgDgCQCAJwCwPjueW+1qMXobZW9zfZFTrnwlkdIV2ZLCmm2zNwmXN2bhVvtf+obTxLFOmwGA
ATzxzckd2Nq4Z3FgYkueyxmr6+FzYo/TBmlnL4MoQDq9i0tOILWzieaKUjh2QzEdRUQimgdL5ari
ZKG1bZN4cgLA6PLE2oUT4VYiO4UUnt1Q1PapeLLI/iqrS8QmQ4iDEkJt0/U5D4PERBvwBUjAk44u
XFm2XvU1Ce7zia3jd+p8pubGPYQKUyQBYChP6k46fO4ht56av3m8ftRMiYxXwUARIClPSGx3TFQ9
y9lYSQDbSFRr52AEsEa9iwfuXkU40YUC98qL1roxbpMexjiBHQ+siSeto4ky/ur0OClUJxXFL0uJ
JHmwlOny6iMH95FEK4zHLK+DGHFAF2A4js2uFcW2e/Bk3sjD/2R+81Yit+YFTYAjyZNIqx00AY4m
TwAAPAEA8AQAwBMAAE8AADwBAAA8AQDwBADAEwAATwAAPAEA8AQAwBMAAMATAABPAAA8AWaP/aun
z766eX0DPAEAB45tvXPso0f37935kJy7eHU/9+KeWOCVARPj8T/+6f/s7v6s/rX3xe6jvztTXH1s
D3zj/Sxo3frF0vJv47Xf+u/T+uLyCq1ClEEZXZ03wapby7BrcfynolhN6UbPoKqembaeNVPDs6iV
EPQE2gtU5M/U10KlVyaFrU+pKEQueO93+cGLHdudCxun7h9Ynkhu60gwVv2TWaO9QroKUDXDMrTa
WkQzouugSWGUbmwelp2AmbKcdVsCccZ6ZWNLse6Fml/UeE9K/Vuy5UOS/Z9snXvrozv3dzbrC8px
+7OPyNmL1/JUwRaOLo3K4kMQSRcwEtvLS9U5o+uhiaV0ySSXI2t7hF7FYWFVpoHFXD9+Qvcv7Gwu
Jcnyn/t4uzh2ZfGvv3Yqfzu+6pVYpTC03ZfWFikNbbaTQNOEKF1X1pPny8an6Ph4/erWN29+fHdJ
hOWPrn+f3b554fzlx9nLE/lVUPedWtxkofwKQVYXpirdJOKkq/JDHtEqq6ZOkTTJTJy8eP5hVPjf
+dGF3OWJv1GUPXWt/C6lzbI55vM+GhsiCRN7yaghj6geH2Cst3zORZwUt+4++L8fvHaltEM6/33n
3Kntd/cOZsQTs1NiLDOtdzqRxdi0/fSgnMRYGF3LqIoVf3jvwcuzr20VKyO+VLFsx61rX+Xf3XuZ
nXkS+Z2RUrVrbTusstOjWbyTJKWgNMIUkUvQq0+n1EsTo4bKhfaHMSi5Zpy6c293/6ukVqnE4LA4
Hrv6+o3d7U8Pihxh2ie1Rrw8MCY///JzCa3GtWSlmRaqcbA+07Yt+fhFqGsenLXtEYVXoYnF1Mr4
q5ak4mPj1eW/M5v8rnp1c/Fnf/B2zsWOWK8+VBGgxVHVzdanh/mlVo5v5Pqv+PNyOLgoLp08+flB
5kZWhN7FRg8IRDKlL00yxCf3HvM3yaWta2988OjeJwe5P/tjWM8dyLt3wP4nADATgCcAAJ4AAHgC
AOAJAIAnADAfSN/j6310xUBxu1Fu15a5U2yp695kfliypE4cw+NAIE9IzptIk5bIY7OvrDW2zwZi
9S7O+aoJ8fpMu1y0N5ZhrCETiRSSKEVQBIiQJ3Lr4YQsD0pHK/8Q52UYI+RcaAKCAKPY8ZZ2RLjc
YMlhaXVQu4BYeWLo75Yf3KQPemfgiPKk1Kas8oJYRE/aPjlp6hAnwAC9yxAcK6nR2CiFR75A6wIO
uzwROtTKQi9/mKqVpmaVIeerd3F8QAGieEK0v0T8L+laxBYkfTMj6VIFRYChehcAAOAJAIAnAACe
AMBUwDoSQAgGDZ3PNLIcG/IEALqxMOgT7ndi458SR/NoaS9qCbefL3gzg54Yt+ukOYlPQUwtIK7+
okrUHCFukqlvVwepkr7S8AIT9g8jTwaDmL+5dYaL2Vxbjhqzj7W5yCQ+BQftuXKLFPYovPnG0jZ/
OZyzNOX/oMlh5gmv+k5O6rZRvm+1mTQ3pCa0+sWb8EYHK9pP6Ic9Sb5V6YkOmkd+Gqzi6SzgJG62
TSPPNNrxI/Ghkh/ByF08MT1Q2tOKMNqNpt8lovERe7dclbydX0lCxROR1LrwFFp1sKVaE4k4JI0j
XZkmq7SC6nN4xMmRtOMdPOFhT0nuh81yEFPZsLmpkP6vKiAFfb5ZU2TifSh9prEQ94MohHwFDpXe
JRZVkDX3MIHGp5F+Uf1IZF+Sxl1SH9oADpN9QrpbD4loZNy0dcO1JqcA5X2ad0AkrwblbPTWWLEm
EDAvnhTe4WFuV+vbSffEKVF4fPdNXLKBRNMjLFK/7v+QCw1yBCPLsRc+7V7xK6lPa58U1QCQftn6
3TaOtX8lzXBYm4c0phzg2+JPwZWvSkV/ujFqXVPgqjyHhEHGJ6oQhZLb1oObyhSPXJxNCa7H6jVv
hZNENRs7HU7S5HQEV/wyPlGFjFBIz6lvf9G/n+HNJ7GgV6UEN2JFz1vhS0xDkym1Cj4xgQ8JcdI/
sqHSZKzg0d/jyQghJlP5SZqs4AXZ75FN2gbIqMExDxIAugGeAAB4AgDgCQBMA/f+J+o4QNzwnDFb
gxsfEuR5kYXfn6Qg2kB8h6+INsBfTX7GENVAs13/RBUXad3ljgxO/N9PbLNDQj8p+XhimeWk3zdu
Kh8s1Qvc7yuiDvBLI+IAMKLeVe9l0m6DIm9xwsXmOrbdUMx9UEQi8k2RLnfSk/iYG0FWABhd79I6
5tYJpZrYIXmcFJ7dUNT2qXiyyP4qsgeHTwGzOvB2xbEpkPAsBMblibOpmddUXxMSrrfaOn7rRbtO
3NdXBADG4wmPNYC49dT8zeP1I2IYLKAHkAdPlJ48TjwYniYRO25xnRjBDAVtJgJd/WFRoa3hqSeN
+h7VIk6YtS3MwmkDB7VUYqyqYAoNy8iWbsIYrZ0HzsYGQ6YFiwxMWV9GGpEny1qQTMFxW9svZwTX
h6bdE2WisPxLOifaZGIlUptwlW41+FXOQNZX9mmG07TCeKb21kG4o6Qw48eUK5RWzYnW582P9orc
7tqLdczyv/Jqc1Fc6ZAc6bO2Esy9/4ltM5TCvpgDUU4tm6aom6QQ2egnhVfzsy7T4BvfIkYZQZDR
acJUHUVqWctTUxS0F6sDE78KJkcoT5lfDkyQtTX/+c1b6edyDnEyniCpWxKjlq6X2ZQkZlOemCeY
zUqYMuswOz53okwWCXC0ReoNQ23tjnpi0syznidPgCz0rkgjmnliMt/g0xqyPhR6F5AFVcrem9m6
ZuofR6JhY0xuMyV51pAnwDjaFy01HFnVkS5ZlR8tmNLMtQjlPVpYVagpsrYC+wQBAPQuAABPAAA8
AQDwBADAEwAATwAAPAEAADwBAPAEAMATAFgH/h+83FdS+l2hWgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-11-09 13:11:42 +1300" MODIFIED_BY="jane clarke" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgments about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUMAAAM8CAIAAABCulVtAAAvC0lEQVR42u2dv27cxhbGCaRJoUKF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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-11-09 13:11:42 +1300" MODIFIED_BY="jane clarke" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeAAAAEACAMAAABcTlUlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-11-05 11:09:33 +1300" MODIFIED_BY="Agustín Ciapponi" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 GnRH agonists versus control, outcome: 1.2 Clinical Pregnancy Rate.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuQAAAJACAMAAADy94OvAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-11-09 12:00:27 +1300" MODIFIED_BY="jane clarke">
<APPENDIX ID="APP-01" MODIFIED="2009-11-05 08:59:08 +1300" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-06-16 14:59:12 +1200" MODIFIED_BY="jane clarke">CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-05 08:59:08 +1300" MODIFIED_BY="[Empty name]">
<P>EBM Reviews - Cochrane Central Register of Controlled Trials &lt;3rd Quarter 2009&gt;:<BR/>
</P>
<P>1     (pituitary adj2 suppress$).tw. (194)</P>
<P>2     artificial cycle$.tw. (12)</P>
<P>3     stimulated cycle$.tw. (95)</P>
<P>4     natural cycle$.tw. (60)</P>
<P>5     aspirin.tw. (4811)</P>
<P>6     acetylsalicylic acid.tw. (1019)</P>
<P>7     sildenafil.tw. (520)</P>
<P>8     antibiotic$.tw. (9477)</P>
<P>9     steroid$.tw. (8510)</P>
<P>10     gonadorelin.tw. (5)</P>
<P>11     GnRHa.tw. (175)</P>
<P>12     GnRH agonist$.tw. (570)</P>
<P>13     exp gonadotropin-releasing hormone/ or exp leuprolide/ or exp nafarelin/ (1580)</P>
<P>14     gonadotropin-releasing hormone$.tw. (630)</P>
<P>15     GnRH analogue$.tw. (157)</P>
<P>16     GnRH a.tw. (956)</P>
<P>17     sildenafil.tw. (520)</P>
<P>18     lhrh.tw. (316)</P>
<P>19     rec-FSH.tw. (19)</P>
<P>20     recombinant follicle stimulating hormone.tw. (113)</P>
<P>21     rFSH.tw. (127)</P>
<P>22     leuprolide.tw. (359)</P>
<P>23     nafarelin.tw. (101)</P>
<P>24     progesterone$.tw. (1979)</P>
<P>25     glucocorticoid$.tw. (1331)</P>
<P>26     luteinizing hormone.tw. (1028)</P>
<P>27     indomethacin.tw. (1986)</P>
<P>28     (estradiol or oestradiol).tw. (4253)</P>
<P>29     piroxicam.tw. (648)</P>
<P>30     estrogen.tw. (3708)</P>
<P>31     corticosteroid$.tw. (6023)</P>
<P>32     hcg.tw. (850)</P>
<P>33     human chorionic gonadotropin$.tw. (329)</P>
<P>34     (endometrin or utrogestin).tw. (4)</P>
<P>35     (endometri$ adj2 prepar$).tw. (53)</P>
<P>36     (uter$ adj2 receptiv$).tw. (12)</P>
<P>37     (endometri$ adj2 receptiv$).tw. (45)</P>
<P>38     (endometri$ adj2 thick$).tw. (359)</P>
<P>39     or/1-38 (41179)</P>
<P>40     FET.tw. (66)</P>
<P>41     frozen embryo$.tw. (36)</P>
<P>42     egg dona$.tw. (6)</P>
<P>43     frozen thaw$.tw. (108)</P>
<P>44     (oocyte$ adj2 don$).tw. (78)</P>
<P>45     (thaw$ adj2 cycle$).tw. (45)</P>
<P>46     (oocyte$ adj2 recipient$).tw. (13)</P>
<P>47     (cryopreserv$ adj2 embryo$).tw. (84)</P>
<P>48     nidation.tw. (4)</P>
<P>49     (embryo$ adj2 implant$).tw. (183)</P>
<P>50     or/40-49 (521)</P>
<P>51     50 and 39 (198)</P>
<P>52     from 51 keep 1-198 (198)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-11-05 09:00:23 +1300" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-06-16 14:56:49 +1200" MODIFIED_BY="jane clarke">EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-05 09:00:23 +1300" MODIFIED_BY="[Empty name]">
<P>EMBASE &lt;1980 to 2009 Week 40&gt;<BR/>
</P>
<P>1     (pituitary adj2 suppress$).tw. (787)</P>
<P>2     artificial cycle$.tw. (76)</P>
<P>3     stimulated cycle$.tw. (596)</P>
<P>4     natural cycle$.tw. (596)</P>
<P>5     aspirin.tw. (55105)</P>
<P>6     acetylsalicylic acid.tw. (5597)</P>
<P>7     sildenafil.tw. (3181)</P>
<P>8     antibiotic$.tw. (137659)</P>
<P>9     steroid$.tw. (121832)</P>
<P>10     gonadorelin.tw. (153)</P>
<P>11     GnRHa.tw. (829)</P>
<P>12     GnRH agonist$.tw. (2627)</P>
<P>13     exp exp gonadorelin/ or exp leuprolide/ or exp nafarelin/ (6409)</P>
<P>14     gonadotropin-releasing hormone$.tw. (8077)</P>
<P>15     GnRH analogue$.tw. (997)</P>
<P>16     GnRH a.tw. (766)</P>
<P>17     sildenafil.tw. (3181)</P>
<P>18     lhrh.tw. (5125)</P>
<P>19     rec-FSH.tw. (32)</P>
<P>20     recombinant follicle stimulating hormone.tw. (268)</P>
<P>21     rFSH.tw. (286)</P>
<P>22     leuprolide.tw. (1302)</P>
<P>23     nafarelin.tw. (281)</P>
<P>24     progesterone$.tw. (41729)</P>
<P>25     glucocorticoid$.tw. (35359)</P>
<P>26     luteinizing hormone.tw. (16270)</P>
<P>27     indomethacin.tw. (26976)</P>
<P>28     (estradiol or oestradiol).tw. (53165)</P>
<P>29     piroxicam.tw. (2771)</P>
<P>30     estrogen.tw. (61201)</P>
<P>31     corticosteroid$.tw. (51734)</P>
<P>32     hcg.tw. (14784)</P>
<P>33     human chorionic gonadotropin$.tw. (7849)</P>
<P>34     (endometrin or utrogestin).tw. (14)</P>
<P>35     (endometri$ adj2 prepar$).tw. (270)</P>
<P>36     (uter$ adj2 receptiv$).tw. (391)</P>
<P>37     (endometri$ adj2 receptiv$).tw. (558)</P>
<P>38     (endometri$ adj2 thick$).tw. (1545)</P>
<P>39     or/1-38 (528085)</P>
<P>40     FET.tw. (544)</P>
<P>41     frozen embryo$.tw. (432)</P>
<P>42     egg dona$.tw. (153)</P>
<P>43     frozen thaw$.tw. (1556)</P>
<P>44     (oocyte$ adj2 don$).tw. (1185)</P>
<P>45     (thaw$ adj2 cycle$).tw. (1149)</P>
<P>46     (oocyte$ adj2 recipient$).tw. (246)</P>
<P>47     (cryopreserv$ adj2 embryo$).tw. (826)</P>
<P>48     nidation.tw. (187)</P>
<P>49     (embryo$ adj2 implant$).tw. (2648)</P>
<P>50     or/40-49 (8033)</P>
<P>51     50 and 39 (1730)</P>
<P>52     Clinical Trial/ (558078)</P>
<P>53     Randomized Controlled Trial/ (174302)</P>
<P>54     exp randomization/ (27081)</P>
<P>55     Single Blind Procedure/ (8566)</P>
<P>56     Double Blind Procedure/ (74240)</P>
<P>57     Crossover Procedure/ (21816)</P>
<P>58     Placebo/ (131990)</P>
<P>59     Randomi?ed controlled trial$.tw. (35178)</P>
<P>60     Rct.tw. (2942)</P>
<P>61     random allocation.tw. (647)</P>
<P>62     randomly allocated.tw. (10522)</P>
<P>63     allocated randomly.tw. (1369)</P>
<P>64     (allocated adj2 random).tw. (565)</P>
<P>65     Single blind$.tw. (7693)</P>
<P>66     Double blind$.tw. (86890)</P>
<P>67     ((treble or triple) adj blind$).tw. (142)</P>
<P>68     placebo$.tw. (113249)</P>
<P>69     prospective study/ (86089)</P>
<P>70     or/52-69 (732685)</P>
<P>71     case study/ (6408)</P>
<P>72     case report.tw. (123396)</P>
<P>73     abstract report/ or letter/ (512736)</P>
<P>74     or/71-73 (640094)</P>
<P>75     70 not 74 (707130)</P>
<P>76     75 and 51 (238)</P>
<P>77     (2008$ or 2009$).em. (1054273)</P>
<P>78     77 and 76 (33)</P>
<P>79     from 78 keep 1-33 (33)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-11-09 12:00:20 +1300" MODIFIED_BY="jane clarke" NO="3">
<TITLE MODIFIED="2008-06-16 14:58:09 +1200" MODIFIED_BY="jane clarke">MEDLINE</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-09 12:00:20 +1300" MODIFIED_BY="jane clarke">
<P>Ovid MEDLINE(R) &lt;1950 to September Week 4 2009&gt;<BR/>
</P>
<P>1     (pituitary adj2 suppress$).tw. (912)</P>
<P>2     artificial cycle$.tw. (87)</P>
<P>3     stimulated cycle$.tw. (581)</P>
<P>4     natural cycle$.tw. (634)</P>
<P>5     aspirin.tw. (28484)</P>
<P>6     acetylsalicylic acid.tw. (6177)</P>
<P>7     sildenafil.tw. (3077)</P>
<P>8     antibiotic$.tw. (174351)</P>
<P>9     steroid$.tw. (149271)</P>
<P>10     gonadorelin.tw. (112)</P>
<P>11     GnRHa.tw. (851)</P>
<P>12     GnRH agonist$.tw. (2683)</P>
<P>13     exp gonadotropin-releasing hormone/ or exp leuprolide/ or exp nafarelin/ (25616)</P>
<P>14     gonadotropin-releasing hormone$.tw. (9018)</P>
<P>15     GnRH analogue$.tw. (1033)</P>
<P>16     GnRH a.tw. (784)</P>
<P>17     sildenafil.tw. (3077)</P>
<P>18     lhrh.tw. (5688)</P>
<P>19     rec-FSH.tw. (31)</P>
<P>20     recombinant follicle stimulating hormone.tw. (250)</P>
<P>21     rFSH.tw. (298)</P>
<P>22     leuprolide.tw. (1273)</P>
<P>23     nafarelin.tw. (239)</P>
<P>24     progesterone$.tw. (56833)</P>
<P>25     glucocorticoid$.tw. (40977)</P>
<P>26     luteinizing hormone.tw. (22111)</P>
<P>27     indomethacin.tw. (30023)</P>
<P>28     (estradiol or oestradiol).tw. (66462)</P>
<P>29     piroxicam.tw. (2253)</P>
<P>30     estrogen.tw. (72853)</P>
<P>31     corticosteroid$.tw. (58639)</P>
<P>32     hcg.tw. (18224)</P>
<P>33     human chorionic gonadotropin$.tw. (9747)</P>
<P>34     (endometrin or utrogestin).tw. (5)</P>
<P>35     (endometri$ adj2 prepar$).tw. (278)</P>
<P>36     (uter$ adj2 receptiv$).tw. (398)</P>
<P>37     (endometri$ adj2 receptiv$).tw. (556)</P>
<P>38     (endometri$ adj2 thick$).tw. (1524)</P>
<P>39     or/1-38 (614718)</P>
<P>40     FET.tw. (552)</P>
<P>41     frozen embryo$.tw. (565)</P>
<P>42     egg dona$.tw. (165)</P>
<P>43     frozen thaw$.tw. (2468)</P>
<P>44     (oocyte$ adj2 don$).tw. (1187)</P>
<P>45     (thaw$ adj2 cycle$).tw. (1271)</P>
<P>46     (oocyte$ adj2 recipient$).tw. (323)</P>
<P>47     (cryopreserv$ adj2 embryo$).tw. (988)</P>
<P>48     nidation.tw. (472)</P>
<P>49     (embryo$ adj2 implant$).tw. (3035)</P>
<P>50     or/40-49 (10071)</P>
<P>51     50 and 39 (1903)</P>
<P>52     randomised controlled trial.pt. (283276)</P>
<P>53     controlled clinical trial.pt. (80951)</P>
<P>54     randomized.ab. (191247)</P>
<P>55     placebo.tw. (119845)</P>
<P>56     clinical trials as topic.sh. (147064)</P>
<P>57     randomly.ab. (138441)</P>
<P>58     trial.ti. (83387)</P>
<P>59     (crossover or cross-over or cross over).tw. (44306)</P>
<P>60     or/52-59 (670395)</P>
<P>61     (animals not (humans and animals)).sh. (3372883)</P>
<P>62     60 not 61 (620296)</P>
<P>63     51 and 62 (164)</P>
<P>64     from 63 keep 1-164 (164)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-11-05 08:58:06 +1300" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-06-16 15:01:51 +1200" MODIFIED_BY="jane clarke">LILACS</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-05 08:58:06 +1300" MODIFIED_BY="[Empty name]">
<P>LILACS (1982 to October 2009)<BR/>((MH Donación de Oocito OR MH Implantación del Embrión OR MH Criopreservación) OR (Pt Cryopreserv$ OR Pt frozen thaw$)) AND ((MH Aspirina OR MH Esteroides OR MH Agentes Antibacterianos OR MH Gonadorelina) OR ((Pt Sildenafil OR Pt Antibiotic$ OR Pt Gonado$ OR Pt GnRH$ OR PT lhrh$)) OR (MH Implantación del Embrión/efectos de drogas)) AND ((Pt ENSAYO CONTROLADO ALEATORIO OR Pt ENSAYO CLINICO CONTROLADO OR Mh ENSAYOS CONTROLADOS ALEATORIOS OR Mh DISTRIBUCIÓN ALEATORIA OR Mh METODO DOBLE CIEGO OR Mh METODO SIMPLECIEGO OR Pt ESTUDIO MULTICÉNTRICO) or ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((Ct ANIMALES OR Mh ANIMALES OR Ct CONEJOS OR Ct RATÓN OR MH Ratas OR MH Primates OR MH Perros OR MH Conejos OR MH Porcinos) AND NOT (Ct HUMANO AND Ct ANIMALES)) [Palavras]</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2009-11-09 12:00:27 +1300" MODIFIED_BY="jane clarke" NO="5">
<TITLE MODIFIED="2009-11-05 08:57:12 +1300" MODIFIED_BY="[Empty name]">Menstrual Disorders and Subfertility Group Specialised Register</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-09 12:00:27 +1300" MODIFIED_BY="jane clarke">
<P>MDSG search (October 2009)</P>
<P>Keywords CONTAINS "Oocyte donation" or "oocyte donors" or "oocyte recipient-age" or "frozen embryo transfer" or "frozen embryos" or "frozen-thawed cycle" or "frozen-thawed embryo transfer" or "frozen-thawed embryos" or "FET" or "cryopreserved embryos" or "cryopreserved-thawed embryos"or "embryo vitrification" or Title CONTAINS  "Oocyte donation" or "oocyte donors" or "oocyte recipient-age" or "frozen embryo transfer" or "frozen embryos" or "frozen-thawed cycle" or "frozen-thawed embryo transfer" or "frozen-thawed embryos" or "FET" or "cryopreserved embryos" or "cryopreserved-thawed embryos"or "embryo vitrification"</P>
<P>AND</P>
<P>Keywords CONTAINS "endometrial development" or "endometrial preparation" or "endometrial priming" or "endometrial receptivity" or "endometrial proliferation" or "endometrial response" or "endometrial thickness" or "utrogestan" or "Endometrin" or "estrogen" or "Sildenafil" or "Glucocorticoids" or "GnRH a" or "GnRH agonist" or "GnRH analogue" or "GnRH analogue" or "GnRH analogues" or "GnRHa" or "GnRHa-gonadotropin" or "Gonadorelin"or "Leuprolide" or "leuprolide acetate" or "Nafarelin" or "Progesterone" or "Luteinising hormone releasing hormone" or "luteinizing hormone" or "luteinizing hormone supplementation" or "Lutenising hormone releasing hormone" or "HCG" or "human chorionic gonadotropin" or "Piroxicam"or "oestrodiol"or "estradiol" or"rFSH" or "recombinant FSH" or "Steriods" or "steroid pretreatment" or "low-dose aspirin" or "aspirin" or "stimulated cycle" or "natural cycle" or "natural cycles" or "pituitary desensitisation" or "pituitary desensitization" or "indomethacin"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2009-11-05 09:03:21 +1300" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-11-05 09:02:39 +1300" MODIFIED_BY="[Empty name]">PSYCHINFO</TITLE>
<APPENDIX_BODY MODIFIED="2009-11-05 09:03:21 +1300" MODIFIED_BY="[Empty name]">
<P>PsycINFO &lt;1806 to October Week 1 2009&gt;</P>
<P>1 (pituitary adj2 suppress$).tw. (35)<BR/>2 artificial cycle$.tw. (5)<BR/>3 stimulated cycle$.tw. (1)<BR/>4 natural cycle$.tw. (28)<BR/>5 aspirin.tw. (479)<BR/>6 acetylsalicylic acid.tw. (89)<BR/>7 sildenafil.tw. (302)<BR/>8 antibiotic$.tw. (942)<BR/>9 steroid$.tw. (5050)<BR/>10 gonadorelin.tw. (2)<BR/>11 GnRHa.tw. (12)<BR/>12 GnRH agonist$.tw. (29)<BR/>13 exp gonadotropin-releasing hormone/ or exp leuprolide/ or exp nafarelin/ (0)<BR/>14 gonadotropin-releasing hormone$.tw. (306)<BR/>15 GnRH analogue$.tw. (11)<BR/>16 GnRH a.tw. (5)<BR/>17 sildenafil.tw. (302)<BR/>18 lhrh.tw. (147)<BR/>19 rec-FSH.tw. (0)<BR/>20 recombinant follicle stimulating hormone.tw. (0)<BR/>21 rFSH.tw. (0)<BR/>22 leuprolide.tw. (41)<BR/>23 nafarelin.tw. (0)<BR/>24 progesterone$.tw. (2644)<BR/>25 glucocorticoid$.tw. (2461)<BR/>26 luteinizing hormone.tw. (950)<BR/>27 indomethacin.tw. (314)<BR/>28 (estradiol or oestradiol).tw. (3673)<BR/>29 piroxicam.tw. (35)<BR/>30 estrogen.tw. (4061)<BR/>31 corticosteroid$.tw. (1429)<BR/>32 hcg.tw. (45)<BR/>33 human chorionic gonadotropin$.tw. (52)<BR/>34 (endometrin or utrogestin).tw. (0)<BR/>35 (endometri$ adj2 prepar$).tw. (1)<BR/>36 (uter$ adj2 receptiv$).tw. (0)<BR/>37 (endometri$ adj2 receptiv$).tw. (0)<BR/>38 (endometri$ adj2 thick$).tw. (6)<BR/>39 or/1-38 (16775)<BR/>40 FET.tw. (25)<BR/>41 frozen embryo$.tw. (9)<BR/>42 egg dona$.tw. (40)<BR/>43 frozen thaw$.tw. (0)<BR/>44 (oocyte$ adj2 don$).tw. (23)<BR/>45 (thaw$ adj2 cycle$).tw. (0)<BR/>46 (oocyte$ adj2 recipient$).tw. (2)<BR/>47 (cryopreserv$ adj2 embryo$).tw. (8)<BR/>48 nidation.tw. (5)<BR/>49 (embryo$ adj2 implant$).tw. (26)<BR/>50 or/40-49 (129)<BR/>51 50 and 39 (4)<BR/>52 from 51 keep 1-4 (4)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>